0000721371-20-000023.txt : 20200206 0000721371-20-000023.hdr.sgml : 20200206 20200206161614 ACCESSION NUMBER: 0000721371-20-000023 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 95 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200206 DATE AS OF CHANGE: 20200206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDINAL HEALTH INC CENTRAL INDEX KEY: 0000721371 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 310958666 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11373 FILM NUMBER: 20582888 BUSINESS ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147573033 MAIL ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: CARDINAL DISTRIBUTION INC DATE OF NAME CHANGE: 19920703 10-Q 1 a20q210q123119form10-q.htm 10-Q Document
false--06-30Q2202000007213715000000007550000007550000003270000003270000002500000500000002800000035000000 0000721371 2019-07-01 2019-12-31 0000721371 2020-01-31 0000721371 2018-10-01 2018-12-31 0000721371 2018-07-01 2018-12-31 0000721371 2019-10-01 2019-12-31 0000721371 2019-06-30 0000721371 2019-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2019-12-31 0000721371 us-gaap:CommonStockMember 2019-07-01 2019-12-31 0000721371 us-gaap:RetainedEarningsMember 2019-12-31 0000721371 us-gaap:CommonStockMember 2019-06-30 0000721371 us-gaap:CommonStockMember 2019-12-31 0000721371 us-gaap:TreasuryStockMember 2019-07-01 2019-12-31 0000721371 us-gaap:TreasuryStockMember 2019-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-12-31 0000721371 us-gaap:RetainedEarningsMember 2019-07-01 2019-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-12-31 0000721371 us-gaap:TreasuryStockMember 2019-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000721371 us-gaap:RetainedEarningsMember 2019-06-30 0000721371 us-gaap:TreasuryStockMember 2018-09-30 0000721371 2018-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000721371 2018-09-30 0000721371 us-gaap:CommonStockMember 2018-09-30 0000721371 us-gaap:TreasuryStockMember 2018-10-01 2018-12-31 0000721371 us-gaap:CommonStockMember 2018-12-31 0000721371 us-gaap:TreasuryStockMember 2018-12-31 0000721371 us-gaap:RetainedEarningsMember 2018-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2018-10-01 2018-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2018-12-31 0000721371 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000721371 us-gaap:RetainedEarningsMember 2018-09-30 0000721371 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-01 2018-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2018-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000721371 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000721371 us-gaap:RetainedEarningsMember 2019-09-30 0000721371 us-gaap:TreasuryStockMember 2019-10-01 2019-12-31 0000721371 us-gaap:CommonStockMember 2019-09-30 0000721371 2019-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-10-01 2019-12-31 0000721371 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000721371 us-gaap:TreasuryStockMember 2019-09-30 0000721371 us-gaap:RetainedEarningsMember 2018-07-01 2018-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000721371 us-gaap:RetainedEarningsMember 2018-06-30 0000721371 us-gaap:TreasuryStockMember 2018-07-01 2018-12-31 0000721371 us-gaap:TreasuryStockMember 2018-06-30 0000721371 us-gaap:CommonStockMember 2018-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2018-07-01 2018-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2018-06-30 0000721371 2018-06-30 0000721371 us-gaap:CommonStockMember 2018-07-01 2018-12-31 0000721371 2019-07-01 0000721371 us-gaap:FacilityClosingMember 2019-12-31 0000721371 us-gaap:EmployeeSeveranceMember 2019-07-01 2019-12-31 0000721371 us-gaap:FacilityClosingMember 2019-07-01 2019-12-31 0000721371 us-gaap:EmployeeSeveranceMember 2019-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2019-12-31 0000721371 us-gaap:FacilityClosingMember 2019-06-30 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2018-10-01 2018-12-31 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2018-07-01 2018-12-31 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2019-07-01 2019-12-31 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2019-10-01 2019-12-31 0000721371 us-gaap:CustomerRelationshipsMember 2019-06-30 0000721371 cah:IPRDTrademarksandOtherMember 2019-06-30 0000721371 cah:TrademarksAndPatentsMember 2019-06-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0000721371 cah:PharmaceuticalMember 2019-07-01 2019-12-31 0000721371 cah:MedicalMember 2019-12-31 0000721371 cah:MedicalMember 2019-07-01 2019-12-31 0000721371 cah:PharmaceuticalMember 2019-06-30 0000721371 cah:PharmaceuticalMember 2019-12-31 0000721371 cah:MedicalMember 2019-06-30 0000721371 us-gaap:CustomerRelationshipsMember 2019-07-01 2019-12-31 0000721371 cah:TrademarksAndPatentsMember 2019-07-01 2019-12-31 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-07-01 2019-12-31 0000721371 cah:IPRDTrademarksandOtherMember 2019-12-31 0000721371 us-gaap:CustomerRelationshipsMember 2019-12-31 0000721371 cah:TrademarksAndPatentsMember 2019-12-31 0000721371 cah:NaviHealthMember 2018-08-01 0000721371 cah:NaviHealthMember 2018-08-01 2018-08-31 0000721371 cah:NaviHealthMember 2018-07-01 2018-12-31 0000721371 cah:NaviHealthMember 2019-06-30 0000721371 cah:NaviHealthMember 2019-12-31 0000721371 cah:OperatingLeaseMember 2019-12-31 0000721371 cah:FinanceLeaseMember 2019-12-31 0000721371 srt:MinimumMember 2019-12-31 0000721371 srt:MaximumMember 2019-12-31 0000721371 2019-07-01 2019-07-01 0000721371 cah:ASC842Member 2019-07-01 2019-07-01 0000721371 cah:A2.616Notesdue2022Member 2019-07-01 2019-12-31 0000721371 us-gaap:CommercialPaperMember 2019-12-31 0000721371 cah:A2.4Notesdue2020Member 2019-11-01 2019-11-30 0000721371 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0000721371 cah:ShortTermCreditFacilitiesMember cah:CommittedReceivablesSalesFacilityProgramMember 2019-12-31 0000721371 cah:A3.2Notesdue2023Member 2019-07-01 2019-12-31 0000721371 cah:A4.6Notesdue2043Member 2019-07-01 2019-12-31 0000721371 cah:A4.9Notesdue2045Member 2019-07-01 2019-12-31 0000721371 cah:A4.368Notesdue2047Member 2019-07-01 2019-12-31 0000721371 cah:FloatingRateNotesdue2022Member 2019-07-01 2019-12-31 0000721371 cah:A3.41Notesdue2027Member 2019-07-01 2019-12-31 0000721371 cah:A4.368Notesdue2047Member 2019-12-31 0000721371 cah:A3.079Notesdue2024Member 2019-12-31 0000721371 cah:A3.2Notesdue2022Member 2019-06-30 0000721371 cah:A4.368Notesdue2047Member 2019-06-30 0000721371 cah:A3.75Notesdue2026Member 2019-12-31 0000721371 cah:A2.616Notesdue2022Member 2019-12-31 0000721371 cah:A3.2Notesdue2023Member 2019-12-31 0000721371 cah:A2.616Notesdue2022Member 2019-06-30 0000721371 cah:A3.2Notesdue2023Member 2019-06-30 0000721371 cah:A3.41Notesdue2027Member 2019-12-31 0000721371 cah:A3.75Notesdue2026Member 2019-06-30 0000721371 cah:A4.5Notesdue2044Member 2019-06-30 0000721371 cah:A4.6Notesdue2043Member 2019-06-30 0000721371 cah:A2.4Notesdue2020Member 2019-12-31 0000721371 cah:A4.625Notesdue2021Member 2019-06-30 0000721371 cah:A4.5Notesdue2044Member 2019-12-31 0000721371 cah:FloatingRateNotesdue2022Member 2019-06-30 0000721371 cah:A4.6Notesdue2043Member 2019-12-31 0000721371 cah:FloatingRateNotesdue2022Member 2019-12-31 0000721371 cah:A2.4Notesdue2020Member 2019-06-30 0000721371 cah:A7.0Debenturesduefiscal2027Member 2019-06-30 0000721371 cah:A3.5Notesdue2025Member 2019-12-31 0000721371 cah:A4.625Notesdue2021Member 2019-12-31 0000721371 cah:A4.9Notesdue2045Member 2019-06-30 0000721371 cah:A7.0Debenturesduefiscal2027Member 2019-12-31 0000721371 cah:A3.079Notesdue2024Member 2019-06-30 0000721371 cah:A4.9Notesdue2045Member 2019-12-31 0000721371 cah:A3.41Notesdue2027Member 2019-06-30 0000721371 cah:A3.5Notesdue2025Member 2019-06-30 0000721371 cah:A3.2Notesdue2022Member 2019-12-31 0000721371 cah:ProductLiabilityLawsuitsMember cah:AlamedaCountyMember us-gaap:SubsequentEventMember 2020-02-04 2020-02-04 0000721371 cah:OpioidLitigationlessCuyahogaandSummitCountiesMember 2019-09-30 0000721371 cah:SterileSurgicalGownRecallMemberDomain 2019-12-31 0000721371 cah:TotalOpioidLitigationMember 2019-09-30 0000721371 cah:SterileSurgicalGownRecallMemberDomain 2019-10-01 2019-12-31 0000721371 cah:PrivatePartiesMember cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2020-02-04 0000721371 cah:ProductLiabilityLawsuitsMember cah:OtherJurisdictionsMember us-gaap:SubsequentEventMember 2020-02-04 2020-02-04 0000721371 cah:CVSHealthMember 2019-07-01 2019-12-31 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2020-02-04 0000721371 cah:OpioidLawsuitsStateDomain us-gaap:SubsequentEventMember 2020-02-04 0000721371 cah:OpioidLitigationlessCuyahogaandSummitCountiesMember 2019-07-01 2019-12-31 0000721371 cah:ClassActionLawsuitsMember cah:PrivatePartiesMember cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2020-02-04 0000721371 cah:OpioidLitigationCuyahogaandSummitCountiesMember 2019-09-30 0000721371 cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2020-02-04 2020-02-04 0000721371 cah:TotalOpioidLitigationnetoftaxMember 2019-09-30 0000721371 cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2020-02-04 2020-02-04 0000721371 cah:TotalOpioidLitigationMember 2019-07-01 2019-12-31 0000721371 cah:PatientRecoveryBusinessMember 2019-06-30 0000721371 cah:CareFusionMember 2019-06-30 0000721371 cah:TotalOpioidLitigationMember 2019-12-31 0000721371 cah:CareFusionMember 2019-12-31 0000721371 cah:PatientRecoveryBusinessMember 2019-12-31 0000721371 srt:MinimumMember us-gaap:InternalRevenueServiceIRSMember 2019-10-01 2019-12-31 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000721371 us-gaap:CurrencySwapMember 2018-09-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-07-01 2018-12-31 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-12-31 0000721371 us-gaap:CurrencySwapMember 2019-12-31 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000721371 us-gaap:CashFlowHedgingMember 2019-12-31 0000721371 us-gaap:FairValueInputsLevel2Member 2019-06-30 0000721371 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-12-31 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-12-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-12-31 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember 2019-07-01 2019-12-31 0000721371 us-gaap:NonUsMember 2019-07-01 2019-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-12-31 0000721371 country:US 2018-07-01 2018-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember 2018-07-01 2018-12-31 0000721371 us-gaap:NonUsMember 2018-07-01 2018-12-31 0000721371 country:US 2019-07-01 2019-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember 2019-10-01 2019-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-06-30 0000721371 us-gaap:CorporateNonSegmentMember 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2019-07-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-07-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-07-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2019-07-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2019-07-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2019-07-01 2019-12-31 0000721371 cah:SterileSurgicalGownRecallMemberDomain 2019-07-01 2019-12-31 0000721371 us-gaap:NonUsMember 2019-10-01 2019-12-31 0000721371 country:US 2019-10-01 2019-12-31 0000721371 country:US 2018-10-01 2018-12-31 0000721371 us-gaap:NonUsMember 2018-10-01 2018-12-31 0000721371 us-gaap:PerformanceSharesMember 2019-12-31 0000721371 us-gaap:PerformanceSharesMember 2019-07-01 2019-12-31 0000721371 us-gaap:PerformanceSharesMember 2019-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-12-31 0000721371 us-gaap:EmployeeStockOptionMember 2018-07-01 2019-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-12-31 0000721371 us-gaap:EmployeeStockOptionMember 2019-10-01 2019-12-31 0000721371 us-gaap:EmployeeStockOptionMember 2018-10-01 2018-12-31 0000721371 us-gaap:PerformanceSharesMember 2019-10-01 2019-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2018-10-01 2018-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-10-01 2019-12-31 0000721371 us-gaap:PerformanceSharesMember 2018-10-01 2018-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-12-31 0000721371 us-gaap:PerformanceSharesMember 2018-07-01 2018-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-12-31 0000721371 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000721371 srt:MinimumMember us-gaap:PerformanceSharesMember 2019-07-01 2019-12-31 0000721371 srt:MaximumMember us-gaap:PerformanceSharesMember 2019-07-01 2019-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 xbrli:pure cah:StateAG iso4217:USD xbrli:shares iso4217:JPY iso4217:USD cah:plaintiff iso4217:EUR xbrli:shares cah:lawsuit cah:segment

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☑
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2019
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission File Number: 1-11373
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
Ohio
 
31-0958666
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
 
 
 
 
 
 
 
7000 Cardinal Place
,
Dublin
,
Ohio
 
43017
(Address of principal executive offices)
 
(Zip Code)
 
 
 
 
 
 
 
 
 
 
 
(614)
 
757-5000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common shares (without par value)
CAH
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  þ    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  þ    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑
 
Accelerated filer
☐
 
Non-accelerated filer
☐
 
Smaller reporting company
☐
 
 
 
 
Emerging growth company
☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  þ
The number of the registrant’s common shares, without par value, outstanding as of January 31, 2020, was the following: 291,783,533.


Cardinal Health  
Q2 Fiscal 2020 Form 10-Q

Table of Contents
 

About Cardinal Health
 
Cardinal Health, Inc. is an Ohio corporation formed in 1979 and is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, “we,” “our,” “us,” and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2020 and fiscal 2019 are to the fiscal years ending or ended June 30, 2020 and June 30, 2019, respectively.
Forward-Looking Statements
 
This Quarterly Report on Form 10-Q for the quarter ended December 31, 2019 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results, trends or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in Exhibit 99.1 to this Form 10-Q and in "Risk Factors" in this form 10-Q and our Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (our “2019 Form 10-K”). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.
Non-GAAP Financial Measures
 
In the "Overview of Consolidated Results" section of MD&A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the “Explanation and Reconciliation of Non-GAAP Financial Measures” section following MD&A in this Form 10-Q.


 
 
 
 1
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


MD&A
Overview
 



Management's Discussion and Analysis of Financial Condition and Results of Operations
The discussion and analysis presented below is concerned with material changes in financial condition and results of operations between the periods specified in our condensed consolidated balance sheets at December 31, 2019 and June 30, 2019, and in our condensed consolidated statements of earnings/(loss) for the three and six months ended December 31, 2019 and 2018. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&A included in our 2019 Form 10-K.



 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
2


MD&A
Overview
 

Overview of Consolidated Results
Revenue
 
chart-482220cd78845318873.jpg
During the three and six months ended December 31, 2019, revenue increased 5 percent to $39.7 billion and 6 percent to $77.1 billion, respectively, primarily due to sales growth from pharmaceutical distribution and specialty solutions customers.
GAAP and Non-GAAP Operating Earnings/(Loss)
 

 
Three Months Ended December 31,
 
Six Months Ended December 31,
(in millions)
2019
 
2018
 
Change
 
2019
 
2018
 
Change
GAAP operating earnings/(loss)
$
334

 
$
504

 
(34
)%
 
$
(4,930
)
 
$
1,320

 
N.M

Surgical gown recall costs
96

 
—

 
 
 
96

 
—

 
 
State opioid assessment related to prior fiscal years
(1
)
 
(29
)
 
 
 
4

 
—

 
 
Restructuring and employee severance
56

 
12

 
 
 
86

 
44

 
 
Amortization and other acquisition-related costs
133

 
157

 
 
 
265

 
314

 
 
Impairments and (gain)/loss on disposal of assets
7

 
8

 
 
 
8

 
(503
)
 
 
Litigation (recoveries)/charges, net
21

 
(15
)
 
 
 
5,694

 
3

 
 
Non-GAAP operating earnings
$
646

 
$
637

 
1
 %
 
$
1,223

 
$
1,178

 
4
%
The sum of the components may not equal the total due to rounding.
GAAP operating earnings during the three months ended December 31, 2019 were unfavorably impacted by a $96 million charge in connection with a voluntary recall for Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns, as described further in the Significant Developments in Fiscal 2020 and Trends section in this MD&A and Note 7 of the "Notes to Condensed Consolidated Financial Statements." Also contributing to the decrease in GAAP operating earnings during the three months ended were restructuring costs mainly as a result of certain enterprise-wide cost-saving initiatives and the adverse impact of Pharmaceutical segment customer contract renewals.
The decrease in GAAP operating earnings during the six months ended December 31, 2019 was primarily due to a $5.63 billion pre-tax charge we recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. As described further in the Significant Developments in Fiscal 2020 and Trends section in this MD&A and Note 7 of the "Notes to Condensed Consolidated Financial Statements", in October 2019, we agreed in principle to a global settlement framework with a leadership group of four state attorneys general that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions. GAAP operating earnings during the six months ended December 31, 2018 were favorably impacted by a $508 million pre-tax gain from the divestiture of our naviHealth Holdings, LLC ("naviHealth") business.
Non-GAAP operating earnings during the three months ended December 31, 2019 were essentially flat due to the performance of our Pharmaceutical segment generics program offset by the adverse impact of Pharmaceutical segment customer contract renewals.


 
 
 
 3
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


MD&A
Overview
 

The increase in non-GAAP operating earnings during the six months ended December 31, 2019 was primarily due to the beneficial impact of enterprise-wide cost-savings measures, growth from specialty solutions and the performance of our Pharmaceutical segment generics program. These positive factors were partially offset by the adverse impact of Pharmaceutical segment customer contract renewals.
GAAP and Non-GAAP Diluted EPS
 
 
Three Months Ended December 31,
 
Six Months Ended December 31,
($ per share)
2019 (2)
 
2018 (2)
 
Change
 
2019 (2) (3)
 
2018 (2)
 
Change
GAAP diluted EPS (1)
$
0.75

 
$
0.93

 
(19
)%
 
$
(15.99
)
 
$
2.88

 
N.M

Surgical gown recall costs
0.24

 
—

 
 
 
0.24

 
—

 
 
State opioid assessment related to prior fiscal years
—

 
(0.07
)
 
 
 
0.01

 
—

 
 
Restructuring and employee severance
0.14

 
0.03

 
 
 
0.22

 
0.11

 
 
Amortization and other acquisition-related costs
0.34

 
0.40

 
 
 
0.67

 
0.79

 
 
Impairments and (gain)/loss on disposal of assets
0.02

 
0.02

 
 
 
0.02

 
(1.22
)
 
 
Litigation (recoveries)/charges, net
0.06

 
(0.04
)
 
 
 
17.66

 
0.01

 
 
Loss on extinguishment of debt
0.01

 
—

 
 
 
0.01

 
—

 
 
Transitional tax benefit, net
(0.04
)
 
0.01

 
 
 
(0.04
)
 
0.01

 
 
Non-GAAP diluted EPS (1)
$
1.52

 
$
1.29

 
18
 %
 
$
2.80

 
$
2.58

 
9
%
The sum of the components may not equal the total due to rounding.
(1)
Diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("diluted EPS")
(2)
The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."
(3)
For the six months ended December 31, 2019, GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 294 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period. Year-to-date fiscal 2020 non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares, which includes potentially dilutive shares.
During the three months ended December 31, 2019, GAAP diluted earnings per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") decreased primarily due to factors discussed above impacting GAAP operating earnings, partially offset by a lower effective tax rate due to favorable changes in jurisdictional mix and discrete tax items.
During the six months ended December 31, 2019, we had a $(15.99) GAAP diluted loss per share due to the charge we recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. The charge had a $(17.49) per share after tax impact on GAAP diluted EPS during the six months ended December 31, 2019. GAAP diluted EPS during the six months ended December 31, 2018 was favorably impacted by a $1.25 per share gain from the divestiture of naviHealth.
During the three months ended December 31, 2019, non-GAAP diluted EPS increased 18 percent to $1.52 per share. This increase was primarily due to the factors discussed above impacting non-GAAP operating earnings, a lower effective tax rate due to favorable changes in jurisdictional mix and a lower share count as a result of share repurchases.
During the six months ended December 31, 2019, non-GAAP diluted EPS increased 9 percent to $2.80 per share. This increase was primarily due to the factors discussed above impacting non-GAAP operating earnings, a lower share count as a result of share repurchases and lower interest expense due to less debt outstanding. The year-over-year comparison was unfavorably impacted by the prior-year benefit from discrete tax items, largely related to international legal entity changes.
Cash and Equivalents
 
Our cash and equivalents balance was $1.7 billion at December 31, 2019 compared to $2.5 billion at June 30, 2019. During the six months ended December 31, 2019, net cash provided by operating activities was $44 million and we deployed $793 million for long-term debt repayments, $350 million for share repurchases, and $287 million for cash dividends. At December 31, 2019, we had $458 million outstanding under our commercial paper program and $225 million outstanding under our committed receivables sales facility.




 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
4


MD&A
Overview
 

Significant Developments in Fiscal 2020 and Trends
Opioid Lawsuits Development
 
In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions (the "Settlement Framework"). This Settlement Framework is subject to contingencies and uncertainties as to final terms, but is the basis for our negotiation of definitive terms and documentation. The Settlement Framework includes (1) a cash component, pursuant to which we would pay up to $5.56 billion over eighteen years, (2) development and participation in a program for free or rebated distribution of opioid abuse treatment medications for a period of ten years, and (3) industry-wide changes to be specified to controlled substance anti-diversion programs. In order to continue working on the Settlement Framework, we also agreed, with two other national distributors, to a $215 million settlement with two plaintiffs counties of a trial that had been scheduled for October 2019; our portion of that settlement is $66 million, which was paid in January 2020.
In connection with these matters, we recorded a total pre-tax charge of $5.63 billion ($5.14 billion after tax) during the six months ended December 31, 2019 in litigation (recoveries)/charges, net, in the condensed consolidated statement of earnings for the cash component. We accrue for contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. Final terms of a settlement under the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We will regularly review these opioid litigation matters to determine whether our accrual is adequate. We are unable to reasonably estimate the liability associated with any potential distribution of treatment medications and any incremental costs for changes to our controlled substance anti-diversion program that we may agree to under the Settlement Framework. The amount of ultimate loss may differ materially from this accrual. See Note 7 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
Also in connection with these matters, we recorded a tax benefit of $487 million, which is net of unrecognized tax benefits of $468 million, during the six months ended December 31, 2019, reflecting our current assessment of the estimated future deductibility of the amount that may be paid under the $5.63 billion accrual taken in connection with the opioid litigation. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the U.S. Tax Cuts and Jobs Act (“Tax Act”). We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act which is subject to further interpretation by the U.S. Internal Revenue Service ("IRS"). Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 8 of the “Notes to the Condensed Consolidated Financial Statements” for additional information.
Surgical Gown Recalls
 
In January, 2020, we issued a voluntary recall for 9.1 million AAMI Level 3 surgical gowns and two voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for 2.9 million Presource Procedure Packs containing affected gowns (together, the "Recalls"). These Recalls were necessary because we discovered in December 2019 that one of our FDA-registered suppliers in China had shifted production of some gowns to unapproved sites with uncontrolled environments. Because of this, we could not assure sterility of the gowns.
In connection with these Recalls, in the three months ended December 31, 2019, we recorded a total charge of $96 million, of which $56 million is within cost of products sold and $40 million is within SG&A in the condensed consolidated statements of earnings. This charge represents our best estimate of costs for the Recalls and include inventory write-off costs and certain remediation and supply disruption costs, such as costs to replace recalled products. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. The amount of ultimate loss may differ materially from this accrual. This charge, and any future increases or adjustments, will be excluded from our non-GAAP results and the results of our Medical segment. See Note 7 of the "Notes to Condensed Consolidated Financial Statements" for additional information.


 
 
 
 5
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


MD&A
Overview
 

In addition to the charge for the three months ended December 31, 2019, we expect that the Recalls will have other negative impacts, which could include: government investigations and enforcement actions by the U.S. Food and Drug Administration or other regulators or U.S. or international governmental bodies (possibly resulting in product seizures, additional recalls, the issuance of safety alerts, the suspension or revocation of the authority to produce, distribute and sell products and other civil or criminal sanctions); losses due to patient claims, including product liability claims and lawsuits; and customer claims unrelated to their direct costs from the supply chain disruption.
Additionally, these surgical gowns and procedure packs are used in surgeries throughout the United States and internationally. Due to quality standards, it is challenging to quickly establish additional or replacement suppliers. These Recalls are expected to result in sustained supply reductions and market shortages. We understand that, due to these supply shortages, surgeries have been delayed or canceled, and we expect that additional surgeries will be delayed or canceled over a period of several weeks or months. This and other aspects of the Recalls could result in reputational harm and loss of customers and sales.
Trends
 
Within our Pharmaceutical segment, segment profit increased during the six months ended December 31, 2019 compared to the prior-year period due, in part, to performance from our generics program, while for the past two fiscal years, Pharmaceutical segment profit had decreases compared to the prior year due, in part, to performance from our generics program. As is generally the case, the frequency, timing, magnitude and profit impact of generic pharmaceutical customer and manufacturer pricing changes remain uncertain and their impact on Pharmaceutical segment profit and consolidated operating earnings in fiscal 2020 could be more or less than we expect.





 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
6


MD&A
Results of Operations
 

Results of Operations
Revenue

chart-9236314201dd5b538cd.jpgchart-0c924314911e5b7b8bf.jpg
 
Three Months Ended December 31,
 
Six Months Ended December 31,
(in millions)
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Pharmaceutical
$
35,714

 
$
33,740

 
6
%
 
$
69,142

 
$
65,155

 
6
%
Medical
4,023

 
4,006

 
—
%
 
7,940

 
7,807

 
2
%
Total segment revenue
39,737

 
37,746

 
5
%
 
77,082

 
72,962

 
6
%
Corporate
(2
)
 
(6
)
 
N.M

 
(6
)
 
(9
)
 
N.M

Total revenue
$
39,735

 
$
37,740

 
5
%
 
$
77,076

 
$
72,953

 
6
%
Pharmaceutical Segment
Pharmaceutical segment revenue growth was primarily due to sales growth from pharmaceutical distribution and specialty solutions customers, which together increased revenue by $2.0 billion and $4.0 billion during the three and six months ended December 31, 2019, respectively.
Medical Segment
Medical segment revenue was essentially flat during the three months ended December 31, 2019 with sales growth from Cardinal Health at-Home Solutions offset by lower sales from products and distribution.
Medical segment revenue increased slightly during the six months ended December 31, 2019 primarily due to sales growth from Cardinal Health at-Home Solutions and products and distribution. The increase was partially offset by the divestiture of naviHealth in the prior year.
Cost of Products Sold
 
Cost of products sold for the three and six months ended December 31, 2019 increased $2.0 billion (6 percent) and $4.1 billion (6 percent) compared to the respective prior-year periods as a result of the factors affecting the changes in revenue and gross margin.





 
 
 
 7
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


MD&A
Results of Operations
 

Gross Margin
 
chart-73ee4c10511c5ef6890.jpgchart-f61e989517785cc7bf1.jpg
 
Three Months Ended December 31,
 
Six Months Ended December 31,
(in millions)
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Gross margin
$
1,714

 
$
1,730

 
(1
)%
 
$
3,393

 
$
3,397

 
—
 %
Gross margin was essentially flat versus prior-year periods during both the three and six months ended December 31, 2019.
Gross margin rate declined 27 basis points during the three months ended December 31, 2019 mainly due to a $56 million charge in connection with the Recalls, as described further in the Significant Developments in Fiscal 2020 and Trends section in this MD&A, the adverse impact of pharmaceutical customer contract renewals, and changes in pharmaceutical distribution product mix, partially offset by the performance of our Pharmaceutical segment generics program.
Gross margin rate declined 26 basis points during the six months ended December 31, 2019 mainly due to the adverse impact of pharmaceutical customer contract renewals, the $56 million charge in connection with the Recalls, as described further in the Significant Developments in Fiscal 2020 and Trends section in this MD&A, and changes in pharmaceutical distribution product mix.
Distribution, Selling, General and Administrative ("SG&A") Expenses
 
 
Three Months Ended December 31,
 
Six Months Ended December 31,
(in millions)
2019
 
2018
 
Change
 
2019
 
2018
 
Change
SG&A expenses
$
1,163

 
$
1,064

 
9
%
 
$
2,270

 
$
2,219

 
2
%
During the three months ended December 31, 2019, SG&A expenses increased primarily due to a $40 million charge in connection with the Recalls as described further in the Significant Developments in Fiscal 2020 and Trends section in this MD&A, higher costs to support sales growth and fluctuations in deferred compensation liabilities, partially offset by the beneficial impact of enterprise-wide cost saving measures. During the three months ended December 31, 2018, SG&A expenses benefited from the reversal of the $34 million that we accrued in the first quarter of fiscal 2019 for the New York Opioid Stewardship Act assessment for opioids sold or distributed in New York state when the New York Opioid Stewardship Act was ruled unconstitutional.
During the six months ended December 31, 2019, SG&A expenses increased slightly due to the higher costs to support the sales growth, the $40 million charge in connection with the Recalls, as described further in the Significant Developments in Fiscal 2020 and Trends section in this MD&A, and fluctuations in deferred compensation liabilities, mostly offset by the beneficial impact of enterprise-wide cost saving measures.




 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
8


MD&A
Results of Operations
 

Segment Profit
 
We evaluate segment performance based on segment profit, among other measures. See Note 13 of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.
chart-f9153a6cb9dd593fb2b.jpgchart-f06b5fff8fb8555489d.jpg
 
Three Months Ended December 31,
 
Six Months Ended December 31,
(in millions)
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Pharmaceutical
$
462

 
$
443

 
4
 %
 
$
860

 
$
851

 
1
%
Medical
195

 
188

 
4
 %
 
365

 
323

 
13
%
Total segment profit
657

 
631

 
4
 %
 
1,225

 
1,174

 
4
%
Corporate
(323
)
 
(127
)
 
154
 %
 
(6,155
)
 
146

 
N.M

Total consolidated operating earnings/(loss)
$
334

 
$
504

 
(34
)%
 
$
(4,930
)
 
$
1,320

 
N.M

Pharmaceutical Segment Profit
Pharmaceutical segment profit during the three months ended December 31, 2019 increased due to the performance of our generics program and growth from specialty solutions, partially offset by the adverse impact of customer contract renewals.
Pharmaceutical segment profit during the six months ended December 31, 2019 increased slightly due to the beneficial impact of cost-savings measures, growth from specialty solutions and the performance of our generics program, mostly offset by the adverse impact of customer contract renewals.
Medical Segment Profit
Medical segment profit during the three months ended December 31, 2019 increased primarily due to the beneficial impact of cost-savings measures, partially offset by the performance of products and distribution.
Medical segment profit during the six months ended December 31, 2019 increased primarily due to beneficial impact of cost-savings measures.
Medical segment financial results do not include the $96 million charge incurred during the three and six months ended December 31, 2019 in connection with the Recalls, as described further in the Significant Developments in Fiscal 2020 and Trends section in this MD&A.
Corporate
The changes in Corporate during the three and six months ended December 31, 2019 were due to the factors discussed in the Other Components of Consolidated Operating Earnings/(Loss) section that follows. Corporate was also adversely impacted by the $96 million charge incurred during the three and six months ended December 31, 2019 in connection with the Recalls, as described further within the Significant Developments in Fiscal 2020 and Trends section in this MD&A. The Recalls charge is included within Corporate to allow investors to better understand the underlying operating results of the Medical segment and to facilitate comparison of Medical segment current financial results to historical financial results and the results of peers.


 
 
 
 9
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


MD&A
Results of Operations
 

Other Components of Consolidated Operating Earnings/(Loss)
 
In addition to revenue, gross margin and SG&A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:
 
Three Months Ended December 31,
 
Six Months Ended December 31,
(in millions)
2019
 
2018
 
2019
 
2018
Restructuring and employee severance
$
56

 
$
12

 
$
86

 
$
44

Amortization and other acquisition-related costs
133

 
157

 
265

 
314

Impairments and (gain)/loss on disposal of assets, net
7

 
8

 
8

 
(503
)
Litigation (recoveries)/charges, net
21

 
(15
)
 
5,694

 
3

Restructuring and Employee Severance
We incurred $42 million and $8 million during the three months ended December 31, 2019 and 2018, respectively, and $62 million and $34 million, during the six months ended December 31, 2019 and 2018, respectively, of expenses in connection with our implementation of certain enterprise-wide cost-saving measures.
Amortization and Other Acquisition-Related Costs
Amortization of acquisition-related intangible assets was $127 million and $133 million for the three months ended December 31, 2019 and 2018, respectively, and $256 million and $266 million for the six months ended December 31, 2019 and 2018, respectively.
Transaction and integration costs associated with the acquisition of the Patient Recovery Business were $3 million and $22 million for the three months ended December 31, 2019 and 2018, respectively, and $4 million and $44 million for the six months ended December 31, 2019 and 2018, respectively.
Impairments and (Gain)/Loss on Disposal of Assets, Net
During the six months ended December 31, 2018, we recognized a pre-tax gain of $508 million related to the divestiture of our naviHealth business.
Litigation (Recoveries)/Charges, Net
During the six months ended December 31, 2019, we recognized a pre-tax charge of $5.63 billion ($5.14 billion after tax) associated with the opioid litigation. See Significant Developments in Fiscal 2020 and Trends section in this MD&A for additional information.
The costs we recognized in connection with the IVC filter product liability claims during the three months ended December 31, 2019 and 2018 were $17 million and $32 million, respectively, and $62 million and $45 million during the six months ended December 31, 2019 and 2018, respectively.
Recoveries in class action antitrust lawsuits recognized were $14 million and $47 million for the three months ended December 31, 2019 and 2018, respectively, and $16 million and $47 million for the six months ended December 31, 2019 and 2018, respectively.
Earnings/(Loss) Before Income Taxes

In addition to the items discussed above, earnings/(loss) before income taxes were impacted by the following:
 
Three Months Ended December 31,
 
Six Months Ended December 31,
(in millions)
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Other (income)/expense, net
$
(12
)
 
$
21

 
 
 
$
2

 
$
25

 
 
Interest expense, net
63

 
76

 
(17
)%
 
129

 
152

 
(15
)%
Loss on extinguishment of debt
4

 
—

 
N.M

 
4

 
—

 
N.M

Other (Income)/Expense, Net
During the three and six months ended December 31, 2019, other (income)/expense, net was favorable compared to the respective prior-year periods primarily due to increased returns from investments, which are used to offset fluctuations in deferred compensation liabilities as discussed further in Note 9.
Interest Expense, Net
The decrease in interest expense during the three and six months ended December 31, 2019 was primarily due to less debt outstanding.



 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
10


MD&A
Results of Operations
 

Provision for/(Benefit from) Income Taxes
 
During the three months ended December 31, 2019 and 2018, the effective tax rate was 21.0 percent and 31.0 percent, respectively. The change in the effective tax rate for the three months ended December 31, 2019 compared to the prior period was primarily due to the favorable impact from changes in jurisdictional mix and discrete items recognized in the second quarter of fiscal 2020, largely driven by changes as a result of tax reform.
During the six months ended December 31, 2019 and 2018, the effective tax rate was 7.2 percent and 23.5 percent, respectively. The change in the effective tax rate for the six months ended December 31, 2019 compared to the prior period was primarily due to the net tax benefit of $487 million related to the opioid litigation pre-tax charge of $5.63 billion, as described further in the Significant Developments in Fiscal 2020 and Trends section in this MD&A.


 
 
 
 11
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


MD&A
Liquidity and Capital Resources
 

Liquidity and Capital Resources
We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations; tax payments; and current and projected debt service requirements, early extinguishment of debt, dividends and share repurchases as well as potential opioid litigation settlement payments associated with the Settlement Framework. If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.
Cash and Equivalents
 
Our cash and equivalents balance was $1.7 billion at December 31, 2019 compared to $2.5 billion at June 30, 2019. At December 31, 2019, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.
During the six months ended December 31, 2019, net cash provided by operating activities was $44 million and we deployed $793 million for long-term debt repayments, $350 million for share repurchases, and $287 million for cash dividends.
Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer
 
payments, inventory purchases and payments to vendors in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.
The cash and equivalents balance at December 31, 2019 includes $788 million of cash held by subsidiaries outside of the United States.



Other Financing Arrangements and Financial Instruments
 
Credit Facilities and Commercial Paper
In addition to cash and equivalents and operating cash flow, other sources of liquidity at December 31, 2019 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At December 31, 2019, we had $458 million outstanding under our commercial paper program and $225 million outstanding under committed receivables sales facility. During the six months ended December 31, 2019, we had maximum amounts outstanding under our commercial paper program and our committed receivables program of $960 million and $700 million, respectively. The maximum combined total daily amounts outstanding was $1.2 billion and the average daily amount outstanding was $88 million.
 
In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. Our revolving credit and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021 and as of the end of every quarter thereafter. As of December 31, 2019, we were in compliance with this financial covenant.
Long-Term Debt and Other Short-Term Borrowings
At December 31, 2019, we had total long-term obligations, including the current portion and other short-term borrowings, of $7.9 billion. In November 2019, we repaid the full principal of the 2.4% Notes due 2019 at maturity for $450 million. During the six months ended December 31, 2019, we early repurchased $207 million of the 2.616% Notes due 2022, $10 million of the 3.2% Notes due 2022, $14 million of the Floating Rate Notes due 2022, $81 million of the 3.41% Notes due 2027, $6 million of the 4.6% Notes due 2043, $2 million of the 4.9% Notes due 2045, and $21 million of the 4.368% Notes due 2047. The repurchases were paid for with available cash and other short-term borrowings. In connection with the early debt repurchases, we recorded a $4 million loss on extinguishment of debt.


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
12


MD&A
Liquidity and Capital Resources
 

Capital Deployment
 
Opioid Settlement Framework
In October 2019, we agreed in principle to a Settlement Framework which includes a cash component, pursuant to which we would pay up to $5.56 billion over eighteen years. We currently expect payment amounts under the Settlement Framework to be spread through the 18-year period subject to participation by states and political subdivisions. See Significant Developments in Fiscal 2020 and Trends section in this MD&A for additional information.
Capital Expenditures
Capital expenditures during the six months ended December 31, 2019 and 2018 were $149 million and $116 million, respectively.
Dividends
On each of May 8, 2019, August 7, 2019 and November 6, 2019, our Board of Directors approved a quarterly dividend of $0.4811 per share, or $1.92 per share on an annualized basis, which were paid on July 15, 2019, October 15, 2019 and January 15, 2020, respectively.

 
Share Repurchases
During the six months ended December 31, 2019, we repurchased $350 million of our common shares under an accelerated share repurchase ("ASR") program. We funded the ASR program with available cash and short-term borrowings. See Note 11 of the "Notes to Condensed Consolidated Financial Statements" for additional information. At December 31, 2019, we had $943 million authorized for share repurchases.


 
 
 
 13
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


MD&A
Other Items
 


Other Items
The MD&A in our 2019 Form 10-K addresses our contractual obligations and off-balance sheet arrangements, as of and for the fiscal year ended June 30, 2019. There have been no subsequent material changes outside of the ordinary course of business to those items except for the agreement in principle on a global settlement framework designed to resolve all pending and future opioid lawsuits and claims brought by states and political subdivisions described in the Significant Developments in Fiscal 2020 and Trends section in this MD&A and Note 7 of the "Notes to Condensed Consolidated Financial Statements."




 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
14


MD&A
Critical Accounting Policies and Sensitive Accounting Estimates
 

Critical Accounting Policies and Sensitive Accounting Estimates
The discussion and analysis presented below is a supplemental disclosure to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at June 30, 2019. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2019 Form 10-K and our From 10-Q for the quarter ended September 30, 2019.
Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management’s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ.
Goodwill
 
Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. There is an option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the quantitative goodwill impairment test. We elected to bypass the qualitative assessment for our annual impairment test in fiscal 2019. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).
Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.
 
Medical Unit Goodwill
For our annual impairment test in fiscal 2019, the fair value of our Medical Unit exceeded its carrying value of $10.8 billion by approximately 4 percent. Although we believe the assumptions used to arrive at the estimate of fair value during the fourth quarter of fiscal 2019 continue to be reasonable and appropriate, changes in key assumptions during fiscal 2020, including a failure to meet expected earnings or other financial plans, or other unanticipated events and circumstances, such as an increase in interest rates or a significant change in industry or economic trends, may affect future estimates.
As noted within the Significant Developments in Fiscal 2020 and Trends section in this MD&A and Note 7 of the "Notes to Condensed Consolidated Financial Statements", we recorded a charge of $96 million within Corporate during the three and six months ended December 31, 2019 in connection with the Recalls that would be allocated to the Medical Unit for purposes of goodwill impairment testing. The Recalls could result in loss of customers and sales. However, at this time, we do not expect these impacts to be meaningfully sustained such that they would indicate the fair value of the Medical Unit is less than its carrying amount.
Adverse changes in key assumptions, including related to our current assumptions about the impact of the Recalls, may result in a decline in fair value below the carrying value in the future resulting in an impairment in our Medical Unit in future periods, which could adversely affect our results of operations.
Loss Contingencies
 
In connection with the opioid litigation as described further in the Significant Developments in Fiscal 2020 and Trends section in this MD&A, we recorded a pre-tax charge of $5.63 billion ($5.14 billion after tax) during the six months ended December 31, 2019. We accrue for contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. Final terms of a settlement under the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the
 
contingencies to any agreement will be satisfied. We will regularly review opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual.
    


 
 
 
 15
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


MD&A
Critical Accounting Policies and Sensitive Accounting Estimates
 

Provision for Income Taxes
 
Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.
In connection with the $5.63 billion pre-tax charge for the opioid litigation, during the six months ended December 31, 2019 we recorded a tax benefit of $487 million, which is net of unrecognized tax benefits of $468 million, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was
 
changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 8 of the Notes to the "Condensed Consolidated Financial Statements" for more information regarding these matters.
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.

Explanation and Reconciliation of Non-GAAP Financial Measures
The "Overview of Consolidated Results" section within MD&A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.
In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and, in most cases, determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.
Exclusions from Non-GAAP Financial Measures
Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:
•
LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results.
•
Surgical gown recall costs includes inventory write-offs and certain remediation and supply disruption costs arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation (AAMI) Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies’ financial results.


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
16


Explanation and Reconciliation of Non-GAAP Financial Measures
 
 

•
State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the fiscal year of the initial assessment. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Reversals of these accruals have occurred when certain assessments were declared unconstitutional.
•
Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.
•
Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions.
•
Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.
•
Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.
•
Loss on extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions.
•
Transitional tax benefit, net related to the Tax Cuts and Jobs Act is excluded because it results from the one-time impact of a very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial performance. The transitional tax benefit includes the initial estimate and subsequent adjustments for the re-measurement of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.
The tax effect for each of the items listed above, other than the transitional tax benefit item, is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.
Definitions
Growth rate calculation: growth rates in this Form 10-Q are determined by dividing the difference between current-period results and prior-period results by prior-period results.
Non-GAAP operating earnings: operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, and (7) litigation (recoveries)/charges, net.
Non-GAAP earnings before income taxes: earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, and (8) loss on extinguishment of debt.
Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings/(loss) attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on extinguishment of debt, each net of tax, and (9) transitional tax benefit, net.
Non-GAAP effective tax rate: provision for/(benefit from) income taxes adjusted for (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-


 
 
 
 17
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Explanation and Reconciliation of Non-GAAP Financial Measures
 
 

related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on extinguishment of debt, and (9) transitional tax benefit, (net) divided by (earnings/(loss) before income taxes adjusted for the first eight items).
Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
18


Explanation and Reconciliation of Non-GAAP Financial Measures
 
 

GAAP to Non-GAAP Reconciliation
(in millions, except per common share amounts)
Operating Earnings/(Loss)
Operating Earnings Growth Rate
Earnings/(Loss) Before Income Taxes
Provision for/(Benefit from) Income Taxes
Net Earnings/(Loss)1
Net Earnings/(Loss)1 Growth Rate
Diluted EPS1,2
Diluted EPS1 Growth Rate
 
Three Months Ended December 31, 2019
GAAP
$
334

(34
)%
$
279

$
59

$
220

(21
)%
$
0.75

(19
)%
Surgical gown recall costs
96

 
96

25

71


0.24


State opioid assessment related to prior fiscal years
(1
)

(1
)
—

(1
)

—


Restructuring and employee severance
56


56

14

42


0.14


Amortization and other acquisition-related costs
133


133

33

100


0.34


Impairments and (gain)/loss on disposal of assets, net
7


7

2

5


0.02


Litigation (recoveries)/charges, net
21


21

3

18


0.06


Loss on extinguishment of debt
—


4

1

3


0.01


Transitional tax benefit, net
—


—

11

(11
)

(0.04
)

Non-GAAP
$
646

1
 %
$
596

$
148

$
448

16
 %
$
1.52

18
 %
 
Three Months Ended December 31, 2018
GAAP
$
504

26
 %
$
407

$
126

$
280

(73
)%
$
0.93

(72
)%
State opioid assessment related to prior fiscal years
(29
)
 
(29
)
(8
)
(21
)
 
(0.07
)
 
Restructuring and employee severance
12


12

3

9


0.03


Amortization and other acquisition-related costs
157


157

39

119


0.40


Impairments and (gain)/loss on disposal of assets, net
8


8

1

7


0.02


Litigation (recoveries)/charges, net
(15
)

(15
)
(4
)
(11
)

(0.04
)

Transitional tax benefit, net
—


—

(3
)
3


0.01


Non-GAAP
$
637

(13
)%
$
540

$
154

$
385

(19
)%
$
1.29

(15
)%
 
Six Months Ended December 31, 2019
GAAP 
$
(4,930
)
N.M

$
(5,065
)
$
(364
)
$
(4,702
)
N.M

$
(15.99
)
N.M

Surgical gown recall costs
96

 
96

25

71

 
0.24

 
State opioid assessment related to prior fiscal years
4


4

1

3


0.01


Restructuring and employee severance
86


86

21

65


0.22


Amortization and other acquisition-related costs
265


265

67

198


0.67


Impairments and (gain)/loss on disposal of assets, net
8


8

2

6


0.02


Litigation (recoveries)/charges, net3
5,694


5,694

501

5,193


17.66


Loss on extinguishment of debt
—


4

1

3


0.01


Transitional tax benefit, net
—


—

11

(11
)

(0.04
)

Non-GAAP 
$
1,223

4
 %
$
1,092

$
265

$
826

6
 %
$
2.80

9
 %
 
Six Months Ended December 31, 2018
GAAP
$
1,320

100
 %
$
1,143

$
269

$
873

(25
)%
$
2.88

(22
)%
Restructuring and employee severance
44


44

11

33


0.11


Amortization and other acquisition-related costs
314


314

74

240


0.79


Impairments and (gain)/loss on disposal of assets, net
(503
)

(503
)
(133
)
(370
)

(1.22
)

Litigation (recoveries)/charges, net
3


3

—

3


0.01


Transitional tax benefit, net
—


—

(3
)
3


0.01


Non-GAAP
$
1,178

(12
)%
$
1,001

$
218

$
782

(5
)%
$
2.58

(1
)%


 
 
 
 19
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Explanation and Reconciliation of Non-GAAP Financial Measures
 
 


1 
Attributable to Cardinal Health, Inc.
2 
For the six months ended December 31, 2019, GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 294 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period. Year-to-date fiscal 2020 non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares, which includes potentially dilutive shares.
3 
Litigation (recoveries)/charges, net includes a pre-tax charge of $5.63 billion ($5.14 billion after tax) recorded in the first quarter of fiscal 2020 related to the opioid litigation.

The sum of the components may not equal the total due to rounding.
We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.



 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
20


Other
 


Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the quantitative and qualitative market risk disclosures included in our 2019 Form 10-K since the end of fiscal 2019 through December 31, 2019.
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of December 31, 2019. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of December 31, 2019, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Legal Proceedings
In addition to the proceeding described below, the legal proceedings described in Note 7 of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.
In June 2019, Melissa Cohen, a purported shareholder, filed an action on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances. The derivative complaint seeks, among other things, unspecified money damages against the defendants and an award of attorneys' fees. In December 2019 and January 2020, similar complaints were filed in the U.S. District Court for the Southern District of Ohio by purported shareholders, Stanley M. Malone and Michael Splaine, respectively. In January, 2020, the court granted the plaintiffs' unopposed motion to consolidate the derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation.
Risk Factors
You should carefully consider the information in this Form 10-Q, including the risk factors below, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2019 Form 10-K, our Form 10-Q for the quarter ended September 30, 2019, and other filings with the SEC since June 30, 2019. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.

The recalls of certain surgical gowns and related Presource Procedure Packs had a negative impact on our financial results in the three months ended December 31, 2019, and are expected to have additional negative financial and operational impacts.
In January, 2020, we issued a voluntary recall for 9.1 million AAMI Level 3 surgical gowns and two voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for 2.9 million Presource Procedure Packs containing affected gowns (together, the "Recalls"). The Recalls were necessary because we discovered in December 2019 that one of our FDA-registered suppliers in China had shifted production of some gowns to unapproved sites with uncontrolled environments. Because of this, we could not assure sterility of the gowns.
In connection with the Recalls, in the three months ended December 31, 2019, we recorded a total charge of $96 million, of which $56
 
million is within cost of products sold and $40 million is within SG&A in the condensed consolidated statements of earnings. This charge represents our best estimate of costs for the Recalls and includes inventory write-off costs and certain remediation and supply disruption costs, such as costs to replace recalled products. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. The amount of ultimate loss may differ materially from this accrual.
In addition to the charge for the three months ended December 31, 2019, we expect that the Recalls will have other negative impacts, which could include: government investigations and enforcement actions by the U.S. Food and Drug Administration or other regulators or U.S. or international governmental bodies (possibly resulting in product seizures, additional recalls, the issuance of safety alerts, the


 
 
 
 21
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Other
 

suspension or revocation of the authority to produce, distribute and sell products and other civil or criminal sanctions); losses due to patient claims, including product liability claims and lawsuits; and customer claims unrelated to their direct costs from the supply disruption.
Additionally, these surgical gowns and procedure packs are used in surgeries throughout the United States and internationally. Due to quality standards, it is challenging to quickly establish additional or replacement suppliers. These Recalls are expected to result in sustained supply reductions and market shortages. We understand that, due to these supply shortages, surgeries have been delayed or canceled, and we expect that additional surgeries will be delayed or canceled over a period of several weeks or months. This and other aspects of the Recalls could result in reputational harm and loss of customers and sales.
The public health crisis involving the abuse of prescription opioid pain medication and our efforts to resolve related claims could have additional or unexpected material negative effects on our business.
Our Pharmaceutical segment distributes prescription opioid pain medications. In recent years, the abuse of prescription opioid pain medication has become a public health crisis.
A significant number of counties, municipalities and other plaintiffs, including a number of state attorneys general, have filed lawsuits against pharmaceutical manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others relating to the manufacturing, marketing or distribution of prescription opioid pain medications. In addition, we are currently being investigated or sued by other states for the same activities and could be named as a defendant in additional lawsuits. The defense and resolution of current and future lawsuits and events relating to these lawsuits are subject to uncertainty and could have a material adverse effect on our results of operations, financial condition, cash flows, liquidity, our ability to pay dividends or repurchase our shares, or have adverse reputational or operational effects on our business.
In October 2019, we agreed in principle to a Settlement Framework and in connection with this development we recorded a pre-tax accrual of $5.56 billion in the six months ended December 31, 2019. This Settlement Framework is subject to contingencies but is the basis for our negotiation of definitive terms and documentation. Final terms of a settlement under the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We will regularly review opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. See Note 7 of the "Notes to Condensed Consolidated Financial Statements" for more information regarding these matters.
Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict. For example,
 
several states have now adopted taxes or other fees on the sale of opioids, and several other states have proposed similar legislative initiatives. These laws and proposals vary in the tax amounts imposed and the means of calculation. Liabilities for taxes or assessments under any such laws could have an adverse impact on our results of operations unless we are able to mitigate them through operational changes or commercial arrangements where permitted.
Ongoing unfavorable publicity regarding the abuse or misuse of prescription opioid pain medications and the role of wholesale distributors in the supply chain of such prescription medications, as well as the continued proliferation of the opioid lawsuits, investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.
We could be subject to adverse changes in the tax laws or challenges to our tax positions.
We are a large multinational corporation with operations in the United States and many foreign countries. As a result, we are subject to the tax laws of many jurisdictions.
From time to time, initiatives are proposed in the United States and other jurisdictions in which we operate that could adversely affect our tax positions, effective tax rate or tax payments. Specific initiatives that may impact us include the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation at the U.S. state level on the basis of gross revenues, recommendations of the recently completed base erosion and profit shifting project undertaken by the Organization for Economic Cooperation and Development and the European Commission’s investigation into illegal state aid.
Additionally, in connection with the $5.63 billion pre-tax charge for the opioid litigation, in the six months ended December 31, 2019, we recorded a tax benefit of $487 million, which is net of unrecognized tax benefits of $468 million, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 8 of the "Notes to Condensed Consolidated Financial Statements" for more information regarding these matters.
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
22


Other
 

some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.
Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
Period
Total Number
of Shares
Purchased (1)
 
Average Price Paid per Share (2)
 
Total Number of Shares
Purchased
as Part of Publicly Announced Programs (2,3)
 
Approximate
Dollar Value of
Shares That May
Yet be Purchased
Under the Program (3)
(in millions)
October 2019
1,214

 
$
48.05

 
—

 
$
1,013

November 2019
255

 
52.92

 
—

 
1,013

December 2019
894,064

 
48.00

 
893,696

 
943

Total
895,533

 
$
48.00

 
893,696

 
$
943

(1)
Reflects 1,214, 255 and 368 common shares purchased in October, November and December 2019, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.
(2)
On August 20, 2019, we entered into an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $350 million, which was completed on December 4, 2019. During the six months ended December 31, 2019, we repurchased 7.3 million common shares at a weighted average price of $48.00 under this program. During December 2019, the ASR program closed and upon settlement, we received 893,696 remaining common shares. Upon closing of the ASR program we have $943 million remaining under our program. See Note 11 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
(3)
On February 7, 2018, our Board of Directors approved a $1.0 billion share repurchase program that expires on December 31, 2020. On November 7, 2018, our Board of Directors approved a $1.0 billion share repurchase program that expires on December 31, 2021 and as of December 31, 2019, we have $943 million authorized for share repurchases remaining under this program.



 
 
 
 23
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Financial Statements
 
 


Condensed Consolidated Statements of Earnings/(Loss)
(Unaudited)
 
Three Months Ended December 31,
 
Six Months Ended December 31,
(in millions, except per common share amounts)
2019
 
2018
 
2019
 
2018
Revenue
$
39,735

 
$
37,740

 
$
77,076

 
$
72,953

Cost of products sold
38,021

 
36,010

 
73,683

 
69,556

Gross margin
1,714

 
1,730

 
3,393

 
3,397

 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
Distribution, selling, general and administrative expenses
1,163

 
1,064

 
2,270

 
2,219

Restructuring and employee severance
56

 
12

 
86

 
44

Amortization and other acquisition-related costs
133

 
157

 
265

 
314

Impairments and (gain)/loss on disposal of assets, net
7

 
8

 
8

 
(503
)
Litigation (recoveries)/charges, net
21

 
(15
)
 
5,694

 
3

Operating earnings/(loss)
334

 
504

 
(4,930
)
 
1,320

 
 
 
 
 
 
 
 
Other (income)/expense, net
(12
)
 
21

 
2

 
25

Interest expense, net
63

 
76

 
129

 
152

Loss on extinguishment of debt
4

 
—

 
4

 
—

Earnings/(loss) before income taxes
279

 
407

 
(5,065
)
 
1,143

 
 
 
 
 
 
 
 
Provision for/(benefit from) income taxes
59

 
126

 
(364
)
 
269

Net earnings/(loss)
220

 
281

 
(4,701
)
 
874

 
 
 
 
 
 
 
 
Less: Net earnings attributable to noncontrolling interests
—

 
(1
)
 
(1
)
 
(1
)
Net earnings/(loss) attributable to Cardinal Health, Inc.
$
220

 
$
280

 
$
(4,702
)
 
$
873

 
 
 
 
 
 
 
 
Earnings/(loss) per common share attributable to Cardinal Health, Inc.:
 
 
 
 
 
 
 
Basic
$
0.75

 
$
0.94

 
$
(15.99
)
 
$
2.90

Diluted
0.75

 
0.93

 
(15.99
)
 
2.88

 
 
 
 
 
 
 
 
Weighted-average number of common shares outstanding:
 
 
 
 
 
 
 
Basic
292

 
299

 
294

 
302

Diluted
294

 
300

 
294

 
303

 
 
 
 
 
 
 
 
Cash dividends declared per common share
$
0.4811

 
$
0.4763

 
$
0.9622

 
$
0.9526

See notes to condensed consolidated financial statements.


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
24


Financial Statements
 
 

Condensed Consolidated Statements of Comprehensive Income/(Loss)
(Unaudited)
 
Three Months Ended December 31,
 
Six Months Ended December 31,
(in millions)
2019
 
2018
 
2019
 
2018
Net earnings/(loss)
$
220

 
$
281

 
$
(4,701
)
 
$
874

 
 
 
 
 
 
 
 
Other comprehensive loss:
 
 
 
 
 
 
 
Foreign currency translation adjustments and other
(1
)
 
(26
)
 
(18
)
 
(29
)
Net unrealized loss on derivative instruments, net of tax
(1
)
 
(1
)
 
(6
)
 
(2
)
Total other comprehensive loss, net of tax
(2
)
 
(27
)
 
(24
)
 
(31
)
 
 
 
 
 
 
 
 
Total comprehensive income/(loss)
218

 
254

 
(4,725
)
 
843

 
 
 
 
 
 
 
 
Less: comprehensive income attributable to noncontrolling interests
—

 
(1
)
 
(1
)
 
(1
)
Total comprehensive income/(loss) attributable to Cardinal Health, Inc.
$
218

 
$
253

 
$
(4,726
)
 
$
842

See notes to condensed consolidated financial statements.



 
 
 
 25
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Financial Statements
 
 

Condensed Consolidated Balance Sheets
(Unaudited)
(in millions)
December 31, 2019
 
June 30, 2019
Assets
 
 
 
Current assets:
 
 
 
Cash and equivalents
$
1,659

 
$
2,531

Trade receivables, net
8,280

 
8,448

Inventories, net
13,799

 
12,822

Prepaid expenses and other
1,998

 
1,946

Total current assets
25,736

 
25,747

 
 
 
 
Property and equipment, net
2,301

 
2,356

Goodwill and other intangibles, net
11,523

 
11,808

Other assets
1,482

 
1,052

Total assets
$
41,042

 
$
40,963

 
 
 
 
Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
21,459

 
$
21,535

Current portion of long-term obligations and other short-term borrowings
1,192

 
452

Other accrued liabilities
2,239

 
2,122

Total current liabilities
24,890

 
24,109

 
 
 
 
Long-term obligations, less current portion
6,742

 
7,579

Deferred income taxes and other liabilities
8,408

 
2,945

 
 
 
 
Shareholders’ equity:
 
 
 
Preferred shares, without par value:
 
 
 
Authorized—500 thousand shares, Issued—none
—

 
—

Common shares, without par value:
 
 
 
Authorized—755 million shares, Issued—327 million shares at December 31, 2019 and June 30, 2019, respectively
2,752

 
2,763

Retained earnings
449

 
5,434

Common shares in treasury, at cost: 35 million shares and 28 million shares at December 31, 2019 and June 30, 2019, respectively
(2,099
)
 
(1,790
)
Accumulated other comprehensive loss
(103
)
 
(79
)
Total Cardinal Health, Inc. shareholders' equity
999

 
6,328

Noncontrolling interests
3

 
2

Total shareholders’ equity
1,002

 
6,330

Total liabilities and shareholders’ equity
$
41,042

 
$
40,963

See notes to condensed consolidated financial statements.



 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
26


Financial Statements
 
 

Condensed Consolidated Statements of Shareholders' Equity
(Unaudited)
 
Common Shares
 
 
 
Treasury Shares
 
Accumulated Other
Comprehensive
Loss
 
Noncontrolling Interests
 
Total
Shareholders’
Equity
(in millions)
Shares Issued
 
Amount
 
Retained
Earnings
 
Shares
 
Amount
 
 
 
 
Three Months Ended December 31, 2019
Balance at September 30, 2019
327

 
$
2,669

 
$
371

 
(34
)
 
$
(2,039
)
 
$
(101
)
 
$
3

 
$
903

Net earnings
 
 
 
 
220

 
 
 
 
 
 
 
—

 
220

Other comprehensive loss, net of tax
 
 
 
 
 
 
 
 
 
 
(2
)
 
 
 
(2
)
Employee stock plans activity, net of shares withheld for employee taxes
—

 
13

 
 
 


 
10

 
 
 
 
 
23

Share repurchase program activity
 
 
70

 


 
(1
)
 
(70
)
 
 
 
 
 
—

Dividends declared
 
 
 
 
(143
)
 
 
 
 
 
 
 
 
 
(143
)
Other
 
 
 
 
1

 
 
 
 
 
 
 
—

 
1

Balance at December 31, 2019
327

 
$
2,752

 
$
449

 
(35
)
 
$
(2,099
)
 
$
(103
)
 
$
3

 
$
1,002

 
Three Months Ended December 31, 2018
Balance at September 30, 2018
327

 
$
2,590

 
$
5,097

 
(27
)
 
$
(1,678
)
 
$
(96
)
 
$
—

 
$
5,913

Net earnings
 
 
 
 
280

 
 
 
 
 
 
 
1

 
281

Other comprehensive loss, net of tax
 
 
 
 
 
 
 
 
 
 
(27
)
 
 
 
(27
)
Employee stock plans activity, net of shares withheld for employee taxes
—

 
18

 
 
 


 
3

 
 
 
 
 
21

Share repurchase program activity
 
 
120

 


 
(2
)
 
(120
)
 
 
 
 
 
—

Dividends declared
 
 
 
 
(143
)
 
 
 
 
 
 
 
 
 
(143
)
Other
 
 
 
 
(1
)
 
 
 
 
 
 
 
(1
)
 
(2
)
Balance at December 31, 2018
327

 
$
2,728

 
$
5,233

 
(29
)
 
$
(1,795
)
 
$
(123
)
 
$
—

 
$
6,043

 
Six Months Ended December 31, 2019
Balance at June 30, 2019
327

 
$
2,763

 
$
5,434

 
(28
)
 
$
(1,790
)
 
$
(79
)
 
$
2

 
$
6,330

Net earnings/(loss)
 
 
 
 
(4,702
)
 
 
 
 
 
 
 
1

 
(4,701
)
Other comprehensive loss, net of tax
 
 
 
 
 
 
 
 
 
 
(24
)
 
 
 
(24
)
Employee stock plans activity, net of shares withheld for employee taxes
—

 
(11
)
 
 
 


 
41

 
 
 
 
 
30

Share repurchase program activity
 
 
—

 


 
(7
)
 
(350
)
 
 
 
 
 
(350
)
Dividends declared
 
 
 
 
(284
)
 
 
 
 
 
 
 
 
 
(284
)
Other
 
 
 
 
1

 
 
 
 
 
 
 
—

 
1

Balance at December 31, 2019
327

 
$
2,752

 
$
449

 
(35
)
 
$
(2,099
)
 
$
(103
)
 
$
3

 
$
1,002

 
Six Months Ended December 31, 2018
Balance at June 30, 2018
327

 
$
2,730

 
$
4,645

 
(18
)
 
$
(1,224
)
 
$
(92
)
 
$
—

 
$
6,059

Net earnings
 
 
 
 
873

 
 
 
 
 
 
 
1

 
874

Other comprehensive loss, net of tax
 
 
 
 
 
 
 
 
 
 
(31
)
 
 
 
(31
)
Employee stock plans activity, net of shares withheld for employee taxes
—

 
(2
)
 
 
 


 
29

 
 
 
 
 
27

Share repurchase program activity
 
 
—

 
 
 
(11
)
 
(600
)
 
 
 
 
 
(600
)
Dividends declared
 
 
 
 
(286
)
 
 
 
 
 
 
 
 
 
(286
)
Other
 
 
 
 
1

 
 
 
 
 
 
 
(1
)
 
—

Balance at December 31, 2018
327

 
$
2,728

 
$
5,233

 
(29
)
 
$
(1,795
)
 
$
(123
)
 
$
—

 
$
6,043

See notes to condensed consolidated financial statements.


 
 
 
 27
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Financial Statements
 
 

Condensed Consolidated Statements of Cash Flows
(Unaudited)
 
Six Months Ended December 31,
(in millions)
2019
 
2018
Cash flows from operating activities:
 
 
 
Net earnings/(loss)
$
(4,701
)
 
$
874

 
 
 
 
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:
 
 
 
Depreciation and amortization
464

 
498

Impairments and loss on sale of other investments
—

 
2

Impairments and (gain)/loss on disposal of assets, net
8

 
(503
)
Loss on extinguishment of debt
4

 
—

Share-based compensation
41

 
41

Provision for bad debts
47

 
40

Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
 
 
 
(Increase)/decrease in trade receivables
121

 
(191
)
Increase in inventories
(991
)
 
(753
)
Increase/(decrease) in accounts payable
(77
)
 
941

Other accrued liabilities and operating items, net
5,128

 
(213
)
Net cash provided by operating activities
44

 
736

 
 
 
 
Cash flows from investing activities:
 
 
 
Acquisition of subsidiaries, net of cash acquired
—

 
(21
)
Additions to property and equipment
(149
)
 
(116
)
Purchase of investments
(6
)
 
(10
)
Proceeds from sale of investments
2

 
2

Proceeds from divestitures, net of cash sold, and disposal of property and equipment
2

 
740

Net cash provided by/(used in) investing activities
(151
)
 
595

 
 
 
 
Cash flows from financing activities:
 
 
 
Net change in short-term borrowings
681

 
—

Reduction of long-term obligations
(793
)
 
(2
)
Net tax withholdings from share-based compensation
(11
)
 
(13
)
Dividends on common shares
(287
)
 
(293
)
Purchase of treasury shares
(350
)
 
(600
)
Net cash used in financing activities
(760
)
 
(908
)
 
 
 
 
Effect of exchange rates changes on cash and equivalents
(5
)
 
(4
)
 
 
 
 
Net increase/(decrease) in cash and equivalents
(872
)
 
419

Cash and equivalents at beginning of period
2,531

 
1,763

Cash and equivalents at end of period
$
1,659

 
$
2,182

See notes to condensed consolidated financial statements.


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
28


Notes to Financial Statements
 
 

Notes to Condensed Consolidated Financial Statements
1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to Note 4 for further information on our equity method investments.
References to "we," "our," and similar pronouns in in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2019 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2020 and 2019 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2020 and June 30, 2019, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the United States Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. To conform to the current year presentation, certain prior year amounts have been reclassified. In addition, financial results presented for this fiscal 2020 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2020. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (the "2019 Form 10-K").
Recently Adopted Financial Accounting Standards
Derivatives and Hedging
In October 2018, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to derivatives and hedging which permits the use of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") as a benchmark interest rate for hedge accounting purposes. This guidance is
 
effective beginning the first quarter of fiscal 2020 and must be applied on a prospective basis. The adoption did not have a material impact on our consolidated financial statements.
Leases
In February 2016, the FASB issued amended accounting guidance that requires lessees to recognize most leases on the balance sheet as a lease liability and corresponding right-of-use asset. The guidance also requires disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted this guidance during the first quarter of fiscal 2020 and elected the transition option which allows us to apply the guidance prospectively. The adoption resulted in the recognition of lease liabilities in the amount of $422 million and did not have a material impact on our results of operations, liquidity or debt covenant compliance under our current debt agreements. The majority of our lease spend relates to certain real estate with the remaining lease spend primarily related to vehicles and equipment. The adoption required certain changes to our systems and processes. See Note 5 for additional information regarding leases.
Recently Issued Financial Accounting Standards Not Yet Adopted
Financial Instruments - Credit Losses
In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. This guidance will be effective for us in the first quarter of fiscal 2021. We are currently evaluating the impact of adoption on our consolidated financial statements.




 
 
 
 29
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Notes to Financial Statements
 
 


2. Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Employee-related costs (1)
$
42

 
$
12

Facility exit and other costs (2)
14

 
—

Total restructuring and employee severance
$
56

 
$
12


 
Six Months Ended December 31,
(in millions)
2019
 
2018
Employee-related costs (1)
$
62

 
$
41

Facility exit and other costs (2)
24

 
3

Total restructuring and employee severance
$
86

 
$
44


(1)
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods.
(2)
Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.
During fiscal 2020 and 2019, we implemented certain enterprise-wide cost-saving initiatives affecting various functional and commercial areas intended to optimize and simplify our operating model and cost structure. We incurred $42 million and $8 million during the three months ended December 31, 2019 and 2018, respectively, and $62 million and $34 million for the six months ended December 31, 2019 and 2018, respectively, in expenses related to these cost savings initiatives, which are reflected in restructuring and employee severance in the condensed consolidated statements of earnings/(loss).
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)
Employee-
Related Costs
 
Facility Exit
and Other Costs
 
Total
Balance at June 30, 2019
$
64

 
$
8

 
$
72

Additions
56

 
8

 
64

Payments and other adjustments
(21
)
 
(3
)
 
(24
)
Balance at December 31, 2019
$
99

 
$
13

 
$
112


 
3. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)
Pharmaceutical
 
Medical
 
Total
Balance at June 30, 2019
$
2,663

 
$
5,715

 
$
8,378

Goodwill acquired, net of purchase price adjustments
(5
)
 
—

 
(5
)
Foreign currency translation adjustments and other
—

 
(17
)
 
(17
)
Balance at December 31, 2019
$
2,658

 
$
5,698

 
$
8,356


Other Intangible Assets
The following tables summarize other intangible assets by class at:
 
December 31, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
 
Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
 
 
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

 
N/A
Total indefinite-life intangibles
22

 
—

 
22

 
N/A
 
 
 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
 
 
Customer relationships
3,550

 
1,670

 
1,880

 
13
Trademarks, trade names and patents
673

 
318

 
355

 
13
Developed technology and other
1,603

 
693

 
910

 
11
Total definite-life intangibles
5,826

 
2,681

 
3,145

 
12
Total other intangible assets
$
5,848

 
$
2,681

 
$
3,167

 
N/A


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
30


Notes to Financial Statements
 
 


 
June 30, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
Indefinite-life intangibles:
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

Total indefinite-life intangibles
22

 
—

 
22

 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
Customer relationships
3,562

 
1,517

 
2,045

Trademarks, trade names and patents
672

 
295

 
377

Developed technology and other
1,602

 
616

 
986

Total definite-life intangibles
5,836

 
2,428

 
3,408

Total other intangible assets
$
5,858

 
$
2,428

 
$
3,430


Total amortization of intangible assets was $127 million and $133 million for the three months ended December 31, 2019 and 2018, respectively, and $256 million and $266 million for the six months ended December 31, 2019 and 2018, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2020 through 2024 is as follows: $258 million, $442 million, $408 million, $358 million and $328 million.
4. Investments
In August 2018, we sold our 98 percent ownership interest in naviHealth Holdings, LLC ("naviHealth") to investor entities controlled by Clayton, Dubilier & Rice in exchange for cash proceeds of $737 million (after adjusting for certain fees and expenses) and a 44 percent equity interest in a partnership that owns 100 percent of the equity interest of naviHealth. We also have certain call rights to reacquire naviHealth. We are accounting for this investment using the equity method of accounting and on a one-month reporting lag.
During the six months ended December 31, 2018, we recognized a pre-tax gain of $508 million related to this divestiture in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings.
The carrying value of this investment was $330 million and $334 million as of December 31, 2019 and June 30, 2019, respectively. During the three and six months ended December 31, 2019, our proportionate share of naviHealth’s net loss, which was recorded in other (income)/ expense, net in the condensed consolidated statements of earnings/(loss), was immaterial.
 
5. Leases
We primarily have operating leases for corporate offices, distribution facilities, vehicles, and equipment. We determine if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of the asset. Our lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.
Beginning July 1, 2019, operating lease right-of-use assets and corresponding operating lease liabilities are recognized in our condensed consolidated balance sheet at commencement date based on the present value of lease payments over the lease term. Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term. As most of our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable.
Our lease agreements include leases that contain lease components and non-lease components. For all asset classes, we have elected to account for both of these provisions as a single lease component. We also, from time to time, sublease portions of our real estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the condensed consolidated financial statements at or for the three and six months ended December 31, 2019.
We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. Short-term lease expense recognized in the three and six months ended December 31, 2019 was not material. In addition, we elected the package of three practical expedients permitted under the transition guidance, which include the carry forward of our leases without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.
Our leases have remaining lease terms from less than 1 year up to approximately 23 years. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option.



 
 
 
 31
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Notes to Financial Statements
 
 


The following table summarizes the components of lease cost:
 
Three Months Ended December 31,
Six Months Ended December 31,
(in millions)
2019
2019
Operating lease cost
$
30

$
61

Finance lease cost




Amortization of right-of-use assets
4

8

Total finance lease cost
4

8

Variable lease cost(1)
11

12

Total lease cost
$
45

$
81

(1)
Primarily includes payments for property taxes, maintenance and insurance.
The following table summarizes supplemental balance sheet information related to leases:
(in millions)
December 31, 2019
Operating Leases
 
Operating lease right-of-use assets
$
404

 
 
   Current portion of operating lease liabilities
102

   Long-term operating lease liabilities
324

Total operating lease liabilities
426

 
 
Finance Leases
 
Finance lease right-of-use assets
14

 
 
Current portion of finance lease liabilities
4

Long-term finance lease liabilities
11

Total finance lease liabilities
$
15


Operating leases are included in other assets, other accrued liabilities, and deferred income taxes and other liabilities in our condensed consolidated balance sheet. Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, and long-term obligations, less current portion in our condensed consolidated balance sheet.
 
The following tables summarizes supplemental cash flow information related to leases:
 
Six Months Ended December 31,
(in millions)
2019
Cash paid for amounts included in the measurement of lease liabilities:


Operating cash flows paid for operating leases
$
61

Financing cash flows paid for finance leases
3

Non-cash right-of-use assets obtained in exchange for lease obligations:

New operating leases
54

New finance leases
17

Amended lease standard adoption impact as of July 1, 2019 (1) 
400

(1)
Includes the effect of $22 million from reclassifying deferred rent as an offset to the lease right-of-use asset in accordance with the transition guidance.
Our operating leases had a weighted-average remaining lease term of 6.3 years and a weighted-average discount rate of 2.9 percent.
Future lease payments under non-cancellable leases as of December 31, 2019 were as follows:
(in millions)
Operating Leases
 
Finance Leases
 
Total
Years Ending December 31,

 

 

Remainder of 2020
$
59

 
$
2

 
$
61

2021
108

 
6

 
114

2022
89

 
4

 
93

2023
67

 
4

 
71

2024
47

 
1

 
48

Thereafter
166

 
—

 
166

Total future lease payments
536

 
17

 
553

Less: leases not yet commenced (1) 
61

 
—

 
61

Less: imputed interest
49

 
2

 
51

Total lease liabilities
$
426

 
$
15

 
$
441

(1)
As of December 31, 2019, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the condensed consolidated balance sheets.
The future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at June 30, 2019 for fiscal 2020 through 2024 and thereafter were as follows: $126 million, $100 million, $76 million, $54 million, $33 million and $94 million.


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
32


Notes to Financial Statements
 
 


6. Long-Term Obligations and Other Short-Term Borrowings
Long-Term Debt and Other Short-Term Borrowings
At December 31, 2019 and June 30, 2019, we had total long-term obligations, including the current portion and other short-term borrowings, of $7.9 billion and 8.0 billion, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These obligations are effectively subordinated to the liabilities of our subsidiaries, including trade payables of 21.5 billion at both December 31, 2019 and June 30, 2019.
In November 2019, we repaid the full principal of the 2.4% Notes due 2019 at maturity for $450 million. During the six months ended December 31, 2019, we early repurchased $207 million of the 2.616% Notes due 2022, $10 million of the 3.2% Notes due 2022, $14 million of the Floating Rate Notes due 2022, $81 million of the 3.41% Notes due 2027, $6 million of the 4.6% Notes due 2043, $2 million of the 4.9% Notes due 2045, and $21 million of the 4.368% Notes due 2047. The repurchases were paid for with available cash and other short-term borrowings. In connection with the early debt repurchases, we recorded a $4 million loss on extinguishment of debt.

 
The following table summarizes long-term obligations and other short-term borrowings at:
(in millions) (1)
December 31, 2019
 
June 30, 2019
2.4% Notes due 2019
$
—

 
$
450

4.625% Notes due 2020
506

 
508

2.616% Notes due 2022
873

 
1,079

3.2% Notes due 2022
238

 
247

Floating Rate Notes due 2022
326

 
340

3.2% Notes due 2023
553

 
551

3.079% Notes due 2024
780

 
781

3.5% Notes due 2024
402

 
402

3.75% Notes due 2025
497

 
494

3.41% Notes due 2027
1,238

 
1,318

4.6% Notes due 2043
340

 
346

4.5% Notes due 2044
342

 
342

4.9% Notes due 2045
443

 
445

4.368% Notes due 2047
574

 
594

7.0% Debentures due 2026
124

 
124

Other Obligations (2)
698

 
10

Total
7,934

 
8,031

Less: current portion of long-term obligations and other short-term borrowings
1,192

 
452

   Long-term obligations, less current portion
$
6,742

 
$
7,579

(1)
Maturities are presented on a calendar year basis.
(2)
Includes $458 million outstanding under our commercial paper program and $225 million outstanding under our committed receivables sales facility.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At December 31, 2019, we had $458 million outstanding under our commercial paper program, $225 million outstanding under committed receivables sales facility and no amount outstanding under our revolving credit facility.
In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.
Our revolving credit and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021


 
 
 
 33
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Notes to Financial Statements
 
 


and as of the end of every quarter thereafter. As of December 31, 2019, we were in compliance with this financial covenant.
7. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health Corporation ("CVS Health")
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term.
Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
We are named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information have led, and may in the future lead, to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
From time to time, we determine that products we manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions can lead to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, action by regulators and product
 
liability claims and lawsuits, including class actions. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates. Except as otherwise disclosed in this footnote, it is not possible for us to reasonably estimate the amount of any possible loss or range of possible losses in the matters described below.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings.
Opioid Lawsuits and Investigations
Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,000 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.
States & Political Subdivisions
Approximately 2,500 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the “MDL”).
In addition, 23 state attorneys general have filed lawsuits against distributors, including us, in various state courts. A trial in New York for cases brought by the New York Attorney General and Nassau and Suffolk counties is scheduled to begin in March 2020.
Additionally, 43 state attorneys general have formed a multi-state task force to investigate the manufacturing, distribution, dispensing and prescribing practices of opioid medications. We have received requests related to the multi-state investigation, as well as separate civil investigative demands, subpoenas or requests for information from these and other state attorneys general offices and governmental authorities.
In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general that is


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
34


Notes to Financial Statements
 
 

designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions (the "Settlement Framework"). This Settlement Framework is subject to contingencies and uncertainties as to final terms, but is the basis for our negotiation of definitive terms and documentation.
The Settlement Framework includes (1) a cash component, pursuant to which we would pay up to $5.56 billion over eighteen years, (2) development and participation in a program for free or rebated distribution of opioid abuse treatment medications for a period of ten years, and (3) industry-wide changes to be specified to controlled substance anti-diversion programs. Final terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. In connection with these matters, in the six months ended December 31, 2019, we accrued $5.56 billion, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to reasonably estimate the liability associated with the other components of the Settlement Framework, the potential distribution of treatment medications and any incremental costs for changes to our controlled substance anti-diversion program that we may agree to.
In the six months ended December 31, 2019, we along with two other national distributors entered into a $215 million settlement with two Ohio counties, Cuyahoga and Summit, to resolve all claims in the first bellwether trial in the MDL, which had been set for trial for October 2019. In connection with this settlement, we accrued $66 million in the six months ended December 31, 2019. This accrual is included in other accrued liabilities in the condensed consolidated balance sheets.
In connection with these matters, we recorded a total pre-tax charge of $5.63 billion ($5.14 billion after tax) during the six months ended December 31, 2019 in litigation (recoveries)/charges, net, in the condensed consolidated statement of earnings for the cash component. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We will regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.
Private Plaintiffs
The Settlement Framework does not address claims by private plaintiffs, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private plaintiffs had brought approximately 365 lawsuits as of February 4, 2020. Of these, 105 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We will continue to vigorously defend ourselves in these matters.
 
Department of Justice Investigations
We have received grand jury subpoenas issued on behalf of the District Courts for the Eastern District of New York and the District of Columbia seeking documents and, in the District of Columbia, testimony, related to our anti-diversion policies and procedures, and our distribution of certain controlled substances. We are cooperating with these requests.
Cordis Product Liability Lawsuits
As of February 4, 2020, we are named as a defendant in 299 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 3,773 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Another 29 lawsuits involving similar claims by approximately 35 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We are vigorously defending ourselves in these lawsuits.
At December 31, 2019, we had a total of $441 million accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $885 million.
Shareholder Securities Litigation
In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them.
Surgical Gown Recalls
In January, 2020, we issued a voluntary recall for 9.1 million AAMI Level 3 surgical gowns and two voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for 2.9 million Presource Procedure Packs containing affected gowns (together, the "Recalls"). These Recalls were necessary because we discovered in December 2019 that one of our FDA-registered suppliers in China had shifted production of some gowns to unapproved sites with uncontrolled environments. Because of this, we could not assure sterility of the gowns.
In connection with these Recalls, in the three months ended December 31, 2019, we recorded a total charge of $96 million, of which $56 million is within cost of products sold and $40 million is


 
 
 
 35
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Notes to Financial Statements
 
 

within SG&A in the condensed consolidated statements of earnings. In our condensed consolidated balance sheet at December 31, 2019, we had $38 million reserved within inventories, net, and $58 million included in other accrued liabilities related to this charge. This charge represents our best estimate of costs for the Recalls and include inventory write-off costs and certain remediation and supply disruption costs, such as costs to replace recalled products. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. The amount of ultimate loss may differ materially from this accrual.
In addition to the charge for the three months ended December 31, 2019, we expect that the Recalls will have other negative impacts, which could include: government investigations and enforcement actions by the U.S. Food and Drug Administration or other regulators or U.S. or international governmental bodies (possibly resulting in product seizures, additional recalls, the issuance of safety alerts, the suspension or revocation of the authority to produce, distribute and sell products and other civil or criminal sanctions); losses due to patient claims, including product liability claims and lawsuits; and customer claims unrelated to their direct costs from the supply disruption. We are not currently able to reasonably estimate the amount of any possible loss or range of possible losses for any of these potential claims or actions.
Other Civil Litigation
Generic Pharmaceutical Antitrust Litigation
In December 2019, pharmaceutical distributors including us were added as defendants in a civil multidistrict litigation consisting of multiple individual and class action lawsuits filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and informed manufacturers that they wished to maintain current customer allocations for the purpose of avoiding price erosion. We intend to vigorously defend ourselves in these matters.
Blood Pressure Medication Recall Litigation
Many participants in the pharmaceutical supply chain, including manufacturers, repackagers (including us), distributors (including us), and retailers have been named as defendants in Multidistrict Litigation in the U.S. District Court for the District of New Jersey (the “Blood Pressure Medication Recall MDL”), which was created in February 2019. The claims arise out of a series of recalls of generic blood pressure medications due to alleged impurities in active pharmaceutical ingredients. In December 2019, two additional medications were added to the Blood Pressure Medication Recall MDL. In January 2020, manufacturers recalled another medication and the FDA continues to investigate other drugs for possible recall. We intend to vigorously defend ourselves in these matters.
 
8. Income Taxes
Fluctuations in our provision for/(benefit from) income taxes as a percentage of pretax earnings (“effective tax rate”) are generally due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Opioid Settlement Framework
In connection with the $5.63 billion pre-tax charge for the opioid litigation, during the six months ended December 31, 2019 we recorded a tax benefit of $487 million, which is net of unrecognized tax benefits of $468 million, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the U.S. Tax Cuts and Jobs Act ("Tax Act"). Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 7 for more information regarding these matters.
Effective Tax Rate
During the three months ended December 31, 2019 and 2018, the effective tax rate was 21.0 percent and 31.0 percent, respectively. The change in the effective tax rate from prior period is primarily due to the favorable impact from changes in jurisdictional mix and discrete items recognized in the second quarter of fiscal 2020, largely driven by changes as a result of tax reform.
During the six months ended December 31, 2019 and 2018, the effective tax rate was 7.2 percent and 23.5 percent, respectively. The change in the effective tax rate from fiscal 2019 to fiscal 2020 is primarily due to the net effects of the Settlement Framework.
Unrecognized Tax Benefits
At December 31, 2019 and June 30, 2019, we had $940 million and $456 million of unrecognized tax benefits, respectively. The December 31, 2019 and June 30, 2019 balances include $791 million and $303 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.
At December 31, 2019 and June 30, 2019, we had $132 million and $122 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
36


Notes to Financial Statements
 
 

activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $350 million, exclusive of penalties and interest.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $171 million and $165 million at December 31, 2019 and June 30, 2019, respectively, and is included in other assets in the condensed consolidated balance sheets.
As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $21 million and $22 million at December 31, 2019 and June 30, 2019, respectively, and is included in other assets in the condensed consolidated balance sheet.
Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.
 
9. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
 
December 31, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents
$
199

 
$
—

 
$
—

 
$
199

Other investments (1)
116

 
—

 
—

 
116

Forward Contracts (2)
—

 
73

 
—

 
73

 
June 30, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Other investments (1)
$
118

 
$
—

 
$
—

 
$
118

Forward Contracts (2)
—

 
53

 
—

 
53


(1)
The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)
The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
10. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.


 
 
 
 37
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Notes to Financial Statements
 
 

Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce volatility in earnings, cash flow and net investments in certain subsidiaries to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense in the condensed consolidated statements of earnings. For the three and six months ended December 31, 2019 and 2018, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During the six months ended December 31, 2019 and 2018, no new pay-floating interest rate swaps were executed. In connection with the debt redemption as described in Note 6, two pay-floating interest rate swaps with notional amounts of $200 million matured in the second quarter of fiscal 2020.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of other comprehensive income/(loss) and reclassified into earnings in the
 
same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
During the six months ended December 31, 2019, we entered into forward interest rate swaps with a total notional amount of $100 million to hedge probable, but not firmly committed, future transactions associated with our debt.
Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December 31, 2019 and 2018. All gains and losses currently included within accumulated other comprehensive loss associated with our foreign exchange forward contracts that are expected to be reclassified into net earnings within the next 12 months are immaterial.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
In August 2019, we entered into a ¥64.0 billion ($600 million) cross-currency swap maturing in 2022.
In September 2018, we entered into a €200 million ($233 million) cross-currency swap maturing in 2023.
Cross-currency swaps designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive income/(loss) until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. There was no ineffectiveness in our net investment hedges during the six months ended December 31, 2019.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $7 million and $8 million expense during the six months ended December 31, 2019 and 2018, respectively. The principal currencies managed through foreign currency contracts are the euro, Canadian dollar, British pound, Japanese yen, and Chinese renminbi.


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
38


Notes to Financial Statements
 
 

Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at December 31, 2019 and June 30, 2019 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)
December 31, 2019
 
June 30, 2019
Estimated fair value
$
8,078

 
$
8,065

Carrying amount
7,934

 
8,031


The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
11. Shareholders' Equity
During the six months ended December 31, 2019, we repurchased 7.3 million common shares having an aggregate cost of $350 million. The average price paid per common share was $48.00. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on August 20, 2019 and was completed on December 4, 2019.
During the six months ended December 31, 2018, we repurchased 11.5 million common shares having an aggregate cost of $600 million. The average price paid per common share was $52.32.
We funded the repurchases with available cash and short-term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)
Foreign
Currency
Translation
Adjustments
 
Unrealized
Gain/(Loss) on
Derivatives,
net of tax
 
Accumulated Other
Comprehensive
Loss
Balance at June 30, 2019
$
(95
)
 
$
16

 
$
(79
)
Other comprehensive loss, before reclassifications
(18
)
 
—

 
(18
)
Amounts reclassified to earnings
—

 
(6
)
 
(6
)
Other comprehensive loss, net of tax
(18
)
 
(6
)
 
(24
)
Balance at December 31, 2019
$
(113
)
 
$
10

 
$
(103
)

 
12. Earnings Per Share Attributable to Cardinal Health, Inc.
The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Weighted-average common shares–basic
292

 
299

Effect of dilutive securities:
 
 
 
Employee stock options, restricted share units and performance share units
2

 
1

Weighted-average common shares–diluted
294

 
300

 
Six Months Ended December 31,
(in millions)
2019
 
2018
Weighted-average common shares–basic
294

 
302

Effect of dilutive securities:
 
 
 
Employee stock options, restricted share units and performance share units
—

 
1

Weighted-average common shares–diluted
294

 
303


The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 4 million for the three months ended December 31, 2019 and 6 million for the six months ended December 31, 2019 (1 million of which would be anti-dilutive as a result of the year-to-date net loss).
The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 5 million during both three months and six months ended December 31, 2018.
13. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products.


 
 
 
 39
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Notes to Financial Statements
 
 



Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.
Revenue
The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical Distribution and Specialty Solutions (1) (2)
$
35,501

 
$
33,534

Nuclear and Precision Health Solutions
213

 
206

Pharmaceutical segment revenue
35,714

 
33,740

Medical distribution and products (3)
3,498

 
3,527

Cardinal Health at-Home Solutions
525

 
479

Medical segment revenue
4,023

 
4,006

  Total segment revenue
39,737

 
37,746

Corporate (4)
(2
)
 
(6
)
Total revenue
$
39,735

 
$
37,740

 
Six Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical Distribution and Specialty Solutions (1) (2)
$
68,713

 
$
64,742

Nuclear and Precision Health Solutions
429

 
413

Pharmaceutical segment revenue
69,142

 
65,155

Medical distribution and products (3)
6,944

 
6,907

Cardinal Health at-Home Solutions
996

 
900

Medical segment revenue
7,940

 
7,807

  Total segment revenue
77,082

 
72,962

Corporate (4)
(6
)
 
(9
)
Total revenue
$
77,076

 
$
72,953


(1)
Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."
(2)
Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)
Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(4)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
 
The following tables present revenue by geographic area:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
United States
$
38,670

 
$
36,716

International
1,067

 
1,030

  Total segment revenue
39,737

 
37,746

Corporate (1)
(2
)
 
(6
)
Total revenue
$
39,735

 
$
37,740

 
Six Months Ended December 31,
(in millions)
2019
 
2018
United States
$
74,980

 
$
70,960

International
2,102

 
2,002

  Total segment revenue
77,082

 
72,962

Corporate (1)
(6
)
 
(9
)
Total revenue
$
77,076

 
$
72,953

(1)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on extinguishment of debt; and provision for income taxes.


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
40


Notes to Financial Statements
 
 



In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $17 million and $12 million for the three months ended December 31, 2019 and 2018, respectively, and $20 million and $19 million for the six months ended December 31, 2019 and 2018, respectively.
In connection with the opioid litigation as discussed further in Note 7, we recognized a pre-tax charge of $5.63 billion during the six months ended December 31, 2019, which was retained at Corporate.
In connection with the surgical gown recall as discussed further in Note 7, we recognized a pre-tax charge of $96 million during the three and six months ended December 31, 2019, which was retained at Corporate.
In connection with the naviHealth divestiture, we recognized a pre-tax gain of $508 million during the six months ended December 31, 2018, which was retained at Corporate.
The following tables present segment profit by reportable segment and Corporate:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical
$
462

 
$
443

Medical
195

 
188

Total segment profit
657

 
631

Corporate
(323
)
 
(127
)
Total operating earnings
$
334

 
$
504

 
Six Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical
$
860

 
$
851

Medical
365

 
323

Total segment profit
1,225

 
1,174

Corporate
(6,155
)
 
146

Total operating earnings/(loss)
$
(4,930
)
 
$
1,320


The following table presents total assets for each reportable segment and Corporate at:
(in millions)
December 31,
2019
 
June 30,
2019
Pharmaceutical
$
23,143

 
$
22,446

Medical
15,490

 
15,284

Corporate
2,409

 
3,233

Total assets
$
41,042

 
$
40,963


 
14. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
The following table provides total share-based compensation expense by type of award:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Restricted share unit expense
$
16

 
$
16

Employee stock option expense
1

 
2

Performance share unit expense
4

 
4

Total share-based compensation
$
21

 
$
22


 
Six Months Ended December 31,
(in millions)
2019
 
2018
Restricted share unit expense
$
33

 
$
30

Employee stock option expense
2

 
6

Performance share unit expense
6

 
5

Total share-based compensation
$
41

 
$
41

The total tax benefit related to share-based compensation was $3 million and $4 million for the three months ended December 31, 2019 and 2018, respectively, and $7 million and $8 million for the six months ended December 31, 2019 and 2018, respectively.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)
Restricted Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
2

 
$
51.65

Granted
2

 
42.40

Vested
(1
)
 
60.37

Canceled and forfeited
—

 
—

Nonvested at December 31, 2019
3

 
$
46.49

At December 31, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $110 million, which is expected to be recognized over a weighted-average period of two years.
Stock Options
Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.


 
 
 
 41
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Notes to Financial Statements
 
 


The following table summarizes all stock option transactions under the Plans:
(in millions, except per share amounts)
Stock
Options
 
Weighted-Average
Exercise Price per
Common Share
Outstanding at June 30, 2019
6

 
$
63.78

Granted
—

 
—

Exercised
—

 
—

Canceled and forfeited
—

 
—

Outstanding at December 31, 2019
6

 
$
63.52

Exercisable at December 31, 2019
6

 
$
63.43


At December 31, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $2 million, which is expected to be recognized over a weighted-average period of one year.
The following tables provide additional detail related to stock options:
(in millions)
December 31, 2019
 
June 30, 2019
Aggregate intrinsic value of outstanding options at period end
$
14

 
$
10

Aggregate intrinsic value of exercisable options at period end
14

 
10

(in years)
December 31, 2019
 
June 30, 2019
Weighted-average remaining contractual life of outstanding options
5
 
5
Weighted-average remaining contractual life of exercisable options
5
 
5

Performance Share Units
Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
 
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)
Performance
Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
0.9

 
$
51.45

Granted
0.6

 
43.68

Vested
(0.1
)
 
48.40

Canceled and forfeited
(0.1
)
 
50.58

Nonvested at December 31, 2019
1.3

 
$
52.71


At December 31, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $28 million, which is expected to be recognized over a weighted-average period of two years if targets are achieved.


 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
42


Exhibits
 
 

Exhibits
Exhibit
Number
Exhibit Description
3.1
3.2
10.1
10.2
10.3
10.4
31.1
31.2
32.1
99.1
101.INS
Inline XBRL Instance Document
101.SCH
Inline XBRL Taxonomy Extension Schema Document
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
Inline XBRL Taxonomy Definition Linkbase Document
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)
Cardinal Health Website
Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when the company posts news releases, SEC filings and certain other information on its website.


 
 
 
 43
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 


Form 10-Q Cross Reference Index
 
 



Form 10-Q Cross Reference Index
Item Number
 
Page
 
 
 
 
Part I. Financial Information
 
Item 1
Item 2
Item 3
Item 4
 
 
 
 
Part II. Other Information
 
Item 1
Item 1A
Item 2
Item 3
Defaults Upon Senior Securities
N/A
Item 4
Mine Safety Disclosures
N/A
Item 5
Other Information
N/A
Item 6
 
N/A
Not applicable
 




 
 
 
 
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
44


Additional Information
 
 

Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Cardinal Health, Inc.
 
 
 
Date:
February 6, 2020
/s/ MICHAEL C. KAUFMANN
 
 
Michael C. Kaufmann
 
 
Chief Executive Officer
 
 
 
 
 
/s/ DAVID C. EVANS
 
 
David C. Evans
 
 
Chief Financial Officer



 
 
 
 45
Cardinal Health | Q2 Fiscal 2020 Form 10-Q
 

 EX-10.1 2 a20q210q123119exhibit101.htm EXHIBIT 10.1 Exhibit
Exhibit 10.1


FIRST AMENDMENT TO THE
CARDINAL HEALTH, INC.
SENIOR EXECUTIVE SEVERANCE PLAN

WHEREAS, Cardinal Health, Inc., an Ohio corporation (the “Company”), has adopted the Cardinal Health, Inc. Senior Executive Severance Plan (the “Plan”);
WHEREAS, the Human Resources and Compensation Committee (the “Committee”) of the Board of Directors of the Company has determined that it would be advisable and in the best interest of the Company to amend the Plan to (a) modify the definition of “Termination for Cause,” (b) eliminate the 60-day delay in payment of the first installment of the Severance Payment (as defined in the Plan), and (c) provide for a “Restricted Period” (as set forth in Annex A of the Plan) of 1.5 years for Participants (as defined in the Plan) at the Senior Vice President level and above who are not Executive Officers (as defined in the Plan); and
WHEREAS, the Committee desires to amend the Plan as set forth herein to reflect such amendments and to correct a typographical error.
NOW, THEREFORE, pursuant to Section 8.2 of the Plan, the Plan is hereby amended as follows:
1.The definition of “COBRA Reimbursement” set forth in Article II of the Plan is hereby amended and restated in its entirety to read as follows:

“COBRA Reimbursement” has the meaning set forth in Section 5.1(e).
2.The definition of “Termination for Cause” set forth in Article II of the Plan is hereby amended and restated in its entirety to read as follows:

“Termination for Cause” means a Termination of Employment on account of (a) the willful and continued failure of the Eligible Employee to perform substantially the Eligible Employee’s duties with any member of the Company Group (other than any such failure resulting from incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to the Eligible Employee by the Administrator or its representative, which specifically identifies the manner in which the Administrator believes that the Eligible Employee has not substantially performed the Eligible Employee’s duties; (b) the willful engaging by the Eligible Employee in illegal conduct or gross misconduct that is materially and demonstrably injurious to any member of the Company Group; (c) the Eligible Employee’s conviction of, or plea of guilty or nolo contendere to, a felony or any crime involving dishonesty or moral turpitude; (d) the Eligible Employee committing or engaging in fraud, embezzlement or theft against the Company; (e) the Eligible Employee’s material breach of any restrictive covenant in favor of the Company Group by which such Eligible Employee is bound; or (f) the Eligible Employee has willfully and materially violated the Company’s Standards of Business Conduct or any other written Company policy. During the Change of Control Period, (A) a Termination of Employment shall not be deemed to be a Termination for Cause unless and until there shall have been delivered to the Eligible Employee a copy of a resolution duly adopted by the affirmative vote of not less than a majority of the entire membership of the Applicable Board (excluding the Eligible Employee, if the Eligible Employee is a member of the Applicable Board) at a meeting of the Applicable Board called and held for such purpose (after reasonable notice is provided to the Eligible Employee and the Eligible Employee is given an opportunity, together with counsel for the Eligible Employee, to be heard



before the Applicable Board), finding that, in the good-faith opinion of the Applicable Board, the Eligible Employee is guilty of the conduct described in clause (a), (b), (e) or (f) above; and (B) for purposes of the immediately preceding sentence, no act, or failure to act, on the part of an Eligible Employee shall be considered “willful” unless it is done, or omitted to be done, by the Eligible Employee in bad faith or without reasonable belief that the Eligible Employee’s action or omission was in the best interests of the Company Group. Any act, or failure to act, based upon (i) authority given pursuant to a resolution duly adopted by the Board or, if the Company is not the ultimate parent corporation of the Company Group and is not publicly traded, the board of directors of the ultimate parent of the Company (the “Applicable Board”), (ii) the instructions of the Chief Executive Officer of the Company (in the case of any Eligible Employee other than the Chief Executive Officer of the Company) or a senior officer of the Company, or (iii) the advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, by the Eligible Employee in good faith and in the best interests of the Company Group.

3.Section 5.1(b) of the Plan is hereby amended and restated in its entirety to read as follows:

(a)    An amount in cash equal to the product of (i) the Participant’s Multiple and (ii) the sum of the Participant’s Annual Base Salary and Target Annual Bonus (the “Severance Payment”), which Severance Payment shall be payable in substantially equal installments over the applicable Severance Period in accordance with the Company’s normal payroll practices.

4.Plan Participants. The chart set forth in Annex A of the Plan is hereby amended and restated in its entirety to read as follows:

Position
Multiple
COC Multiple
Restricted Period
Chief Executive Officer (“CEO”)
2.0x
2.5x
2 years
Executive Officers (other than the CEO)
1.5x
2.0x
2 years
Senior Vice President and Above (other than Executive Officers and the CEO)
1.5x
2.0x
1.5 year
 
 
 
 
5.Miscellaneous.

(a)Full Force and Effect. Except as expressly amended by this Amendment, all terms and conditions of the Plan shall remain in full force and effect.

(b)Governing Law. This Amendment shall be governed by the substantive laws, but not the choice of law rules, of the State of Ohio.

Adopted by the Human Resources and Compensation Committee on November 5, 2019.


 EX-10.2 3 a20q210q123119exhibit102.htm EXHIBIT 10.2 Exhibit
Exhibit 10.2


SECOND AMENDMENT TO THE
AMENDED CARDINAL HEALTH, INC. 2011 LONG-TERM INCENTIVE PLAN
Effective November 5, 2019, the following amendments are made to the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (the “Plan”):
1.
The following new definitions are added to Section 2 of the Plan:

“(ss)
“Company Group” means the Company and its Affiliates.
(tt)
“Competitor” means, unless the Administrator determines otherwise in an Award Agreement or elsewhere, any person or business that competes with the products or services provided by a member of the Company Group for which Participant had business responsibilities within 24 months prior to Termination of Employment or about which Participant obtained confidential information (as defined by the applicable Company Group policies or agreements).
(uu)
“Competitor Conduct” means, unless the Administrator determines otherwise in an Award Agreement or elsewhere, accepting employment with, or directly or indirectly providing services to, a Competitor in the United States. If Participant has a Termination of Employment and Participant’s responsibilities to the Company Group were limited to a specific territory or territories within or outside the United States during the 24 months prior to the Termination of Employment, then Competitor Conduct will be limited to that specific territory or territories.
(vv)
“Misconduct” means, unless the Administrator determines otherwise in an Award Agreement or elsewhere:
(i)
disclosing or using any of the Company Group’s confidential information (as defined by the applicable Company Group policies and agreements) without proper authorization from the Company Group or in any capacity other than as necessary for the performance of Participant’s assigned duties for the Company Group;

(ii)
violation of the Standards of Business Conduct or any successor code of conduct or other applicable Company Group policies, including but not limited to conduct which would constitute a breach of any representation or certificate of compliance signed by Participant;

(iii)
fraud, gross negligence or willful misconduct by Participant, including but not limited to fraud, gross negligence or willful misconduct causing or contributing to a material error resulting in a restatement of the financial statements of any member of the Company Group;

(iv)
directly or indirectly soliciting or recruiting for employment or contract work on behalf of a person or entity other than a member of the Company Group, any person who is an employee, representative, officer or director in the Company Group or who held one or more of those positions at any time within the 12 months prior to Participant’s Termination of Employment;




(v)
directly or indirectly inducing, encouraging or causing an employee of the Company Group to terminate his or her employment or a contract worker to terminate his or her contract with a member of the Company Group;

(vi)
any action by Participant or his or her representatives that either does or could reasonably be expected to undermine, diminish or otherwise damage the relationship between the Company Group and any of its customers, prospective customers, vendors, suppliers or employees known to Participant; or

(vii)
breaching any provision of any employment or severance agreement with a member of the Company Group.”

2.
The following new Section 13(e) is added to the Plan:

“(e)    Special Forfeiture and Repayment Rules. Effective July 1, 2019, if a Participant engages in Misconduct or Competitor Conduct during employment or within 12 months after the Termination of Employment for any reason, then (i) the Participant forfeits any Cash Award that has not yet been paid and (ii) the Participant shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to (A) the amount of any Cash Award paid to the Participant at any time within the last 12 months less (B) $1.00.”



 EX-10.3 4 a20q210q123119exhibit103.htm EXHIBIT 10.3 Exhibit
Exhibit 10.3


CARDINAL HEALTH, INC.
RESTRICTED SHARE UNITS AGREEMENT

This Restricted Share Units Agreement (this “Agreement”) is entered into in Franklin County, Ohio. On [grant date] (the “Grant Date”), Cardinal Health, Inc., an Ohio corporation (the “Company”), has awarded to [employee name] (“Awardee”) [# of shares] Stock Units (the “Restricted Share Units” or “Award”), representing an unfunded unsecured promise of the Company to deliver common shares, without par value, of the Company (the “Shares”) to Awardee as set forth in this Agreement. The Restricted Share Units have been granted pursuant to the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (the “Plan”), and are subject to all provisions of the Plan, which are incorporated in this Agreement by reference, and are subject to the provisions of this Agreement. Capitalized terms used in this Agreement which are not specifically defined have the meanings ascribed to such terms in the Plan.
1.Vesting of Restricted Share Units.

(a)General. [CLIFF ALTERNATIVE: The Restricted Share Units vest on the [ ] anniversary of the Grant Date (the “Vesting Date”), subject to the provisions of this Agreement, including those relating to Awardee’s continued employment with the Company and its Affiliates (collectively, the “Cardinal Group”).] [INSTALLMENT ALTERNATIVE: The Restricted Share Units vest in [ ] installments, which will be as nearly equal as possible, on the [ ] anniversaries of the Grant Date (each a “Vesting Date” with respect to the portion of the Restricted Share Units scheduled to vest on such date), subject in each case to the provisions of this Agreement, including those relating to Awardee’s continued employment with the Company and its Affiliates (collectively, the “Cardinal Group”).]

(b)Change of Control. In the event of a Change of Control prior to a Termination of Employment, the Restricted Share Units (to the extent not previously vested or forfeited) vest in full, except to the extent that a Replacement Award is provided to Awardee in accordance with Section 16(b) of the Plan. Any Replacement Award must vest in full upon (i) a Termination for Good Reason by Awardee, (ii) a Termination of Employment by the Company or its successor in the Change of Control other than a Termination for Cause, or (iii) Awardee’s death or Disability, in each case, occurring at or during the period of two years after the Change of Control. In addition, if a Replacement Award is provided, any Restricted Share Units that would vest in accordance with Paragraphs 3(b) or (c) in connection with Awardee’s Retirement or Disability if Awardee’s Termination of Employment occurred on the date of the Change of Control will for purposes of this Agreement vest at the time of the Change of Control.

2.Transferability. The Restricted Share Units are not transferable.

3.Termination of Employment.

(a)General. Except as set forth in Paragraphs 1(b) and 3(b), (c) and (d), if a Termination of Employment occurs, then any unvested Restricted Share Units are forfeited by Awardee immediately after such Termination of Employment.

(b)Death or Disability. If a Termination of Employment by reason of Awardee’s death or Disability occurs at least 6 months after the Grant Date, then any outstanding unvested Restricted Share Units immediately vest in full and are not forfeited.

(c)Retirement. If a Termination of Employment by reason of Awardee’s Retirement occurs at



least 6 months after the Grant Date, then a Ratable Portion of each unvested installment of the outstanding Restricted Share Units immediately vests and is not forfeited. Such “Ratable Portion,” with respect to the applicable installment, is an amount equal to such installment of the Restricted Share Units scheduled to vest on a future Vesting Date multiplied by a fraction, the numerator of which is the number of days from the Grant Date through the date of the Termination of Employment, and the denominator of which is the number of days from the Grant Date through such Vesting Date. 1 

(d)Involuntary Termination with Severance. If (i) Paragraph 3(c) is not applicable, but Awardee has attained either (A) age 53 and at least eight years of continuous service with the Cardinal Group or (B) age 59 and at least four years of continuous service with the Cardinal Group, in each case including service with an Affiliate of the Company prior to the time that such Affiliate became an Affiliate of the Company, (ii) a Termination of Employment by the Cardinal Group (other than a Termination for Cause) occurs at least 6 months after the Grant Date, and (iii) no later than 45 days after the Termination of Employment, Awardee enters into a written separation agreement and general release of claims with the Cardinal Group (in such form as may reasonably be presented by the Company) (a “Separation Agreement”), and Awardee does not timely revoke such Separation Agreement, then a Ratable Portion of each unvested installment of the outstanding Restricted Share Units immediately vests and is not forfeited.

4.Special Forfeiture and Repayment Rules. This Agreement contains special forfeiture and repayment rules intended to encourage conduct that protects the Cardinal Group’s legitimate business assets and discourage conduct that threatens or harms those assets. The Company does not intend to have the benefits of this Agreement reward or subsidize conduct detrimental to the Company, and therefore will require the forfeiture of the benefits offered under this Agreement and the repayment of gains obtained from this Agreement, according to the rules specified below. Activities that trigger the forfeiture and repayment rules are divided into two categories: Misconduct and Competitor Conduct.

(a)Misconduct. During employment with the Cardinal Group and for three years after the Termination of Employment for any reason, Awardee agrees not to engage in Misconduct. If Awardee engages in Misconduct during employment or within three years after the Termination of Employment for any reason, then

(i)Awardee immediately forfeits the Restricted Share Units that have not yet vested or that vested at any time within three years prior to the date the Misconduct first occurred and have not yet been paid pursuant to Paragraph 5, and those forfeited Restricted Share Units automatically terminate, and

(ii)Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to (A) the gross gain to Awardee resulting from the payment of Restricted Share Units pursuant to Paragraph 5 that had vested at any time within three years prior to the date the Misconduct first occurred less (B) $1.00. The gross gain is the Fair Market Value of the Shares represented by the Restricted Share Units on the date of receipt.
As used in this Agreement, “Misconduct” means
(A)disclosing or using any of the Cardinal Group’s confidential information (as defined by the applicable Cardinal Group policies and agreements) without proper authorization from the Cardinal Group or in any capacity other than as necessary for the performance of Awardee’s assigned duties for the Cardinal Group;

1This provision is an alternative that may not be included in every award agreement.



(B)violation of the Standards of Business Conduct or any successor code of conduct or other applicable Cardinal Group policies, including but not limited to conduct which would constitute a breach of any representation or certificate of compliance signed by Awardee;

(C)fraud, gross negligence or willful misconduct by Awardee, including but not limited to fraud, gross negligence or willful misconduct causing or contributing to a material error resulting in a restatement of the financial statements of any member of the Cardinal Group;

(D)directly or indirectly soliciting or recruiting for employment or contract work on behalf of a person or entity other than a member of the Cardinal Group, any person who is an employee, representative, officer or director in the Cardinal Group or who held one or more of those positions at any time within the 12 months prior to Awardee’s Termination of Employment;

(E)directly or indirectly inducing, encouraging or causing an employee of the Cardinal Group to terminate his/her employment or a contract worker to terminate his/her contract with a member of the Cardinal Group;

(F)any action by Awardee and/or his or her representatives that either does or could reasonably be expected to undermine, diminish or otherwise damage the relationship between the Cardinal Group and any of its customers, prospective customers, vendors, suppliers or employees known to Awardee; or

(G)breaching any provision of any employment or severance agreement with a member of the Cardinal Group.

Nothing in this Agreement will prevent Awardee from testifying truthfully as required by law, prohibit or prevent Awardee from filing a charge with or participating, testifying or assisting in any investigation, hearing, whistleblower proceeding or other proceeding before any federal, state or local government agency (e.g., Equal Employment Opportunity Commission, National Labor Relations Board, Securities and Exchange Commission, etc.), or prevent Awardee from disclosing Cardinal Group’s confidential information in confidence to a federal, state or local government official for the purpose of reporting or investigating a suspected violation of law.
(b)Competitor Conduct. If Awardee engages in Competitor Conduct during employment or within one year after the Termination of Employment for any reason, then

(i)Awardee immediately forfeits the Restricted Share Units that have not yet vested or that vested at any time within one year prior to the date the Competitor Conduct first occurred and have not yet been paid pursuant to Paragraph 5, and those forfeited Restricted Share Units automatically terminate, and

(ii)Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to (A) the gross gain to Awardee resulting from the payment of Restricted Share Units pursuant to Paragraph 5 that had vested at any time since the earlier of one year prior to the date the Competitor Conduct first occurred or one year prior to the Termination of Employment, if applicable, less (B) $1.00. The gross gain is the Fair Market Value of the Shares represented by the Restricted Share Units on the date of receipt.



As used in this Agreement, “Competitor Conduct” means accepting employment with, or directly or indirectly providing services to, a Competitor in the United States. If Awardee has a Termination of Employment and Awardee’s responsibilities to the Cardinal Group were limited to a specific territory or territories within or outside the United States during the 24 months prior to the Termination of Employment, then Competitor Conduct will be limited to that specific territory or territories. A “Competitor” means any person or business that competes with the products or services provided by a member of the Cardinal Group for which Awardee had business responsibilities within 24 months prior to Termination of Employment or about which Awardee obtained confidential information (as defined by the applicable Cardinal Group policies or agreements).
(c)General.

(i)Nothing in this Paragraph 4 constitutes or is to be construed as a “noncompete” covenant or other restraint on employment or trade. The provisions of this Paragraph 4 do not prevent, nor are they intended to prevent, Awardee from seeking or accepting employment or other work outside the Cardinal Group. The execution of this Agreement is voluntary. Awardee is free to choose to comply with the terms of this Agreement and receive the benefits offered or else reject this Agreement with no adverse consequences to Awardee’s employment with the Cardinal Group.

(ii)Awardee agrees to provide the Company with at least 10 days’ written notice prior to accepting employment with or providing services to a Competitor within one year after Termination of Employment.

(iii)Awardee acknowledges receiving sufficient consideration for the requirements of this Paragraph 4, including Awardee’s receipt of the Restricted Share Units. Awardee further acknowledges that the Company would not provide the Restricted Share Units to Awardee without Awardee’s promise to abide by the terms of this Paragraph 4. The parties also acknowledge that the provisions contained in this Paragraph 4 are ancillary to, or part of, an otherwise enforceable agreement at the time this Agreement is made.

(iv)Awardee may be released from the obligations of this Paragraph 4 if and only if the Administrator determines, in writing and in the Administrator’s sole discretion, that a release is in the best interests of the Company.

5.Payment.

(a)    General. Subject to the provisions of Paragraph 4 and Paragraphs 5(b), (c), (d) and (e), Awardee is entitled to receive from the Company (without any payment by or on behalf of Awardee other than as described in Paragraph 9) the Shares represented by the vested Restricted Share Units on the Vesting Date.
(b)    Death. To the extent that Restricted Share Units are vested on the date of Awardee’s Termination of Employment due to death, Awardee is entitled to receive the corresponding Shares from the Company on the date of death.

(c)Disability, Retirement and Other Separations from Service. To the extent that Restricted Share Units are vested as the result of Disability, Retirement or otherwise on the date of Awardee’s “separation from service” (determined in accordance with Section 409A of the Code), Awardee is entitled


to receive the corresponding Shares from the Company on the date that is 60 days after Awardee’s “separation from service”; provided, however, that if Awardee on the date of separation from service is a “specified employee” (certain employees of the Cardinal Group within the meaning of Section 409A of the Code determined using the identification methodology selected by the Company from time to time), to the extent necessary to avoid the imposition of tax under Section 409A of the Code, Awardee is entitled to receive the corresponding Shares from the Company six months after the date of Awardee’s separation from service or, if earlier, the date of Awardee’s death.

(d)Change of Control. To the extent that Restricted Share Units are vested on the date of a Change of Control, Awardee is entitled to receive the corresponding Shares from the Company on the date of the Change of Control; provided, however, that if such Change of Control would not qualify as a permissible date of distribution under Section 409A(a)(2)(A)(v) of the Code and the regulations thereunder, and where Section 409A of the Code applies to such distribution as a deferral of compensation, Awardee is entitled to receive the corresponding Shares from the Company on the date that would have otherwise applied pursuant to Paragraphs 5(a), (b) or (c).

(e)Elections to Defer Receipt. Elections to defer receipt of the Shares beyond the date of payment provided in this Agreement may be permitted in the discretion of the Administrator pursuant to procedures established by the Administrator in compliance with the requirements of Section 409A of the Code.

6.Dividend Equivalents. Awardee is not entitled to receive cash dividends on the Restricted Share Units, but will receive a dividend equivalent payment from the Company in an amount equal to the dividends that would have been paid on each Share underlying the Restricted Share Units if it had been outstanding between the Grant Date and the payment date of any such Share (i.e., based on the record date for cash dividends). Subject to an election to defer receipt as permitted under Paragraph 5(e), the Company shall pay dividend equivalent payments in cash as soon as reasonably practicable after the payment date of the Restricted Share Units to which such dividend equivalents relate.

7.Right of Set-Off. By accepting the Restricted Share Units, Awardee consents to a deduction from, and set-off against, any amounts owed to Awardee that are not treated as “non-qualified deferred compensation” under Section 409A of the Code by any member of the Cardinal Group from time to time (including, but not limited to, amounts owed to Awardee as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the Cardinal Group by Awardee under this Agreement.

8.No Shareholder Rights. Awardee has no rights of a shareholder with respect to the Restricted Share Units, including no right to vote the Shares represented by the Restricted Share Units, until such Shares vest and are paid to Awardee.

9.Withholding Tax.

(a)Generally. Awardee is liable and responsible for all taxes owed in connection with the Restricted Share Units (including taxes owed with respect to the cash payments described in Paragraph 6), regardless of any action the Company takes with respect to any tax withholding obligations that arise in connection with the Restricted Share Units. The Company does not make any representation or undertaking regarding the tax treatment or the treatment of any tax withholding in connection with the grant, vesting or payment of the Restricted Share Units or the subsequent sale of Shares issuable pursuant to the Restricted Share Units. The Company does not commit and is under no obligation to structure the


Restricted Share Units to reduce or eliminate Awardee’s tax liability.

(b)Payment of Withholding Taxes. Prior to any event in connection with the Restricted Share Units (e.g., vesting or payment) that the Company determines may result in any domestic or foreign tax withholding amounts being paid by the Company, whether national, federal, state or local, including any employment tax obligation (the “Tax Withholding Obligation”), Awardee is required to arrange for the satisfaction of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company. Awardee’s acceptance of this Agreement constitutes Awardee’s instruction and authorization to the Company to withhold on Awardee’s behalf the number of Shares from those Shares issuable to Awardee under this Award as the Company determines to be sufficient to satisfy the Tax Withholding Obligation. In the case of any amounts withheld for taxes pursuant to this provision in the form of Shares, the amount withheld may not exceed the amount legally required, and withholding above the minimum withholding requirements shall be available only if and to the extent that the Administrator has authorized such. The Company has the right to deduct from all cash payments paid pursuant to Paragraph 6 the amount of any taxes which the Company is required to withhold with respect to such payments.

10.Governing Law/Venue for Dispute Resolution/Costs and Legal Fees. This Agreement is governed by the laws of the State of Ohio, without regard to principles of conflicts of law, except to the extent superseded by the laws of the United States of America. The parties agree and acknowledge that the laws of the State of Ohio bear a substantial relationship to the parties and/or this Agreement and that the Restricted Share Units and benefits granted in this Agreement would not be granted without the governance of this Agreement by the laws of the State of Ohio. In addition, all legal actions or proceedings relating to this Agreement must be brought exclusively in state or federal courts located in Franklin County, Ohio and the parties executing this Agreement hereby consent to the personal jurisdiction of such courts. Awardee acknowledges that the covenants contained in Paragraph 4 are reasonable in nature, are fundamental for the protection of the Company’s legitimate business and proprietary interests, and do not adversely affect Awardee’s ability to earn a living. In the event that it becomes necessary for the Company to institute legal proceedings under this Agreement, Awardee is responsible to the Company for all costs and reasonable legal fees incurred by the Company in connection with the proceedings. Any provision of this Agreement which is determined by a court of competent jurisdiction to be invalid or unenforceable or to disqualify the Award under any Applicable Law should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by the provision, without invalidating or rendering unenforceable the remaining provisions of this Agreement.

11.Defend Trade Secrets Act Notice. Under the U.S. Defend Trade Secrets Act of 2016, Awardee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law; (b) is made to Awardee’s attorney in relation to a lawsuit for retaliation against Awardee for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

12.Action by the Administrator. The parties agree that the interpretation of this Agreement rests exclusively and completely within the sole discretion of the Administrator. The parties agree to be bound by the decisions of the Administrator with regard to the interpretation of this Agreement and with regard to any and all matters set forth in this Agreement. In fulfilling its responsibilities under this Agreement, the Administrator may rely upon documents, written statements of the parties, financial reports or other material as the Administrator deems appropriate. The parties agree that there is no right to


be heard or to appear before the Administrator and that any decision of the Administrator relating to this Agreement, including whether particular conduct constitutes Misconduct or Competitor Conduct, is final and binding. The Administrator may delegate its functions under this Agreement to an officer of the Cardinal Group designated by the Administrator, to the extent permitted under the Plan.

13.Prompt Acceptance of Agreement. The Restricted Share Unit grant evidenced by this Agreement will, at the discretion of the Administrator, be forfeited if this Agreement is not manually executed and returned to the Company, or electronically executed by Awardee by indicating Awardee’s acceptance of this Agreement in accordance with the acceptance procedures set forth on the Company’s third-party equity plan administrator’s web site, within 90 days of the Grant Date.

14.Electronic Delivery and Consent to Electronic Participation. The Company may, in its sole discretion, decide to deliver any documents related to the Restricted Share Unit grant under and participation in the Plan or future Restricted Share Units that may be granted under the Plan by electronic means or to request Awardee’s consent to participate in the Plan by electronic means. Awardee hereby consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company, including the acceptance of restricted share unit grants and the execution of restricted share unit agreements through electronic signature.

15.Notices. All notices, requests, consents and other communications required or provided under this Agreement to be delivered by Awardee to the Company will be in writing and will be deemed sufficient if delivered by hand, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to the Company at the address set forth below:

Cardinal Health, Inc.
7000 Cardinal Place
Dublin, Ohio 43017
Attention: Deputy General Counsel

All notices, requests, consents and other communications required or provided under this Agreement to be delivered by the Company to Awardee may be delivered by e-mail or in writing and will be deemed sufficient if delivered by e-mail, hand, facsimile, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to Awardee.
16.Employment Agreement, Offer Letter or Other Arrangement. To the extent a written employment agreement, offer letter or other arrangement (“Employment Arrangement”) that was approved by the Human Resources and Compensation Committee or the Board of Directors or that was approved in writing by an officer of the Company pursuant to delegated authority of the Human Resources and Compensation Committee provides for greater benefits to Awardee with respect to vesting of the Award on Termination of Employment by reason of specified events than provided in this Agreement or in the Plan, then the terms of such Employment Arrangement with respect to vesting of the Award on Termination of Employment by reason of such specified events supersede the terms of this Agreement to the extent permitted by the terms of the Plan.

17.Recoupment. This Agreement will be administered in compliance with Section 10D of the Exchange Act and any applicable rules or regulations promulgated by the Securities and Exchange Commission or any national securities exchange or national securities association on which the Shares


may be traded. In its discretion, moreover, the Administrator may require repayment to the Company of all or any portion of this Award if the amount of the Award was calculated based upon the achievement of financial results that were subsequently the subject of a restatement of the Company’s financial statements, Awardee engaged in misconduct that caused or contributed to the need for the restatement of the financial statements, and the amount payable to Awardee would have been lower than the amount actually paid to Awardee had the financial results been properly reported. This Paragraph 17 is not the Company’s exclusive remedy with respect to such matters. Except as otherwise required by Applicable Law, this Paragraph 17 will not apply after a Change of Control.

18.Amendment. Any amendment to the Plan is deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto; provided, however, that no amendment may impair the rights of Awardee with respect to an outstanding Restricted Share Unit unless agreed to by Awardee and the Company, which agreement must be in writing and signed by Awardee and the Company. Other than following a Change of Control, no such agreement is required if the Administrator determines in its sole discretion that such amendment either (a) is required or advisable in order for the Company, the Plan or the Restricted Share Units to satisfy any Applicable Law or to meet the requirements of any accounting standard or (b) is not reasonably likely to significantly diminish the benefits provided under the Restricted Share Units, or that any such diminishment has been adequately compensated, including pursuant to Section 16(c) of the Plan.

19.Adjustments. The number of Shares issuable for each Restricted Share Unit and the other terms and conditions of the Award evidenced by this Agreement are subject to adjustment as provided in Section 16 of the Plan.

20.Compliance with Section 409A of the Code. To the extent applicable, it is intended that this Agreement comply with the provisions of Section 409A of the Code. This Agreement shall be administered in a manner consistent with this intent, and any provision that would cause this Agreement or the Plan to fail to satisfy Section 409A of the Code shall have no force or effect until amended to comply with Section 409A of the Code (which amendment may be retroactive to the extent permitted by Section 409A of the Code and may be made by the Company without the consent of Awardee).

21.No Right to Future Awards or Employment. The grant of the Restricted Share Units under this Agreement to Awardee is a voluntary, discretionary award being made on a one-time basis and it does not constitute a commitment to make any future awards. The grant of the Restricted Share Units and any payments made under this Agreement will not be considered salary or other compensation for purposes of any severance pay or similar allowance, except as otherwise required by law. Nothing contained in this Agreement confers upon Awardee any right to be employed or remain employed by the Company or any of its Affiliates, nor limits or affects in any manner the right of the Company or any of its Affiliates to terminate the employment or adjust the compensation of Awardee.

22.Successors and Assigns. Without limiting Paragraph 2, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of Awardee, and the successors and assigns of the Company.

CARDINAL HEALTH, INC.

By: __________________                        
Its: __________________                        





ACCEPTANCE OF AGREEMENT
Awardee hereby: (a) acknowledges that he or she has received a copy of the Plan, a copy of the Company’s most recent annual report to shareholders and other communications routinely distributed to the Company’s shareholders, and a copy of the Plan Description pertaining to the Plan; (b) accepts this Agreement and the Restricted Share Units granted to him or her under this Agreement subject to all provisions of the Plan and this Agreement, including the provisions in the Agreement regarding “Special Forfeiture and Repayment Rules” set forth in Paragraph 4 and “Recoupment” set forth in Paragraph 17; (c) represents that he or she understands that the acceptance of this Agreement through an on-line or electronic system, if applicable, carries the same legal significance as if he or she manually signed the Agreement; (d) agrees that no transfer of the Shares delivered in respect of the Restricted Share Units may be made unless the Shares have been duly registered under all applicable Federal and state securities laws pursuant to a then-effective registration which contemplates the proposed transfer or unless the Company has received a written opinion of, or satisfactory to, its legal counsel that the proposed transfer is exempt from such registration; and (e) acknowledges that any Cash Awards granted to Awardee under the Plan are subject to the “Special Forfeiture and Repayment Rules” set forth in Section 13(e) of the Plan and “Recoupment” set forth in Section 20 of the Plan and agrees to be bound by these provisions with respect to such Cash Awards.
____________________                        
Awardee’s Signature

____________________                        
Date


 EX-10.4 5 a20q210q123119exhibit1.htm EXHIBIT 10.4 Exhibit
Exhibit 10.4

















CARDINAL HEALTH DEFERRED COMPENSATION PLAN
















Amended and Restated Effective January 1, 2020




TABLE OF CONTENTS
 
 
 Page

ARTICLE I
DEFINITIONS AND GENERAL PROVISIONS
1
ARTICLE II
ELIGIBILITY AND PARTICIPATION
6
ARTICLE III
DEFERRED COMPENSATION AND MATCHING CREDITS
7
ARTICLE IV
VESTING
12
ARTICLE V
DISTRIBUTION OF BENEFITS
13
ARTICLE VI
PLAN ADMINISTRATION
17
ARTICLE VII
AMENDMENT AND TERMINATION
20
ARTICLE VIII
MISCELLANEOUS PROVISIONS      
21
Appendix A
Claims and Appeals
24
    



CARDINAL HEALTH
DEFERRED COMPENSATION PLAN
The Cardinal Health Deferred Compensation Plan (the “Plan”) is hereby amended and restated effective as of January 1, 2020 by Cardinal Health, Inc., an Ohio corporation (the “Company”), for the benefit of members of the Board of Directors of the Company and a select group of the management and highly compensated employees of the Company and of its affiliated entities which participate in this Plan with the consent of the Company.
Background Information
A.    The Company desires to continue to maintain the Plan in order to provide its Directors and certain of its highly compensated and management employees with the opportunity to defer a portion of the base salary, bonuses and other cash compensation otherwise payable to them.

B.    The Company intends for the Plan to continue to be an unfunded, nonqualified deferred compensation arrangement as provided under the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) and to satisfy the requirements of a “top hat” plan thereunder and under Labor Reg. Sec. 2520.104-23.

C.    This amended and restated Plan is intended to continue to comply with the requirements of The American Jobs Creation Act of 2004 (“AJCA”), Section 409A of the Internal Revenue Code of 1986, as amended (“Code”), and final regulations and other rulings issued by the Internal Revenue Service (“IRS”) thereunder.
ARTICLE I

DEFINITIONS AND GENERAL PROVISIONS

1.1 Definitions. Unless the context requires otherwise, the terms defined in this Article shall have the meanings set forth below unless the context clearly requires another meaning. When the defined meaning is intended, the term is capitalized:

(a)Account. The bookkeeping account described in Section 3.4 under which benefits and earnings are credited on behalf of a Participant.

(b)Administrative Committee.    The Financial Benefit Plans Committee of the Company.

(c)Beneficiary. The person(s) entitled to receive any distribution hereunder upon the death of a Participant. The Beneficiary for benefits payable under this Plan shall be the beneficiary designated by the Participant in accordance with procedures established by the Administrative Committee as of the Participant’s date of death, or, in the absence of any such designation, the Participant’s estate.

(d)Board. The Board of Directors of the Company.

(e)Change of Control. For purposes of the Plan, a Change of Control means:



A. the acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (a “Person”) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 30 percent or more of either (i) the then outstanding Shares of the Company (the “Outstanding Shares”) or (ii) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Voting Securities”); provided, however, that for purposes of this Subsection A., the following acquisitions do not constitute a Change of Control: (I) any acquisition directly from the Company or any corporation controlled by the Company, (II) any acquisition by the Company or any corporation controlled by the Company, (III) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (IV) any acquisition by any corporation that is a Non-Control Acquisition (as defined in Subsection C. of this Section); or

B. during any period of two consecutive years, individuals who, as of the beginning of such two-year period, constitute the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board of the Company; provided, however, that any individual becoming a Director subsequent to the beginning of such two-year period whose election, or nomination for election by the Company’s shareholders, was approved by a vote of at least a majority of the Directors then comprising the Incumbent Board will be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of Directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

C. consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of the Company or the acquisition by the Company of assets or shares of another corporation (a “Business Combination”), unless, such Business Combination is a Non-Control Acquisition. A “Non-Control Acquisition” means a Business Combination where: (i) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Shares and Outstanding Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50 percent of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership immediately prior to such Business Combination of the Outstanding Shares and Outstanding Voting Securities, as the case may be, (ii) no Person (excluding any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 30 percent or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination (including any ownership that existed in the Company or the company being acquired, if any), and (iii) at least a majority of the members of the board of directors of the corporation resulting from


such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination; or

D. approval by the shareholders of the Company of a complete liquidation or dissolution of the Company.

(f)Code. The Internal Revenue Code of 1986, as amended from time to time.

(g)Committee. The Human Resources and Compensation Committee of the Board.

(h)Company. Cardinal Health, Inc.

(i)Compensation. Amounts paid or payable by the Employer to an Eligible Employee for a Plan Year which are includable in income for federal tax purposes, including base salary and variable compensation in the form of bonuses (except as otherwise provided herein). In addition, cash dividend-equivalent payments under share unit award agreements (“Share Units”) may also be deferred hereunder by Eligible Employees who are Reporting Persons in accordance with procedures established from time to time by the Committee and that comply with Code Section 409A. Notwithstanding the foregoing, the following amounts are excluded from Compensation: (i) other cash or non-cash compensation, expense reimbursements or other benefits or contributions by the Employer to any other employee benefit plan, other than pre-tax salary deferrals into the Qualified Plan or any Code Section 125 plan sponsored by the Company or any of its affiliates; (ii) any bonus payment if such bonus payment is wholly or partially payable without regard to the attainment of a Performance-Based goal (i.e., guaranteed); (iii) commissions; (iv) amounts realized (A) from the exercise of a stock option, (B) when restricted stock (or property) held by a Participant either becomes freely transferable or is no longer subject to a substantial risk of forfeiture, (C) when the Shares underlying Share Units are payable to a Participant, or (D) from the sale, exchange or other disposition of stock acquired under a qualified stock option; and (iv) any amounts that are required to be withheld from a Participant’s wages from the Employer pursuant to Code Section 3102 to satisfy the Participant’s tax obligations under Code Section 3101. With respect to Directors, “Compensation” means any and all fees paid for service as a member of the Board, including fees for attendance at meetings or committee meetings, and cash dividend-equivalent payments under deferred settlement Share Units.

(j)Director. A member of the Board of Directors of the Company who is not also an Eligible Employee.

(k)Distribution Options. A single lump sum or annual installment payments over a period of five or ten years. Except to the extent that another Distribution Option is timely elected by a Participant in accordance with the terms of the Plan and Code Section 409A and regulations thereunder, the form of payment of the Participant’s Account shall be the Standard Option.

(l)Eligible Employee. Any employee of an Employer who is (i) an employee who is a Reporting Person or (ii) (A) among a select group of management or highly compensated employees (within the meaning of Sections 201(2), 301(a)(3) and 401(a) of ERISA), and (B) designated by the Company as eligible to make Compensation deferral contributions under Article II of the Plan in accordance with eligibility criteria established from time to time by the Administrative Committee, the Committee or the Board. In lieu of expressly designating individual employees as Eligible Employees, the Company may establish eligibility criteria providing for designation as Eligible Employees of all employees who satisfy such criteria.



(m)Employer. The Company and any affiliate thereof or successor thereto which adopts and participates in the Plan. Any affiliate that has U.S. employees and is a member of a controlled group of corporations or other business entities within the meaning of Code Sections 414(b) and (c) that includes Cardinal Health, Inc. may participate in the Plan. Such participation in the Plan shall continue only so long as the affiliate remains a member of a controlled group of corporations or other business entities within the meaning of Code Sections 414(b) and (c) that includes Cardinal Health, Inc.

(n)ERISA. The Employee Retirement Income Security Act of 1974, as amended from time to time.

(o)Participant. Any Director or any Eligible Employee who meets the eligibility requirements for participation in the Plan as set forth in Article II and who earns benefits under the Plan.

(p)Participation Agreement. An agreement, in written or electronic form as established by the Administrative Committee from time to time, by which a Participant agrees to defer some of his Compensation and/or makes an election of the time and/or form of payment of amounts credited to the Participant’s Account in accordance with the Plan.

(q)Performance-Based. A bonus or other payment of Compensation is Performance-Based if the amount of the payment or the entitlement thereto is contingent on the satisfaction of organizational or individual performance criteria relating to a performance period of at least 12 consecutive months. The organizational or individual performance criteria shall be established in writing no later than 90 days after the beginning of the period of service to which the criteria relate, and the outcome must be substantially uncertain at the time the criteria are established. Notwithstanding the above, a Performance-Based Bonus may be based on subjective performance criteria, provided that:

A.The subjective performance criteria are bona fide and relate to the performance of the Participant, a group of service providers that includes the Participant, or a business unit for which the Participant provides services (which may include the entire organization); and

B.the determination that any subjective performance criteria have been met is not made by the Participant or a family member of the Participant (as defined in Code Section 267(c)(4) applied as if the family of an individual includes the spouse of any member of the family), or a person under the effective control of the Participant or such a family member, and no amount of the Compensation of the person making such determination is effectively controlled in whole or in part by the Participant or such a family member.

(r)Plan. The Cardinal Health Deferred Compensation Plan, as set forth herein, and as such Plan may be amended from time to time hereafter.

(s)Plan Year. The fiscal year of the Plan, which is the 12 consecutive month period beginning January 1 and ending December 31.

(t)Qualified Plan. The Cardinal Health 401(k) Savings Plan, as amended from time to time.

(u)Reporting Person. Eligible Employees and Directors who are subject to Section 16 of the Securities Exchange Act of 1934, as amended.



(v)Retirement. An Eligible Employee’s Separation from Service with the Employer following attainment of age 65 or retirement from the Board of any Director.

(w)Separation from Service. An Eligible Employee separates from service with the Employer if the Eligible Employee dies, retires or otherwise has a termination of employment with the Employer. Whether a termination of employment has occurred is determined based on whether the facts and circumstances indicate that the Employer and the Eligible Employee reasonably anticipated that no further services would be performed after a certain date or that the level of bona fide services the Eligible Employee would perform after such date (as an employee or independent contractor) would permanently decrease to no more than 20 percent of the average level of bona fide services performed over the immediately preceding 36-month period (or the full period in which the Eligible Employee provided services to the Employer if the Eligible Employee has been providing services for less than 36 months). An Eligible Employee will not be deemed to have experienced a Separation from Service if such Eligible Employee is on military leave, sick leave, or other bona fide leave of absence, to the extent such leave does not exceed a period of six months or, if longer, such longer period of time during which a right to re-employment is protected by either statute or contract. If the period of leave exceeds six months and the individual does not retain a right to re-employment under an applicable statute or by contract, the employment relationship is deemed to terminate on the first date immediately following such six-month period. In the case of a Director, a separation from service occurs upon the termination of the Director’s service on the Board, provided, however, that a Director who is also providing services to the Employer as an independent contractor, does not have a Separation from Service until he has separated from service both as a Director and as an independent contractor. If an Eligible Employee provides services both as an employee and as a member of the Board, the services provided as a Director are generally not taken into account in determining whether the Eligible Employee has a Separation from Service as an employee for purposes of the Plan, in accordance with final regulations under Code Section 409A.

(x)Shares. The common shares, without par value, of the Company.

(y)Standard Option. A single lump sum payment.

(z)Total Disability. Occurs when a Participant is unable to engage in any substantial gainful activity and has qualified for benefits under the Company’s long term disability plan by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months. A Participant shall also be deemed to be totally disabled if determined to be totally disabled by the Social Security Administration. The Administrative Committee may require the Participant to submit to periodic medical examinations at the Participant’s expense to confirm the existence and continuation of a Total Disability.

1.2 General Provisions. The masculine wherever used herein shall include the feminine; singular and plural forms are interchangeable. Certain terms of more limited application have been defined in the provisions to which they are principally applicable. The division of the Plan into Articles and Sections with captions is for convenience only and is not to be taken as limiting or extending the meaning of any of its provisions.

ARTICLE II

ELIGIBILITY AND PARTICIPATION



2.1 General Eligibility Conditions. To become eligible to participate in the Plan, an individual must be (i) a Director, or (ii) an Eligible Employee. In order to receive a benefit under the Plan, however, a Participant must also meet the requirements of Sections 2.2 and 2.3. An Eligible Employee or a Director shall be considered eligible to participate in the Plan effective as of the date he first becomes a Director or an Eligible Employee in accordance with this Plan (the “Eligibility Effective Date”).

2.2 Specific Conditions for Active Participation. To participate actively in the Plan (i.e., to make deferrals hereunder), a Participant must execute or acknowledge a Participation Agreement in accordance with the terms and conditions of the Plan. Each Participation Agreement shall be maintained by or on behalf of the Administrative Committee and must be executed, acknowledged, filed or submitted electronically within 30 days of the Eligibility Effective Date and, for all subsequent deferral elections after initial participation, in advance of the beginning of the calendar year during which such compensation is expected to be earned, or at such other time as may be required or permitted by regulations issued under Code Section 409A. In all cases, a Participant’s election to defer Compensation shall be made prior to the time any of the Compensation covered by such election is to be earned by such Participant. Elections to participate and defer Compensation shall be irrevocable with respect to the Compensation to which they apply and may be amended, revoked or suspended by the Participant only effective as of the January 1st following the amendment, revocation or suspension in accordance with procedures established by the Administrative Committee, unless transition rules and regulations under Code Section 409A permit amendment, revocation or suspension as of some other time. With respect to Matching, Employer Contribution Credits and Social Security Supplement Credits, the Eligible Employee must designate a time and form of payment within 30 days of the Eligibility Effective Date; provided, however, that with respect to any Participant whose initial Eligibility Effective Date occurs on or after January 1, 2016, the initial Distribution Option applicable to the portion of such Participant’s Account that is attributable to any Employer Contribution Credit and/or Social Security Supplement Credit (as defined in Section 3.3 herein) credited to such Participant’s Account during the Plan Year in which the Participant’s Eligibility Effective Date first occurs (or, to the extent that there is no Employer Contribution Credit or Social Security Supplement Credit credited to such Participant’s Account during such Plan Year, any Employer Contribution Credit and/or Social Security Supplement Credit credited to such Participant’s Account during the next succeeding Plan Year) shall be the Standard Option, notwithstanding any installment Distribution Option election that may be made by such Participant in accordance this Section 2.2 for the remainder of the Participant’s Account.

2.3 Suspension of Active Participation. Any Participant who ceases to be an Eligible Employee or a Director for a given Plan Year shall cease to have any right to defer Compensation for such Plan Year or to receive Matching, Employer Contribution Credits and Social Security Supplement Credits for such Plan Year. However, any amounts credited to the Account of a Participant whose participation is suspended shall otherwise continue to be maintained under the Plan in accordance with its terms, and any election to defer Compensation made by a Participant, once it has become irrevocable in accordance with the Plan, shall continue to be irrevocable with respect to Compensation to which it applies for the remainder of the Plan Year for which it is made, notwithstanding any subsequent change in the Participant’s eligibility during such Plan Year.

2.4 Termination of Participation. Once a Director or an Eligible Employee becomes a Participant, such individual shall continue to be a Participant until such individual (i) ceases to be described as a Director or as an Eligible Employee, and (ii) ceases to have any vested interest in the Plan (as a result of distributions made to such Participant or his Beneficiary, if applicable, or otherwise).

ARTICLE III



DEFERRED COMPENSATION AND MATCHING CREDITS

3.1 Deferred Compensation Credits. Pursuant to the provisions of Article II and this Article III, a Participant and the Employer may, by mutual agreement, provide for deferred and postponed payment of a percentage of the Participant’s Compensation which otherwise would be paid during the applicable Plan Year(s) for services to be rendered in such year(s). Except as otherwise provided herein with respect to Performance-Based Compensation, all elections to defer Compensation must be made within 30 days after the Participant’s Eligibility Effective Date and, for subsequent elections after initial eligibility, prior to the calendar year during which the Compensation is expected to be earned or at such other time as may be specified under regulations issued under the Code. In the case of the deferral of any Performance-Based Compensation, such election must be made no later than six months before the end of the performance period, provided that in no event may an election to defer Performance-Based Compensation be made after such Compensation has become readily ascertainable within the meaning of Code Section 409A. Notwithstanding the foregoing, in the case of the deferral of any Performance-Based Compensation with a performance period exceeding one year in length, the deferral election must be made no later than halfway through such performance period. If an Eligible Employee has ceased being eligible to participate in the Plan (other than the accrual of earnings on his Account, if any), regardless of whether all amounts deferred under the Plan have yet been paid, and subsequently becomes eligible to participate in the Plan again, the Eligible Employee may be treated, to the extent permitted by Code Section 409A as being initially eligible to participate in the Plan if he has not been eligible to participate in the Plan (other than the accrual of earnings on his Account, if any) at any time during the 24-month period ending on the date the employee again becomes an Eligible Employee under the Plan.

A Participant who is an Eligible Employee may defer between one percent and 50 percent of Compensation that is not Performance-Based Compensation and may make one or more separate elections for the deferral of from one percent to 80 percent of Performance-Based Compensation from each plan or arrangement offering the opportunity to earn such Compensation. A Participant who is a Director may defer between 20 percent and 100 percent of Compensation. The Company may, in its discretion, establish and change from time to time the minimum and maximum amount that may be so deferred for Participants who are not Reporting Persons. Elections shall be made in accordance with procedures established by the Administrative Committee. The Employer will credit the deferred compensation amount agreed to for each Plan Year to the Participant’s Account from time to time as soon as administratively practicable after the deferred amounts otherwise would have been earned and paid to the Participant. All contributions under this provision to the Accounts of Participants in the Plan, as adjusted for earnings or losses (described below), are referred to as “Deferred Compensation Credits.”

In addition to the Deferred Compensation Credits described above, Reporting Persons who have elected to defer receipt of Shares to be issued under Share Units awarded on or after November 1, 2006, shall automatically have 100 percent of the cash dividend-equivalents that are vested and payable under such Share Units deferred under this Plan. Such amounts shall be referred to as “Deferred Cash Equivalent Credits.” Deferred Cash Equivalent Credits are always 100 percent vested and nonforfeitable but are not eligible for Matching Credits.

3.2 Matching Credits. The Employer may, in its discretion, credit to a Participant’s Account each Plan Year during which the Participant is an Eligible Employee an amount equal to a percentage of the Participant’s Deferred Compensation Credits as a matching contribution. The amount of any such contributions may vary from year to year or among Participants in the discretion of the Employer. In general, such matching contributions may be made at the same rate as is applicable to the Participant under the Qualified Plan, but only with respect to the first $100,000 of Compensation in excess of the maximum amount


of Compensation recognized under the Qualified Plan under Section 401(a)(17) of the Code. All contributions under this provision to the Accounts of Participants in the Plan, as adjusted for earnings or losses (described below), are referred to as “Matching Credits.” The Employer may, in its discretion, also make an additional matching contribution to the Accounts of certain Participants who have been required to forfeit Employer matching contributions under the Qualified Plan. Such contributions, if any, shall be in an amount equal to the Employer matching contribution forfeited under the Qualified Plan by an affected Participant and shall be made and allocated to the Accounts of affected Participants in the Plan Year during which such forfeitures occur. Any additional Employer matching contributions under the foregoing sentence shall be fully vested when made and subject to the distribution elections in effect with respect to the Participant’s Account as of the beginning of the Plan Year in which the contribution is made.

3.3 Employer Contribution and Social Security Supplement Credits. The Employer may, in its discretion, credit to the Participant’s Account each Plan Year (a) an amount equal to a percentage of the Participant’s Compensation from the Employer for the fiscal year ending within the Plan Year in excess of the dollar limitation applicable to such fiscal year under Section 401(a)(17) of the Code, but not more than an excess of $100,000 above such compensation limit, and (b) such other amount as the Employer may determine, in its sole discretion. All contributions under this provision to the Accounts of Participants in the Plan, as adjusted for earnings or losses (described below), are referred to as “Employer Contribution Credits.” In addition, the Employer may make an additional discretionary contribution for a Plan Year to the Participant’s Account, as determined by the Employer in its discretion, equal to a percentage of the Participant’s Compensation from the Employer for the fiscal year ending within the Plan Year in excess of the dollar limitation applicable to such fiscal year under Section 401(a)(17) of the Code, but not more than an excess of $100,000 above such compensation limit, for the purpose of supplementing the benefits the Participant will receive at retirement under the Social Security program. All contributions under this provision to the Accounts of Participants in the Plan, as adjusted for earnings or losses (described below), are referred to as “Social Security Supplement Credits.” Contributions made to Participant Accounts under this Section may be subject to additional requirements as established from time to time by the Administrative Committee, such as a requirement to be employed on the last day of the year for which such contribution is made. The Employer may, in its discretion, also make an additional contribution to the Accounts of certain Participants who have been required to forfeit Employer contributions (other than matching contributions) under the Qualified Plan. Such contributions, if any, shall be in an amount equal to the Employer contribution forfeited under the Qualified Plan by an affected Participant and shall be made and allocated to the Accounts of affected Participants in the Plan Year during which such forfeitures occur. Any additional Employer contributions under the foregoing sentence shall be subject to the vesting requirements applicable to Employer Contribution Credits and the distribution elections in effect with respect to the Participant’s Account as of the beginning of the Plan Year in which the contribution is made.

3.4 Record of Account. Solely for the purpose of measuring the amount of the Employer’s obligations to each Participant or his beneficiaries under the Plan, the Employer will maintain a separate bookkeeping record, an “Account,” for each Participant in the Plan. The Company, in its discretion, may either credit a hypothetical earnings rate to the Participant’s Account balance for the Plan Year, or may actually invest an amount equal to the amount credited to the Participant’s Account from time to time in an account or accounts in its name with investment media or companies, which investment options may include some or all of those used for investment purposes under the Qualified Plan, as determined by the Company in its discretion. The Company may also establish a deferred compensation trust that qualifies as a so-called “rabbi” trust meeting applicable requirements of Code Section 409A. The Participant may change the allocation of his Account among the applicable investment alternatives then available under the Plan in accordance with procedures established by the Administrative Committee from time to time. In no event, however, shall a Participant who is a Reporting Person be permitted to change any amounts invested in any other investment alternative


to a Cardinal Stock Account (as defined below). In addition, a Participant who is a Reporting Person shall not be permitted to change any investment in a Cardinal Stock Account to any other investment alternative. After a Participant ceases to be a Reporting Person, such Participant may again change investments into or out of a Cardinal Stock Account in accordance with rules established by the Administrative Committee and without regard to the above restrictions. The Company is not obligated to make any particular investment options available, however, if investments are in fact made, and may, from time to time in its sole discretion, change the investment alternatives. Nothing herein shall be construed to confer on the Participant the right to continue to have any particular investment available.

The Company will credit the Participant’s Account with hypothetical or actual earnings or losses at least quarterly based on the earnings rate declared by the Company or the performance results of the Employer’s account(s) invested pursuant to the Company’s or the Participant’s directions, and shall determine the fair market value of the Participant’s Account based on the bookkeeping record or the fair market value of the portion of the Employer’s accounts representing the Participant’s Account. The determination of the earnings, losses or fair market value of the Participant’s Account may be adjusted by the Company to reflect its payroll, income or other taxes or costs associated with the Plan, as determined by the Company in its sole discretion.

3.5 Special Rules Applicable to Investments in Shares. Subject to the provisions of this Article III, a Participant may also elect to have all or a portion of his Account, but not including any Deferred Cash Equivalent Credits, to be deemed invested in Shares (such dollar amounts shall be referred to as the “Share Election Accumulations”). On the date when the amounts to be credited to the Participant’s Share Election Accumulations are otherwise allocated to his Account, the Company will credit to a separate sub-account (the Participant’s “Cardinal Stock Account”) a number of hypothetical Shares (and fractions thereof) having a Value equal to the Share Election Accumulations. For purposes of this Plan, the “Value” of a Share on a particular day shall mean the closing trading price of a Share on the New York Stock Exchange on that day (or, if there is no trading of the Shares on that day, on the most recent previous date on which trading occurred). With respect to any Director, any election made pursuant to this Section shall be irrevocable for all amounts credited to a Participant’s Account during the Plan Year for which the election is made. Any election made by a Director pursuant to this Section shall remain in effect for amounts credited to the Participant’s Account in subsequent Plan Years unless the Participant delivers a written notice to the Secretary of the Company setting forth a different investment election or otherwise makes a different investment election in accordance with procedures established by the Committee from time to time. Any such change in investment election shall be applied to future Plan Years until further notice is given by the Participant changing the election in accordance with the requirements of this Section. Except for Directors, no other Reporting Person may elect to invest future contributions in his Account in Shares. Such other Reporting Person may again elect to invest future contributions in his Account in Shares subject to this Section 3.5 after he ceases to be a Reporting Person. For the avoidance of doubt, a Participant’s election to have any portion of his Account deemed invested in Shares shall not create with respect to such Participant any ownership or voting rights in such Shares.
If any Organic Change shall occur, then the Committee shall make such substitutions or adjustments as it deems appropriate and equitable to each Participant’s Cardinal Stock Account (if any). In the case of Organic Changes, such adjustments may include, without limitation, (x) the cancellation of outstanding Shares in exchange for payments of cash, property or a combination thereof having an aggregate value equal to the value of such Shares, as determined by the Committee in its sole discretion, (y) the substitution of other property (including, without limitation, cash or other securities of the Company and securities of entities other than the Company) for the Shares, and (z) in connection with any Disaffiliation, arranging for the assumption or replacement of Shares with new shares based on other property or other securities (including, without limitation, other securities of the Company and securities of entities other


than the Company), by the affected subsidiary, affiliate or division or by the entity that controls such subsidiary, affiliate or division following such Disaffiliation (as well as any corresponding adjustments to awards that remain based upon Company securities). An “Organic Change” includes (i) a stock dividend, stock split, reverse stock split, share combination, or recapitalization or similar event affecting the capital structure of the Company (each, a “Share Change”), or (ii) a merger, consolidation, acquisition of property or shares, separation, spin-off, reorganization, stock rights offering, liquidation, disaffiliation from the Company of a subsidiary or division (“Disaffiliation”), or similar event affecting the Company or any of its subsidiaries (each, an “Organic Change”). If the assets held in the Participant’s Cardinal Stock Account immediately after such adjustment are not equity securities, then the Participant shall be permitted to re-direct the investment thereof into the other investment choices then available under this Plan.

In the case of the Cardinal Stock Account (if any) of a Participant other than a Reporting Person (as of the Dividend Payment Date), the earnings (or losses) credited to such account shall consist solely of dividend equivalent credits pursuant to this paragraph. Whenever a dividend or other distribution is made with respect to the Shares, then the Cardinal Stock Account of a Participant who is not a Reporting Person (as of the Dividend Payment Date) shall be credited, on the payment date for such dividend or other distribution (the “Dividend Payment Date”), with a number of additional Shares having a Value, as of the Dividend Payment Date, based upon the number of Shares deemed to be held in the Participant’s Cardinal Stock Account as of the record date for such dividend or other distribution (the “Dividend Record Date”), if such Shares were outstanding. If such dividend or other distribution is in the form of cash, the number of Shares so credited shall be a number of Shares (and fractions thereof) having a Value, as of the Dividend Payment Date, equal to the amount of cash that would have been distributed with respect to the Shares deemed to be held in the Participant’s Cardinal Stock Account as of the Dividend Record Date, if such Shares were outstanding. If such dividend or other distribution is in the form of Shares, the number of Shares so credited shall equal the number of such Shares (and fractions thereof) that would have been distributed with respect to the Shares deemed to be held in the Participant’s Cardinal Stock Account as of the Dividend Record Date, if such Shares were outstanding. If such dividend or other distribution is in the form of property other than cash or Shares, the number of Shares so credited shall be a number of Shares (and fractions thereof) having a Value, as of the Dividend Payment Date, equal to the value of the property that would have been distributed with respect to the Shares deemed to be held in the Participant’s Cardinal Stock Account as of the Dividend Record Date, if such Shares were outstanding. The value of such property shall be its fair market value as of the Dividend Payment Date, determined by the Board based upon market trading if available and otherwise based upon such factors as the Board deems appropriate.

With respect to a Participant who is a Reporting Person on the Dividend Payment Date, the cash value of the dividend or other distribution shall be invested in an alternate investment option under the Plan, as determined by the Administrative Committee in its sole discretion. To the extent that the dividend or other distribution is made in a form other than cash, the Shares or other property shall be liquidated to cash as soon as administratively practicable and thereafter invested as indicated herein.

ARTICLE IV

VESTING

4.1 Vesting. A Participant always will be 100 percent vested in amounts credited to his Account as Deferred Compensation Credits, Deferred Cash Equivalent Credits, Matching Credits made on or after January 1, 2005 and earnings allocable thereto. The Participant or his Beneficiaries shall be entitled to benefits from Matching Credits made prior to January 1, 2005, Employer Contribution Credits and Social


Security Supplement Credits allocated to his Account by the Employer, and earnings thereon, only upon satisfaction of the vesting requirements of this Article IV. The Participant shall become 100 percent vested in his Account upon his Retirement, death, or Total Disability. The Participant shall also become 100 percent vested in his Account if the Participant is terminated by the Company without Cause or the Participant terminates employment with the Company for Good Reason within two years after a Change of Control. For this purpose, “Cause” means termination of employment by the Company on account of any act of fraud or intentional misrepresentation or embezzlement, intentional misappropriation, or conversion of assets of the Company or any affiliate, or the intentional and repeated violation of the written policies or procedures of the Company, provided that for a Participant who is party to an individual severance or employment agreement defining Cause, “Cause” has the meaning set forth in such agreement. For purposes of the Plan, a Participant’s termination will not be deemed to be a termination without “Cause” if, after the Participant’s employment has terminated, facts and circumstances are discovered that would have, in the opinion of the Committee, met the definition of “Cause.” For this purpose, “Good Reason” means, unless otherwise provided in an individual severance or employment agreement to which the Participant is a party, termination by the Participant on account of any of the following: (i) a material reduction in the Participant’s total compensation; (ii) a material reduction in the Participant’s annual or long-term incentive opportunities (including a material adverse change in the method of calculating the Participant’s annual or long--term incentives); (iii) a material diminution in the Participant’s duties, responsibilities, or authority; or (iv) a relocation of more than 50 miles from the Participant’s office or location, except for travel reasonably required in the performance of the Participant’s responsibilities. If the Participant has a Separation from Service with the Employer for any reason other than Retirement, death, Total Disability, or following a Change of Control under the circumstances described above, all rights of the Participant, his Beneficiaries, executors, administrators, or any other person to receive benefits under this Plan derived from amounts credited as Matching Credits made prior to January 1, 2005, Employer Contribution Credits and Social Security Supplement Credits shall vest as of the date that the Participant has completed three Years of Service with the Employer. A “Year of Service” for this purpose means a period of 12 consecutive calendar months during which the Participant was employed by the Employer, defined to include all members of a controlled group of corporations or other business entities within the meaning of Code Sections 414(b) and (c) that includes Cardinal Health, Inc. If a Participant has a Separation from Service before that date (other than due to a Change of Control, Retirement, death or Total Disability), all Matching Credits made prior to January 1, 2005, Employer Contribution Credits and Social Security Supplement Credits shall be forfeited. If the Participant has a Separation from Service but is subsequently re-employed by the Employer, no benefits forfeited hereunder shall be reinstated unless otherwise determined by the Company in its sole discretion. A Participant who has completed one Year of Service but less than three Years of Service and is terminated from employment under the terms of a designated reduction in force, a divestiture or designated layoff, shall receive additional ratable vesting credit hereunder determined by multiplying the portion of this Account that is subject to the vesting provisions of this Section 4.1 by a fraction, the numerator of which is the Participant’s calendar months of service calculated from his or her date of hire and the denominator of which is 36, and by rounding the product up to the next whole percentage. A month of service shall be included in the calculation of additional vesting credit under this Section if the Participant has performed at least one hour of service during the calendar month. In no event shall a Participant be more than 100 percent vested in any amounts credited to his Account.

4.2 Confidentiality and Non-Competition Agreement. In its discretion, the Employer may require any Eligible Employee selected to become a Participant in the Plan to execute a Confidentiality and Non-Competition Agreement with the Employer in consideration of the benefits to be provided hereunder.

ARTICLE V

DISTRIBUTION OF BENEFITS



5.1 Distribution Timing. A Participant shall receive payment of the amounts credited to his Account upon his Separation from Service due to Retirement or any other reason, or upon his death or Total Disability. The Participant will begin to receive the amount credited to his Account as of such date beginning on the first regular payment processing date to occur at least six months after the date of the Participant’s Separation from Service for reasons other than death or Total Disability. The regular payment processing dates shall be the first business day coinciding with or next following January 15 and July 15 of each calendar year. If payment is to be made in a lump sum, it shall occur on the first regular payment processing date as described above. If payment is to be made in annual installments, it shall commence on such first regular payment processing date, with subsequent annual installments to occur on the same regular payment processing date each year thereafter until the Participant’s Account is distributed in full. In the case of a Participant’s death or Total Disability before payment of the Participant’s Account has commenced, the Participant (or the Participant’s Beneficiaries) will receive or begin to receive the amount credited to his Account on the 15th of the month following notice to the record keeper for the Plan of the Participant’s death or Total Disability, or as soon as administratively practicable, but not more than 90 days, after the date of death or Total Disability. Payment of all such amounts will be made in accordance with the deferral election made under Section 5.5, which may provide for a different time or form of payment for distributions made upon death or Total Disability. In addition, in the case of the deferral of Performance-Based Compensation under the Long Term Incentive Cash Program, payment of all such amounts credited to a Participant’s Account will be made in accordance with the separate deferral election made for such amounts under Section 3.1, which may provide for a different time or form of payment from other amounts credited to the Participant’s Account.

5.2 Distribution upon Retirement or Other Separation from Service; Form of Payment. Upon Retirement or Separation from Service other than due to death or Disability, the Participant shall be eligible to receive payment of the amounts credited to the Participant’s Account in the Standard Option commencing as of the date specified in Section 5.1, above. Alternatively, a Participant may elect another Distribution Option at the time of initial enrollment in the Plan (subject to such limitations as are set forth in the Plan, including in Section 2.2 hereof). The Participant may make a one-time election to change his election of a Distribution Option pursuant to an election made during the annual deferral election period prior to the beginning of a Plan Year, provided said election is made at least 12 months prior to the date that payments would have otherwise begun under such option and provided that payments will also be deferred to a new commencement date that is at least five years later than the original commencement date (i.e., five years after the date of the Participant’s Separation from Service). A Participant may not change a Distribution Option or a distribution date in a manner that does not comply with Code Section 409A. If a Distribution Option election is made or changed and distribution is triggered before 12 months have elapsed, the distribution will be made in accordance with the Distribution Option election in effect prior to the change or, if none, in accordance with the Standard Option. If an annual installment payment method is the selected Distribution Option, the amount of the annual benefit shall equal the amount necessary to fully distribute the Participant’s Account as an annual benefit payable over the installment period, consistent with the following methodology: the amount payable as the annual installment shall equal the value of the Participant’s Account as of the most recent Account valuation date, multiplied by a fraction, the numerator of which is one and the denominator of which is the number of annual installments remaining in the installment period elected by the Participant. For example, assuming a 10 year installment payment period applies, the amount distributed at each of the distribution dates would represent the value of the Participant’s Account as of the most recent valuation date preceding the actual distribution date times the following factors: year one - 10 percent (1/10); year two - 11.11 percent (1/9); year three - 12.5 percent (1/8); year four - 14.29 percent (1/7); year five - 16.66 percent (1/6); year six - 20 percent (1/5); year seven - 25 percent (1/4); year eight - 33.33 percent (1/3); year nine - 50 percent (1/2) and year ten - 100 percent (1/1). Payments of amounts credited


to the Participant’s Account will be made in U.S. dollars, including amounts credited to the Participant’s Cardinal Stock Account, if any.

5.3 Distribution upon Death. In the event of the death of the Participant while receiving benefit payments under the Plan, the Beneficiary or Beneficiaries designated by the Participant shall be paid the remaining payments due under the Plan in accordance with the method of distribution in effect to the Participant at the date of death. In the event of the death of the Participant prior to the commencement of the distribution of benefits under the Plan, such benefits shall be paid to the Beneficiary or Beneficiaries designated by the Participant, beginning as soon as practicable after the Participant’s death.

5.4 Distribution in the Event of Total Disability. Upon the Participant’s Total Disability, the Participant shall be eligible to receive payment of the amounts credited to his Account commencing as soon as practicable after the Administrative Committee is satisfied of the determination of the existence of a Total Disability with respect to such Participant. Total Disability shall be considered to have ended and entitlement to a disability benefit shall cease if the Participant (i) is re-employed by the Employer or one of its affiliates, or (ii) engages in any substantial gainful activity, except for such employment as is found by the Administrative Committee in its sole discretion to be for the primary purpose of rehabilitation or not incompatible with a finding of Total Disability. If entitlement to a disability benefit ceases in accordance with the provisions of this paragraph, the Participant shall not be prevented from qualifying for a benefit under another provision of the Plan. Notwithstanding the foregoing, in no event shall Disability payments cease to a Participant if to do so would violate Code Section 409A.

5.5 Form of Payment upon Death or Total Disability. Benefits payable upon death or Total Disability shall be paid in the Standard Option unless another Distribution Option was timely elected by the Participant upon initial enrollment in the Plan (and subject to such limitations as are set forth in the Plan, including in Section 2.2 hereof) or at least 12 months prior to his death or Total Disability. Each Participant may elect a Distribution Option to apply to distributions made upon death or Total Disability that is different from the Distribution Option applicable to other payment events. The Participant may make a one-time election to change his election of a Distribution Option for death or Total Disability pursuant to an election made during the annual deferral election period prior to the beginning of a Plan Year, provided said election is made at least 12 months prior to the date that payments would have otherwise begun under such option. If a Distribution Option election is made or changed after initial enrollment and the Participant dies or suffers a Total Disability before 12 months have elapsed, the distribution will be made in accordance with the Distribution Option in effect prior to the change or, if none, in accordance with the Standard Option.
 
5.6 Lump Sum Distribution of Small Amounts or upon a Change of Control. If the value of a Participant’s entire Account as of the date it becomes distributable is not greater than the applicable dollar amount under Section 402(g)(1)(B) of the Code, then the Participant’s entire Account balance shall be payable as a single lump sum notwithstanding any other election that may be in effect. In addition, if a Participant has a Separation from Service within two years of a change of control of the Company (as defined in Treasury Regulations Section 1.409A-3(i)(5)), then the Participant’s Account shall be payable in a single lump sum on the first regular payment processing date next following the Participant’s Separation from Service following the change of control, and alternative elections in effect by the Participant shall no longer apply. Notwithstanding the foregoing, if the Participant is a “specified employee” (determined in accordance with Treasury Regulations issued under Code Section 409A) for the year in which the Separation from Service occurs, such lump sum payment shall be made on the first business day that is at least six months after the Separation from Service occurs.



5.7 Withdrawals for Unforeseeable Emergency. Upon the occurrence of an unforeseeable emergency, the Participant shall be eligible to receive payment of the amount necessary to satisfy such emergency plus amounts necessary to pay taxes reasonably anticipated as a result of the distribution, after taking into account the extent to which such hardship is or may be relieved through reimbursement or compensation by insurance or otherwise or by liquidation of the participant’s assets (to the extent such liquidation would not itself cause severe financial hardship), or by cessation of deferrals under the Plan. The amount determined to be properly distributable under this section and applicable regulations under Code Section 409A shall be payable in a single lump sum only. For the purposes of this section, the term “unforeseeable emergency” means a severe financial hardship to the Participant resulting from an illness or accident of the Participant, the Participant’s spouse, or a dependent of the Participant (as defined in Code Section 152(a)); loss of the Participant’s property due to casualty, including the need to rebuild a home following damage not otherwise covered by insurance, for example, not as a result of a natural disaster; or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant, including imminent foreclosure of or eviction from the Participant’s primary residence, the need to pay for medical expenses, including non-refundable deductibles, the cost of prescription drugs, and the need to pay for funeral expenses of a spouse, beneficiary, or dependent. It shall be the responsibility of the Participant seeking to make a withdrawal under this section to demonstrate to the Administrative Committee that an unforeseeable emergency has occurred and to document the amount properly distributable hereunder. After a distribution on account of an unforeseeable emergency, a Participant’s deferral elections shall cease and such Participant will not be permitted to participate in the Plan or elect additional deferrals until the next enrollment following one full year from the date of the distribution on account of an unforeseeable emergency. Such future deferral elections following a distribution on account of an unforeseeable emergency will be treated as an initial deferral election and subject to the rules applicable thereto under the Plan and Code Section 409A.

5.8 Acceleration of Payment. The acceleration of the time and/or form of any payment determined in accordance with the provisions of this Article V, above, shall not be made except due to unforeseeable emergency, as described above, or as set forth below and otherwise permitted by Code Section 409A and the Treasury Regulations and other guidance issued thereunder:

(a) Domestic Relations Order. A payment of all or part of the Participant’s Account may be made to a spouse, former spouse or other dependent under the terms of a domestic relations order (as defined in Code Section 414(p)(1)(B)). The Administrative Committee shall determine whether a payment should be made pursuant to the terms of a domestic relations order and the time and form of such payment.

(b) Employment Taxes. A payment of all or part of the Participant’s Account may be made to the extent necessary to pay the Federal Insurance Contributions Act (“FICA”) tax imposed under Code Sections 3101, 3121(a), and 3121(v)(2) on amounts deferred under the Plan (the “FICA Amount”), income tax at source on wages imposed under Code Section 3401 or the corresponding withholding provisions of applicable state, local, or foreign tax laws as a result of the payment of the FICA Amount, and to pay the additional income tax at source on wages attributable to the pyramiding Code Section 3401 wages and taxes. The total payment under this Section shall not exceed the aggregate of the FICA Amount and the income tax withholding related to such FICA Amount.

(c) Payment of State, Local or Foreign Taxes. Payment may be made to reflect payment of state, local or foreign tax obligations arising from participation in the Plan that apply to an amount deferred under the Plan before the amount is paid or made available to the Participant, plus the income tax at source on wages imposed under Code Section 3401 as a result of such payment; provided, however, that the amount of the payment may not exceed the amount of the taxes due, and the income tax withholding related to such state, local and foreign tax amount.



(d) Income Inclusion under Code Section 409A. Payment may be made at any time the Plan fails to meet the requirements of Code Section 409A and the Treasury Regulations issued thereunder; provided, however, that payment cannot exceed the amount required to be included in income as a result of the failure to comply.

(e) Certain Offsets. Payment may be made as satisfaction of a debt of the Participant to the Employer where: (1) the debt is incurred in the ordinary course of the employment relationship; (2) the entire amount of the offset in any of the Participant’s taxable years does not exceed $5,000; and (3) the reduction is made at the same time and in the same amount as the debt otherwise would have been due and collected from the Participant.

(f) Other Accelerations. The Company may in its discretion accelerate any payment due under the Plan to the extent permitted by Code Section 409A and the regulations thereunder.

5.9 Delay of Payment. The Company may in its discretion delay any payment due under the Plan to the extent permitted by Code Section 409A and the regulations thereunder.

5.10 Assignment and Assumption of Liabilities. In the discretion of the Company, upon the cessation of participation in the Plan by any Participant solely due to the employer of that Participant no longer qualifying as a member of the controlled group of Cardinal Health, Inc. within the meaning of Code Sections 414(b) and (c), all liabilities associated with the Account of such Participant may be transferred to and assumed by the Participant’s employer under a deferred compensation plan established by such employer that is substantially identical to this Plan and that preserves the deferral and payment elections in effect for the Participant under this Plan to the extent required by Code Section 409A. Any such Participant shall not be deemed to have incurred a Separation from Service for purposes of the Plan by virtue of his employer’s ceasing to be a member of the controlled group of Cardinal Health, Inc. The foregoing provision shall be interpreted and administered in compliance with the requirements of Code Section 409A.

ARTICLE VI

PLAN ADMINISTRATION

6.1 Administration. The Plan shall be administered by the Administrative Committee as an unfunded deferred compensation plan that is not intended to meet the qualification requirements of Code Section 401 and that is intended to meet all applicable requirements of Code Section 409A.

6.2 Administrative Committee Meetings and Membership. The Administrative Committee shall be comprised of the following members: (1) Senior Vice President of the Company overseeing Benefits; (2) An individual designated by the Chief Human Resources Officer (“CHRO”) of the Company; (3) Treasurer of the Company; and (4) An individual designated by the Chief Financial Officer (“CFO”) of the Company. Each Member of the Administrative Committee shall serve without the need of a formal appointment or resignation, so long as she or he holds the position, or is designated in writing as the stated designee of the CHRO or CFO. The designee of the CFO shall chair the Administrative Committee.

The Administrative Committee shall meet quarterly as determined by the Administrative Committee and at such other times as necessary to perform its duties. A majority of the members of the Administrative Committee constitutes a quorum. The Administrative Committee may act by a majority vote at a meeting or by a writing approved by a majority of its members without a meeting. The


Administrative Committee may adopt such rules and procedures as are necessary or appropriate, as determined in the Administrative Committee’s discretion, to carry out its responsibilities with respect to the Plan.

6.3 Administrative Committee. The Administrative Committee shall have full power, authority and discretion to control and manage the operation and administration of the Plan. The discretionary authority of the Administrative Committee shall include, but not be limited to, the following:

(a) To determine all questions relating to the rights and status of Eligible Employees and Participants, the value of a Participant’s Account, and the nonforfeitable percentage of each Participant’s Account;

(b) To adopt rules and procedures necessary for the proper and efficient administration of the Plan, provided the rules and procedures are not inconsistent with the terms of this Plan;

(c) To construe, interpret and enforce the terms of the Plan and the rules and regulations it adopts, including the discretionary authority to interpret the Plan documents, documents related to the Plan’s operation, and findings of fact;

(d) To review and render decisions respecting claims (including appeals of denied claims) in accordance with the Plan’s claims procedures;

(e) To furnish an Employer with information that the Employer may require for tax or other purposes;

(f) To engage such legal, accounting, recordkeeping, clerical, investment and/or administrative services that it may deem necessary or appropriate for the proper administration or operation of the Plan;

(g) To engage the services of agents whom it may deem advisable to assist it with the performance of its duties;

(h) To delegate responsibility (including the responsibilities described in this Section 6.3) to others, including, but not limited to benefits staff of the Company and third parties engaged to provide services to the Plan;

(i) To keep such records, books of account, data and other documents as may be necessary for the proper administration of the Plan;

(j) To prepare and distribute to Participants and Beneficiaries information concerning the Plan and their rights under the Plan;

(k) To determine the times and places for holding meetings of the Administrative Committee and the notice to be given of such meetings; and

(l) To do all things necessary or appropriate to operate and administer the Plan in accordance with its provisions and in compliance with applicable provisions of law.

Without limiting the powers set forth herein, the Administrative Committee shall have the power to change or waive any requirements of the Plan to conform with Code Section 409A or other applicable law or to meet special circumstances not anticipated or covered in the Plan.



When making a determination or calculation, the Administrative Committee shall be entitled to rely upon all valuations, certificates and reports furnished by any funding agent or service provider, upon all certificates and reports made by an accountant, upon all opinions given by any legal counsel selected or approved by the Administrative Committee, and upon any information furnished by a Participant or Beneficiary (including the legal counsel or other representative thereof), an Employer, or the Trustee. The members of the Administrative Committee, the Committee, and the Company and its officers and directors shall, except as otherwise provided by law, be fully protected in respect of any action taken or suffered by them in good faith in reliance upon any such valuations, certificates, reports, opinions, advice, or other information.

Benefits under the Plan shall be paid only if the Administrative Committee (or its delegate) decides in its discretion that the applicant is entitled to such benefits under the Plan.

6.4 Statement of Participant’s Account. The Administrative Committee shall, as soon as practicable after the end of each Plan Year, provide to each Participant a statement setting forth the Account of such Participant under Section 3.4 as of the end of such Plan Year. Such statement shall be deemed to have been accepted as correct unless written notice to the contrary is received by the Administrative Committee within 30 days after providing such statement to the Participant. Account statements may be provided more often than annually in the discretion of the Administrative Committee.

6.5 Filing Claims. Any Participant, Beneficiary or other individual (hereinafter the “claimant”) entitled to benefits under the Plan, or otherwise eligible to participate herein, shall be required to make a claim with the Administrative Committee (or its designee) requesting payment or distribution of such Plan benefits (or written confirmation of Plan eligibility, as the case may be), on such form or in such manner as the Administrative Committee shall prescribe. Unless and until a claimant makes proper application for benefits in accordance with the rules and procedures established by the Administrative Committee, such claimant shall have no right to receive any distribution from or under the Plan. If a claimant’s application is wholly or partially denied, the procedures set forth in Appendix A shall apply.

6.6 Payment of Expenses. All costs and expenses incurred in administering the Plan shall be paid from the Plan unless the Company elects to pay the costs and expenses.

ARTICLE VII

AMENDMENT AND TERMINATION

7.1 Amendment. The Company may amend the Plan at any time and in any respect through a written resolution adopted or approved by the Board, or by:

(a) the Administrative Committee, with respect to any amendment that: (i) is required to comply with a change in applicable law, or (ii) when aggregated with any other amendment or amendments approved on the same date, is reasonably expected to have an annual financial impact on the Company of $5 million or less;

(b) the CHRO of the Company, with respect to any amendment that, when aggregated with any other amendment or amendments approved on the same date, is reasonably expected to have an annual financial impact on the Company of $20 million or less; or

(c) the Chief Executive Officer of the Company.



However, no amendment shall operate retroactively so as to affect adversely any rights to which a Participant may be entitled under the provisions of the Plan as in effect prior to such action.

7.2 Termination. The Company reserves the right to suspend, discontinue or terminate the Plan, at any time in whole or in part; provided, however, that a suspension, discontinuance or termination of the Plan shall not accelerate the obligation to make payments to any person not otherwise currently entitled to payments under the Plan, unless otherwise specifically so determined by the Company and permitted by Code Section 409A (including a termination and liquidation of the Plan by the Company in accordance with Treasury Regulation § 1.409A-3(j)(4)(ix)) and applicable law, relieve the Company of its obligations to make payments to any person then entitled to payments under the Plan, or reduce any existing Account balance.

ARTICLE VIII

MISCELLANEOUS PROVISIONS

8.1 Employment Relationship. For purposes of determining if there has been a Separation from Service, the Employer is defined to include all members of a controlled group of corporations or other business entities within the meaning of Code Sections 414(b) and (c) that includes Cardinal Health, Inc. as modified by this Section. A Participant shall be considered to be in the employ of the Employer and its related affiliates and subsidiaries as long as he remains an employee of the Company, any subsidiary corporation of the Company, or any corporation to which substantially all of the assets and business of the Company are transferred. For this purpose, a subsidiary corporation of the Company is any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company if, as of the date such determination is to be made, each of the corporations other than the last corporation in the unbroken chain owns stock possessing greater than 50 percent of the total combined voting power of all classes of stock in one of the other corporations in such chain. Nothing in the adoption of the Plan or the crediting of deferred compensation shall confer on any Participant the right to continued employment by the Company or an affiliate or subsidiary corporation of the Company, or affect in any way the right of the Company or such affiliate or subsidiary to terminate his employment at any time. Any question as to whether and when there has been a Separation from Service of a Participant’s employment, and the cause of such Separation from Service, shall be determined by the Administrative Committee, and its determination shall be final.

8.2 Facility of Payments. Whenever, in the opinion of the Administrative Committee, a person entitled to receive any payment, or installment thereof, is under a legal disability or is unable to manage his financial affairs, the Administrative Committee shall have the discretionary authority to direct payments to such person’s legal representative or to a relative or friend of such person for his benefit; alternatively, the Administrative Committee may in its discretion apply the payment for the benefit of such person in such manner as the Administrative Committee deems advisable. Any such payment or application of benefits made in good faith in accordance with the provisions of this Section shall be a complete discharge of any liability of the Administrative Committee with respect to such payment or application of benefits.

8.3 Funding. All benefits under the Plan are unfunded and the Company shall not be required to establish any special or separate fund or to make any other segregation of assets in order to assure the payment of any amounts under the Plan; provided, however, that in order to provide a source of payment for its obligations under the Plan, the Company may establish a trust fund, provided that the assets of any such trust shall remain subject to the claims of the Company’s creditors in the event of the Company’s bankruptcy or insolvency, and further provided that no assets will be transferred to or set aside in any such trust at a time


or in a manner that would result in a violation of Section 409A. The right of a Participant or his Beneficiary to receive a distribution hereunder shall be an unsecured claim against the general assets of the Company, and neither the Participant nor his Beneficiary shall have any rights in or against any amounts credited under the Plan or any other specific assets of the Company. All amounts credited under the Plan to the benefit of a Participant shall constitute general assets of the Company and may be disposed of by the Company at such time and for such purposes as it may deem appropriate.

8.4 Anti-Assignment. No right or benefit under the Plan shall be subject to anticipation, alienation, sale, assignment, pledge, encumbrance or charge; and any attempt to anticipate, alienate, sell, assign, pledge, encumber or charge the same shall be void. No right or benefit shall be liable for or subject to the debts, contracts, liabilities, or torts of the person entitled to such benefits. If a Participant, a Participant’s spouse, or any Beneficiary should become bankrupt or attempt to anticipate, alienate, sell, assign, pledge, encumber or charge any right to benefits under the Plan, then those rights, in the discretion of the Administrative Committee, shall cease. In this case, the Administrative Committee may hold or apply the benefits at issue or any part thereof for the benefit of the Participant, the Participant’s spouse, or Beneficiary in such manner as the Administrative Committee may deem proper.

8.5 Unclaimed Interests. If the Administrative Committee shall at any time be unable to make distribution or payment of benefits hereunder to a Participant or any Beneficiary of a Participant by reason of the fact that his whereabouts is unknown, the Administrative Committee shall so certify, and thereafter the Administrative Committee shall make a reasonable attempt to locate such missing person. If such person continues missing for a period of three years following such certification, the interest of such Participant in the Plan shall, in the discretion of the Administrative Committee, be distributed to the Beneficiary of such missing person.

8.6 References to Code, Statutes and Regulations. Any and all references in the Plan to any provision of the Code, ERISA, or any other statute, law, regulation, ruling or order shall be deemed to refer also to any successor statute, law, regulation, ruling or order.

8.7 Liability. The Company, and its directors, officers and employees, shall be free from liability, joint or several, for personal acts, omissions, and conduct, and for the acts, omissions and conduct of duly constituted agents, in the administration of the Plan, except to the extent that the effects and consequences of such personal acts, omissions or conduct shall result from willful misconduct. However, this Section shall not operate to relieve any of the aforementioned from any responsibility or liability for any responsibility, obligation, or duty that may arise under ERISA.

8.8 Tax Consequences of Compensation Reductions. The income tax consequences to Participants of Compensation reductions under the Plan shall be determined under applicable federal, state and local tax law and regulation. It is intended that the Plan will comply with the provisions of Code Section 409A, and the Plan will be construed, administered and governed in a manner that effects such intent. Although the Company shall use its best efforts to avoid the imposition of taxation, interest or penalties under Section 409A of the Code, the tax treatment of deferrals under the Plan is not warranted or guaranteed.

8.9 Company as Agent for Related Employers. Each employer which participates in the Plan by so doing shall be deemed to have appointed the Company its agent to exercise on its behalf all of the powers and authority hereby conferred upon the Company by the terms of the Plan, including but not limited to the power to amend and terminate the Plan. The Company’s authority shall continue unless and until the employer terminates its participation in the Plan.



8.10 Governing Law; Severability. The Plan shall be construed according to the laws of the State of Ohio, including choice of law provisions, and all provisions hereof shall be administered according to the laws of that State, except to the extent preempted by federal law. A final judgment in any action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. In the event that any one or more of the provisions of the Plan shall for any reason be held to be invalid, illegal, or unenforceable, such invalidity, illegality or unenforceability shall not affect any other provision of the Plan, but the Plan shall be construed as if such invalid, illegal, or unenforceable provisions had never been contained herein, and there shall be deemed substituted such other provision as will most nearly accomplish the intent of the parties to the extent permitted by applicable law.

8.11 Taxes. The Company shall be entitled to withhold any taxes from any distribution hereunder or from other compensation then payable, or to require a Participant to pay or to make arrangements satisfactory to the Company for the payment of such taxes, as the Company believes necessary, appropriate, or required under relevant law.

Cardinal Health, Inc.
 
/s/ Ola Snow

By: Ola Snow
Title: Chief Human Resources Officer    

 
Date: 12/18/2019
 
 
 



Appendix A - Claims and Appeals

A Participant or Beneficiary (hereinafter, the “claimant”) or his or her authorized representative may file (or may be deemed to have filed) a claim under the Plan pursuant to rules and procedures established by the Administrative Committee. The claims reviewer designated by the Administrative Committee shall determine initial claims.

A.
DENIAL OF CLAIM. If any claim under the Plan (other than a claim based on Total Disability) is wholly or partially denied by the claims reviewer, the claimant shall be given notice of the denial. This notice shall be furnished in writing or electronically, within a reasonable period of time after receipt of the claim by the claims reviewer. This period shall not exceed 90 days after receipt of the claim, except that if special circumstances require an extension of time, written notice of the extension (which shall not exceed an additional 90 days) shall be furnished to the claimant. The notice of denial shall be written in a manner calculated to be understood by the claimant and shall set forth the following information:

(i)        the specific reasons for the denial;

(ii)        specific references to the Plan provisions on which the denial is based;

(iii)
a description of any additional material or information necessary for the claimant to perfect the claim and an explanation of why this material or information is necessary;

(iv)
an explanation that a full and fair review of the denial by the claims reviewer may be requested by the claimant or his or her authorized representative by filing with the Administrative Committee a written request for review within 60 days of the notice of denial;

(v)
an explanation that if a review is requested, the claimant or his or her authorized representative may review pertinent documents and submit issues and comments in writing within the same 60-day period referenced in subsection (iv) above;

(vi)
a statement of the claimant’s right to bring a civil action under section 502 of ERISA; and

(vii)
such other information as may be required to be included in the notice of denial under ERISA.

B.
APPEAL OF DENIED CLAIM. If a claimant requests a review of a claim that was wholly or partially denied by the claims reviewer, such review shall be conducted by the Administrative Committee. The Administrative Committee’s decision upon review shall be made no later than 60 days following receipt of the written request for review, unless special circumstances require an extension of time for processing, in which case the claimant shall be notified of the need for such extension of time prior to the expiration of such 60-day period. In no event shall the Administrative Committee’s decision upon review be made later than 120 days following receipt of the written request for review. If a claim is wholly or partially denied upon review, the claimant shall be given written or electronic notice of the decision promptly. The notice shall be written in a manner calculated to be understood by the claimant and shall set forth the following information:


(i)        the specific reasons for the denial;

(ii)        specific references to the Plan provisions on which the denial is based;

(iii)
a statement that the claimant is entitled to receive documents and information relevant to the claim;

(iv)
a statement that the claimant may bring a civil action under section 502 of ERISA; and

(v)        such other information as may be required under ERISA.

C.
DENIAL OF CLAIM BASED ON TOTAL DISABILITY. If any claim under the Plan based on Total Disability is wholly or partially denied by the claims reviewer, the claimant shall be given notice of the denial. This notice shall be furnished in writing or electronically, within a reasonable period of time after receipt of the claim by the claims reviewer. This period shall not exceed 45 days after receipt of the claim, except that such 45-day period may be extended by 30 days if an extension is necessary to process the claim due to matters beyond the control of the claims reviewer. A written notice of the extension, and when the claims reviewer expects to decide the claim, will be furnished to the claimant within the initial 45-day period. This period may be extended for an additional 30 days beyond the original extension. If an additional 30-day extension is needed, a written notice of the additional extension, including the reason for the additional extension and when the claims reviewer expects to decide the claim, will be furnished to the claimant before the end of the first 30-day extension period. However, if a period of time is extended due to a claimant’s failure to submit information necessary to decide a claim, the period for making a determination by the claims reviewer will be tolled from the date on which the notification of the extension is sent to the claimant until the date on which the claimant responds to the request for additional information.

The notice of denial shall be written in a culturally and linguistically appropriate manner pursuant to the rules set forth at 29 C.F.R. § 2560.503-1(o), and in a manner calculated to be understood by the claimant, and shall set forth the following information:

(i)        the specific reasons for the denial;

(ii)        specific references to the Plan provisions on which the denial is based;

(iii)
a description of any additional material or information necessary for the claimant to perfect the claim and an explanation of why this material or information is necessary;

(iv)
a description of the Plan’s appeals procedures and applicable time limits, including a statement that a full and fair review of the denial by the claims reviewer may be requested by the claimant or his or her authorized representative by filing with the Administrative Committee a written request for review within 60 days of the notice of denial and, to the extent applicable, a statement of the right to bring a civil action under section 502(a) of ERISA following an adverse determination on review;

(v)
a discussion of the decision, including an explanation of the basis for disagreeing with, or not following: (i) the views presented by the claimant to the claims reviewer of


healthcare professionals treating the claimant and vocational professionals who evaluated the claimant; (ii) the views of medical or vocational experts whose advice was obtained on behalf of the claims reviewer in connection with a claimant’s adverse determination, without regard to whether the advice was relied upon in making the determination; and (iii) a disability determination regarding the claimant presented by the claimant to the claims reviewer made by the Social Security Administration;

(vi)
if the determination is based on medical necessity or experimental treatment or similar exclusion or limit, either an explanation of the scientific or clinical judgment for the determination, applying the terms of the Plan to the relevant medical circumstances, or a statement that such explanation will be provided free of charge upon request;

(vii)
either the specific internal rules, guidelines, protocols, standards or other similar criteria of the Plan relied upon in making the adverse determination, or a statement that such rules, guidelines, protocols, standards, or other similar criteria of the Plan do not exist;

(viii)
a statement that the claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to his or her claim;

(ix)
an explanation that if a review is requested, the claimant or his or her authorized representative may review pertinent documents and submit issues and comments in writing within the same 60-day period referenced in subsection (iv) above;

(x)
a statement of the claimant’s right to bring a civil action under section 502 of ERISA; and

(xi)
such other information as may be required to be included in the notice of denial under ERISA.

D.
APPEAL OF DENIED CLAIM BASED ON TOTAL DISABILITY. If a claim based on Total Disability is denied, a claimant, or his or her representative, may appeal the denied claim in writing within 180 days of receipt of the written notice of denial. The claimant may submit any written comments, documents, records, and any other information relating to the claim. Upon request, the claimant will also have access to, and the right to obtain copies of, all documents, records and information relevant to his or her claim free of charge.
E.

A full review of the information in the claim file and any new information submitted to support the appeal will be conducted. The claim decision on review will be made by the Administrative Committee. The Administrative Committee will consist of individuals who were not involved in the initial claim determination, and who are not subordinate to any person involved in the initial claim determination. This review will not afford any deference to the initial claim determination.
If the initial adverse decision was based in whole or in part on a medical judgment, the Administrative Committee will consult with a healthcare professional who has appropriate training and experience in the field of medicine involved in the medical judgment, was not consulted in the initial adverse determination and is not a subordinate of the healthcare professional who was consulted in the initial adverse determination.



Before an adverse determination on review is issued, the Administrative Committee will provide the claimant, free of charge, with any new or additional evidence considered, relied upon, or generated by (or at the direction of) the Administrative Committee in connection with the review of the claim. Such evidence will be provided as soon as possible and sufficiently in advance of the date on which the notice of adverse benefit determination on review is required to be provided to give the claimant a reasonable opportunity to respond prior to that date.

Before the Administrative Committee issues an adverse determination on review based on a new or additional rationale, the Administrative Committee will provide the claimant, free of charge, with the rationale. The rationale will be provided as soon as possible and sufficiently in advance of the date on which the notice of adverse benefit determination on review is required to be provided to give the claimant a reasonable opportunity to respond prior to that date.

The Administrative Committee will make a determination on an appealed claim within 45 days of the receipt of an appeal request. This period may be extended for an additional 45 days if the Administrative Committee determines that special circumstances require an extension of time. A written notice of the extension, the reason for the extension and the date that the Administrative Committee expects to render a decision will be furnished to the claimant within the initial 45-day period. However, if the period of time is extended due to a claimant’s failure to submit information necessary to decide the appeal, the period for making the benefit determination will be tolled from the date on which the notification of the extension is sent until the date on which the claimant responds to the request for additional information.

If the claim on appeal is denied in whole or in part, a claimant will receive a written notification of the denial. The notice will follow the rules of 29 C.F.R. § 2560.503-1(o) for culturally and linguistically appropriate notices and will be written in a manner calculated to be understood by the claimant. The notice will include:

(i)        the specific reason(s) for the adverse determination;

(ii)
references to the specific Plan provisions on which the determination was based;

(iii)
a statement regarding the right to receive upon request and free of charge reasonable access to, and copies of, all records, documents and other information relevant to the claim;

(iv)
a statement of the right to bring a civil action under section 502(a) of ERISA following an adverse benefit determination on review;

(v)
a discussion of the decision, including an explanation of the basis for disagreeing with or not following: (i) the views presented by the claimant to the Administrative Committee of healthcare professionals treating the claimant and vocational professionals who evaluated the claimant; (ii) the views of medical or vocational experts whose advice was obtained by or on behalf of the Administrative Committee in connection with a claimant’s adverse determination, without regard to whether the advice was relied upon in making the determination; and (iii) a disability determination regarding the claimant presented by the claimant to the Administrative Committee made by the Social Security Administration;



(vi)
if the determination is based on medical necessity or experimental treatment or similar exclusion or limit, either an explanation of the scientific or clinical judgment for the determination, applying the terms of the Plan to the relevant medical circumstances, or a statement that such explanation will be provided free of charge upon request; and

(vii)
either the specific internal rules, guidelines, protocols, standards or other similar criteria of the Plan relied upon in making the adverse benefit determination, or a statement that such rules, guidelines, protocols, standards, or other similar criteria of the Plan do not exist.

A claimant has the right to request a written explanation of any violation of these claims procedures. The Administrative Committee will provide an explanation within 10 days of any such request.

E.
EXHAUSTION OF CLAIMS PROCEDURES AND STATUTE OF LIMITATIONS FOR CIVIL ACTIONS. Any Participant, Beneficiary, or other person made subject to these claims procedures must follow and exhaust such claims procedures before taking action in any other forum regarding a claim for benefits under the Plan or alleging a violation of or seeking any remedy under any provision of ERISA or other applicable law. No suit or legal action may be commenced after the earlier of (1) one year after the date of the notice of the final decision on appeal, or (2) one year after the date that a timely notice of final decision on appeal would have been required to be issued if a timely appeal had been filed.


 EX-31.1 6 a20q210q123119exhibit311.htm EXHIBIT 31.1 Exhibit
 
 
Exhibit 31.1


I, Michael C. Kaufmann, certify that:
1.
I have reviewed this Form 10-Q of Cardinal Health, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 6, 2020
/s/ MICHAEL C. KAUFMANN
 
Michael C. Kaufmann
 
Chief Executive Officer
 



 EX-31.2 7 a20q210q123119exhibit312.htm EXHIBIT 31.2 Exhibit
 
 
Exhibit 31.2


I, David C. Evans, certify that:
1.
I have reviewed this Form 10-Q of Cardinal Health, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 6, 2020
/s/ DAVID C. EVANS
 
David C. Evans
 
Chief Financial Officer
 



 EX-32.1 8 a20q210q123119exhibit3.htm EXHIBIT 32.1 Exhibit
 
 
Exhibit 32.1


Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Michael C. Kaufmann, Chief Executive Officer of Cardinal Health, Inc. (the “Company”) and David C. Evans, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that:
(1)
the Periodic Report on Form 10-Q for the quarter ended December 31, 2019 containing the financial statements of the Company (the “Periodic Report”), which this statement accompanies, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(2)
the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 6, 2020
 
/s/ MICHAEL C. KAUFMANN
 
Michael C. Kaufmann
 
Chief Executive Officer
 
/s/ DAVID C. EVANS
 
David C. Evans
 
Chief Financial Officer



 EX-99.1 9 a20q210q123119exhibit9.htm EXHIBIT 99.1 Exhibit
 
 
Exhibit 99.1




Statement Regarding Forward-Looking Information
As used in this exhibit, “we,” “our,” “us” and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including this Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (the “2019 Form 10-K”), our quarterly reports on Form 10-Q and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include:
•
competitive pressures in the markets in which we operate, including pricing pressures;
•
uncertainties relating to the pricing of generic pharmaceuticals;
•
uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches;
•
our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation;
•
with respect to our distribution services agreements with branded pharmaceutical manufacturers, changes in the amount of service fees we receive or, in cases where part of our compensation under these agreements is based on branded pharmaceutical price appreciation, changes in the frequency or magnitude of such price appreciation;
•
changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals;
•
changes in the timing or frequency of the introduction of branded pharmaceuticals;
•
risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the risk that the outcome of these lawsuits and investigations could have a material adverse effect on our results of operations, financial condition, cash flows or liquidity;
•
potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us;
•
risks associated with the ongoing discussions regarding a potential global settlement of certain opioid lawsuits and investigations against us, including the risk that we could fail to reach a final settlement, that any final settlement reached could require us to pay more than we currently anticipate or could have a negative effect on our liquidity or ability to return money to shareholders and the risk that any injunctive or non-monetary remedies we may agree to could have unintended consequences;
•
potential adverse impact to our financial results resulting from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications;
•
our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx;
•
costs or claims resulting from a quality issue related to the manufacture of some of our sterile surgical downs, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits;
•
actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions;
•
any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption;
•
uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage infrastructure and cost challenges, and to improve its performance;
•
risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment;
•
uncertainties with respect to our cost-savings initiatives or other restructuring activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel;
•
difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining requisite regulatory consents or approvals associated with those activities;



•
manufacturing disruptions, whether due to regulatory action, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities;
•
risks arising from possible violations of healthcare fraud and abuse laws;
•
risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws;
•
risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;
•
risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements;
•
risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations;
•
changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications;
•
material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers;
•
unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix;
•
risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;
•
uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All;
•
reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services;
•
changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices;
•
changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits;
•
changes in hospital buying groups or hospital buying practices;
•
changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution;
•
changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid;
•
continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers;
•
disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks;
•
risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented;
•
the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, qui tam actions, government investigations, shareholder lawsuits or other legal proceedings;
•
possible losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products;
•
our ability to maintain adequate intellectual property protections;
•
the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions;
•
our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives;
•
increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities;


•
shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes;
•
the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available;
•
bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount;
•
risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations;
•
uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business;
•
risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;
•
our ability to introduce and market new products and our ability to keep pace with advances in technology;
•
significant charges to earnings if goodwill or intangible assets become impaired;
•
uncertainties relating to general political, business, industry, regulatory and market conditions; and
•
other factors described in the “Risk Factors” section of the 2019 Form 10-K and Form 10-Q for the three-months ended September 30, 2019.
The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “will,” “should,” “could,” “would,” “project,” “continue,” “likely,” and similar expressions generally identify “forward-looking statements,” which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.



 EX-101.SCH 10 cah-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Commitments, Contingent Liabilities and Litigation link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Financial Instruments (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Investments Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2408406 - Disclosure - Leases Schedule of Future Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Leases Schedule of Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Leases Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Leases Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Restructuring and Employee Severance link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Restructuring and Employee Severance Narative (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Restructuring and Employee Severance (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2418406 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Segment Information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2418405 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details) link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Share-Based Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2419405 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 2419407 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 2419406 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Shareholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 cah-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 cah-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 cah-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Gown Recall [Axis] Gown Recall [Axis] Gown Recall [Axis] Gown Recall [Domain] Gown Recall [Domain] [Domain] for Gown Recall [Axis] Sterile Surgical Gown Recall [Member] [Domain] Sterile Surgical Gown Recall [Member] [Domain] Sterile Surgical Gown Recall [Member] [Domain] Sterile Surgical Gown Recall [Axis] Sterile Surgical Gown Recall [Axis] Sterile Surgical Gown Recall [Axis] [Axis] Sterile Surgical Gown Recall [Domain] Sterile Surgical Gown Recall [Domain] [Domain] for Sterile Surgical Gown Recall [Axis] [Axis] Opioid Litigation [Axis] Opioid Litigation [Axis] Opioid Litigation Opioid Litigation [Domain] Opioid Litigation [Domain] Opioid Litigation [Domain] Total Opioid Litigation [Member] Total Opioid Litigation [Member] Total Opioid Litigation Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] naviHealth [Member] naviHealth [Member] naviHealth [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Estimated Litigation Liability Estimated Litigation Liability Inventory Recall Expense Inventory Recall Expense Pre-Tax Gain on Divestiture Pre-Tax Gain on Divestiture Pre-Tax Gain on Divestiture Number of operating segments Number of Operating Segments Number of reportable segments Number of Reportable Segments Project costs on investment and other spending Project Costs On Investment And Other Spending Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses. Derivative Instruments and Hedging Activities Disclosure [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Estimated fair value Debt Instrument, Fair Value Disclosure Carrying Amount of Long-Term and other Short-Term Borrowings Carrying Amount of Long-Term and other Short-Term Borrowings Carrying Amount of Long-Term and other Short-Term Borrowings Segment Revenue from External Customers by Geographic Area [Table] Segment Revenue from External Customers by Geographic Area [Table] Segment Revenue from External Customers by Geographic Area [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments Operating Segments [Member] Corporate Corporate, Non-Segment [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] UNITED STATES UNITED STATES Non-US [Member] Non-US [Member] Segment Revenue from External Customers by Geographic Area [Line Items] Segment Revenue from External Customers by Geographic Area [Line Items] [Line Items] for Segment Revenue from External Customers by Geographic Area [Table] Revenue Revenues Share-based Payment Arrangement [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Restricted Share Unit Restricted Stock Units (RSUs) [Member] Employee Stock Option Share-based Payment Arrangement, Option [Member] Performance Share Unit Performance Shares [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Total share-based compensation Share-based Payment Arrangement, Expense Derivative [Table] Derivative [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Fair Value Hedging Fair Value Hedging [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative, Name [Domain] Derivative Contract [Domain] Cash Flow Hedging [Member] Cash Flow Hedging [Member] Interest Rate Swap Interest Rate Swap [Member] Currency Swap [Member] Currency Swap [Member] Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] Derivative [Line Items] Derivative [Line Items] Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Derivative Liability, Notional Amount Derivative Liability, Notional Amount Segment Information Segment Reporting Disclosure [Text Block] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Pharmaceutical Pharmaceutical Member Pharmaceutical [Member] Medical Medical Member Medical [Member] Total assets Assets Equity [Abstract] Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and equivalents Cash and Cash Equivalents, at Carrying Value Trade receivables, net Receivables, Net, Current Inventories, net Inventory, Net Prepaid expenses and other Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Goodwill and other intangibles, net Intangible Assets, Net (Including Goodwill) Other assets Other Assets, Noncurrent Total assets Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Current portion of long-term obligations and other short-term borrowings Long-term Debt and Lease Obligation, Current Other accrued liabilities Other Accrued Liabilities, Current Total current liabilities Liabilities, Current Long-term obligations, less current portion Long-term Debt and Lease Obligation Deferred income taxes and other liabilities Deferred Tax and Other Liabilities, Noncurrent Shareholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred shares, without par value: Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Authorized—500 thousand shares, Issued—none Preferred Stock, Value, Issued Common shares, without par value: Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Authorized—755 million shares, Issued—327 million shares at December 31, 2019 and June 30, 2019, respectively Common Stock, Value, Issued Retained earnings Retained Earnings (Accumulated Deficit) Common shares in treasury, at cost: 35 million shares and 28 million shares at December 31, 2019 and June 30, 2019, respectively Treasury Stock, Value Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total Cardinal Health, Inc. shareholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total shareholders’ equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities and shareholders’ equity Liabilities and Equity Schedule of Total Share-based Compensation Expense by Type of Award Share-based Payment Arrangement, Cost by Plan [Table Text Block] Schedule of Stock Option Transactions Under the Plans Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Additional Data Related to Stock Option Activity Additional Stock Option Plan Data [Table Text Block] A disclosure of additional data related to all stock option activity Schedule of Transactions Related to Restricted Share Units Under the Plans Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of Transactions Related to Performance Share Units Under the Plans Schedule of Nonvested Performance-based Units Activity [Table Text Block] Leases [Abstract] Schedule of Lease Costs Lease, Cost [Table Text Block] Leases Supplemental Balance Sheet Information LeasesSupplementalBalanceSheetInformation [Table Text Block] [Table Text Block] for LeasesSupplementalBalanceSheetInformation [Table] Leases Supplemental Cash Flow Information Lease Payments [Table Text Block] [Table Text Block] for Lease Payments [Table] Schedule of Future Lease Payments Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Income Statement [Abstract] Cost of products sold Cost of Goods and Services Sold Gross margin Gross Profit Operating expenses: Operating Expenses [Abstract] Distribution, selling, general and administrative expenses Selling, General and Administrative Expense Restructuring and employee severance Restructuring Charges Amortization and other acquisition-related costs Amortization and other acquisition-related costs The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Impairments and (gain)/loss on disposal of assets, net Gain (Loss) on Sale of Assets and Asset Impairment Charges Litigation (recoveries)/charges, net Gain (Loss) Related to Litigation Settlement Operating earnings/(loss) Operating Income (Loss) Other (income)/expense, net Other Nonoperating Income (Expense) Interest expense, net Interest Expense Loss on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt Earnings/(loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for/(benefit from) income taxes Income Tax Expense (Benefit) Net earnings/(loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Less: Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net earnings/(loss) attributable to Cardinal Health, Inc. Net Income (Loss) Attributable to Parent Earnings/(loss) per common share attributable to Cardinal Health, Inc.: Earnings Per Share, Basic [Abstract] Basic (in shares) Income (Loss) from Continuing Operations, Per Basic Share Income (Loss) from Continuing Operations, Per Diluted Share Income (Loss) from Continuing Operations, Per Diluted Share Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average number of common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Cash dividends declared per common share Common Stock, Dividends, Per Share, Declared Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Current portion of operating lease liabilities Operating Lease, Liability, Current Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Total operating lease liabilities Operating Lease, Liability Finance lease right-of-use assets Finance Lease, Right-of-Use Asset Current portion of finance lease liabilities Finance Lease, Liability, Current Long-term finance lease liabilities Finance Lease, Liability, Noncurrent Total finance lease liabilities Finance Lease, Liability Goodwill and Intangible Assets Disclosure [Abstract] Goodwill [Table] Schedule of Goodwill [Table] Operating and Reportable Segment Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill [Roll Forward] Beginning balance Goodwill Goodwill, Transfers Goodwill, Transfers Foreign currency translation adjustments and other Goodwill, Foreign Currency Translation Gain (Loss) Ending balance Restructuring Charges [Abstract] Employee-related costs Severance Costs Facility Exit and Other Costs Facility Exit and Other Costs Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services. Total restructuring and employee severance Fair Value Disclosures [Abstract] Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Performance Share Units Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Performance Share Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Nonvested at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Canceled and forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Nonvested at end of period (in shares) Weighted-Average Grant Date Fair Value per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested at beginning of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Canceled and forfeited (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Nonvested at end of period (in usd per share) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Award vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Earnings Per Share [Abstract] Earnings Per Share Attributable to Cardinal Health, Inc. Earnings Per Share [Text Block] Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Canceled and forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Outstanding at end of period (in shares) Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-Average Exercise Price per Common Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding at beginning of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Canceled and forfeited (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Outstanding at end of period (in usd per share) Exercisable at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Segment Profit by Reportable Segment Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Assets by Reportable Segment Reconciliation of Assets from Segment to Consolidated [Table Text Block] Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Statement [Line Items] Statement [Line Items] Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Reclassification of deferred rent in accordance with ASC 842 Reclassification of deferred rent in accordance with ASC 842 Reclassification of deferred rent in accordance with ASC 842 Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Share-Based Compensation Share-based Payment Arrangement [Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Treasury Shares Treasury Stock [Member] Class of Stock [Line Items] Class of Stock [Line Items] Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Payments for Repurchase of Common Stock Payments for Repurchase of Common Stock Treasury shares acquired, average price per share (in usd per share) Treasury Stock Acquired, Average Cost Per Share Treasury Stock Acquired Shares Treasury Stock Acquired Shares Treasury Stock Acquired Shares Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Total operating earnings Narative [Abstract] Narative [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Enterprise Wide Cost Saving Measures [Member] Enterprise Wide Cost Saving Measures [Member] Enterprise Wide Cost Saving Measures Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Costs Restructuring Costs Long-Term Obligations and Other Short-Term Borrowings [Abstract] Long-Term Obligations and Other Short-Term Borrowings [Abstract] Schedule of Debt [Table Text Block] Schedule of Debt [Table Text Block] Schedule of Goodwill by Reportable Segment Schedule of Goodwill [Table Text Block] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share Schedule of Weighted Average Number of Shares [Table Text Block] Long-Term Obligations and Other Short-Term Borrowings Debt Disclosure [Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2.4% Notes due 2020 [Member] 2.4% Notes due 2020 [Member] 2.4% Notes due 2020 2.616% Notes due 2022 [Member] 2.616% Notes due 2022 [Member] 2.616% Notes due 2022 3.41% Notes due 2027 [Member] 3.41% Notes due 2027 [Member] 3.41% Notes due 2027 Committed Receivables Sales Facility Program [Member] Committed Receivables Sales Facility Program [Member] Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables. 4.6% Notes due 2043 [Member] 4.6% Notes due 2043 [Member] 4.6% Notes due 2043 4.9% Notes due 2045 [Member] 4.9% Notes due 2045 [Member] 4.9% Notes due 2045 4.368% Notes due 2047 [Member] 4.368% Notes due 2047 [Member] 4.368% Notes due 2047 3.2% Notes due 2023 [Member] 3.2% Notes due 2023 [Member] 3.2% Notes due 2023 Floating Rate Notes due 2022 [Member] Floating Rate Notes due 2022 [Member] Floating Rate Notes due 2022 Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Commercial Paper [Member] Commercial Paper [Member] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Short Term Credit Facilities Member Short Term Credit Facilities Member Other short-term credit facilities and an unsecured line of credit Debt Instrument [Line Items] Debt Instrument [Line Items] Total Long-Term and Short-Term Obligations Total Long-Term and Short-Term Obligations Total Long-Term and Short-Term Obligations Line of Credit Facility, Fair Value of Amount Outstanding Line of Credit Facility, Fair Value of Amount Outstanding Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Notes Payable Repurchased Notes Payable Repurchased Principal Amount of Notes Payable Repurchased during the year Repayments of Notes Payable Repayments of Notes Payable Gain (Loss) on Extinguishment of Debt Commitments and Contingencies Disclosure [Abstract] Loss Contingencies Loss Contingencies [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Total Opioid Litigation, net of tax [Member] Total Opioid Litigation, net of tax [Member] Total Opioid Litigation, net of tax Lawsuit Type [Axis] Lawsuit Type [Axis] Lawsuit Type [Axis] Lawsuit Type [Domain] Lawsuit Type [Domain] [Domain] for Lawsuit Type [Axis] Class Action Lawsuits [Member] Class Action Lawsuits [Member] Class Action Lawsuits [Member] Plaintiff Type [Axis] Plaintiff Type [Axis] Plaintiff Type [Axis] Plaintiff Type [Domain] Plaintiff Type [Domain] [Domain] for Plaintiff Type [Axis] Private Parties [Member] Private Parties [Member] Private Parties [Member] Tax Matters Agreement [Axis] Tax Matters Agreement [Axis] Tax Matters Agreement [Axis] Tax Matters Agreement [Domain] Tax Matters Agreement [Domain] [Domain] for Tax Matters Agreement [Axis] Alameda County [Member] Alameda County [Member] Alameda County [Member] Other Jurisdictions [Member] Other Jurisdictions [Member] Other Jurisdictions [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Opioid Lawsuits [Member] Opioid Lawsuits [Member] Opioid Lawsuits [Member] Product Liability Lawsuits Product Liability Lawsuits [Member] Product Liability Lawsuits [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] CVS Health CVS Health [Member] CVS Health [Member] Litigation Case Litigation Case [Axis] Litigation Case Type Litigation Case [Domain] Opioid Lawsuits State [Domain] Opioid Lawsuits State [Domain] Opioid Lawsuits State [Domain] Opioid Litigation, less Cuyahoga and Summit Counties [Member] Opioid Litigation, less Cuyahoga and Summit Counties [Member] Opioid Litigation, less Cuyahoga and Summit Counties Opioid Litigation, Cuyahoga and Summit Counties [Member] Opioid Litigation, Cuyahoga and Summit Counties [Member] Opioid Litigation, Cuyahoga and Summit Counties Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Inventory, Net Long-term Purchase Commitment, Period Long-term Purchase Commitment, Period Maximum quarterly payment Maximum Quarterly Payment Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved. Loss Contingency, Lawsuits, Number Loss Contingency, Lawsuits, Number Loss Contingency, Lawsuits, Number Number of State Attorneys General filing lawsuits Number of State Attorneys General filing lawsuits Number of State Attorneys General filing lawsuits InvestigationbyMultitateTaskForce InvestigationbyMultitateTaskForce Investigation by Multitate Task Force Cash Component For Settlement Framework, Term Cash Component For Settlement Framework, Term Cash Component For Settlement Framework, Term Opioid Total Settlement, Cuyahoga and Summit Counties Opioid Total Settlement, Cuyahoga and Summit Counties Opioid Total Settlement, Cuyahoga and Summit Counties Loss Contingency, New Claims Filed, Number Loss Contingency, New Claims Filed, Number Loss Contingency, Number of Plaintiffs Loss Contingency, Number of Plaintiffs Loss Contingency Accrual Loss Contingency Accrual Cost of Goods and Services Sold Selling, General and Administrative Expense Other Accrued Liabilities, Current Financial Instruments Financial Instruments Disclosure [Text Block] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Operating Lease, Cost Operating Lease, Cost Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Total finance lease cost Total Finance Lease Cost Total Finance Lease Cost Variable lease cost Variable Lease, Cost Total lease cost Lease, Cost Schedule of Segment Reporting Information, by Segment [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Subsegments [Axis] Subsegments [Axis] Subsegments [Domain] Subsegments [Domain] Pharmaceutical Distribution and Specialty [Member] Pharmaceutical Distribution and Specialty [Member] Pharmaceutical Distribution and Specialty [Member] Nuclear Precision Health Services [Member] Nuclear Precision Health Services [Member] Nuclear Precision Health Services [Member] Medical distribution and products [Member] Medical distribution and products [Member] Medical distribution and products [Member] Cardinal Health At Home [Member] Cardinal Health At Home [Member] Cardinal Health At Home [Member] Total revenue Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net earnings/(loss) Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Loss on Sale of Investments Loss on Sale of Investments Share-based compensation Share-based Payment Arrangement, Noncash Expense Provision for bad debts Accounts Receivable, Credit Loss Expense (Reversal) Change in operating assets and liabilities, net of effects from acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] (Increase)/decrease in trade receivables Increase (Decrease) in Receivables Increase in inventories Increase (Decrease) in Inventories Increase/(decrease) in accounts payable Increase (Decrease) in Accounts Payable Other accrued liabilities and operating items, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Acquisition of subsidiaries, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Additions to property and equipment Payments to Acquire Property, Plant, and Equipment Purchase of investments Purchase of available-for-sale securities and other investments The cash outflow from purchases of available-for-sale securities and other investments. Proceeds from sale of investments Proceeds from sale of available-for-sale securities and other investments The cash inflow from sales of available-for-sale securities and other investments. Proceeds from divestitures and disposal of property and equipment and held for sale assets Proceeds from divestitures and disposal of property and equipment and held for sale assets Proceeds from divestitures and disposal of property and equipment and held for sale assets Net cash provided by/(used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net change in short-term borrowings Proceeds from (Repayments of) Short-term Debt Reduction of long-term obligations Repayments of Long-term Debt Net proceeds/(tax withholdings) from share-based compensation Net proceeds/(tax withholdings) from share-based compensation The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Dividends on common shares Payments of Ordinary Dividends, Common Stock Payments for Repurchase of Common Stock Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rates changes on cash and equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase/(decrease) in cash and equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and equivalents at beginning of period Cash and equivalents at end of period Cover page. Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Accounting Policies [Abstract] Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Weighted-average common shares–basic (in shares) Effect of dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Employee stock options, restricted share units, and performance share units (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Weighted-average common shares–diluted (in shares) Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] ASC 842 ASC 842 [Member] ASC 842 New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification Operating Lease, Payments Operating Lease, Payments Finance Lease, Principal Payments Finance Lease, Principal Payments Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee- Related Costs Employee Severance [Member] Facility Exit and Other Costs Facility Closing [Member] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Beginning Balance Restructuring Reserve Additions Payments and other adjustments Payments for Restructuring Ending Balance Summary of Restructuring and Employee Severance Restructuring and Related Costs [Table Text Block] Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Stock Options Restricted Share Units Vesting Period in years for Shares Vesting Period in years for Shares Vesting Period in years for Shares Tax benefit related to share-based compensation Share-based Payment Arrangement, Expense, Tax Benefit Exercisable period of plans (in years) Exercisable period of plans, in years The instrument's contractual term. Target performance goal (as a percent) Commitments, Contingent Liabilities and Litigation Commitments and Contingencies Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustments and other Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Net unrealized loss on derivative instruments, net of tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax Total other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax Total comprehensive income/(loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Total comprehensive income attributable to Cardinal Health, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Operating Leases Operating Lease [Member] Operating Lease Finance Leases Finance Lease [Member] Finance Lease Remainder of 2020 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Remainder of 2020 Finance Lease, Liability, Payments, Remainder of Fiscal Year Remainder of 2020 Lessee Lease Liability Payments Remainder Of Fiscal Year Lessee Lease Liability Payments Remainder Of Fiscal Year 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Finance Lease, Liability, Payments, Due Year Two 2021 Lessee Lease Liability Payments Due Year Two Lessee Lease Liability Payments Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Finance Lease, Liability, Payments, Due Year Three 2022 Lessee Lease Liability Payments Due Year Three Lessee Lease Liability Payments Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Finance Lease, Liability, Payments, Due Year Four 2023 Lessee Lease Liability Payments Due Year Four Lessee Lease Liability Payments Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five 2024 Finance Lease, Liability, Payments, Due Year Five 2024 Lessee Lease Liability Payments Due Year Five Lessee Lease Liability Payments Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Thereafter Finance Lease, Liability, Payments, Due after Year Five Thereafter Lessee Lease Liability Payments Due After Year Five Lessee Lease Liability Payments Due After Year Five Total future lease payments Lessee, Operating Lease, Liability, Payments, Due Total future lease payments Finance Lease, Liability, Payment, Due Total future lease payments Total Lease Liability Payments Due Total undiscounted Lease Liability Payments Due for both operating and financing leases Less: leases not yet commenced (1) Lessee Operating Lease Liability Not Yet Commenced, Amount Lessee Operating Lease Liability Not Yet Commenced, Amount Less: leases not yet commenced (1) Lessee Finance Lease Liability Not Yet Commenced, Amount Lessee Finance Lease Liability Not Yet Commenced, Amount Less: leases not yet commenced (1) Total Lease Liability Not Yet Commenced, Amount Total Lease Liability Not Yet Commenced, Amount Less: imputed interest Operating Lease Imputed Interest Operating Lease Imputed Interest Less: imputed interest Finance Lease Imputed Interest Finance Lease Imputed Interest Less: imputed interest Total Lease Liability Undiscounted Excess Amount Total Lease Liability Undiscounted Excess Amount Total lease liabilities Total lease liabilities Total Lease Liability Total Lease Liability Total Lease Liability Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Amortization of intangible assets Amortization of Intangible Assets Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Estimated annual amortization of intangible assets - Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Two Estimated annual amortization of intangible assets - Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Three Estimated annual amortization of intangible assets - Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Four Estimated annual amortization of intangible assets - Year Five Finite-Lived Intangible Assets, Amortization Expense, Year Five Aggregate intrinsic value of outstanding options at period end Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value of exercisable options at period end Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restructuring and Employee Severance Restructuring and Related Activities Disclosure [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Recent Financial Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares that would be antidilutive as a result of net loss shares that would be antidilutive as a result of net loss shares that would be antidilutive as a result of net loss Leases Leases [Text Block] Leases [Text Block] Investments, Debt and Equity Securities [Abstract] Investment [Table] Investment [Table] Investment [Line Items] Investment [Line Items] Noncontrolling Interest, Ownership Percentage by Parent Noncontrolling Interest, Ownership Percentage by Parent Partnership Indirect Ownership Partnership Indirect Ownership Partnership Indirect Ownership Proceeds from Divestiture of Businesses Proceeds from Divestiture of Businesses Equity Method Investment, Ownership Percentage Equity Method Investment, Ownership Percentage Equity Method Investments Equity Method Investments Investments Investment Holdings, Schedule of Investments [Text Block] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] IPR&D, trademarks and other IPR&D,TrademarksandOther [Member] Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style. Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Net Intangible Indefinite-lived Intangible Assets (Excluding Goodwill) Finite-Lived Intangible Assets, Major Class Name Customer relationships Customer Relationships [Member] Trademarks, trade names and patents Trademarks And Patents Member The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law. Developed technology and other Developed Technology Rights [Member] Gross Intangible Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Intangible Finite-Lived Intangible Assets, Net Weighted- Average Remaining Amortization Period (Years) Finite-Lived Intangible Assets, Remaining Amortization Period Gross Intangible, Total other intangible assets Intangible Assets, Gross (Excluding Goodwill) Net Intangible, Total other intangible assets Intangible Assets, Net (Excluding Goodwill) Restricted Share Units Weighted-Average Grant Date Fair Value per Share Debt Disclosure [Abstract] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] 4.625% Notes due 2021 [Member] 4.625% Notes due 2021 [Member] 4.625% Notes due 2021 3.2% Notes due 2022 [Member] 3.2% Notes due 2022 [Member] 3.2% Notes due 2022 3.079% Notes due 2024 [Member] 3.079% Notes due 2024 [Member] 3.079% Notes due 2024 3.5% Notes due 2025 [Member] 3.5% Notes due 2025 [Member] 3.5% Notes due 2025 3.75% Notes due 2026 [Member] 3.75% Notes due 2026 [Member] 3.75% Notes due 2026 4.5% Notes due 2044 [Member] 4.5% Notes due 2044 [Member] 4.5% Notes due 2044 7.0% Debentures due fiscal 2027 [Member] 7.0% Debentures due fiscal 2027 [Member] 7.0% Debentures due fiscal 2027 Notes Payable Notes Payable Other Borrowings Other Borrowings Long-term Debt and Lease Obligation, Current Long-term Debt and Lease Obligation Reclassification out of Accumulated Other Comprehensive Loss [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] AOCI Attributable to Parent AOCI Attributable to Parent [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] AOCI, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Balance at beginning of period Other comprehensive loss, before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified to earnings Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Balance at end of period Fair Value Measurements, Recurring and Nonrecurring Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Recurring Fair Value, Recurring [Member] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Level 3 Fair Value, Inputs, Level 3 [Member] Assets: Assets, Fair Value Disclosure [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other investments Investments, Fair Value Disclosure Forward contracts Derivative Assets (Liabilities), at Fair Value, Net Preferred shares, authorized Preferred Stock, Shares Authorized Preferred shares, issued Preferred Stock, Shares Issued Common shares, authorized Common Stock, Shares Authorized Common shares, issued Common Stock, Shares, Issued Common shares in treasury Treasury Stock, Shares Statement of Stockholders' Equity [Abstract] Common Stock Common Stock [Member] Retained Earnings Retained Earnings [Member] Treasury Stock Accumulated Other Comprehensive Income/(Loss) Noncontrolling Interest Noncontrolling Interest [Member] Statement of Stockholders' Equity Balance at beginning of period (in shares) Treasury, balance at beginning of period (in shares) Treasury, balance at beginning of period Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Parent Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Treasury shares acquired (in shares) Dividends Dividends Other Stockholders' Equity, Other Balance at end of period (in shares) Treasury, balance at end of period (in shares) Treasury, balance at end of period Income Taxes Tax Credit Carryforward [Table] Tax Matter [Axis] Tax Matter [Axis] Tax Matter [Axis] Tax Matter [Domain] Tax Matter [Domain] [Domain] for Tax Matter [Axis] Patient Recovery Business Patient Recovery Business [Member] Patient Recovery Business [Member] CareFusion [Member] CareFusion [Member] CareFusion [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Internal Revenue Service (IRS) [Member] Internal Revenue Service (IRS) [Member] Income Taxes Tax Credit Carryforward [Line Items] Income Tax Expense (Benefit) Unrecognized tax benefits Unrecognized Tax Benefits Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized tax benefits, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Estimated range of decrease in unrecognized tax benefits within the next 12 months Decrease in Unrecognized Tax Benefits is Reasonably Possible Open Tax Year Open Tax Year Indemnification Receivable Indemnification Receivable Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes. Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncement, Early Adoption [Axis] New Accounting Pronouncement, Early Adoption [Axis] New Accounting Principles, Early Adoption [Domain] New Accounting Principles, Early Adoption [Domain] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Lease Liabilities established as a Result of the adoption of ASC 842 Lease Liabilities established as a Result of the adoption of ASC 842 Lease Liabilities established as a Result of the adoption of ASC 842 Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] EX-101.PRE 14 cah-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 chart-0c924314911e5b7b8bf.jpg begin 644 chart-0c924314911e5b7b8bf.jpg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end GRAPHIC 16 chart-73ee4c10511c5ef6890.jpg begin 644 chart-73ee4c10511c5ef6890.jpg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end GRAPHIC 17 chart-482220cd78845318873.jpg begin 644 chart-482220cd78845318873.jpg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end GRAPHIC 18 chart-9236314201dd5b538cd.jpg begin 644 chart-9236314201dd5b538cd.jpg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end GRAPHIC 19 chart-f06b5fff8fb8555489d.jpg begin 644 chart-f06b5fff8fb8555489d.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" #( 0H# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &NVQ&;&=JLV/7:" M/?^"X7@3X?^/O^"H'PYU3X!>+KGQ#_P $Z-(\!7GAZ&U\:Z2?^&F- M9\>WOA?PW9^&_"$9\.F3P7J&G^._B!\.?"-VVHCQ(K3>-=+O8X^#9R?NA("T M;J.K(P'U*D#]:_EF^*O_ 25_:H^(/[FUTJ\L'_"+X4?\$?OVR/!WQ@_8V;XB_"SXC^,_ -O^S[_P27\/ M?$F]^'/[6GP8^%/@GX _$C]@?0='A\5VGQ.T'6OAM\3_ (D?%VV\/^,M#3Q_ M\(%^ .K^'](\1:[KWB7P[XNUCP[8ZK/XL/:?\.P/VX!\2O"G@P_LO_"P^'_@ ME\9O^"Q'CF/]K=?BQ\-5\<_M':)_P4%^"O[54?PE\_PG%86OC3P_+I'BWXJ> M O /Q2MO'.K2"QU;P_X7UCPU'KG@_2K_ %G1@#^B;P;^V_\ L]7VF?LOZ-\4 M?B]\$/A#\;OVK/AGX#^(/PV^!>L_';X8^(?%OB6Y\:>'=-U=]%^'6H:-K8L/ MBS86>IWT^A:/XO\ L5_X>\9SV?VOPQ->PW4,=>-_M)?\%2?V5O@I\%OVQ/B M-\./BI\(?VB_B1^Q5\.?$GQ ^+?P%^&?QF\#7?Q#T/\ X1FZBTZ^T7Q+::=/ MXBOO"%Q!JTAT74;K4]$N$T?64;2-1@BU/%G7Y.?L_P#[!/[9?[.GQ*^$EIK/ M[&OP0_:>\/\ Q8_9:_X)%_#+QGX]^+'Q'^&MSX9_8D\:?L*>&4T'XLV]OX4U M."\\:^/98=1DD^)?P1UKX,O-;?\ "WX(]0\03:1ID,&KR?'NO?\ !+K_ (*C M?%>/]M+4?B=\&]$L?%OQ2_80_P""@'[+O@JT\/\ Q2_9;\+?!74O''QE_:8^ M"_Q;^%-U\%OA;\+/ O@#5/AI\.O&OA'PCKEYXG\3_&KQ9X\^*WB3XF1:SJ_Q M"E\,03:9J'B4 _I,_;F_;=U+]D?P=\"CX)^$47QH^+_[3/QDT/X&?!GX>ZU\ M4?"_P2\&7OC35? GC+XDW,WC?XO>,=/U71?".DV?A;P)KJ:=%::%XA\2>*O$ MDVC>&?#7A^_U#4]UL[X>_P#!03X76'P(\"?%K]LZVTK_ ()Z^+?%GQ'\5?!N M]^%_[5/Q \'>!;F+XH^$?$VK^'+K1_ _C+7;OP_X?^*7A7Q+!I'_ EWP^\= M>%(VTCQ?X$U'3/$T,5E;S310>5_\%._@5\6OC3\"?AAX3\*?LP?"#]MKX;:1 MX_TVX_:&_9%^*6H>#?"FJ_%;X>2>"O$&C6.J?"#XI^-IK70/A[\6/AIXZN_# MWC'0K^ZU3PXFOZ+;>(- B\5Z'<7EN]S^"/Q&_P""2'[?&H_ S]F0WGPD^*/C MG0_"%E_P4-^%%M^R1X'_ &XOAEH?Q'_9Z_9Z_:Q\.M+\/^)_#L?P\O_&&G^%+C0=0 /ZM? M%/[7/[+'@?XKZ?\ GQI^T?\#/"7QIU;3O#.K:7\)_$GQ5\$:)\1M2T[QIXE MT[P;X0O+'P;J.M6^OW<'BGQ7J^E^'?#S06,C:SK&HV5CIRW$US$K^:>*/^"C M_P#P3]\$WGBO3_%W[;7[*/AN_P# MA%M&FB2]Q$?Y._COH6A_ 3]N2#]C^SM M/V;?B)XW\5_\%%_^"(GQ2L-9\5?&&XUW]LKX>6?P@T/]E+X87/PQ\(^ ?$OP MFT#QK\:O#F@^"?AQJ_CZ]^/W@S5;#X;Z'\-?$WQ"MO&T6@^/[B]\)C[UC_X) M%_&V[;X):MJWP ^%&H^(?#DG_!?75O'6K:AJ?PRO=1F\0?MP_$?7K_\ 91U2 MYO9A6.F76I-+<7'P^TO&C:XVEHLEJH!_11J_[4_[,^@?$[X;_ M 5UO]H+X*Z3\7_C#H2^)_A1\,-1^)_@NT\??$GPY)%/<6^N^!O"<^LIK7BC M2+R"TOI[#4-&L[NVU&'3M2EL)+E-/O6@\F\2_P#!17]B#P[HGQ;U>W_:D^!/ MBV\^"'P@\8_'7XB^%? _Q7\ >*O&6A_#+P)-J-CXB\23>'=.\1M>1VEIK6FR M^&S+=&U@3Q%/9:36^_^=+X7?\ !(C]L#PE^TQ^REK_ ,1_A?\ $'QO M\/?^%9?\$E-2\=ZW\.OVL?@_\-/ 'P$^)'[!/PM\"^&_%^F?$_PAX@^%_P 1 M?BE\8[OPYX\\%77C'X31_ _6_#7A;Q?<^+_$FA>+=?\ "5I?7OB:[]6\ ?\ M!)/]I/3OAG^S;X>U/X/?#'0_%VD_#;_@NOX2^-6K'Q!X F\_4?VX/B+KFM?L MRKXAOM+6[NO&VG:SHDN@R:CSJY\#6NF6.GZK#:R:=;6T0!^MOQI_X*9>$O"O M[ ?PM_;O_9_^',G[2&D?'#5OV+?"'AW6_"OC'Q>F@^,8II;VRT77M&UG2+V^MGL;FYASOV?/^"I? MPV\5:3^T!I?[9/AC0O\ @GW\6/V8/B1X8^&WQB\"_';XW?"?5?"5A?\ CSX0 M_P#"]? >K>$OC#H>KV/@KQ;IOB?X8VNO>(H;2(:?KVG0^%_$(U'284L&E;Y3 M^)'[#?QW^.__ 1J_9$_8\U?X*7'PC^*/@WQ!^P-I/Q>^&'A_P"*O@SP[JWA M7PS\ _CU\*]2^,GB?PQ\4?AMK<&AVFO:EX-\&^(OB+X>U3P?K*>*8]4U>T2T M<>,XY(AU/QS_ ."2'PU\)^&OV-O ?[+WPE_X2#P[X5_X*@_ K]L+]I_6_BS\ M4_$?Q/\ ''C30/A]\-?B=X5U+QUXR\;_ !N\2^+O%GQ$U719[SP%I6C^%3J5 MU]DT^+&B:7;06MXY /TQ'[;7['C>/T^%(_:D_9\7XG/\-E^,0^'TOQ?\"0^, MA\*F\,CQL?B$_AN77$U:/PBO@G/C)M;DM4LD\)JWB1Y%T0-?C\H_@K_P7L^% MWQ"_9WU?]KOXA?"WPA\-_P!G&P^$W[4?QGM/$&B?M4?!+XC?%"Z\,?L^^,OA M1X.\*>%;OX,V]QX7\2V7Q5^+6H_$^ULQX.@OM1TKX_ CX?W'P:O/^"LES_P4ONOVZ[CX@>!;CQ)3XKS>))[*1_@/<3.6^$'-2TG2IM3UBQO+>PF4 _J]^''Q"\(?%GP! MX+^)W@#Q!HOBSP1\0/"^A>,?"?B;PYK&F^(-!U[P]XCTVVU72M5T?7-&N;S2 M=6TZ\L[J*6UU#3;NYLKJ,B6VGEB96/:UX_\ L^PZY;_ [X1V_B;X6I\$?$-O M\.O!]OK7P@CU/P?K4?PSU.WT*R@O?!$>K?#]G\#ZC'X=N(WTU+WPF?\ A'[A M81)I86T:-1[!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 8_B#7M&\*Z'K'B;Q%J-II&@>'M*U'7-;U:^E$-EI>CZ19SZCJFHW< MQ!$5K8V%M<7=Q(>$AA=CTK\Z_@A_P4>\*?$L?#_Q+\1_"G@W]GWX6?$7]DKX M2?M7Z5XX^)_[07PGT[6M(T?XZ?%K5/AQ\+/"?BKX;W5]I?C#P\WBC2I/!6KV MOC>_MD\$S>,O&(^$^FZKJ7B[0KYIOI_]L+X<^)/C#^R9^T_\)/!P3_A+OBE^ MSQ\;?ASX6+R"%!XC\_%'X&?#_PKXU^'?Q@_P""0?\ P2T^!.G6GB'QIX/T9[CQ_P#!+]N[ MP/\ '?XV_#SQ+HFN72O9#PG\,=+U^'6$U.(:?J'B&PU'P5&)-:66TH _J;^$ M_P"T%\"?CSX%O/B?\$_C)\+OBY\.-.U/7]%U#QY\-O'?AGQKX0LM6\+N4\1: M==^(O#VI:AI5O>:, LNHV\UTDEM;207;J+6X@FD\%A_X*4?\$]KJYBLK/]N' M]DN\O+GQ%X$\(VMM;?M"_"J>6Z\4?$_3/[:^'6@6RQ>*7\_5/&NDA]2\-6L6 M^35+**:YMP8X92GC?[+'[*WQ ^"VK_\ !4&&7P7X<\)>&?VD/VJO$?Q4^"&F M>';SPW;:9JOA+5_V1/V?OA:^J3Z7HACMO"]W??$7P)XL@O;+5+:ROYF@.MW$ M4EKJ,%W&?V<_A%#\4(?^"$W[,7[&]K/%XA^%6GW MD?[7/@GX^R_$GXIZ:FOAC# UQ9>5X@O/B5'=G3/$&KH@BU>ZOH48 '[2?$C_ M (*$^#/ _P"T'H'A_P 2?LY>%=9\9+^T'^U-^S5X.^(NA?%+X4^,_$FF:%^S MY^Q!>?MGZMK6J/X=TK7/$GPTO/',5CJ7P^E^$/BK4/#_ (NT,'3?B%K%I>>' M/$6B6NH>D_LV_P#!2[X=_&;X:W_QJ^*&G?#[]G/X/:9^R#^QO^UKJOCOQ]^T M'\+;J'PSI'[67@CQ+XQ?PUX]T#[3HOB+X X)9/#VL6L/YQ>)/^"%?AQX$UF3X0^$/&VO?!'X'_\ !O\ :H_P*U3XH>!+/0_V MA_&'_!.3P1\<]#_:*^!-_K]U=ZCX7T:;3-7^(WASQ!X!\2^,;>7X>^)/%_AG M0)OMS:7#=W]D ?TAZQ^W+^QAX>^%_A+XV:]^UC^SCHOPA\>Z!X@\4>!OB9JW MQH^'FG^!_&>@>$YK&U\4:EX4\377B"/2O$,'AZ]U+3[#6UTFYNY],U&\M=/O M8H;V:.W.CXA_;._9&\)^+O@_X!\3?M/_ +/V@^-OV@M+TG7/@9X5U;XO^ K# M7?B_HGB!TB\/:Q\-M.N-=2Y\9:5XCGD2U\-ZAH27EGX@O'2RT::]NF\FOP6^ M O\ P3 _:2E_:#_9:^.7Q=^ ?PS\+>!KW]KK_@J/^U3\1_@%<^*_AYXZT3]F M72OVKO@1X%^&WPA^'EM;VL4W@_QSXDUKQ5X0UKQKX]O?AW9WOAC0_%_C[Q)/ M:WMS8%]2N_FMO^"8'_!0[P'X8_X)Y:?\)?@9%H_QG^'7[)W[#GP,^,WQ1OOC MM^SWXT_9TL+K]G?XH7/B7Q)X2_:C_9I^*W@3QC>_$?2/AUH6K>)-6^!/Q,_9 M>\3V?Q"@\6ZZ\5_=:*=%T/78 #^H3]FG]HW1OVC-#^*5Q:^'KSPAXI^"_P > M_BY^SW\1?"5]?1ZI-HOBWX7^(_LUC?0ZE#:6,5YI/COP%JO@CXG>')/LD$Z> M'/&^E6UY&M[;W.?I"ORW_P""<5A=:S\3O^"G7QAM(Y;?P5\7/^"B7CF#P(L2 MXTG5K7X$? ;X _LS^.O$NFR(%AG.I?%OX0?$'1[ZXB5UGOO#4SF>8C*_J10 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 $ ]1GZUG:5I&E:'9)INBZ;I^DZ?'+=SQV.F65KI]FD]_>7&H7TR6MG%# M LMY?W5U>W4BQA[B[N)[F9GGFDD;1HH **** "BBB@ H(!Z@''3-%% &=I6D M:5H5DFFZ+IFGZ1I\3ZA>S1VMG%# DMY?75S>W4BQA[ MB[N)[F9GGFED;1HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH ***_-2\^/WQ:BN[N)/%05(KN[B M1?[%T$[4BN98T7)TTD[451DDDXR222: /TKHK\S/^&@?BY_T-8_\$F@?_*RC M_AH'XN?]#6/_ 2:!_\ *R@#],Z*_,S_ (:!^+G_ $-8_P#!)H'_ ,K*WO"O MQU^*>I>*/#6G7OB<36=_X@T:RNX?['T./S;6[U*VM[B+S(].21/,BD=-\;JZ MYW(RL 0 ?HK7PY^V)^T-X_\ @9WR]AW_<=?E1_P4H_X_?@__P!>WCK_ -'^%* / M'O\ AX'\>O\ GV^'O_A+ZG_\TM'_ \#^/7_ #[?#W_PE]3_ /FEKX?HH ^X M/^'@?QZ_Y]OA[_X2^I__ #2T?\/ _CU_S[?#W_PE]3_^:6OA^B@#]_/V3?BY MXK^-/PQOO%WC)-(35K?QAK.AQC1+&?3[/[%86>DSP%H)[V_7_)"=5_[*1XF_]-OAZONR@ HHHH **** "BBB@ HHHH * M*3/U_(_X49'O^1_PH 6BDR/?\C_A1D>_Y'_"@!:*3(]_R/\ A2T %%9NIZSI M&BQQ2ZOJFG:7%/(8H9=2OK2QCED"ES'&]W-"LCA 6*(68*"Q )K'_X3KP5_ MT-_A?_PH='_^3: .JHKE?^$Z\%?]#?X7_P#"AT?_ .3:/^$Z\%?]#?X7_P#" MAT?_ .3: .JHKE?^$Z\%?]#?X7_\*'1__DVM?3-:T?6DEDT?5=-U6.!UCFDT MV_M+](9&7>J2M:33+&[+\P5RK%?F (YH TZ_'*__ ./^_P#^O^__ /2R>OV- MK\@"I17Q3XE_;-MM'_ &M]3_9/\/\ P2^*'Q"U M3PK\&Y/B]XZ\8^"[SP/=2>';?4-&O]<\'Z-I?PXU7Q)I7C[QI:>*O[-;PHOB MSPUIUUH6E?$77/#/@ZZ>263Q+J'AKQVY_P""E'V7X#>)/CTW[)OQXO=$^&'C MCXL^%?CQIND>+/@EJ^F?!K1O@GH_AG7?'WBN^^(]IXZ_X5_\0);:W\5VGA_2 M/!?P]U75_$^I_$;P_P"//AM,NG>)?!>HI< 'Z<5U'@?_ )'7P=_V-7AW_P!/ M%G7Q;\*OVIK+XG?M!?&/]GJX^%'Q%\!:[\*/#>D^-K'Q'XKNO!]SIOC;P1K? MBW5_!>C^(WT'P[KNK>)_AD_BC4M$O=?^'WA[XGZ?X?\ $?Q"^'87X@Z!IPT: M.ZBMOM+P/_R.O@[_ +&KP[_Z>+.@#]<*_*C_ (*4?\?OP?\ ^O;QU_Z/\*5^ MJ]?E1_P4H_X_?@__ ->WCK_T?X4H _+\ D@ $DD DDDX &223P 23P!F MC!P3M;"L%8E3A6.<(QQA6.#A3ACM; ^4X^.OV^[V?3_V2?B]EUF_OK/2H;^9?SR\/?&B#4=?\ V%/$/PO^)?Q=/Q+U7P=<>$+_ . _B?XP M^,?B-XFUSPB_PY^/FC> O&VB:! M14=?S#6/Q:U+Q?\ LFZ5?^+_ (X6FCZKX/\ %&C?%/Q2GC;]HW]JGQ/H7[0W MQ0U+]DRZ\7:K^S]H_P 0_ -W\.?%_P (/CI9>-I-07Q_\$=,\0S>!=+^*>H^ M'+'P-X6UM;.^\(M_3/HMU-?:+HM]<:==Z/<7NBZ/>W&CZ@YDU#1Y[S2[2ZGT MC4)"%,FH:3-,^G7TI :2[M9I& 9B* /V^_X)Y?\ )"=5_P"RD>)O_3;X>K[L MKX3_ .">7_)"=5_[*1XF_P#3;X>K[LH **** "BBB@ HHHH **** /S"^)7B MOQ3:_$+QM;6OB;Q%;6T'BC68H+>WUS5(((8DNV"10PQ72QQ1H.$C1511PH K MSR?XA^(;:\T[3[GQYK5M?ZNU\FDV%QXMOH+[57TRS.H:FFEVI MO]16QBG:PL0;R[$-M^]KI/BC_P E(\=_]C9K?_I8]?@Q^W1X8NK?_@HS^P5\ M0]#^#GBWXM^+K4Z;X;T2PU_X:Z_XB^%^F:7:_$#5=5\5>-/AY\7O"FM6TWP- M^,_PFT+5KWXC^-HO'NFM\-_B=\.M,\+:1J?]M7&D2:9 ?N+)\0?$4,=Q+-X M\UJ"*SFBM[R6?Q=>016=Q.+6*6*">:)(9I89 MHXG=XI%7^8+]I;]F_6].^ _[3OPVM?!_Q=\2^"C_ ,%3OBUXPF\=^+/A)\0O MVN=>GT#5?V*-,TOPU\1/$GPHNX;G7/CGIOCOXMZO9^ ]#\9@W.A_"'QQJFB> M/]).GO\ #K3K+3_4OV+/A?\ %30O^"B=GX_\9? OXC> ->U#X0:UHWQ"M?$_ M@_Q7JB^!O#7_ RQ^R)H7@S7]=_:ZU%/['_:"L?%?Q$\"^,?A[H'P">XFN_@ MOXST'QO\38TBU36M:EG /Z,/^$R\8_\ 0V^*/_"AU?\ ^3*_6ZV)-O;DDDF& M(DDY))1222>22>IK\;:_9&U_X]K?_KA#_P"BUH _./\ X*2(C^ _AJ'1' \; MZ@0'17P?^$:O^1N!P>V1CCBOR"E2SACDFG2S@AACDFFGG%M!!!#$C2S33SS; M(8((8D>6:>9TBAB1Y972-&8?K_\ \%(O^1#^&O\ V.^H?^HU?U^%OQ\\+Q>. M/@=\8/!DWA;Q'XXA\5_#3QGX>E\&^#M9TGP]XN\4QZKH=W:OH/A;6]?#:#IW MB+4A(;?19==5]$FU%K>SU>.73;JZB< ZG1?&_P /O$GA[P[XM\/>+?!>N^%? M%][::;X3\2Z/K^@ZCH'B?4K^2\AL=,\/:O:7J?$GX5Z)I/BC7M:^(7PUTC0O ^I1Z+XWUO5/&G@^PT?P7K,S MV\<.C^,-4N]5AL?"VK2O=VB1Z9K]QIU](]S B6[-*BM^37P#^#GC;6?A/^PC MXQU?X-ZCHNN_";]N#P[XB\/7D'P]C^%6I_\ "E]4TGQ#-XG^,WQ3^#/@_6+O MP1X3\7:YKUO!HOB?Q2FG1ZG?:/8:5JMA9^%[3QA?:+)Y#H_[)_BK2]1^-D7B M;X9?M47'P4T74?A-X>L[+X;_ :^!WA?XZ>)_$/@S]IKXR?&"T\=0Z?J&N_$ M#0_VH=,\$6OC#3K[4/BIJ6D6WB+Q7I/B70-'T[PR+GP5XJ1 #]Z](U#0?$&E M:;KV@7VBZ[H>M6%IJNC:WHMUI^K:/J^EW\"7-CJ>E:II\ES8:EIU[;21W%G? M65Q/:W4$B36\TD3JQ_8+_@FPB)X.^*(1$0'Q=HI(1%3)_P"$?7D[0,GMDYXX MK\+?V<[+XAZ;\ ?@OI_Q;TZRTCXGV/PR\'V?CS2M.L-"TJTTWQ+;:1!%>V(T MOPM'%X8TVZMD6"+5+#PU''X>L]774+?1$33([51^ZG_!-K_D3_BC_P!C=HO_ M *CZT ?I57XY7_\ Q_W_ /U_W_\ Z63U^QM?CE?_ /'_ '__ %_W_P#Z63T M?G1\;?V(_%_QD_:]^%G[1X^/.H^$?#OPJ\(:\G@[0M(^'7@6]^(GP_\ B+<^ M']0\,6>I_#SXGZE92ZE9_#_Q,FN2^+_B-\._%.G>*-!\0^*/"NE6$<-OX=\6 M>([2V\(\3?\ !-GX\:KX9TG3--_:V^'L^J:Q^THW[4'QIT;Q7^RI:77P1^+? MCKP[X(\!>#/ACI4_P/\ !_QD\(Z3HGACPMJ?@2W^+WB_1I?$VKZ9\4OCI>P^ M/O%6G/;:-I^B5^P=% 'R!\-?V8_&'A7]IGQW^TCX_P#C?=?$S4M;\":]\,?! M/A^#X9>%/AY=:%X)\3?$+3?B3/8?$;Q1X6OFG^,^J>"]1TFS\)?"77O$&C:- MJ/@CP ^IZ7=/KVN:[K&NW?W/X'_Y'7P=_P!C5X=_]/%G7+UU'@?_ )'7P=_V M-7AW_P!/%G0!^N%?E1_P4H_X_?@__P!>WCK_ -'^%*_5>ORH_P""E'_'[\'_ M /KV\=?^C_"E 'Y:7UE9ZG8WVF:C:V]]IVIV5YINHV%W$EQ:7^G:A;2V=_8W MEO(&BN+2\M)YK:ZMY5:.:"62)U*L13XK6V@6T2"VMXEL+-=/L1'#$ILK!(X( MEL;1PF^VLQ%:VL9M862!EMK7]K%_Y?V:#R_MX MF^T"_P#+,>S[?]I_TG[?M^V"Y)N!/YWSU-110!^UG_!/+_DA.J_]E(\3?^FW MP]7W97PG_P $\O\ DA.J_P#92/$W_IM\/5]V4 %%%% !1110 4444 %?GW^T MO_P53_X)[?L=?$>/X1_M-?M6_"KX-?$F7P[I7BV/P?XQO]8MM8?PYK<]_;:5 MJXBL=%OX?LE]/I=_'"WG[RUK*&11M+?H)5:6SM9VWS6T$KX"[I((I&P,X&YT M8X&3@9P* /Y=O'__ 6;_P""5NK^-_%VJ6'[=?P(GLM1\1:I>VDR7OC)EDM[ MBX:2-PR^#2C J>J,RD@[25PQX\_\%B/^"6K,C-^W'\"6:,L49KGQBS(64HQ1 MCX,+(60E&*%2R$HV5)%?U:?V9I__ #XV?_@+;_\ QJC^S-._Y\;/_P !+?\ M^-4 ?RH#_@L=_P $NP5(_;I^!X*+M0B_\; HIR"B$>#LHA#,"JD*0S CYCEO M_#XO_@ESM5/^&Y_@9L4EE3[;XTV*S !F5/\ A#=H9@ "P ) )( K^K'^S-. M_P"?&S_\!+?_ .-4?V9IW_/C9_\ @);_ /QJ@#^4W_A\7_P2X_Z/E^!?_@9X MS_\ F-K]-(/^"_G_ 1QCAA0_P#!07]G\E(HT.-6\38RJ '&?"X.,CN ?4 \ M5^OW]F:=_P ^-G_X"6__ ,:I?[.L/^?*T_\ 6W_ /C5 '\TG[6&TFT&^M5N'$7A1U6,7#Q1$LRD MO+&%##>4_-C_ (>D?\$[SU_:^^$'_?\ \7__ #)5_<"=,T\];&S/UM;<_P X MJ3^R]-_Y\++_ ,!+;_XU0!_#_P#\/2/^"=__ $=[\(.N?]?XOZ^O_(I=??K2 M?\/1_P#@G;S_ ,9>?!_GD_OO%W)]3_Q27-?W _V7IO\ SX67_@);?_&J/[+T MW_GPLO\ P$MO_C5 '\/_ /P](_X)WCI^U]\(/^__ (O_ /F2K](/V&O^"UG_ M 2H^%_ACQ_9^./VY_@;H%UJWB73+RP@OK_Q7!)<6UOHL=M+.@E\*(&C$Y:+ M*EB&1PP4;2W],']EZ;_SX67_ ("6W_QJE&F:>.EC9CZ6MN/Y14 ?D-_P_P#O M^".'_203X ?^#;Q+_P#,Q7YGWG_!8[_@EK)>7DB?MS_ IDDO+R1&6\\:89)+ MJ9T89\&#AE8,..A'0Y _JJ_LZP_Y\K3_ ,!;?_XU2?V9IW_/C9_^ EO_ /&J M /Y3?^'Q?_!+C_H^7X%_^!GC/_YC:/\ A\7_ ,$N/^CY?@7_ .!GC/\ ^8VO MZLO[,T[_ )\;/_P$M_\ XU1_9FG?\^-G_P" EO\ _&J /Y3?^'Q?_!+C_H^7 MX%_^!GC/_P"8VM_PG_P65_X)86'BKPS?7?[=7P)AM;+Q#HEW>,PD5O;: MG:S32L?^$-X6.-&=CV )K^I/^S-._P"?&S_\!+?_ .-4?V9I_P#SXV?_ ("V M_P#\:H _(;_A_P#?\$FIBPOO%D_\$[_^COOA!_W_ /%__P R5?W ?V7IO_/A9?\ @);?_&J/ M[+TW_GPLO_ 2V_\ C5 '\/\ _P /2?\ @G?_ -'??"#_ +_^+_\ YDJ/^'I/ M_!.__H[[X0?]_P#Q?_\ ,E7]P']EZ;_SX67_ ("6W_QJC^R]-_Y\++_P$MO_ M (U0!_.=^Q9_P6^_X).?#;X1:AX?\9_MV? O0]7F\<:]JD=E>ZCXIAF-C=6. MC16\^R7PLA*2O;3!6 (.T@'((']!?PW^(W@CXO\ P^\$_%3X:^)--\8_#WXC M^%- \<>!_%>CO+)I7B3PGXHTRVUG0-=TV2>*"9['5=,N[:]M7EABD:&9"\:, M2HZ<:;IXX%C9@>@M;_%_B/]E7X+?$:Z^%/QC_:.M?&GA6QN?#GB;0=7T_PY M\0O$WA;X17,$GB?QM\*_@_XDU&70_BKXSCUO0M7TB[\,^-Y_"O@WQGIWAA[R M_P#3O!O[5?C+5_VC'^"7CG]G_P 6?#3PSXJMOC)<_!OXA:YXM\.7^H_$*'X# M>)/#/AGQSJ6M?#BQ@C\0> ?#NOOXJTWQ%\+M?O-1UZV\8>$Y+;4];B\%ZAK? MAO1M9^.?VA/V,OVU]2T'XQ?!/X#?$GX"W'[+WQL^*7CKXK>//"WQ&TWQII/Q MAG\._&+Q&_B_X[? GPAXRT?3/$7A+0(/'WBG5?&?B+P3\9M3TB_O_AQ_PETG MAC5/AIXXLM+T[Q#:^_? #X+?M9^'OVK/C=\8?CYI/[.GBGP[XXN/&/A[XC_#/Q!\,=&^'OA#29M/A/BKXPZ]H?C?5 M==\??$YX]6U"YU/PYH?@30?!(!6\(?M@?M._$?Q;\:8_AY^R)X(\1_#7X6>, MOVA_AYH'B2;]JO1-)^(GC_QG\"[OQ3X;T_2K?X6S_!^:T\,V_P 0?'GARW\. M:=J&K_$&:'0--UBU\3:FEQ:Q/8R=!X)_X*'?#+XG:/XC\=?#3P9X_P#'GPP\ M$?L_>$OC)XU\0^%]&N-:\7:1XY^(DAG\$_LX6/PXTJVOMGXV:!X%TJ#XER>!/BW\1=6\4>'_ EK7CN[TBW\47+:1X;FT70] M4LDOYM(!TJ"WL6FLK>!CV7[/'[-UU\$O!'[0'A@MX0BO/C-^T/\ M*_&Q+CP MSITNG6SK\;_&NK>(]+D\1@V-I+?>)K33KNQL_$.H*ETMS-:!;:[NH(X6H \% M\3?\%&1HFF?#/Q;8? ;Q;JGP]O?@%\ _VD?VA/%\WC?P9I(_9_\ AQ^T=J^H M^'O )32+II;GXI:YI>H^&_&^K>-[#PY<:-::'X/\'WVLZ;J.O:YJOA_PIJOZ M8JVX9]V!^JL5(_,'GOUK\8?C%_P3'\7?%S0OV6O NMW/P8OO#/P^_9]^#/P$ M^,WB2[;XN:7XS;1_A7JGAW7M6/A/2O"_B+2/A[\9-#\47.E7MKX*\.?M >&K MW3O@;XIDB^+G@=+_ ,1:AKWAK4/V>5=HQ[LQ^K,6/X D@>U 'SO^T;\>KKX' MZ'X)M/"_@#5_BS\5/BSXZMOAI\)?AEHVMZ-X8?Q3XK?PWXE\:ZM=:WXKU\MI M7A'P?X0\#>#?%?C'Q=XDN;35+FSTC1'L=#T/Q%XGU30O#^J?-T7[;'QCU?P] MX@\->%OV0?%>M?M)^ /B%)X$^*?P?N/BOX'TCP'X%T\_#NU^*FC_ !&F^/4V MFW7AW4OA[XZ\)ZIHVG?#O4CX3T[7-9\=WM]X.\3>'_!DOA/QKJ7A[W/]J#X+ M^/OB7!\*/'WP;U_PAX>^-?P#^(TOQ(^';?$+3M8U'P!XGCUGP-XP^&7C?P%X MT_X1Z:/Q!I>C>+/!/CG6([#Q+H4.H:EX2\6:=X9\3?V)XDL-+U#PUK/YC:[^ MQO\ \%*?$OA;XM6_B[Q%^R=XV\6_'WXP^#]<^/,5GX[^,_PB\&_$K]GCP;\) M$\'>&/@#I]_X5^%WBSQAX1AA\50.?BUXBL+:%OC3X/U/Q!I.GP_#'1O%=[X1 MT, ^Y/B=^VIXGLOA'^R-\1?@%\%K/XK:_P#MB:EX=3P!X0^(GQ6TSX(67A_0 M=<^ GCC]H"75/%7BZ/PC\3[2+4+'PUX)GTA='TO2=0AO]9OX6MM7&GPF[EYS MQM^W[J7P4-WX;^/_ ,$KGP7\4-7^!>B?%'X1>"? ?Q MOB?8?';XB7_CB+X: M:O\ 'X8>*CX0\&Q:E\1=&\<^+?@QIL;7^CV-CJ6C_&/0?$T:6ND^&O&4FC= ME\$O'7C[1M6\,WGB7PYH,D'A[0C*?V*+CP3X8^'/A;P/\ LB?%C4_&NA>$X_#-G9V6@>%O^&;/C1\$ M/#F@?#;3=.TTZ;X;ET/4?B)X$>.?^"@/B MKX.^)O$H^-G[,'CKP)\-;#PI\7+SP=XZL_'/@[7-9^(/C7X&^!1XV\;Z#H?P MYOHO#7B*Q\&>(C9:]H/PF^)>K75MIWCC4M,TV\UK0O!&B^,/!VHZU],_LW_' M;Q+\9=/^(.C?$7X7W'P:^+/PE\;0>"/B)\/F\9:/\0M,L;K5_!WA;XA^%]9\ M-^-]#L-(L_$F@Z[X/\9:-,;I]%T>[TWQ!:>(?#]S8N='34+_ .$/'W['/[6O MQP^+G[4<_P 8KS]GF;X=_%SP%\1_A%\$/B5HOC?XM:K\1_@/\++ZST?4O GA M_1_@MJ/P^T;X^#;CXFWO@KP/XGU&*^L5\'6?C&'QKJKOX;T'79;7X8^(G_!0[]H M"R\._#7XC_!3]CSPY\4?A%\9OC-#\'/A7XR\8_M-V7PBUGQ=)KGC+5/!O@/X MAP^$9_@KXWDM?AQ\0CHMYXK\*ZR=:GU.]\$7WA[Q -&8ZS]CL_O+]J7X17/[ M0'[,W[0_P*LGT&*_^,WP.^+'PKT^?Q1:R7OANWU#X@> ]>\*6%SKUI!;W<]Q MH]M>:K!<:C#;VMQ( M_!GCCQ'8_#2SU?Q%<_"F\^'7A.[U/X6>#O&?Q/TC1==\7:7XQF\0)X9LK[QR MG@<6$,^F6_MO[27[47QF^&7QB^&GP1^!/[/_ (.^-?BWQS\-/B5\4]7N_'G[ M0-E\!M$\-^'_ (>>*_AOX.-I:7D_PO\ B=<>(]6UC5OB/:.EM%::7#I]GIES M+-+;[X8_P#",7/CG_A.]=?2/"NO M7U_9^%KG78[<0_1WQW_8:^$W[2W[2?PJ^*_QW^%_P9^,WPY^&/P6^+7@;2_! M7Q7\":3X]GTOQ]\0?B#\'O%&G^+_ ]8^)-(U/1=.%GH?P^US2;^^CD@U%E^),G[1NE>+&T2R6;X/>'?AIH_Q$O-:U=]!2:/XE?#O6/A#%GQ3JWAZ M;4:GB#]ONW?3?B/:_#KX(?$'QAX[T#]ISPG^RK\+_!WB:XMOA:GQ8\;>*/AG MX<^*K>-(]6\5Z?)<^#/A3I/A74?$^IOXLU;0=0U3Q!I7@C4=5\'^&O$$.O\ MA&+6_9KC]GJ:;]M#0_VHP/"7V71_V8O$OP"3=ISGQNDNN_%KPI\156VU7[$8 MX_"GV;PZT=SIW]H*[:M]EG2S,:R3#PKX_P#['?CGXF>'/VDX]"D^%NN:O\4O MV@/@S\;O ^C^.;_XG>&+2S7X6_"[X0>!9K-_B5\*=4\/_%+X3>.#JWP^U76? M"'Q.^%^H7NL^%WFTK[5INMZ;>>(?#]V ?6_P"^,=G\=_A3X?^)5KX=U3PA>W MM_XM\,>*/!VM7FE:CJG@[QY\.?&GB'X;_$;PC>:GH5U?:-JTOA;QUX3\1:(F MK:5&M.U;4M9UN#P_!XI\8ZM;:-)X@UG6/$EYIL%M?>) M-6U37KK4K^XK>!O@#)X2_:L_:&_:(=?"GD_&?X4_LY_#VT:PTUH?%T'O^"BW[5^L> M$UU:]_8;\ :;XH\0?M0:W^R9\/?#47[96FZAIWB+XE^!]3^+%A\1KW7_ !(O M[/=K_P (CX8T-/A)K%QX=O1HNOZGXK.I:? ^D:"Q9S]?^ _VMKO7O@S^T!X[ M\=_"G6/AS\3OV8)?'&E_%_X0S^*]!\4&SUSPG\--)^+^C-X4\=:-!%I?B;PK MX]^'OB;PIXB\+>))-&T>\BCUJ;2_$'A[1O$&AZSH]K\]^-/V0OVA]$^'GAMO MA#J?P5\0?$[P1_P4*^,?[8NA:7\2M<\?>%O >K>$/B=XB^.=W9^%=5U_PIX0 M\5^(]-\3Z3H_Q)+KP/:>)K7X8^ [J]^">@? KX<^%/#MQKGF>+-9T3PIX M6\'Z%J.O^)=0T[3-3\1^)]4\4:Q9>']"L+G2]!L #SKP7^W9\;[#X>^!_C-^ MT/\ LO>#/A'\&_&GB_X+:#=>-_ W[3NC?&:7P)X;^-L%[IFB>/\ X@Z2?A-\ M.8-!\+>'O'.J_#3PSXNO+?6-2BT+1_'&I>.KZX@\->!]:FN$\7?\%#O&>G_# MS5OC9X$_94\=>/O@7X-]9^*)\>>%?!VD77[/WP?UFP\/WOQ2\)Q>)=/ MBM_%7B;XBW5MXU\4_"'X9VVI61\8_"[PI8^.M0\:>&YO'/@_P]J/5Z-_P3V^ M$/P]_8?^+_[+/P:^%'P)^%?B'XS?LW:]\(_'.I^"_AYH_A;PAXS\;ZO\'=4^ M&Z>*?&UIH6B6]]XCL!J&JW5S/-J5C>ZH^EW-TGDO I?"2?"VZNX_AQ\ M+/'L'B3X8?#H:%J'B/3?AIJL>B:+K7C8>#]9U^*]L/!5AI5T >Q_#7]LZ;Q] M\>IOA;>?"'Q!X8^''B37OC7X,^#WQFN_%/A[4[+XD^-_V^"- M/C_M[P/!::Y:^*5\"ZGJM[J/_"8Z=X$\67]]9>%<>'+?Q%]R5^='PJ_9,^+W MA']H+3O$/BWQG\/=3^ _PN\>?M-_%CX.:=HFF^)HOBEJ7CG]J_QAJOC+Q9;? M$>YU1YO#$&D?#:;QI\2M#\+ZCX;GN=2\:Z=XGT.[UVT\,W?A>]C\4_HO0 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % *%%% !1110!__V0$! end GRAPHIC 20 chart-f61e989517785cc7bf1.jpg begin 644 chart-f61e989517785cc7bf1.jpg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end GRAPHIC 21 chart-f9153a6cb9dd593fb2b.jpg begin 644 chart-f9153a6cb9dd593fb2b.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" #( 0H# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^#/^"@?[9?BO]B[X=?"# MQ%\/O@-?_M(?$?XY?M&?#3]FOX>?"^P^)/AOX3_VGXQ^)VG^++[2+R\\;>+- M*U?0M+L;8^%)H;@WUO#&QNXY#=1+$RR?%?A+_@M[\,K+6OA7X9_:0^$5W^R9 MK6I?M)?M,?LN?M'7GQF^,7PTM/!7[-GQ$_9Q_9WTO]HZ74+WXAZ?*WA'XC>$ M?B%X4\4^"=,\):WI&H: [ZKXFA@:SN;FV%G=^[_\%7/V.O''[;/@']DSX9>% M=/UB[\->$/V[?@#\5_C'J'ACXE7OPE\8>&_@WX/TKXB6?C/Q)X,\;:+JNB>* MM,\3Z9+K^D?V8/!NIVGBIS/,^E2H8IF7Q#7?^"4WP[^%_P"T)_P34@_9X^"F MA7'[//P*^/O[7OQQ_:0NOB#XWOOB1XGUWQS\;OV8/%/@#1OB9XQU7XN:WXK\ M;?%OQUX@^(4_ANRN];OK_5M4T2SL-.ND-CI&CVJ6P!^CWBG]MS]CKP1J?P9T M;QA^U/\ L]>&=5_:*L]*U'X#:?KGQA\ Z9=?&/3==:UCT/5/AI%=Z[$WC+2] M:N+_ $^TT?4]#%W8:G>ZA86-E*_"NN_M:_LV:) MXB\!W\FE>.=&UCXV_#G2[_P7JT7B#Q-X4DTGQ;!?>(8&\-ZHGB7P9XMT%M.U MDV5Z-6\-:[8^1Y^EWB1?RH?%7_@E9_P5 UO]E[]DK]FC0_@KX?GT'X;_ +%G M[/\ X'\6'P?\3_V6?"K6GQC^$/[3OB+XJ^+OA]\8_'/BSP'XD^+_ ,1_ANW@ MF+PA?? GP7\)/B!X%^'>F_$:3Q/JOQ$U:RBFAN)/T1M_^"8/QJN/#$VG:S\' MO .H7_BC_@X8\6?M^^/([[Q!X(O5\1?LMM\8?&_BOPCXNUN:4L-;U*R\/7?A M>[MOAW?O=ZY83*;+^SU>WFB !^T?P\_;?_8V^+>J3Z)\+OVJ_P!G?XAZQ:_# M)/C1=Z7X,^,GP^\1ZA9?"5G:-_B1?6FE:_ZU\)/@=\"])^(GACP/_ ,%_;.\A\3R?"S4_ VM>)/VT/BUI?B3] MC+1_B/X=-M>:;\0?!'B3PEI&GZ;XA\/ZQ8ZQHWA'0[&S\,>+=-M=.5M,'A?P MM_X)K?\ !0SP=)K7[07B_P#9DN/BQXM\+?MJ_L5_M:VG[/?Q:^.O[*M[X[^, M/AOX3_LH_&S]FOQWX,;7_A=X&^'?[-G@OQC\*/$?CKPW\0OA1X87P]HWP\L_ M#FBZ'HNG>,K[Q1:7%]I8!_4)KO[9?[(_A>'X+7/B/]I_]G[0K;]H^6TA_9_N MM6^,/@"PMOC8^H+9&P/PJN+C7XX/'D=Z^IZ3!:3>&Y-0AN+O5](LHI&O-4L( M+CK)?VD/V?(5NWF^./PDB33_ (F>)/@Q?O)\1/":+9?%WP=X8U7QMXN^%]VS M:LJV_P 0?"_@W0M;\6>(?!\I37]&\-Z1J>MZA80:=8W-Q'_++^U%_P $I?VP M/CAXN^!'B^Z_9%\.^"O WQ+_ &0[?]FSXL_LR?L9?M7?"/\ 9T^&7[-^J2_M M2?$/XX7,OB[Q/X^^!WQ"G\9^ =6\-_$/1==\:ZA^SYX1B\9CXV?#ZZN]"LM: M\/:QX=U[1_IWPG^PM^VWH7[8O_"-:E\ ?"FI?LU:=_P6@^)W_!2"7X_O\7_ M#?\ "1_"_P",O[*?Q%^$C^![7X03!_&#:_X3\4^*GT_QU#OAWJ_A7Q-\'K;Q+JGC&&UGTSQ4?&>O^.(9V\*_#ZQ3 M0=%\97&GZUXOT2!_;V_X*'_L&K\%9OVCO^&S/V7V^ EOXP/P]E^,4?QS^'$O MPX7Q[L:<>"O^$NC\0OH[>+'LU;4H_#R7+:M+I.-7BM'TPB[K^;7X/?"_P"T'XN^+?ACP[:^'(M+M9H+BPM;;X5G7;7Q/9ZYJ.F:]8>( M;0V4,$=I]IO/D7X!?\%0_B/\?_VAIO!OA?\ 8L^(%S^RQ=?M$?&[]EG3OVI? M"_Q-\)>/-7\*_%CX$WWCC1-?O_CO^S_X;T:7QG\!OAAXL\2?#W7O#_@3QQXO M\17%W?7NH>"9_$7ASPY9>.O#\TWCW_!)W]AS]I']ECQEX U;XU>#M)\-V/AK M_@E=^PA^RAJ,VG^,/#/B4-\7OV>_B1^TSJ?Q!TJUAT34+N:31HM$^('A#5-) MUYTCL-1@U@6D3+J6G:I967S?X,_8/_;(?_@HW\+?C;/^RC\,_@E\0_!/[3_Q M(\9_'S_@HY\%/C5X?\">#_VQ_P!D?5;'XDIX0^#_ ,1/V1_"5_#JNN?&76+# MQ#\.M'\6^*/'WAF[LO#?B7X?WGCW0/'NJW.M16T(!^[^@_MD_LD^*(_C5-X< M_:<^ .NQ?LWRW\7[04ND_%[P#J$?P2?2TOFU(_%62UUZ1/ <>GMI>K0WL_B1 MM/@MKK1]7LY9%N]+OX+?GHOV]OV()OAX?BW'^U]^S,WPO6]M=,?XA#XX_#8> M#(]5OO .H_%.STB7Q(?$8TJ+5[GX;:1JOCN'2I;E-1D\)Z;?:ZMJ=/M9YD_C MXD_X)3_'?]F/]AK]J*Y_:BT#5/AS-^S]^SI\-_AAIGQN^,'[4OA#XI?LU_'7 MP_X!_;9^$/[0^H>&="^"'P<^ #_$_P"&WP8^+$OPULU\7^,_CMXFU_Q/\.]5 M^)WBRTU?P_J_@U/%WCF7ZV_8F^$NN?M[?&3QI\=O"OP?_9WNOA+X8_X+;_!W M]I'X@>'?@[\3OAU\9_@%HOA?P?\ \$I;[X<:M?\ @GXC:-H?A[P'\9/%7AGX MQ^/_ .OCJ\^'^CW]E#\3[CQ+>Z7'[K7I0#^FGX>?MJ_L?_ !;N/%%I M\,/VI/V>_B#<^"/AUI'Q=\9P>#?C%X \1R>$OA9KNFC6=)^(GB9=+U^Y_L'P M7>Z.T6JIXDU3[+I4>G7%I>W%S#;W=L\N+:_M\?L07OPHTOXZVO[7O[-,_P & M=;O_ !3I.C?%./XV_#H^ -5U?P1HVH>(O&&D:?XJ/B$:/=ZOX8T#2M1UK7M* MANGU'3-+LKB_NK6.V3S#_-!HW_!%']K0?LI:-\%-"^&_PV^%OC#4/^"8_P#P M4,_9Q\4:CI/BWP3:Z=>?%SXT_MY?"+]H;X3^"_$.J>&1-?ZGX?\ '_PS\!ZU MHVJ^)EM-;T3P@NLSV.M6DNZ72;[Z+_9Q_P""9O[0$WBO]E;XB_$[]GGQYX:& MG?\ !2#6_P!IKX_^$_VF/VEO@#^TUXP/A3P_^PIXW_9Z\%?$B_'PK^&_P[^% M&GZS/XQN/!&A:9X1\"6'C37%T?PGX3\>^(=:T[6(KS2M /VJT7_ (*)?LF> M*/VF_@I^REX1^+O@OQ=\2/VA/V=O$O[3WPEOO#7C#P=J_A;QO\,=!UO2=(L) M?"^IVGB"2\\2ZSXNL[CQ3XK\)V7A_3=2M]2\'?#/XE>();VVMO"EXI^$OVAO M^"R'C+]GOX\?M3>&M5_8E\<>+_V5/V+/B-\!_AY^T?\ M5^&/C=\,8KSP--\ M=_!GPH\9:5KUE\!==L],\<^*M%\-VOQW]O 4AF@M_G[ M_@GE_P $^/VEOV5OCK_P3P\8>/?V=O!U]H?PT_9*_;D_9Q^*'BO0/&?PKN;[ MX!:M\1OVM&^/GP7UNW@ENHM;\5>'==\!66H> M.LOAO_ &C>>#;GQQJEKJUK MI6AR:Y]L]WT7_@D5\//C/_P4 _;K_:7_ &M? 'B;Q=X"\?\ QU_9G^(/P \) MQ_'?Q[8?"3QK8_!_]G;X-:&WB+XG_ ?P7XRTOP3XNU?PG\8/ ^H-HT7Q7\.: MTUS;Z5ID\-G/HD5DK@'Z9ZQ^V_\ L;>'KGXJ6>N_M5?L\:1=? S2+_7?C1;Z MA\8O 5I-\)M*TSQE>_#J^O/B.DVNHW@N.W\?:=?>"V3Q"-/F?Q3:S:#%%)J: M_9C\B_M#?\%9?@A\,?B%^P/\-_@IJGP>_:'U+]O[XA:GH7PU\3V'[2?PU\!? M#^S^''AFW1O$_P 0](\7WD7B:U\=ZO<:S-;^"?A]X!T"WAO/B#\0I)/!=OKN MCZQ"8F_/SQ5_P31_:0TCX+?&'Q/X<^"?@/QU\4--_P""Y_Q'_P""DUO\%;[Q MIX'TB']JGX$6_P 4_$=]X%\%:SXVU(2^%]#\2R>'-?TCX@>#-$^). M?A%;^*_ /BV+]E/0OVI?AMHNF?!#X7>'-4L+=-&\4ZU;>/\ 09?'?BN^^&<1 M\,>'/B)XL\0:SH]R]I##J]R ?J!^RK_P4\^"/[2OQ-\ _L^74GAKP5^T?XK_ M &4_ 7[6&M?#30_C!\*/B]H.B^%/'_B#7-#L_#7AOXB?#KQ+?:3\1]$]-F\/V7@WQ/X+\0#4Y+7Q18"OTLK^P\>>#OB+X2T[3/%/@VXU+0XX_"$VF>()H[>QT,#^CB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(\0:]HWA70M9\3>(M1M-( MT#P]I6HZYK>K7TH@LM+T?2+.?4=4U&[F((BM;"PMKB[N)",)#"['I7YX_ ;_ M (*.>"OBKIWASQC\2- \%?L]?#'Q;^S-^SK^TAHOC#XF_'[X4VFLVEG^T]\0 M?'OA'X6>#?%W@&:^TOQ3X,U#7M&\/^"M6TGQ)K<$7A;Q)XK\=W?PV\,ZAJ_B M3P1X@D?Z8_;"^'/B3XP_LF?M/_"3P<$_X2[XI?L\?&WX<^%B\@A0>(_''PQ\ M4^&-"W2D@1*=5U2T4R$C8#NSQ7\V7_#$?QL_;-^"7@GXL?#'P!X5\9_"OXT_ ML(?\$)O!>GZ?XB\4>#+=+S4OV3?VP]0^,G[2O@KQ3XW-EJV MF:O:^1KFM6VI^$+"*^UBVN]/0 _IS^&'[1GP!^-7PNE^-OP@^-/PK^)WP>MT M\127'Q1\!>//#7BKP!;IX2>Y3Q0]QXMT74;S1($\/FSN6UEIKQ!I\<+S77EQ M8D/C-G_P46_8$U/4M-T;2_VU?V4]4U?6O&WA7X;Z/IFG?'_X6WU[JOC[QQI, M.N^#?!^G6]KXGEEO/$'BG2IXKW0=.MUDGU*-BML'E5HQ\J_L^_L?_%CX5_!C M_@JUX _X0?PWX8G_ &F?VIOVK?B?\!-$T'6/#5OI6L^#OBM^SY\,?!7A34KJ M/2FBT_PC=:SXW\/^(5U#3M4CM;RS=6U?4(UBODE?\B?'?_!&K]HJZ^ FL^%? M!_[/GPFM/B$G_!*S_@DC^S?X>GM==^%VF7EG^T'^S1^TM>_$W]I6TM?$@:.: MVEMO#D&A:K/XY:X2U\>7NEZ9:V.J:G?6$*6X!^J_Q;_X*YVWP?\ '6H>"==^ M D.LO%X__P""@O@_3-2\)?'WX9^+DGTW]@_]F[3_ -H>YU7Q#9^%;37)O WB M+XG6UW-X37X;^+)--\;?#BXAMM<\5:==6.J6%K+[I^SW_P %'?A_\5_ OQ"^ M+7Q6L?AW^SI\(_A]\!_V3_COJWC[QS^T-\)]3M=&T7]ISX06_P 4GT[XA:-: MWVF:U\)T\%7-[:>%]+U?X@6FC6OQ0DG.N>"+>;3XI(E_&CX@?\$M?VT==^+G MQ:\5Z5\-_#$NA^*_VK/^"V_Q2T6Y;XD^#+>6Z\&_MG_L.^%/@I^SYJZ1K&G3JM[X1LXEUCQ EMI\J2GE-._X)3?MN^'O"^N>*W^$/@K MQIJ_PXU#_@A?\4=)^!>I_%'P3:Z/^TG=_L ?L[ZG\/?C]\%=2UZ[DOO"_AVY MTSQAJ]OK/@#6O'4!\$^(O%7A/P[?RSIHK2:A;@']%?BG]NC]AS1/A3X:^+?C M']K']F72_@S\2_"VO^(_"'C_ ,0_&;X;VW@'QYX3T/4]&\,^*=0\.ZYJ&O#1 MO$^EZ/K?B?0O#GB!=/EO5T_5];T[1=2AAO;Z*U>Y;_M-_L5_"7Q;\(OV?+'X M[?LU_#WQI\6]&T_7?@?\'[#XB?#3PMK?Q \/^(99)]&U?X;^"K#4K&37])\1 MS?:9-!O- L)[;Q'<178TB2_FAN-GX%?"?_@E=^TOK'QG^%/QJ^*_[/WPS\-> M%O%7C/\ X+%_&OQ%\ KWQ9\-?&^A_LRZQ^VIX%_9P\&?!;X:V#VR2^%?$WB3 MQ+=?"WQ[XO\ B+K_ ,/K2Z\'Z#XH\>>)H(=2FL=0:]U/S32_^"97[>WPY\7? M\$\;OX3_ (M/#/CSP%^S+_P3#^%?[0?Q4NOC?\ L_\ C_\ 9TFN_P!D^P\. MZ3\2=#_:&_9N^*?@/Q)XPUSQQ\-=$@\5Z;^SC\6?V4/%]MJ\VL:QINL:QJWA MV^TN+54 /Z7/V7OVC=(_:7\!^*?$]KH%QX-\3_#SXQ?&3X%?$CP/>:K;:W>> M$?B'\%?B'KO@37K%]5L[6RMM1T[6[33-)\:>&M0CM;R6\$MQ)$ MGTC7Y:_\$O--N[V+]O[XK6\,2>#/CE_P4L_:;\9?#BXM)8Y=-U7PO\.]*^&? M[-VJ^(=+DB_=36'B7XA? OQSK<-Y"6M]1:[?4H);B*[2XE_4J@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ (!ZC/ MUK.TK2-*T.R33=%TW3])T^.6[GCL=,LK73[-)[^\N-0OIDM;.*&!9;R_NKJ] MNI%C#W%W<3W,S//-)(VC10 4444 %%%% !00#U ..F:** ,[2='TG0-/MM(T M/3-/T;2K)&CL]-TJRM=.T^U1Y9)G2VLK**"V@1II9)66*) TDCR$%W8G1HHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DR/?\C_A0?ZC^ M8K\E-=U[7DUS6T77=;55UK6%55UG4U5574[M5556["JJJ JJH 50 * /U MKR/?\C_A1D>_Y'_"OQ__ .$@U_\ Z#VN_P#@ZU7_ .3*/^$@U_\ Z#VN_P#@ MZU7_ .3* /V R/?\C_A1D>_Y'_"OQ_\ ^$@U_P#Z#VN_^#K5?_DRNT^'&N:W M-\0?!$4VM:S-%)XKT*.2*;5]2EBD1]1@5DDBDNFCD1E)#(ZLK D,"#B@#]3: MJ75_96.PWEW:V@E+",W-Q#;^84P6">47_?J/_XFCRXO^>47_?J/_P")H _J%_M[1/\ H+Z7_P"# M&R_^/T?V]HG_ $%]+_\ !C9?_'Z_EZ\N+_GE%_WZC_\ B:/+B_YY1?\ ?J/_ M .)H _J4M[FWNXA-:SPW,+%E$L$LGXK_ #%?C]K_ /R'M=_[#FM?^G2[K]@3 MT_%?YBOQ^U__ )#VN_\ 8&_P#L M8/&?_J27U?8U?'/["/\ R;IX;_[&#QG_ .I)?5]C4 %%%% !1110 4444 %% M%(> 3Z T +17Q7X[_:,\;>&/&7B7P]8:7X9FLM'U6:QMI;NTU)[EXHXH7#3- M#JD,;2$R-DI$BX ^45R?_#57Q"_Z _A'_P M7_^7- 'Z 45^?\ _P -5?$+ M_H#^$?\ P"U?_P"7-'_#57Q"_P"@/X1_\ M7_P#ES0!^@%%?!5A^U%X_NK^P MM9-(\)B.ZOK*UD*6>K!Q'-5L+*ZU5[=YK:R/A[2+HVT1M[>W41?:)YIL,K-OD M;YL$ 'W">GXK_,5^/VO_P#(>UW_ +#FM?\ ITNZ_8$]/Q7^8K\?M?\ ^0]K MO_8'M'AX%\<):^+XO%'A[7];E M\1W&C6GA#P?J=YK?R2O_ 5^\3:I^SO\,_C3HOPH^#5I)XW^-GCWX:ZWXNU? MXG_&O7_V=_"_@WP!\)O!WQ0UKXA7_P 1/ 7[/>M_$30;;3;_ ,=Z5\-M>?QQ M\+/#'A;1O%V@^+M:D\3R^ ;/3_%$_P!J?'[_ ()_?#W]I/XWZ5\4?BA\1?BM MJG@.U\!^)/"^I? J'Q)9Q_#Z;Q/K/A'4OA[:>//#=S<:/=^)O >I?\(9XBUZ MV\4:9X.UW1]'\;>(++P=K_B2QOWT34[36^6/_!-_07^&'BOX;2?M3_M7++\4 MM=UB?X[>,]/\5_#G1=;^.W@76OA!X.^ ,WPM^('A_2OAO;> K?PUI?P>\!>& M?"/AKQ#X6\+:'X]\.7<>M^*=.\3+KWB34YR >]_"/]HW5_BA^T1^TK\#K[X7 M:YX%TWX!Z/\ !?5=!\6^(M3TV6[^*EA\5X_B7O\ %FA:'I5SJ$>D^ AG7.CQWGVY\,_^2B^!/^QMT#_TY6]?,7@_X(>% M_!'Q@^)_QCT6^U1-3^*'@#X'_#B]\-.MD/#OA_0/@)9^/-/\)-H3) -5:YOK M/Q_?0:L-2O+N()I>F&R6%FO&G^G?AG_R47P)_P!C;H'_ *@#]8:_+_P#X M*5?\@_X.?]A#QQ_Z1>&Z_4"OR_\ ^"E7_(/^#G_80\'O .BW=]XPUW1?#-K)K.HZ9H]Q#;O:P?:;VV^,=+_;_ /%Z_%'X"^#] M2T3X*>)?"7Q$^$?A/QYXO\4_#/Q9XV\3VNI7VO\ @OXV^+=6U+X;>*KG1M/\ M$:5IVAGX-IINF?#OXFSZ1\3OB#J'BJ^MO MKJ4/@77+R?] ?C'\+-&^-'PW\ M3?#?7-7\4^';77[>V>S\2>"?$&H>&/%?AK7-*O(-5\/^(=#UC398IHKO2-8M M+2[DL;D3Z5K-FEUHVL6=WI=_=0/\_>%OV#/@'X4UGP+K-FGQ"O8_!D/AJ[U/ MPSJGQ!UB_P# WQ,\:^$4\>MX<^)_Q6\*7$;VOC+XAZ/=_%+XB7UAKDES8VZS M^*)1=Z=>II.B#3P#XVT7_@IA\3?$OP>T_P"(/ACP;\!/$?B:?0/B7\8=;\,V M7B3XQZ1!X0^#?PJ^ OASX]Z_X5UV+Q3X+T36;SXKZ[IWB6R\*^ _&_AZ#5_@ MOXQ\B_\ &FE74ND6CZ6W[%Z=?V^JZ=IVJV9JZ=I^JV?FJ%E^QZI90:A:> M:HX67[-:HX63$I[SXS7-M;&VT>'6[GXP^(Y? M%:?"^T^'K?"6#X"#Q#Y"W7_"C$^%[MX%/@<1B[?1L7+>(#K8&JC[P1(XD2** M..&*)$BAAB4)%##$@CAAB0<)##$J11(.$C14' % '[J?L(_\FZ>&_P#L8/&? M_J27U?8U?'/["/\ R;IX;_[&#QG_ .I)?5]C4 %%%% !1110 4444 %(W0_0 M_P J6D;H?H?Y4 ?E=\7O^2H>._\ L8KK_P!$6U?"?Q$_:Q\(?#[]I#X1_LP) MX"^+'CGQW\4M";Q9J&J_#[PE#XB\-?"[P?=:IK?A_0O%WQ$F_M2UUF#P[J_B M+PYK>G7VH^'='UV'PAI^FS^(_%S:5H[6TES]V?%[_DJ'CO\ [&*Z_P#1%M7Y M._M<_L:_$[]HO]HG]F#XG^%_B=X5^'_A'X.:E<:EK&N6/@V2U^/G@:_LM3.O M3ZG\%OBOHVL:5>VUK\3K.*S^'_C;P5XYLO%7@+3;&T@\9VWAK4-8>[MY #O/ M$?\ P4)_9P\,?#C]K_XKWVN:S<^"/V+/&L_PW^)VK:=8V-W_ ,)3X_@\-:'K M1\(_#"(:HG_"4ZI+KFOVO@"U:Y;2;.Z\9VFJPPW+Z#IT^N#O/"G[6?@7Q7^T M!_PSJO@KXM>'_%%[X"U+X@^%_&'B;P7!I?PW\=:;XZQXRL_!GB!-;NM M6U1_"%O\4?"%G>^(;KP[IW@?Q!K)=7\*Z[:6OYF7G_ 1:U%?A M-\>?A/I/[:'QZCTCQ;J6C:U\%'U.+X7S0>'M2T+]E35?V;;2/XOV=E\(+>T\ M86TUKXBUJ*XU+PK:Z1XHA\+QZ9J>G:Y9?$]]9\8ZE]I_#3]D7XM^%_VE/AE\ M9_'/QM\)>-_#WP;^"6J_!SPI?6'PQ_X13X[>/O#_ (@\'^!=$E\&_'CXAZ/J MMIX.^('PY\">-?#'B7XL_#>RTWP-H&L6GCGQO<7-ZMA%HY.L 'Z*Z/\ \AC2 M/^POI/\ Z<;6OV&'3\6_F:_'G1_^0QI'_87TG_TXVM?L,.GXM_,T ?GM_P % M&O\ DD_@O_LHUM_ZB_B.OPV^*7C_ $[X4_#3X@_$_5],U?6M*^'?@SQ)XVU+ M2- ABGUO4['PUI5SJMS8Z7'.\=L+NXBMFC2>ZECL[-#)>WLD=I;3NO[D_P#! M1K_DD_@O_LHUM_ZB_B.OQ.\7Z#>>*?"GB3PUI_BGQ%X'U#7M#U/2+'QGX1DL M8O%/A.\O[62WM?$?AY]3M;[33J^CSO'?646HV=UI]S)#]EOH)+6>52 ?&FB_ MMP6$OPM_9C\:^*?AG>Z1XO\ VH/B[X-^%OA#P3X7\>^#_B)I,.D^*?&.E>%; MCXN6_C_PG)>Z)J/PQTI-?\/R_;KBUTK6+K7_ !!HG@^;3[#5=2@N##X-_;:U M7XJZ7\5=4^#7P&U'XEQ> /%L7AG0ULOCG\$]%EU>QM_$GC;PWKWBOXE:=?:W M<>(?@%H.E+X#U/Q/IR^.]!O[_P 3>#]6\-ZQI=NDM]J5EH_D7AC_ ()8_#VS M\*_#J3Q)\4/B+'\5?"/Q*\,_$G7/&'PVUK5?A1X*UA]&^)?AOXEZGX5TCX3^ M!=5T+PAH.FZKJGA72[FVUY+>X\0:9XH>Z\="2[\0& PS^)?^"9L4_A[XF>&O M 'Q]U;P+I'Q"EF\/IITGPA\$:S:6?P@UKXT>+OV@?&WPA\6SZ5K/A'6_BGHW MC/XC^+)=/U'7_%NM1:O;_"VQD^&4<4^E:]K]]? 'Z$?"/XCZ3\8OA5\-?BWH M&GZKI6A_$[P)X5\?:1IFN100ZSIVG>+-%L]:M++4TM99[4WEM#>+%++:3S6= MSM6ZLYI;2>&1OW&_X)P_\DT\??\ 90%_]1?0Z_%?P;I.LZ!X2\,:'XBUNP\2 MZ[HV@Z7I6K^(-*\+:=X'TO6+[3[2.UEO],\&:/=7ND^$].F$2"Q\.:9=W.GZ M/;)%8V/VH_X)P_\DT\??\ 90%_]1?0Z /T3/3\5_F*_'[7_P#D/:[_ M -AS6O\ TZ7=?L">GXK_ #%?C]K_ /R'M=_[#FM?^G2[H R:*** "NW^&?\ MR47P)_V-N@?^G*WKB*[?X9_\E%\"?]C;H'_IRMZ /UAK\O\ _@I5_P @_P"# MG_80\+=6T[]NSX$7-C MJ.LS75K/'>^,F22&2"W (9?!I5L,K(2C,I96VLR[6;B/^'Q?_!+C_H^7X%_^ M!GC/_P"8VOZLO[,T_P#Y\;/_ ,!;?_XU1_9FG?\ /C9_^ EO_P#&J /Y3?\ MA\7_ ,$N/^CY?@7_ .!GC/\ ^8VC_A\7_P $N/\ H^7X%_\ @9XS_P#F-K^K M+^S-._Y\;/\ \!+?_P"-4?V9IW_/C9_^ EO_ /&J /Y6],_X+'_\$M(=3TR: M7]NCX$QQ0ZGILTLC7GC0*D45];R2.Q'@PG:B*SMQ]U3C)P#^E0_X+_?\$U*P\<6VI7-G9:AXKGGCL1X? MUVU>Z98O"CA8H[BXMXF+,IWSQA0V6*_F-_P])_X)W_\ 1WWP@_[_ /B__P"9 M*O[@3IFGGK8V9^MK;G^<5)_9>F_\^%E_X"6W_P :H _A_P#^'I/_ 3O_P"C MOOA!_P!__%__ ,R5'_#TG_@G?_T=]\(/^_\ XO\ _F2K^X#^R]-_Y\++_P ! M+;_XU1_9>F_\^%E_X"6W_P :H _A_P#^'I/_ 3O_P"COOA!_P!__%__ ,R5 M?IE^P_\ \%LO^"4?PQ\!>,-,\;?MU? O0=0U+QH=0M+.]U#Q7!-+9+X?T>T% MRHE\)HK1/ =K#(!R!_5#_9UA_S MY6G_ ("V_P#\:I/[,T[_ )\;/_P$M_\ XU0!_*;_ ,/B_P#@EQ_T?+\"_P#P M,\9__,;1_P /B_\ @EQ_T?+\"_\ P,\9_P#S&U_5E_9FG?\ /C9_^ EO_P#& MJ/[,T[_GQL__ $M_P#XU0!_*;_P^+_X)%7VB9[695W8R4.,X./Z=/[.L/^?*T_\ 6W_ M /C5(=,T\];&S/UM;<_SBH _A^_X>D_\$[_^COOA!_W_ /%__P R5'_#TG_@ MG?\ ]'??"#_O_P"+_P#YDJ_N _LO3?\ GPLO_ 2V_P#C5']EZ;_SX67_ ("6 MW_QJ@#^'_P#X>D_\$[_^COOA!_W_ /%__P R5'_#TG_@G?\ ]'??"#_O_P"+ M_P#YDJ_N _LO3?\ GPLO_ 2V_P#C5']EZ;_SX67_ ("6W_QJ@#^>W]D7_@N/ M_P $E/A]\$=!\->+?V\O@/I&MV^L>*;JXT^ZU+Q5#<017VO7MQ:F1)?"D9_? M6[1SH5W*8Y4^;?N1?WL^&_Q&\$?%_P"'W@GXJ?#7Q)IOC'X>_$?PIH'CCP/X MKT=Y9-*\2>$_%&F6VLZ!KNFR3Q03/8ZKIEW;7MJ\L,4C0S(7C1B5'3C3=/' ML;,#T%K;C_VE5Q55%5$551%"JJ@*JJHP%55 P !P!0 ZBBB@ HHHH * M*** "D) !)Z $G R< 9X Y/TI:0C((R1D$9'49'4>XZB@#\X?&W[?FK^%?$G MQ#\4:=^SWXO\1_LJ_!;XC77PI^,?[1UKXT\*V-SX<\3:#J^G^'/B%XF\+?"* MY@D\3^-OA7\'_$FHRZ'\5?&<>MZ%J^D7?AGQO/X5\&^,].\,/>7_ *=X-_:K M\9:O^T8_P2\<_L_^+/AIX9\56WQDN?@W\0M<\6^'+_4?B%#\!O$GAGPSXYU+ M6OAQ8P1^(/ /AW7W\5:;XB^%VOWFHZ];>,/"MQ>"]0UOPWHVL_'/[0G M[&7[:^I:#\8O@G\!OB3\!;C]E[XV?%+QU\5O'GA;XC:;XTTGXPS^'?C%XC?Q M?\=O@3X0\9:/IGB+PEH$'C[Q3JOC/Q%X)^,VIZ1?W_PX_P"$ND\,:I\-/'%E MI>G>(;7W[X ?!;]K/P]^U9\;OC#\?-)_9T\4^'?'%QXQ\/?#CX@^$_B)\5]1 M^)?@7X.6/B>"^^%'PCT?X9^(/ACHWP]\(:3-I\)\5?&'7M#\;ZKKOC[XG/'J MVH7.I^'-#\":#X) *WA#]L#]IWXC^+?C3'\//V1/!'B/X:_"SQE^T/\ #S0/ M$DW[5>B:3\1/'_C/X%W?BGPWI^E6_P +9_@_-:>&;?X@^//#EOXQDZ#P3_ ,%#OAE\3M'\1^.OAIX,\?\ CSX8>"/V?O"7 MQD\:^(?"^C7&M>+M(\<_$20S^"?V<+'X<:5;7VN:I\5_P )@+S1M?\ 9H_8:^%'P.\>?%_XUZK\,/@S>_M ?$WXV_M! M>/3\;- \"Z5!\2Y/ GQ;^(NK>*/#_A+6O'=WI%OXHN6TCPW-HNAZI9)?S:0# MI4%O8M-96\#'LOV>/V;KKX)>"/V@/#!;PA%>?&;]H?\ :5^-B7'AG3I=.MG7 MXW^-=6\1Z7)XC!L;26^\36FG7=C9^(=05+I;F:T"VUW=01PM0!X+XF_X*,C1 M-,^&?BVP^ WBW5/A[>_ +X!_M(_M">+YO&_@S21^S_\ #C]H[5]1\/> 2FD7 M32W/Q2US2]1\-^-]6\;V'ARXT:TT/P?X/OM9TW4=>US5?#_A35?TQ5MPS[L# M]58J1^8//?K7XP_&+_@F/XN^+FA?LM>!=;N?@Q?>&?A]^S[\&?@)\9O$EVWQ M'/V@/#5[IWP-\4 MR1?%SP.E_P"(M0U[PUJ'[/*NT8]V8_5F+'\ 20/:@#YW_:-^/5U\#]#\$VGA M?P!J_P 6?BI\6?'5M\-/A+\,M&UO1O##^*?%;^&_$OC75KK6_%>OEM*\(^#_ M AX&\&^*_&/B[Q)']4^;HOVV/C'J_A[Q!X: M\+?L@^*]:_:3\ ?$*3P)\4_@_G:YK/CN]OO!WB;P_X,E\)^-=2\/>Y_M0?!?Q]\2X M/A1X^^#>O^$/#WQK^ ?Q&E^)'P[;XA:=K&H^ /$\>L^!O&'PR\;^ O&G_"/3 M1^(-+T;Q9X)\)="AU#4O"7BS3O#/B;^Q/$EAI>H>&M9_,;7?V-_P#@ MI3XE\+?%JW\7>(OV3O&WBWX^_&'P?KGQYBL_'?QG^$7@WXE?L\>#?A(G@[PQ M\ =/O_"OPN\6>,/",,/BJ!S\6O$5A;0M\:?!^I^(-)T^'X8Z-XKO?".A@'W) M\3OVU/$]E\(_V1OB+\ O@M9_%;7_ -L34O#J> /"'Q$^*VF?!"R\/Z#KGP$\ M-OV_= M2^"AN_#?Q_\ @E<^"_BAJ_P+T3XH_"+P3X#^(%M\3[#X[?$2_P#'$7PTU?X M_##Q4?"'@V+4OB+HWCGQ;\&--C:_T>QL=2T?XQZ#XFC2UTGPUXRDT;LOCC^Q M]HG[4.A_L>:!\=_AK\"/$_@SX,>/6^(7Q;^#>L^'1X]^%.I7S_LX_%CX6:?H M7@/2/$_A>SL=2TSPEXZ\?:-JWAF\\2^'-!D@\/:$;F+3].U=;2P7N?B)^RWX M8U[Q3^Q1<>"?#'PY\+>!_P!D3XL:GXUT+PG'X9L[.RT#PM_PS9\:/@AX!/AK8>%/BY>>#O'5GXY\':YK/Q!\:_ WP*/&WC?0=#^'-]%X: M\16/@SQ$;+7M!^$WQ+U:ZMM.\<:EIFFWFM:%X(T7QAX.U'6OIG]F_P".WB7X MRZ?\0=&^(OPON/@U\6?A+XV@\$?$3X?-XRT?XA:98W6K^#O"WQ#\+ZSX;\;Z M'8:19^)-!UWP?XRT:8W3Z+H]WIOB"T\0^'[FQ/OV.?VM?CA\7 M/VHY_C%>?L\S?#OXN> OB/\ "+X(?$K1?&_Q:U7XC_ ?X67UGH^I>!/#^C_! M;4?A]HWPYFO_ !+\0_#>A>.?CWKMO\3TUOXAO8Z+X9CU2/PKX'\$Z/H_VK^S M!\)_BQX)F^+_ ,1_CSJ'PZN_B_\ '#Q]I/BSQ'IGPG7Q-+X \*:+X0^'WA#X M:>$_#>@ZKXQM['Q-KKOIWA.Y\5:QJNJ:9I936_%>H:18V1TW2+2^OP#JOV@_ MC[9?L[Z?\-_%GBCPU>'/BC\(OC-\9H?@Y\*_&7C']INR^$6L^+I-<\9:IX-\!_$. M'PC/\%?&\EK\./B$=%O/%?A763K4^IWO@B^\/>(!HS'6?L=G]Y?M2_"*Y_: M_9F_:'^!5D^@Q7_QF^!WQ8^%>GS^*+62]\-V^H?$#P'KWA2PN=>M(+>[GN-' MMKS58+C48;>UN+A[2*400RS;$/G_ ,8OV==9\>>#?V:_"7A6_P##'A^W^!WQ MO^ /Q)O[:6VN[73)_#/P@ED_M#0O#MKIMHR6MW- M5% 'S';?\%#/BUI/BCQWJOQ!_94L_#G[/OPG^,_A#X!_%/XP^'/C_H'B[Q'X M,\<>(['X:6>K^(KGX4WGPZ\)W>I_"SP=XS^)^D:+KOB[2_&,WB!/#-E?>.4\ M#BPAGTRW]M_:2_:B^,WPR^,7PT^"/P)_9_\ !WQK\6^.?AI\2OBGJ]WX\_:! MLO@-HGAOP_\ #SQ7\-_!QM+2\G^%_P 3KCQ'JVL:M\1[1TMHK32X=/L],N99 MKFXDN((1\WZ_^QM^U3XL\8?M"?"?5-;_ &?])_9-_:#_ &F=,^.WBGQ7I^K_ M !/U7X_W/@^'_A5&I^(_A5;^#)?#&C?#G1)O%M]\,?\ A&+GQS_PG>NOI'A7 M7KZ_L_"USKL=N(?H[X[_ +#7PF_:6_:3^%7Q7^._PO\ @S\9OAS\,?@M\6O MVE^"OBOX$TGQ[/I?C[X@_$'X/>*-/\7^'K'Q)I&IZ+IPL]#^'VN:3?WT,-/OXM M<^'?C3PLOQ)D_:-TKQ8VB62S?![P[\--'^(EYK6KOH*31_$KX=ZQ\(8L^*=6 M\/3:C4\0?M]V[Z;\1[7X=?!#X@^,/'>@?M.>$_V5?A?X.\37%M\+4^+'C;Q1 M\,_#GQ5;QI'JWBO3Y+GP9\*=)\*ZCXGU-_%FK:#J&J>(-*\$:CJO@_PUX@AU M_P (Q:W[-)?@$F[3G/C=)==^+7A3XBJMMJ MOV(QQ^%/LWAUH[G3O[05VU;[+.EF8UDF'A7Q_P#V._'/Q,\.?M)QZ%)\+=!]'\'_BE\)O'!U;X M?:KK/A#XG?"_4+W6?"[S:5]JTW6]-O/$/A^[ /K?X!?&.S^._P *?#_Q*M?# MNJ>$+V]O_%OACQ1X.UJ\TK4=4\'>//ASXT\0_#?XC>$;S4]"NK[1M6E\+>.O M"?B+1$U;2KF73]8AL8=2LBEO>1QI\B:;^WWK/B_5X?A#\/?@;$/'WP)UWXA6_A73OAGIGP6TN+5(/B)XO\ B.?!FM0V_P ._BE!XP^!\WPL MURV\(SWGB>Q^-OAV]72X%\+^.(M"^C/V0O@"G[,?[/O@;X.M=:#>:AHMSXT\ M3>(I_"NE7^B^%V\8?$SQ]XI^)_C-/#6G:MJ6LZW!X?@\4^,=6MM&D\0:SK'B M2\TV"VOO$FK:IKUUJ5_<5O WP!D\)?M6?M#?M$.OA3R?C/\ "G]G/X>VC6&F MM#XNCF^"VH_'*\U)_$6I&SB2\TRZ3XHZ.F@Q1WMU+;MIVHKZ_XD7]GNU_X1'PQH:?"36+CP[>C1=?U/Q6=2T^!](T%BSGZ_\!_M;7>O M?!G]H#QWX[^%.L?#GXG?LP2^.-+^+_PAG\5Z#XH-GKGA/X::3\7]&;PIXZT: M"+2_$WA7Q[\/?$WA3Q%X6\22:-H]Y%'K4VE^(/#VC>(-#UG1[7Y[\:?LA?M# MZ)\//#;?"'4_@KX@^)W@C_@H5\8_VQ="TOXE:YX^\+> ]6\(?$[Q%\<[NS\* MZKK_ (4\(>*_$>F^)])T?XN64L]Q9^'-2TB;5='N+=)GLIX[@^L>"?V9/BQ) M\%OVLH/B9XH^'\OQ]_:X/C?5/$EUX'M/$UK\,? =U>_!/0/@5\.?"GAVXUSS M/%FLZ)X4\+>#]"U'7_$NH:=IFI^(_$^J>*-8LO#^A6%SI>@V !YUX+_;L^-] MA\/? _QF_:'_ &7O!GPC^#?C3Q?\%M!NO&_@;]IW1OC-+X$\-_&V"]TS1/'_ M ,0=)/PF^',&@^%O#WCG5?AIX9\77EOK&I1:%H_CC4O'5]<0>&O ^M37">+O M^"AWC/3_ (>:M\;/ G[*GCKQ]\"_#C_%SQOK/Q1/CSPKX.TBZ_9^^#^LV'A^ M]^*7A.+Q+I\5OXJ\3?$6ZMO&OBGX0_#.VU*R/C'X7>%+'QUJ'C3PW-XY\'^' MM1ZO1O\ @GM\(?A[^P_\7_V6?@U\*/@3\*_$/QF_9NU[X1^.=3\%_#S1_"WA M#QGXWU?X.ZI\-T\4^-K30M$M[[Q'8#4-5NKF>;4K&]U1]+N;I/)>YGDC?B_V MD_V;?VK?%*?LP>!O@UI'[-/BKX"?!KPYX>O?'OP@^*GCGXH_#'1/&OQ*\!2^ M$D^%MU=Q_#CX6>/8/$GPP^'0T+4/$>F_#358]$T76O&P\'ZSK\5[8>"K#2KH M ]C^&O[9TWC[X]3?"V\^$/B#PQ\./$FO?&OP9\'OC-=^*?#VIV7Q)\;_ +.' MB*/PG\8=!O?!&GQ_V]X'@M-++^^LO"N/#EOXB^ MY*_.CX5?LF?%[PC^T%IWB'Q;XS^'NI_ ?X7>//VF_BQ\'-.T33?$T7Q2U+QS M^U?XPU7QEXLMOB/-=.\3Z'=Z[:>&;O MPO>Q^*?T7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB 4@ HHHH **** "BBB@ HHHH __]D! end XML 22 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares
shares in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Earnings Per Share [Abstract]        
Weighted-average common shares–basic (in shares) 292 299 294 302
Effect of dilutive securities:        
Employee stock options, restricted share units, and performance share units (in shares) 2 1 0 1
Weighted-average common shares–diluted (in shares) 294 300 294 303
XML 23 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Jun. 30, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying Amount of Long-Term and other Short-Term Borrowings $ 7,934 $ 8,031
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Estimated fair value $ 8,078 $ 8,065
JSON 24 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a20q210q123119form10-q.htm": { "axisCustom": 5, "axisStandard": 27, "contextCount": 256, "dts": { "calculationLink": { "local": [ "cah-20191231_cal.xml" ] }, "definitionLink": { "local": [ "cah-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a20q210q123119form10-q.htm" ] }, "labelLink": { "local": [ "cah-20191231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cah-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cah-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 556, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 14, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 19 }, "keyCustom": 45, "keyStandard": 332, "memberCustom": 45, "memberStandard": 37, "nsprefix": "cah", "nsuri": "http://www.cardinal.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.cardinal.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Goodwill and Other Intangible Assets", "role": "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Investments", "role": "http://www.cardinal.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "cah:LeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Leases", "role": "http://www.cardinal.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "cah:LeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings", "role": "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowings", "shortName": "Long-Term Obligations and Other Short-Term Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Commitments, Contingent Liabilities and Litigation", "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigation", "shortName": "Commitments, Contingent Liabilities and Litigation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Income Taxes", "role": "http://www.cardinal.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Fair Value Measurements", "role": "http://www.cardinal.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Financial Instruments", "role": "http://www.cardinal.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Shareholders' Equity", "role": "http://www.cardinal.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.", "role": "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthInc", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Statements of Earnings", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "shortName": "Condensed Consolidated Statements of Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Segment Information", "role": "http://www.cardinal.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Share-Based Compensation", "role": "http://www.cardinal.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Restructuring and Employee Severance (Tables)", "role": "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables", "shortName": "Restructuring and Employee Severance (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "role": "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Leases (Tables)", "role": "http://www.cardinal.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables)", "role": "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsTables", "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.cardinal.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Financial Instruments (Tables)", "role": "http://www.cardinal.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.cardinal.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncTables", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - Segment Information (Tables)", "role": "http://www.cardinal.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.cardinal.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "I2020Q1ASC842", "decimals": "-6", "first": true, "lang": null, "name": "cah:LeaseLiabilitiesestablishedasaResultoftheadoptionofASC842", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)", "role": "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "I2020Q1ASC842", "decimals": "-6", "first": true, "lang": null, "name": "cah:LeaseLiabilitiesestablishedasaResultoftheadoptionofASC842", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "role": "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails", "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "role": "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails", "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - Restructuring and Employee Severance Narative (Details)", "role": "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails", "shortName": "Restructuring and Employee Severance Narative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD_us-gaap_RestructuringPlanAxis_cah_EnterpriseWideCostSavingMeasuresMember", "decimals": "-6", "lang": null, "name": "us-gaap:RestructuringCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails", "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "role": "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)", "role": "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "shortName": "Goodwill and Other Intangible Assets (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "lang": null, "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "I2018Q1navi_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cah_NaviHealthMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407401 - Disclosure - Investments Investments (Details)", "role": "http://www.cardinal.com/role/InvestmentsInvestmentsDetails", "shortName": "Investments Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "I2018Q1navi_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cah_NaviHealthMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "td", "tr", "table", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "D2020Q1SD", "decimals": "-6", "first": true, "lang": null, "name": "cah:ReclassificationofdeferredrentinaccordancewithASC842", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Leases (Details)", "role": "http://www.cardinal.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "td", "tr", "table", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "D2020Q1SD", "decimals": "-6", "first": true, "lang": null, "name": "cah:ReclassificationofdeferredrentinaccordancewithASC842", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Leases Schedule of Lease Costs (Details)", "role": "http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails", "shortName": "Leases Schedule of Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "cah:LeasesSupplementalBalanceSheetInformationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Leases Supplemental Balance Sheet Information (Details)", "role": "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "cah:LeasesSupplementalBalanceSheetInformationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "cah:LeasePaymentsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Leases Supplemental Cash Flow Information (Details)", "role": "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails", "shortName": "Leases Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "cah:LeasePaymentsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "cah:LesseeLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408406 - Disclosure - Leases Schedule of Future Lease Payments (Details)", "role": "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails", "shortName": "Leases Schedule of Future Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "cah:LesseeLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "cah:TotalLongTermandShortTermObligations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)", "role": "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "D2020Q2NotesPayable_us-gaap_DebtInstrumentAxis_cah_A2.4Notesdue2020Member", "decimals": "-6", "lang": null, "name": "us-gaap:RepaymentsOfNotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)", "role": "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails", "shortName": "Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411401 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)", "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "shortName": "Commitments, Contingent Liabilities and Litigation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "I2020Q2lawsuits_srt_LitigationCaseAxis_cah_OpioidLawsuitsStateDomain_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "0", "lang": null, "name": "cah:LossContingencyLawsuitsNumber", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412401 - Disclosure - Income Taxes (Narrative) (Details)", "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)", "role": "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "shortName": "Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Financial Instruments (Narrative) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "shortName": "Financial Instruments (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails", "shortName": "Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - Shareholders' Equity (Narrative) (Details)", "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails", "shortName": "Shareholders' Equity (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember", "decimals": "2", "lang": null, "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "role": "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "decimals": "-6", "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncNarrativeDetails", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417403 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - Segment Information (Narrative) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "shortName": "Segment Information (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418403 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "shortName": "Segment Information (Revenue by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_cah_PharmaceuticalMember", "decimals": "-6", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418404 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails", "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-6", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418405 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)", "role": "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "shortName": "Segment Information Revenue From External Customers By Geographic Areas (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD_srt_StatementGeographicalAxis_country_US", "decimals": "-6", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418406 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "shortName": "Segment Information (Assets by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_cah_PharmaceuticalMember", "decimals": "-6", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - Share-Based Compensation (Narrative) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "shortName": "Share-Based Compensation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419403 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails", "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419404 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails", "shortName": "Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419405 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "shortName": "Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "cah:AdditionalStockOptionPlanDataTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-6", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419406 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-6", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419407 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": "-6", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Restructuring and Employee Severance", "role": "http://www.cardinal.com/role/RestructuringAndEmployeeSeverance", "shortName": "Restructuring and Employee Severance", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a20q210q123119form10-q.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 83, "tag": { "cah_A2.4Notesdue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.4% Notes due 2020", "label": "2.4% Notes due 2020 [Member]", "terseLabel": "2.4% Notes due 2020 [Member]" } } }, "localname": "A2.4Notesdue2020Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A2.616Notesdue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.616% Notes due 2022", "label": "2.616% Notes due 2022 [Member]", "terseLabel": "2.616% Notes due 2022 [Member]" } } }, "localname": "A2.616Notesdue2022Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.079Notesdue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.079% Notes due 2024", "label": "3.079% Notes due 2024 [Member]", "terseLabel": "3.079% Notes due 2024 [Member]" } } }, "localname": "A3.079Notesdue2024Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.2Notesdue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.2% Notes due 2022", "label": "3.2% Notes due 2022 [Member]", "terseLabel": "3.2% Notes due 2022 [Member]" } } }, "localname": "A3.2Notesdue2022Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.2Notesdue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.2% Notes due 2023", "label": "3.2% Notes due 2023 [Member]", "terseLabel": "3.2% Notes due 2023 [Member]" } } }, "localname": "A3.2Notesdue2023Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.41Notesdue2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.41% Notes due 2027", "label": "3.41% Notes due 2027 [Member]", "terseLabel": "3.41% Notes due 2027 [Member]" } } }, "localname": "A3.41Notesdue2027Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.5Notesdue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.5% Notes due 2025", "label": "3.5% Notes due 2025 [Member]", "terseLabel": "3.5% Notes due 2025 [Member]" } } }, "localname": "A3.5Notesdue2025Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.75Notesdue2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.75% Notes due 2026", "label": "3.75% Notes due 2026 [Member]", "terseLabel": "3.75% Notes due 2026 [Member]" } } }, "localname": "A3.75Notesdue2026Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A4.368Notesdue2047Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.368% Notes due 2047", "label": "4.368% Notes due 2047 [Member]", "terseLabel": "4.368% Notes due 2047 [Member]" } } }, "localname": "A4.368Notesdue2047Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A4.5Notesdue2044Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.5% Notes due 2044", "label": "4.5% Notes due 2044 [Member]", "terseLabel": "4.5% Notes due 2044 [Member]" } } }, "localname": "A4.5Notesdue2044Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A4.625Notesdue2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.625% Notes due 2021", "label": "4.625% Notes due 2021 [Member]", "terseLabel": "4.625% Notes due 2021 [Member]" } } }, "localname": "A4.625Notesdue2021Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A4.6Notesdue2043Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.6% Notes due 2043", "label": "4.6% Notes due 2043 [Member]", "terseLabel": "4.6% Notes due 2043 [Member]" } } }, "localname": "A4.6Notesdue2043Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A4.9Notesdue2045Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "4.9% Notes due 2045", "label": "4.9% Notes due 2045 [Member]", "terseLabel": "4.9% Notes due 2045 [Member]" } } }, "localname": "A4.9Notesdue2045Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A7.0Debenturesduefiscal2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "7.0% Debentures due fiscal 2027", "label": "7.0% Debentures due fiscal 2027 [Member]", "terseLabel": "7.0% Debentures due fiscal 2027 [Member]" } } }, "localname": "A7.0Debenturesduefiscal2027Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_ASC842Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ASC 842", "label": "ASC 842 [Member]", "terseLabel": "ASC 842" } } }, "localname": "ASC842Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "domainItemType" }, "cah_AdditionalStockOptionPlanDataTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A disclosure of additional data related to all stock option activity", "label": "Additional Stock Option Plan Data [Table Text Block]", "terseLabel": "Schedule of Additional Data Related to Stock Option Activity" } } }, "localname": "AdditionalStockOptionPlanDataTableTextBlock", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "cah_AlamedaCountyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alameda County [Member]", "label": "Alameda County [Member]", "terseLabel": "Alameda County [Member]" } } }, "localname": "AlamedaCountyMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_Amortizationandotheracquisitionrelatedcosts": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Amortization and other acquisition-related costs", "terseLabel": "Amortization and other acquisition-related costs" } } }, "localname": "Amortizationandotheracquisitionrelatedcosts", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "cah_CVSHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CVS Health [Member]", "label": "CVS Health [Member]", "terseLabel": "CVS Health" } } }, "localname": "CVSHealthMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_CardinalHealthAtHomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cardinal Health At Home [Member]", "label": "Cardinal Health At Home [Member]", "terseLabel": "Cardinal Health At Home [Member]" } } }, "localname": "CardinalHealthAtHomeMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_CareFusionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CareFusion [Member]", "label": "CareFusion [Member]", "terseLabel": "CareFusion [Member]" } } }, "localname": "CareFusionMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_CarryingAmountofLongTermandotherShortTermBorrowings": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings", "label": "Carrying Amount of Long-Term and other Short-Term Borrowings", "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings" } } }, "localname": "CarryingAmountofLongTermandotherShortTermBorrowings", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "cah_CashComponentForSettlementFrameworkTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Component For Settlement Framework, Term", "label": "Cash Component For Settlement Framework, Term", "terseLabel": "Cash Component For Settlement Framework, Term" } } }, "localname": "CashComponentForSettlementFrameworkTerm", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "durationItemType" }, "cah_ClassActionLawsuitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Action Lawsuits [Member]", "label": "Class Action Lawsuits [Member]", "terseLabel": "Class Action Lawsuits [Member]" } } }, "localname": "ClassActionLawsuitsMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_CommittedReceivablesSalesFacilityProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.", "label": "Committed Receivables Sales Facility Program [Member]", "terseLabel": "Committed Receivables Sales Facility Program [Member]" } } }, "localname": "CommittedReceivablesSalesFacilityProgramMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount", "label": "Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount", "terseLabel": "Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount" } } }, "localname": "DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_EnterpriseWideCostSavingMeasuresMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Enterprise Wide Cost Saving Measures", "label": "Enterprise Wide Cost Saving Measures [Member]", "terseLabel": "Enterprise Wide Cost Saving Measures [Member]" } } }, "localname": "EnterpriseWideCostSavingMeasuresMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails" ], "xbrltype": "domainItemType" }, "cah_ExercisablePeriodOfPlansInYears": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The instrument's contractual term.", "label": "Exercisable period of plans, in years", "terseLabel": "Exercisable period of plans (in years)" } } }, "localname": "ExercisablePeriodOfPlansInYears", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "cah_FacilityExitAndOtherCosts": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.", "label": "Facility Exit and Other Costs", "terseLabel": "Facility Exit and Other Costs" } } }, "localname": "FacilityExitAndOtherCosts", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_FinanceLeaseImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease Imputed Interest", "label": "Finance Lease Imputed Interest", "terseLabel": "Less: imputed interest" } } }, "localname": "FinanceLeaseImputedInterest", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_FinanceLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Lease", "label": "Finance Lease [Member]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "cah_FloatingRateNotesdue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Floating Rate Notes due 2022", "label": "Floating Rate Notes due 2022 [Member]", "terseLabel": "Floating Rate Notes due 2022 [Member]" } } }, "localname": "FloatingRateNotesdue2022Member", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "cah_GownRecallAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gown Recall [Axis]", "label": "Gown Recall [Axis]", "terseLabel": "Gown Recall [Axis]" } } }, "localname": "GownRecallAxis", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_GownRecallDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Gown Recall [Axis]", "label": "Gown Recall [Domain]", "terseLabel": "Gown Recall [Domain]" } } }, "localname": "GownRecallDomain", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_IPRDTrademarksandOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "IPR&D,TrademarksandOther [Member]", "terseLabel": "IPR&D, trademarks and other" } } }, "localname": "IPRDTrademarksandOtherMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cah_IndemnificationReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.", "label": "Indemnification Receivable", "terseLabel": "Indemnification Receivable" } } }, "localname": "IndemnificationReceivable", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_InvestigationbyMultitateTaskForce": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investigation by Multitate Task Force", "label": "InvestigationbyMultitateTaskForce", "terseLabel": "InvestigationbyMultitateTaskForce" } } }, "localname": "InvestigationbyMultitateTaskForce", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "integerItemType" }, "cah_LawsuitTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lawsuit Type [Axis]", "label": "Lawsuit Type [Axis]", "terseLabel": "Lawsuit Type [Axis]" } } }, "localname": "LawsuitTypeAxis", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "stringItemType" }, "cah_LawsuitTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Lawsuit Type [Axis]", "label": "Lawsuit Type [Domain]", "terseLabel": "Lawsuit Type [Domain]" } } }, "localname": "LawsuitTypeDomain", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_LeaseLiabilitiesestablishedasaResultoftheadoptionofASC842": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease Liabilities established as a Result of the adoption of ASC 842", "label": "Lease Liabilities established as a Result of the adoption of ASC 842", "terseLabel": "Lease Liabilities established as a Result of the adoption of ASC 842" } } }, "localname": "LeaseLiabilitiesestablishedasaResultoftheadoptionofASC842", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LeasePaymentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for Lease Payments [Table]", "label": "Lease Payments [Table Text Block]", "terseLabel": "Leases Supplemental Cash Flow Information" } } }, "localname": "LeasePaymentsTableTextBlock", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cah_LeasesSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for LeasesSupplementalBalanceSheetInformation [Table]", "label": "LeasesSupplementalBalanceSheetInformation [Table Text Block]", "terseLabel": "Leases Supplemental Balance Sheet Information" } } }, "localname": "LeasesSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cah_LeasesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leases [Text Block]", "label": "Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesTextBlock", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "cah_LesseeFinanceLeaseLiabilityNotYetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Finance Lease Liability Not Yet Commenced, Amount", "label": "Lessee Finance Lease Liability Not Yet Commenced, Amount", "terseLabel": "Less: leases not yet commenced (1)" } } }, "localname": "LesseeFinanceLeaseLiabilityNotYetCommencedAmount", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Due After Year Five", "label": "Lessee Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Five", "label": "Lessee Lease Liability Payments Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Four", "label": "Lessee Lease Liability Payments Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Three", "label": "Lessee Lease Liability Payments Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Two", "label": "Lessee Lease Liability Payments Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Remainder Of Fiscal Year", "label": "Lessee Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "LesseeLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeOperatingLeaseLiabilityNotYetCommencedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lessee Operating Lease Liability Not Yet Commenced, Amount", "label": "Lessee Operating Lease Liability Not Yet Commenced, Amount", "terseLabel": "Less: leases not yet commenced (1)" } } }, "localname": "LesseeOperatingLeaseLiabilityNotYetCommencedAmount", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LongTermObligationsandOtherShortTermBorrowingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]", "label": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]" } } }, "localname": "LongTermObligationsandOtherShortTermBorrowingsAbstract", "nsuri": "http://www.cardinal.com/20191231", "xbrltype": "stringItemType" }, "cah_LossContingencyLawsuitsNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Lawsuits, Number", "label": "Loss Contingency, Lawsuits, Number", "terseLabel": "Loss Contingency, Lawsuits, Number" } } }, "localname": "LossContingencyLawsuitsNumber", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "integerItemType" }, "cah_MaximumQuarterlyPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.", "label": "Maximum Quarterly Payment", "terseLabel": "Maximum quarterly payment" } } }, "localname": "MaximumQuarterlyPayment", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "monetaryItemType" }, "cah_MedicalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical [Member]", "label": "Medical Member", "terseLabel": "Medical" } } }, "localname": "MedicalMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_MedicaldistributionandproductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical distribution and products [Member]", "label": "Medical distribution and products [Member]", "terseLabel": "Medical distribution and products [Member]" } } }, "localname": "MedicaldistributionandproductsMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_NarativeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Narative [Abstract]", "label": "Narative [Abstract]" } } }, "localname": "NarativeAbstract", "nsuri": "http://www.cardinal.com/20191231", "xbrltype": "stringItemType" }, "cah_NaviHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "naviHealth [Member]", "label": "naviHealth [Member]", "terseLabel": "naviHealth [Member]" } } }, "localname": "NaviHealthMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/InvestmentsInvestmentsDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.", "label": "Net proceeds/(tax withholdings) from share-based compensation", "terseLabel": "Net proceeds/(tax withholdings) from share-based compensation" } } }, "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_NotesPayableRepurchased": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Principal Amount of Notes Payable Repurchased during the year", "label": "Notes Payable Repurchased", "terseLabel": "Notes Payable Repurchased" } } }, "localname": "NotesPayableRepurchased", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "cah_NuclearPrecisionHealthServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nuclear Precision Health Services [Member]", "label": "Nuclear Precision Health Services [Member]", "terseLabel": "Nuclear Precision Health Services [Member]" } } }, "localname": "NuclearPrecisionHealthServicesMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_NumberofStateAttorneysGeneralfilinglawsuits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of State Attorneys General filing lawsuits", "label": "Number of State Attorneys General filing lawsuits", "terseLabel": "Number of State Attorneys General filing lawsuits" } } }, "localname": "NumberofStateAttorneysGeneralfilinglawsuits", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "integerItemType" }, "cah_OperatingLeaseImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Lease Imputed Interest", "label": "Operating Lease Imputed Interest", "terseLabel": "Less: imputed interest" } } }, "localname": "OperatingLeaseImputedInterest", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_OperatingLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Lease", "label": "Operating Lease [Member]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLawsuitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Lawsuits [Member]", "label": "Opioid Lawsuits [Member]", "terseLabel": "Opioid Lawsuits [Member]" } } }, "localname": "OpioidLawsuitsMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLawsuitsStateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Lawsuits State [Domain]", "label": "Opioid Lawsuits State [Domain]", "terseLabel": "Opioid Lawsuits State [Domain]" } } }, "localname": "OpioidLawsuitsStateDomain", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLitigationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Litigation", "label": "Opioid Litigation [Axis]", "terseLabel": "Opioid Litigation [Axis]" } } }, "localname": "OpioidLitigationAxis", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_OpioidLitigationCuyahogaandSummitCountiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Litigation, Cuyahoga and Summit Counties", "label": "Opioid Litigation, Cuyahoga and Summit Counties [Member]", "terseLabel": "Opioid Litigation, Cuyahoga and Summit Counties [Member]" } } }, "localname": "OpioidLitigationCuyahogaandSummitCountiesMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLitigationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Litigation [Domain]", "label": "Opioid Litigation [Domain]", "terseLabel": "Opioid Litigation [Domain]" } } }, "localname": "OpioidLitigationDomain", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLitigationlessCuyahogaandSummitCountiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Litigation, less Cuyahoga and Summit Counties", "label": "Opioid Litigation, less Cuyahoga and Summit Counties [Member]", "terseLabel": "Opioid Litigation, less Cuyahoga and Summit Counties [Member]" } } }, "localname": "OpioidLitigationlessCuyahogaandSummitCountiesMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidTotalSettlementCuyahogaandSummitCounties": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Opioid Total Settlement, Cuyahoga and Summit Counties", "label": "Opioid Total Settlement, Cuyahoga and Summit Counties", "terseLabel": "Opioid Total Settlement, Cuyahoga and Summit Counties" } } }, "localname": "OpioidTotalSettlementCuyahogaandSummitCounties", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "monetaryItemType" }, "cah_OtherJurisdictionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Jurisdictions [Member]", "label": "Other Jurisdictions [Member]", "terseLabel": "Other Jurisdictions [Member]" } } }, "localname": "OtherJurisdictionsMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_PartnershipIndirectOwnership": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Partnership Indirect Ownership", "label": "Partnership Indirect Ownership", "terseLabel": "Partnership Indirect Ownership" } } }, "localname": "PartnershipIndirectOwnership", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/InvestmentsInvestmentsDetails" ], "xbrltype": "percentItemType" }, "cah_PatientRecoveryBusinessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patient Recovery Business [Member]", "label": "Patient Recovery Business [Member]", "terseLabel": "Patient Recovery Business" } } }, "localname": "PatientRecoveryBusinessMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_PharmaceuticalDistributionandSpecialtyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharmaceutical Distribution and Specialty [Member]", "label": "Pharmaceutical Distribution and Specialty [Member]", "terseLabel": "Pharmaceutical Distribution and Specialty [Member]" } } }, "localname": "PharmaceuticalDistributionandSpecialtyMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_PharmaceuticalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharmaceutical [Member]", "label": "Pharmaceutical Member", "terseLabel": "Pharmaceutical" } } }, "localname": "PharmaceuticalMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_PlaintiffTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plaintiff Type [Axis]", "label": "Plaintiff Type [Axis]", "terseLabel": "Plaintiff Type [Axis]" } } }, "localname": "PlaintiffTypeAxis", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "stringItemType" }, "cah_PlaintiffTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Plaintiff Type [Axis]", "label": "Plaintiff Type [Domain]", "terseLabel": "Plaintiff Type [Domain]" } } }, "localname": "PlaintiffTypeDomain", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_PreTaxGainonDivestiture": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Pre-Tax Gain on Divestiture", "label": "Pre-Tax Gain on Divestiture", "terseLabel": "Pre-Tax Gain on Divestiture" } } }, "localname": "PreTaxGainonDivestiture", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/InvestmentsInvestmentsDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_PrivatePartiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Private Parties [Member]", "label": "Private Parties [Member]", "terseLabel": "Private Parties [Member]" } } }, "localname": "PrivatePartiesMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from divestitures and disposal of property and equipment and held for sale assets", "label": "Proceeds from divestitures and disposal of property and equipment and held for sale assets", "terseLabel": "Proceeds from divestitures and disposal of property and equipment and held for sale assets" } } }, "localname": "Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from sales of available-for-sale securities and other investments.", "label": "Proceeds from sale of available-for-sale securities and other investments", "terseLabel": "Proceeds from sale of investments" } } }, "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_ProductLiabilityLawsuitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product Liability Lawsuits [Member]", "label": "Product Liability Lawsuits [Member]", "terseLabel": "Product Liability Lawsuits" } } }, "localname": "ProductLiabilityLawsuitsMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_ProjectCostsOnInvestmentAndOtherSpending": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.", "label": "Project Costs On Investment And Other Spending", "terseLabel": "Project costs on investment and other spending" } } }, "localname": "ProjectCostsOnInvestmentAndOtherSpending", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from purchases of available-for-sale securities and other investments.", "label": "Purchase of available-for-sale securities and other investments", "negatedLabel": "Purchase of investments" } } }, "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_ReclassificationofdeferredrentinaccordancewithASC842": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Reclassification of deferred rent in accordance with ASC 842", "label": "Reclassification of deferred rent in accordance with ASC 842", "terseLabel": "Reclassification of deferred rent in accordance with ASC 842" } } }, "localname": "ReclassificationofdeferredrentinaccordancewithASC842", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]", "label": "Segment Revenue from External Customers by Geographic Area [Line Items]", "terseLabel": "Segment Revenue from External Customers by Geographic Area [Line Items]" } } }, "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "xbrltype": "stringItemType" }, "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Segment Revenue from External Customers by Geographic Area [Table]", "label": "Segment Revenue from External Customers by Geographic Area [Table]", "terseLabel": "Segment Revenue from External Customers by Geographic Area [Table]" } } }, "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaTable", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "xbrltype": "stringItemType" }, "cah_Sharesthatwouldbeantidilutiveasaresultofnetloss": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "shares that would be antidilutive as a result of net loss", "label": "shares that would be antidilutive as a result of net loss", "terseLabel": "shares that would be antidilutive as a result of net loss" } } }, "localname": "Sharesthatwouldbeantidilutiveasaresultofnetloss", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cah_ShortTermCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other short-term credit facilities and an unsecured line of credit", "label": "Short Term Credit Facilities Member", "terseLabel": "Short Term Credit Facilities Member" } } }, "localname": "ShortTermCreditFacilitiesMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "cah_SterileSurgicalGownRecallAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sterile Surgical Gown Recall [Axis] [Axis]", "label": "Sterile Surgical Gown Recall [Axis]", "terseLabel": "Sterile Surgical Gown Recall [Axis]" } } }, "localname": "SterileSurgicalGownRecallAxis", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_SterileSurgicalGownRecallDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Sterile Surgical Gown Recall [Axis] [Axis]", "label": "Sterile Surgical Gown Recall [Domain]", "terseLabel": "Sterile Surgical Gown Recall [Domain]" } } }, "localname": "SterileSurgicalGownRecallDomain", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_SterileSurgicalGownRecallMemberDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sterile Surgical Gown Recall [Member] [Domain]", "label": "Sterile Surgical Gown Recall [Member] [Domain]", "terseLabel": "Sterile Surgical Gown Recall [Member] [Domain]" } } }, "localname": "SterileSurgicalGownRecallMemberDomain", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TaxMatterAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Matter [Axis]", "label": "Tax Matter [Axis]", "terseLabel": "Tax Matter [Axis]" } } }, "localname": "TaxMatterAxis", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_TaxMatterDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Tax Matter [Axis]", "label": "Tax Matter [Domain]", "terseLabel": "Tax Matter [Domain]" } } }, "localname": "TaxMatterDomain", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TaxMattersAgreementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Matters Agreement [Axis]", "label": "Tax Matters Agreement [Axis]", "terseLabel": "Tax Matters Agreement [Axis]" } } }, "localname": "TaxMattersAgreementAxis", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_TaxMattersAgreementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Tax Matters Agreement [Axis]", "label": "Tax Matters Agreement [Domain]", "terseLabel": "Tax Matters Agreement [Domain]" } } }, "localname": "TaxMattersAgreementDomain", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TotalFinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total Finance Lease Cost", "label": "Total Finance Lease Cost", "totalLabel": "Total finance lease cost" } } }, "localname": "TotalFinanceLeaseCost", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total Lease Liability", "label": "Total Lease Liability", "terseLabel": "Total Lease Liability" } } }, "localname": "TotalLeaseLiability", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLeaseLiabilityNotYetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total Lease Liability Not Yet Commenced, Amount", "label": "Total Lease Liability Not Yet Commenced, Amount", "terseLabel": "Less: leases not yet commenced (1)" } } }, "localname": "TotalLeaseLiabilityNotYetCommencedAmount", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLeaseLiabilityPaymentsDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total undiscounted Lease Liability Payments Due for both operating and financing leases", "label": "Total Lease Liability Payments Due", "terseLabel": "Total future lease payments" } } }, "localname": "TotalLeaseLiabilityPaymentsDue", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total Lease Liability Undiscounted Excess Amount", "label": "Total Lease Liability Undiscounted Excess Amount", "terseLabel": "Less: imputed interest" } } }, "localname": "TotalLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLongTermandShortTermObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total Long-Term and Short-Term Obligations", "label": "Total Long-Term and Short-Term Obligations", "terseLabel": "Total Long-Term and Short-Term Obligations" } } }, "localname": "TotalLongTermandShortTermObligations", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalOpioidLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Opioid Litigation", "label": "Total Opioid Litigation [Member]", "terseLabel": "Total Opioid Litigation [Member]" } } }, "localname": "TotalOpioidLitigationMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TotalOpioidLitigationnetoftaxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Opioid Litigation, net of tax", "label": "Total Opioid Litigation, net of tax [Member]", "terseLabel": "Total Opioid Litigation, net of tax [Member]" } } }, "localname": "TotalOpioidLitigationnetoftaxMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_TrademarksAndPatentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Trademarks And Patents Member", "terseLabel": "Trademarks, trade names and patents" } } }, "localname": "TrademarksAndPatentsMember", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cah_TreasuryStockAcquiredShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Stock Acquired Shares", "label": "Treasury Stock Acquired Shares", "terseLabel": "Treasury Stock Acquired Shares" } } }, "localname": "TreasuryStockAcquiredShares", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cah_VestingPeriodinyearsforShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vesting Period in years for Shares", "label": "Vesting Period in years for Shares", "terseLabel": "Vesting Period in years for Shares" } } }, "localname": "VestingPeriodinyearsforShares", "nsuri": "http://www.cardinal.com/20191231", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r356" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r357" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r359" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r354" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "invest_InvestmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment [Line Items]", "terseLabel": "Investment [Line Items]" } } }, "localname": "InvestmentLineItems", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "invest_InvestmentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment [Table]", "terseLabel": "Investment [Table]" } } }, "localname": "InvestmentTable", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r99", "r112" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case Type" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r117", "r191", "r193", "r349" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r116", "r191", "r192", "r348", "r352", "r353" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r38", "r43", "r44", "r249" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Foreign Currency Translation Adjustments" } } }, "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r39", "r43", "r44", "r249" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax" } } }, "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r41", "r42", "r43" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r40", "r43", "r44", "r249" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income/(Loss)", "verboseLabel": "AOCI Attributable to Parent" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r86" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r198", "r221", "r224" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total share-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r75", "r132", "r139" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r94" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r40", "r43", "r44", "r249" ], "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r103", "r321", "r336" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r36" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r200", "r223" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r263", "r266" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r237", "r238" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r21", "r77" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and equivalents at end of period", "periodStartLabel": "Cash and equivalents at beginning of period", "terseLabel": "Cash and equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase/(decrease) in cash and equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r160", "r169" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments, Contingent Liabilities and Litigation" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared per common share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Common shares, without par value:" } } }, "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Common shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Authorized\u2014755 million shares, Issued\u2014327 million shares at December 31, 2019 and June 30, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r47", "r49", "r50" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r47", "r49", "r243", "r252" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income/(loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r61" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold", "verboseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Currency Swap [Member]" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r10", "r11", "r12", "r322", "r323", "r335" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r288" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Estimated fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r28", "r80", "r181", "r184", "r185", "r186", "r292", "r293", "r295", "r334" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.", "label": "Deferred Tax and Other Liabilities, Noncurrent", "terseLabel": "Deferred income taxes and other liabilities" } } }, "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r75", "r101" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r253" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "terseLabel": "Forward contracts" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative, Name [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r264", "r265", "r269", "r273" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r261", "r264", "r269" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r268", "r270" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotionalAmount": { "auth_ref": [ "r255", "r256", "r258" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative liability.", "label": "Derivative Liability, Notional Amount", "terseLabel": "Derivative Liability, Notional Amount" } } }, "localname": "DerivativeLiabilityNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r83", "r254", "r257", "r258", "r261", "r262", "r267", "r269", "r275", "r276", "r278" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "verboseLabel": "Developed technology and other" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsInvestmentsDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r187", "r333" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedTerseLabel": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Earnings/(loss) per common share attributable to Cardinal Health, Inc.:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Earnings Per Share Attributable to Cardinal Health, Inc." } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthInc" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r289" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rates changes on cash and equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r82", "r227", "r228" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r222" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r221" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Tax benefit related to share-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee- Related Costs" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options", "verboseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r121" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsInvestmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r22", "r104", "r120" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Facility Exit and Other Costs" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r279", "r280", "r281", "r285" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring", "verboseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r194", "r195", "r196", "r280", "r316" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r279", "r280", "r282", "r283", "r286" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedging" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r194", "r195", "r196", "r280", "r317" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r194", "r195", "r196", "r280", "r318" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "verboseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r194", "r195", "r196", "r280", "r319" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r284", "r286" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r300", "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total lease liabilities", "verboseLabel": "Total finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion of finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "terseLabel": "Total future lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r302", "r308" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Finance Lease, Principal Payments" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Finance lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r301", "r305", "r314" ], "calculation": { "http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails": { "order": 1.0, "parentTag": "cah_TotalFinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r138" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r140" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Estimated annual amortization of intangible assets - Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r140" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Estimated annual amortization of intangible assets - Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r140" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Estimated annual amortization of intangible assets - Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r140" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Estimated annual amortization of intangible assets - Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r133", "r135", "r138", "r142", "r320" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r138", "r320" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Intangible" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r133", "r137" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Net Intangible" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted- Average Remaining Amortization Period (Years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r194", "r272" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract [Member]" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "auth_ref": [ "r75" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net" } } }, "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r161" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedTerseLabel": "Litigation (recoveries)/charges, net" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r75", "r174", "r175" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on Extinguishment of Debt", "verboseLabel": "Gain (Loss) on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r125", "r126" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r127" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Foreign currency translation adjustments and other" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTransfers": { "auth_ref": [ "r128" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Transfers", "terseLabel": "Goodwill, Transfers" } } }, "localname": "GoodwillTransfers", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r60" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r261", "r274" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r81" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings/(loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r52", "r56", "r90", "r91", "r92", "r327", "r329", "r331", "r343" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Basic (in shares)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r52", "r56", "r90", "r91", "r92", "r93", "r331", "r343", "r345" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Income (Loss) from Continuing Operations, Per Diluted Share" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsInvestmentsDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r78", "r102", "r235" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income Tax Expense (Benefit)", "verboseLabel": "Provision for/(benefit from) income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r74" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Increase/(decrease) in accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r74" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Increase in inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r74" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Other accrued liabilities and operating items, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r74" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedTerseLabel": "(Increase)/decrease in trade receivables" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r134", "r141" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r141" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Net Intangible" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r134", "r141" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Gross Intangible, Total other intangible assets" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r131", "r136" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Net Intangible, Total other intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible Assets, Net (Including Goodwill)", "terseLabel": "Goodwill and other intangibles, net" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r53", "r100", "r291", "r294", "r332" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Service (IRS) [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r34", "r124" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "verboseLabel": "Inventory, Net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRecallExpense": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.", "label": "Inventory Recall Expense", "terseLabel": "Inventory Recall Expense" } } }, "localname": "InventoryRecallExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investment holdings. This includes the information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.", "label": "Investment Holdings, Schedule of Investments [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentHoldingsScheduleOfInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Other investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Axis]", "terseLabel": "Lease Arrangement, Type [Axis]" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Domain]", "terseLabel": "Lease Arrangement, Type [Domain]" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r312", "r314" ], "calculation": { "http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Total future lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r325", "r340" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r288" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Line of Credit Facility, Fair Value of Amount Outstanding" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r29", "r161" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Estimated Litigation Liability" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r12" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "terseLabel": "Long-term obligations, less current portion", "verboseLabel": "Long-term Debt and Lease Obligation" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current", "terseLabel": "Current portion of long-term obligations and other short-term borrowings", "verboseLabel": "Long-term Debt and Lease Obligation, Current" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r28", "r173" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Long-term Purchase Commitment, Period", "terseLabel": "Long-term Purchase Commitment, Period" } } }, "localname": "LongtermPurchaseCommitmentPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r170", "r171" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r170", "r171" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r161" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss Contingency Accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r161", "r162", "r163", "r165", "r166", "r167", "r168", "r170", "r171" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Loss Contingency, New Claims Filed, Number" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Loss Contingency, Number of Plaintiffs" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossOnSaleOfInvestments": { "auth_ref": [ "r58", "r59", "r75", "r328", "r346" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The difference between the carrying value and the sale price of an investment. A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale.", "label": "Loss on Sale of Investments", "terseLabel": "Loss on Sale of Investments" } } }, "localname": "LossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r33", "r324", "r339" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Noncontrolling Interest, Ownership Percentage by Parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsInvestmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r72" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r72" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by/(used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r72", "r73", "r76" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r45", "r48", "r55", "r76", "r95", "r330", "r344" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net earnings/(loss) attributable to Cardinal Health, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r45", "r48", "r246", "r251" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPrinciplesEarlyAdoptionMember": { "auth_ref": [ "r86", "r87" ], "lang": { "en-US": { "role": { "documentation": "Represents a group of guidance that has been adopted early.", "label": "New Accounting Principles, Early Adoption [Domain]", "terseLabel": "New Accounting Principles, Early Adoption [Domain]" } } }, "localname": "NewAccountingPrinciplesEarlyAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementEarlyAdoptionAxis": { "auth_ref": [ "r86", "r87" ], "lang": { "en-US": { "role": { "documentation": "The financial statement line items and the effect of the guidance on financial statement line items by guidance implemented if the entity elects earlier application.", "label": "New Accounting Pronouncement, Early Adoption [Axis]", "terseLabel": "New Accounting Pronouncement, Early Adoption [Axis]" } } }, "localname": "NewAccountingPronouncementEarlyAdoptionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.", "label": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification", "terseLabel": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification" } } }, "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r86", "r87" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Financial Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument [Member]" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r12", "r323", "r337" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.", "label": "Open Tax Year", "terseLabel": "Open Tax Year" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Total operating earnings", "totalLabel": "Operating earnings/(loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r306", "r314" ], "calculation": { "http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "verboseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r303", "r308" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r311", "r314" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r310", "r314" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r296", "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "Operating Leases, Future Minimum Payments Due, Next Twelve Months" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r296", "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Five Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r296", "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Four Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r296", "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Three Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r296", "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Two Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r296", "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Operating Leases, Future Minimum Payments, Due Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r99", "r112" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r7", "r26" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities", "verboseLabel": "Other Accrued Liabilities, Current" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherBorrowings": { "auth_ref": [ "r326" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity.", "label": "Other Borrowings", "terseLabel": "Other Borrowings" } } }, "localname": "OtherBorrowings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]", "terseLabel": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r43", "r51" ], "calculation": { "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "verboseLabel": "Other comprehensive loss, before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": { "auth_ref": [ "r39" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax", "terseLabel": "Net unrealized loss on derivative instruments, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r37", "r290" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments and other" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r46", "r49", "r51", "r180" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive loss, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r46", "r49", "r243", "r244", "r248" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income)/expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r68" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Payments for Repurchase of Common Stock", "terseLabel": "Payments for Repurchase of Common Stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r70", "r149" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Payments and other adjustments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r68" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends on common shares" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r66" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition of subsidiaries, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r67" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Share Units", "verboseLabel": "Performance Share Unit" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Preferred shares, without par value:" } } }, "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred shares, authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred shares, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Authorized\u2014500 thousand shares, Issued\u2014none" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from Divestiture of Businesses" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [ "r84" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Net change in short-term borrowings" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r45", "r48", "r71", "r103", "r113", "r243", "r245", "r247", "r251", "r252" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net earnings/(loss)", "totalLabel": "Net earnings/(loss)", "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r8", "r9", "r145", "r342" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r57", "r122" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for bad debts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r15", "r20", "r341", "r350" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Trade receivables, net" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r43", "r44", "r51" ], "calculation": { "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified to earnings" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r108", "r110" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Assets by Reportable Segment" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r107", "r110" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r107", "r110" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Segment Profit by Reportable Segment" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r106", "r110" ], "lang": { "en-US": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r69" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Reduction of long-term obligations" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r69" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "terseLabel": "Repayments of Notes Payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Share Units", "verboseLabel": "Restricted Share Unit" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Employee Severance" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeverance" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r75", "r148", "r153", "r157" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring and employee severance", "totalLabel": "Total restructuring and employee severance" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring Charges [Abstract]" } } }, "localname": "RestructuringChargesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Additions", "verboseLabel": "Restructuring Costs" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r149", "r154" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r187", "r338" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r54", "r98", "r99", "r111" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue", "verboseLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r309", "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r309", "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r279", "r280" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r133", "r137" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r133", "r137" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r298" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Lease Payments" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r129", "r130" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r129", "r130" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill by Reportable Segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r141", "r143" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]", "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r151", "r152", "r155" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r151", "r152", "r155" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of Restructuring and Employee Severance" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r149", "r156" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r97", "r103", "r105", "r109", "r129" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r200", "r223" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r203", "r215", "r217" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Transactions Under the Plans" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r30", "r79", "r177", "r178", "r179", "r181", "r182", "r183", "r184", "r185", "r186", "r187" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r63", "r123" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Distribution, selling, general and administrative expenses", "verboseLabel": "Selling, General and Administrative Expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r75", "r148", "r153", "r157" ], "calculation": { "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "verboseLabel": "Employee-related costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r74" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Canceled and forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Canceled and forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested at end of period (in shares)", "periodStartLabel": "Nonvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Share Units", "verboseLabel": "Performance Share Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at end of period (in usd per share)", "periodStartLabel": "Nonvested at beginning of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value per Share", "verboseLabel": "Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Canceled and forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Canceled and forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of outstanding options at period end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r205", "r223" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (in usd per share)", "periodStartLabel": "Outstanding at beginning of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price per Common Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r197", "r202" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Target performance goal (as a percent)", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of exercisable options at period end" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r103", "r129", "r147", "r150", "r158", "r347" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Operating and Reportable Segment" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r32", "r180" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "verboseLabel": "Statement of Stockholders' Equity" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails", "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails", "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r13", "r14", "r180", "r187" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r14", "r180", "r187", "r207" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r13", "r14", "r187", "r199", "r216" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "negatedTerseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r119" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "terseLabel": "Total Cardinal Health, Inc. shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r241", "r242", "r250" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]", "terseLabel": "Income Taxes" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]", "terseLabel": "Income Taxes" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Treasury shares acquired, average price per share (in usd per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r31", "r188" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock", "verboseLabel": "Treasury Shares" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r31", "r188" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)", "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)", "terseLabel": "Common shares in treasury" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r14", "r180", "r187" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedLabel": "Treasury shares acquired (in shares)", "negatedTerseLabel": "Treasury Stock, Shares, Acquired" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r31", "r188", "r189" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Common shares in treasury, at cost: 35 million shares and 28 million shares at December 31, 2019 and June 30, 2019, respectively", "negatedPeriodEndLabel": "Treasury, balance at end of period", "negatedPeriodStartLabel": "Treasury, balance at beginning of period" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r226", "r232" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, interest and penalties accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r233" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r307", "r314" ], "calculation": { "http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r93" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Employee stock options, restricted share units, and performance share units (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r89", "r93" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average common shares\u2013diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r88", "r93" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares\u2013basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "stringItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r287": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996" }, "r351": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r354": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r355": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r356": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r357": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r358": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r359": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" } }, "version": "2.1" } XML 25 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Shareholders' Equity
 6 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Shareholders' Equity
11. Shareholders' Equity
During the six months ended December 31, 2019, we repurchased 7.3 million common shares having an aggregate cost of $350 million. The average price paid per common share was $48.00. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on August 20, 2019 and was completed on December 4, 2019.
During the six months ended December 31, 2018, we repurchased 11.5 million common shares having an aggregate cost of $600 million. The average price paid per common share was $52.32.
We funded the repurchases with available cash and short-term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)
Foreign
Currency
Translation
Adjustments
 
Unrealized
Gain/(Loss) on
Derivatives,
net of tax
 
Accumulated Other
Comprehensive
Loss
Balance at June 30, 2019
$
(95
)
 
$
16

 
$
(79
)
Other comprehensive loss, before reclassifications
(18
)
 
—

 
(18
)
Amounts reclassified to earnings
—

 
(6
)
 
(6
)
Other comprehensive loss, net of tax
(18
)
 
(6
)
 
(24
)
Balance at December 31, 2019
$
(113
)
 
$
10

 
$
(103
)
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments, Contingent Liabilities and Litigation
 6 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments, Contingent Liabilities and Litigation
7. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health Corporation ("CVS Health")
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term.
Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
We are named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information have led, and may in the future lead, to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
From time to time, we determine that products we manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions can lead to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, action by regulators and product
liability claims and lawsuits, including class actions. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates. Except as otherwise disclosed in this footnote, it is not possible for us to reasonably estimate the amount of any possible loss or range of possible losses in the matters described below.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings.
Opioid Lawsuits and Investigations
Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,000 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.
States & Political Subdivisions
Approximately 2,500 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the “MDL”).
In addition, 23 state attorneys general have filed lawsuits against distributors, including us, in various state courts. A trial in New York for cases brought by the New York Attorney General and Nassau and Suffolk counties is scheduled to begin in March 2020.
Additionally, 43 state attorneys general have formed a multi-state task force to investigate the manufacturing, distribution, dispensing and prescribing practices of opioid medications. We have received requests related to the multi-state investigation, as well as separate civil investigative demands, subpoenas or requests for information from these and other state attorneys general offices and governmental authorities.
In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general that is
designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions (the "Settlement Framework"). This Settlement Framework is subject to contingencies and uncertainties as to final terms, but is the basis for our negotiation of definitive terms and documentation.
The Settlement Framework includes (1) a cash component, pursuant to which we would pay up to $5.56 billion over eighteen years, (2) development and participation in a program for free or rebated distribution of opioid abuse treatment medications for a period of ten years, and (3) industry-wide changes to be specified to controlled substance anti-diversion programs. Final terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. In connection with these matters, in the six months ended December 31, 2019, we accrued $5.56 billion, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to reasonably estimate the liability associated with the other components of the Settlement Framework, the potential distribution of treatment medications and any incremental costs for changes to our controlled substance anti-diversion program that we may agree to.
In the six months ended December 31, 2019, we along with two other national distributors entered into a $215 million settlement with two Ohio counties, Cuyahoga and Summit, to resolve all claims in the first bellwether trial in the MDL, which had been set for trial for October 2019. In connection with this settlement, we accrued $66 million in the six months ended December 31, 2019. This accrual is included in other accrued liabilities in the condensed consolidated balance sheets.
In connection with these matters, we recorded a total pre-tax charge of $5.63 billion ($5.14 billion after tax) during the six months ended December 31, 2019 in litigation (recoveries)/charges, net, in the condensed consolidated statement of earnings for the cash component. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We will regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.
Private Plaintiffs
The Settlement Framework does not address claims by private plaintiffs, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private plaintiffs had brought approximately 365 lawsuits as of February 4, 2020. Of these, 105 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We will continue to vigorously defend ourselves in these matters.
Department of Justice Investigations
We have received grand jury subpoenas issued on behalf of the District Courts for the Eastern District of New York and the District of Columbia seeking documents and, in the District of Columbia, testimony, related to our anti-diversion policies and procedures, and our distribution of certain controlled substances. We are cooperating with these requests.
Cordis Product Liability Lawsuits
As of February 4, 2020, we are named as a defendant in 299 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 3,773 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Another 29 lawsuits involving similar claims by approximately 35 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We are vigorously defending ourselves in these lawsuits.
At December 31, 2019, we had a total of $441 million accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $885 million.
Shareholder Securities Litigation
In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them.
Surgical Gown Recalls
In January, 2020, we issued a voluntary recall for 9.1 million AAMI Level 3 surgical gowns and two voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for 2.9 million Presource Procedure Packs containing affected gowns (together, the "Recalls"). These Recalls were necessary because we discovered in December 2019 that one of our FDA-registered suppliers in China had shifted production of some gowns to unapproved sites with uncontrolled environments. Because of this, we could not assure sterility of the gowns.
In connection with these Recalls, in the three months ended December 31, 2019, we recorded a total charge of $96 million, of which $56 million is within cost of products sold and $40 million is
within SG&A in the condensed consolidated statements of earnings. In our condensed consolidated balance sheet at December 31, 2019, we had $38 million reserved within inventories, net, and $58 million included in other accrued liabilities related to this charge. This charge represents our best estimate of costs for the Recalls and include inventory write-off costs and certain remediation and supply disruption costs, such as costs to replace recalled products. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. The amount of ultimate loss may differ materially from this accrual.
In addition to the charge for the three months ended December 31, 2019, we expect that the Recalls will have other negative impacts, which could include: government investigations and enforcement actions by the U.S. Food and Drug Administration or other regulators or U.S. or international governmental bodies (possibly resulting in product seizures, additional recalls, the issuance of safety alerts, the suspension or revocation of the authority to produce, distribute and sell products and other civil or criminal sanctions); losses due to patient claims, including product liability claims and lawsuits; and customer claims unrelated to their direct costs from the supply disruption. We are not currently able to reasonably estimate the amount of any possible loss or range of possible losses for any of these potential claims or actions.
Other Civil Litigation
Generic Pharmaceutical Antitrust Litigation
In December 2019, pharmaceutical distributors including us were added as defendants in a civil multidistrict litigation consisting of multiple individual and class action lawsuits filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and informed manufacturers that they wished to maintain current customer allocations for the purpose of avoiding price erosion. We intend to vigorously defend ourselves in these matters.
Blood Pressure Medication Recall Litigation
Many participants in the pharmaceutical supply chain, including manufacturers, repackagers (including us), distributors (including us), and retailers have been named as defendants in Multidistrict Litigation in the U.S. District Court for the District of New Jersey (the “Blood Pressure Medication Recall MDL”), which was created in February 2019. The claims arise out of a series of recalls of generic blood pressure medications due to alleged impurities in active pharmaceutical ingredients. In December 2019, two additional medications were added to the Blood Pressure Medication Recall MDL. In January 2020, manufacturers recalled another medication and the FDA continues to investigate other drugs for possible recall. We intend to vigorously defend ourselves in these matters.
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Other Intangible Assets
 6 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets
3. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)
Pharmaceutical
 
Medical
 
Total
Balance at June 30, 2019
$
2,663

 
$
5,715

 
$
8,378

Goodwill acquired, net of purchase price adjustments
(5
)
 
—

 
(5
)
Foreign currency translation adjustments and other
—

 
(17
)
 
(17
)
Balance at December 31, 2019
$
2,658

 
$
5,698

 
$
8,356


Other Intangible Assets
The following tables summarize other intangible assets by class at:
 
December 31, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
 
Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
 
 
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

 
N/A
Total indefinite-life intangibles
22

 
—

 
22

 
N/A
 
 
 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
 
 
Customer relationships
3,550

 
1,670

 
1,880

 
13
Trademarks, trade names and patents
673

 
318

 
355

 
13
Developed technology and other
1,603

 
693

 
910

 
11
Total definite-life intangibles
5,826

 
2,681

 
3,145

 
12
Total other intangible assets
$
5,848

 
$
2,681

 
$
3,167

 
N/A
 
June 30, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
Indefinite-life intangibles:
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

Total indefinite-life intangibles
22

 
—

 
22

 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
Customer relationships
3,562

 
1,517

 
2,045

Trademarks, trade names and patents
672

 
295

 
377

Developed technology and other
1,602

 
616

 
986

Total definite-life intangibles
5,836

 
2,428

 
3,408

Total other intangible assets
$
5,858

 
$
2,428

 
$
3,430


Total amortization of intangible assets was $127 million and $133 million for the three months ended December 31, 2019 and 2018, respectively, and $256 million and $266 million for the six months ended December 31, 2019 and 2018, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2020 through 2024 is as follows: $258 million, $442 million, $408 million, $358 million and $328 million.
XML 29 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)
$ in Millions
Jul. 01, 2019
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]  
Lease Liabilities established as a Result of the adoption of ASC 842 $ 422
XML 30 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)
$ in Millions
 6 Months Ended
Dec. 31, 2019
USD ($)
Goodwill [Roll Forward]  
Beginning balance $ 8,378
Goodwill, Transfers (5)
Foreign currency translation adjustments and other 17
Ending balance 8,356
Pharmaceutical  
Goodwill [Roll Forward]  
Beginning balance 2,663
Goodwill, Transfers (5)
Foreign currency translation adjustments and other 0
Ending balance 2,658
Medical  
Goodwill [Roll Forward]  
Beginning balance 5,715
Goodwill, Transfers 0
Foreign currency translation adjustments and other 17
Ending balance $ 5,698
XML 32 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Long-Term Obligations and Other Short-Term Borrowings (Tables)
 6 Months Ended
Dec. 31, 2019
Long-Term Obligations and Other Short-Term Borrowings [Abstract]  
Schedule of Debt [Table Text Block]
The following table summarizes long-term obligations and other short-term borrowings at:
(in millions) (1)
December 31, 2019
 
June 30, 2019
2.4% Notes due 2019
$
—

 
$
450

4.625% Notes due 2020
506

 
508

2.616% Notes due 2022
873

 
1,079

3.2% Notes due 2022
238

 
247

Floating Rate Notes due 2022
326

 
340

3.2% Notes due 2023
553

 
551

3.079% Notes due 2024
780

 
781

3.5% Notes due 2024
402

 
402

3.75% Notes due 2025
497

 
494

3.41% Notes due 2027
1,238

 
1,318

4.6% Notes due 2043
340

 
346

4.5% Notes due 2044
342

 
342

4.9% Notes due 2045
443

 
445

4.368% Notes due 2047
574

 
594

7.0% Debentures due 2026
124

 
124

Other Obligations (2)
698

 
10

Total
7,934

 
8,031

Less: current portion of long-term obligations and other short-term borrowings
1,192

 
452

   Long-term obligations, less current portion
$
6,742

 
$
7,579

(1)
Maturities are presented on a calendar year basis.
(2)
Includes $458 million outstanding under our commercial paper program and $225 million outstanding under our committed receivables sales facility.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to Note 4 for further information on our equity method investments.
References to "we," "our," and similar pronouns in in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2019 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2020 and 2019 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2020 and June 30, 2019, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the United States Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. To conform to the current year presentation, certain prior year amounts have been reclassified. In addition, financial results presented for this fiscal 2020 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2020. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (the "2019 Form 10-K").
Recent Financial Accounting Standards
Recently Adopted Financial Accounting Standards
Derivatives and Hedging
In October 2018, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to derivatives and hedging which permits the use of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") as a benchmark interest rate for hedge accounting purposes. This guidance is
effective beginning the first quarter of fiscal 2020 and must be applied on a prospective basis. The adoption did not have a material impact on our consolidated financial statements.
Leases
In February 2016, the FASB issued amended accounting guidance that requires lessees to recognize most leases on the balance sheet as a lease liability and corresponding right-of-use asset. The guidance also requires disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted this guidance during the first quarter of fiscal 2020 and elected the transition option which allows us to apply the guidance prospectively. The adoption resulted in the recognition of lease liabilities in the amount of $422 million and did not have a material impact on our results of operations, liquidity or debt covenant compliance under our current debt agreements. The majority of our lease spend relates to certain real estate with the remaining lease spend primarily related to vehicles and equipment. The adoption required certain changes to our systems and processes. See Note 5 for additional information regarding leases.
Recently Issued Financial Accounting Standards Not Yet Adopted
Financial Instruments - Credit Losses
In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. This guidance will be effective for us in the first quarter of fiscal 2021. We are currently evaluating the impact of adoption on our consolidated financial statements.
EXCEL 34 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 35 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]        
Revenue $ 39,735 $ 37,740 $ 77,076 $ 72,953
Cost of products sold 38,021 36,010 73,683 69,556
Gross margin 1,714 1,730 3,393 3,397
Operating expenses:        
Distribution, selling, general and administrative expenses 1,163 1,064 2,270 2,219
Restructuring and employee severance 56 12 86 44
Amortization and other acquisition-related costs 133 157 265 314
Impairments and (gain)/loss on disposal of assets, net 7 8 8 (503)
Litigation (recoveries)/charges, net 21 (15) 5,694 3
Operating earnings/(loss) 334 504 (4,930) 1,320
Other (income)/expense, net (12) 21 2 25
Interest expense, net 63 76 129 152
Loss on Extinguishment of Debt 4 0 4 0
Earnings/(loss) before income taxes 279 407 (5,065) 1,143
Provision for/(benefit from) income taxes 59 126 (364) 269
Net earnings/(loss) 220 281 (4,701) 874
Less: Net earnings attributable to noncontrolling interests 0 (1) (1) (1)
Net earnings/(loss) attributable to Cardinal Health, Inc. $ 220 $ 280 $ (4,702) $ 873
Earnings/(loss) per common share attributable to Cardinal Health, Inc.:        
Basic (in shares) $ 0.75 $ 0.94 $ (15.99) $ 2.90
Income (Loss) from Continuing Operations, Per Diluted Share $ 0.75 $ 0.93 $ (15.99) $ 2.88
Weighted-average number of common shares outstanding:        
Basic (in shares) 292 299 294 302
Diluted (in shares) 294 300 294 303
Cash dividends declared per common share $ 0.4811 $ 0.4763 $ 0.9622 $ 0.9526
XML 36 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases Supplemental Balance Sheet Information (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Leases [Abstract]  
Operating lease right-of-use asset $ 404
Current portion of operating lease liabilities 102
Long-term operating lease liabilities 324
Total operating lease liabilities 426
Finance lease right-of-use assets 14
Current portion of finance lease liabilities 4
Long-term finance lease liabilities 11
Total finance lease liabilities $ 15
XML 37 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Jun. 30, 2019
Debt Instrument [Line Items]    
Other Borrowings $ 698 $ 10
Total Long-Term and Short-Term Obligations 7,934 8,031
Long-term Debt and Lease Obligation, Current 1,192 452
Long-term Debt and Lease Obligation 6,742 7,579
2.4% Notes due 2020 [Member]    
Debt Instrument [Line Items]    
Notes Payable 0 450
4.625% Notes due 2021 [Member]    
Debt Instrument [Line Items]    
Notes Payable 506 508
2.616% Notes due 2022 [Member]    
Debt Instrument [Line Items]    
Notes Payable 873 1,079
3.2% Notes due 2022 [Member]    
Debt Instrument [Line Items]    
Notes Payable 238 247
Floating Rate Notes due 2022 [Member]    
Debt Instrument [Line Items]    
Notes Payable 326 340
3.2% Notes due 2023 [Member]    
Debt Instrument [Line Items]    
Notes Payable 553 551
3.079% Notes due 2024 [Member]    
Debt Instrument [Line Items]    
Notes Payable 780 781
3.5% Notes due 2025 [Member]    
Debt Instrument [Line Items]    
Notes Payable 402 402
3.75% Notes due 2026 [Member]    
Debt Instrument [Line Items]    
Notes Payable 497 494
3.41% Notes due 2027 [Member]    
Debt Instrument [Line Items]    
Notes Payable 1,238 1,318
4.6% Notes due 2043 [Member]    
Debt Instrument [Line Items]    
Notes Payable 340 346
4.5% Notes due 2044 [Member]    
Debt Instrument [Line Items]    
Notes Payable 342 342
4.9% Notes due 2045 [Member]    
Debt Instrument [Line Items]    
Notes Payable 443 445
4.368% Notes due 2047 [Member]    
Debt Instrument [Line Items]    
Notes Payable 574 594
7.0% Debentures due fiscal 2027 [Member]    
Debt Instrument [Line Items]    
Notes Payable $ 124 $ 124
XML 38 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Retained Earnings
Treasury Stock
Accumulated Other Comprehensive Income/(Loss)
Noncontrolling Interest
Balance at beginning of period (in shares) at Jun. 30, 2018   327.0        
Balance at beginning of period at Jun. 30, 2018 $ 6,059 $ 2,730 $ 4,645   $ (92) $ 0
Treasury, balance at beginning of period (in shares) at Jun. 30, 2018       (18.0)    
Treasury, balance at beginning of period at Jun. 30, 2018       $ (1,224)    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 874         1
Net Income (Loss) Attributable to Parent 873          
Other Comprehensive Income (Loss), Net of Tax (31)          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (31)       (31)  
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture          
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture (27) $ (2)   $ (29)    
Payments for Repurchase of Common Stock (600)     $ (600)    
Treasury shares acquired (in shares)       (11.0)    
Dividends (286)   (286)      
Other 0   1     1
Balance at end of period (in shares) at Dec. 31, 2018   327.0        
Balance at end of period at Dec. 31, 2018 6,043 $ 2,728 5,233   (123) 0
Treasury, balance at end of period (in shares) at Dec. 31, 2018       (29.0)    
Treasury, balance at end of period at Dec. 31, 2018       $ (1,795)    
Balance at beginning of period (in shares) at Sep. 30, 2018   327.0        
Balance at beginning of period at Sep. 30, 2018 5,913 $ 2,590 5,097   (96) 0
Treasury, balance at beginning of period (in shares) at Sep. 30, 2018       (27.0)    
Treasury, balance at beginning of period at Sep. 30, 2018       $ (1,678)    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 281         1
Net Income (Loss) Attributable to Parent 280          
Other Comprehensive Income (Loss), Net of Tax (27)          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (27)       (27)  
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture          
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture (21) (18)   $ (3)    
Payments for Repurchase of Common Stock 0 $ 120   $ (120)    
Treasury shares acquired (in shares)       (2.0)    
Dividends (143)   (143)      
Other 2   (1)     1
Balance at end of period (in shares) at Dec. 31, 2018   327.0        
Balance at end of period at Dec. 31, 2018 $ 6,043 $ 2,728 5,233   (123) 0
Treasury, balance at end of period (in shares) at Dec. 31, 2018       (29.0)    
Treasury, balance at end of period at Dec. 31, 2018       $ (1,795)    
Balance at beginning of period (in shares) at Jun. 30, 2019 327.0 327.0        
Balance at beginning of period at Jun. 30, 2019 $ 6,330 $ 2,763 5,434   (79) 2
Treasury, balance at beginning of period (in shares) at Jun. 30, 2019 (28.0)     28.0    
Treasury, balance at beginning of period at Jun. 30, 2019 $ (1,790)     $ 1,790    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (4,701)         1
Net Income (Loss) Attributable to Parent (4,702)          
Other Comprehensive Income (Loss), Net of Tax (24)          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (24)       (24)  
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture (30) (11)   (41)    
Payments for Repurchase of Common Stock (350) $ 0   $ (350)    
Treasury shares acquired (in shares)       (7.3)    
Dividends (284)   (284)      
Other $ (1)   (1)     0
Balance at end of period (in shares) at Dec. 31, 2019 327.0 327.0        
Balance at end of period at Dec. 31, 2019 $ 1,002 $ 2,752 449   (103) 3
Treasury, balance at end of period (in shares) at Dec. 31, 2019 (35.0)     (35.0)    
Treasury, balance at end of period at Dec. 31, 2019 $ (2,099)     $ (2,099)    
Balance at beginning of period (in shares) at Sep. 30, 2019   327.0        
Balance at beginning of period at Sep. 30, 2019 903 $ 2,669 371   (101) 3
Treasury, balance at beginning of period (in shares) at Sep. 30, 2019       34.0    
Treasury, balance at beginning of period at Sep. 30, 2019       $ 2,039    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 220         0
Net Income (Loss) Attributable to Parent 220          
Other Comprehensive Income (Loss), Net of Tax (2)          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (2)          
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture (23) (13)   (10)    
Payments for Repurchase of Common Stock 0 $ 70   $ (70)    
Treasury shares acquired (in shares)       (1.0)    
Dividends (143)   (143)      
Other $ (1)   1     0
Balance at end of period (in shares) at Dec. 31, 2019 327.0 327.0        
Balance at end of period at Dec. 31, 2019 $ 1,002 $ 2,752 $ 449   $ (103) $ 3
Treasury, balance at end of period (in shares) at Dec. 31, 2019 (35.0)     (35.0)    
Treasury, balance at end of period at Dec. 31, 2019 $ (2,099)     $ (2,099)    
XML 39 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)
shares in Millions
 6 Months Ended
Dec. 31, 2019
$ / shares
shares
Stock Options  
Outstanding at beginning of period (in shares) | shares 6
Granted (in shares) | shares 0
Exercised (in shares) | shares 0
Canceled and forfeited (in shares) | shares 0
Outstanding at end of period (in shares) | shares 6
Exercisable at end of period (in shares) | shares 6
Weighted-Average Exercise Price per Common Share  
Outstanding at beginning of period (in usd per share) | $ / shares $ 63.78
Granted (in usd per share) | $ / shares 0
Exercised (in usd per share) | $ / shares 0
Canceled and forfeited (in usd per share) | $ / shares 0
Outstanding at end of period (in usd per share) | $ / shares 63.52
Exercisable at end of period (in usd per share) | $ / shares $ 63.43
XML 40 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information Revenue From External Customers By Geographic Areas (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue $ 39,735 $ 37,740 $ 77,076 $ 72,953
UNITED STATES        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue 38,670 36,716 74,980 70,960
Non-US [Member]        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue 1,067 1,030 2,102 2,002
Operating Segments        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue 39,737 37,746 77,082 72,962
Corporate        
Segment Revenue from External Customers by Geographic Area [Line Items]        
Revenue $ (2) $ (6) $ (6) $ (9)
XML 41 a20q210q123119form10-q_htm.xml IDEA: XBRL DOCUMENT 0000721371 2019-07-01 2019-12-31 0000721371 2020-01-31 0000721371 2018-10-01 2018-12-31 0000721371 2018-07-01 2018-12-31 0000721371 2019-10-01 2019-12-31 0000721371 2019-06-30 0000721371 2019-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2019-12-31 0000721371 us-gaap:CommonStockMember 2019-07-01 2019-12-31 0000721371 us-gaap:RetainedEarningsMember 2019-12-31 0000721371 us-gaap:CommonStockMember 2019-06-30 0000721371 us-gaap:CommonStockMember 2019-12-31 0000721371 us-gaap:TreasuryStockMember 2019-07-01 2019-12-31 0000721371 us-gaap:TreasuryStockMember 2019-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-12-31 0000721371 us-gaap:RetainedEarningsMember 2019-07-01 2019-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-12-31 0000721371 us-gaap:TreasuryStockMember 2019-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000721371 us-gaap:RetainedEarningsMember 2019-06-30 0000721371 us-gaap:TreasuryStockMember 2018-09-30 0000721371 2018-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000721371 2018-09-30 0000721371 us-gaap:CommonStockMember 2018-09-30 0000721371 us-gaap:TreasuryStockMember 2018-10-01 2018-12-31 0000721371 us-gaap:CommonStockMember 2018-12-31 0000721371 us-gaap:TreasuryStockMember 2018-12-31 0000721371 us-gaap:RetainedEarningsMember 2018-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2018-10-01 2018-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2018-12-31 0000721371 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000721371 us-gaap:RetainedEarningsMember 2018-09-30 0000721371 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-01 2018-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2018-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000721371 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000721371 us-gaap:RetainedEarningsMember 2019-09-30 0000721371 us-gaap:TreasuryStockMember 2019-10-01 2019-12-31 0000721371 us-gaap:CommonStockMember 2019-09-30 0000721371 2019-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-10-01 2019-12-31 0000721371 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000721371 us-gaap:TreasuryStockMember 2019-09-30 0000721371 us-gaap:RetainedEarningsMember 2018-07-01 2018-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-12-31 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000721371 us-gaap:RetainedEarningsMember 2018-06-30 0000721371 us-gaap:TreasuryStockMember 2018-07-01 2018-12-31 0000721371 us-gaap:TreasuryStockMember 2018-06-30 0000721371 us-gaap:CommonStockMember 2018-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2018-07-01 2018-12-31 0000721371 us-gaap:NoncontrollingInterestMember 2018-06-30 0000721371 2018-06-30 0000721371 us-gaap:CommonStockMember 2018-07-01 2018-12-31 0000721371 2019-07-01 0000721371 us-gaap:FacilityClosingMember 2019-12-31 0000721371 us-gaap:EmployeeSeveranceMember 2019-07-01 2019-12-31 0000721371 us-gaap:FacilityClosingMember 2019-07-01 2019-12-31 0000721371 us-gaap:EmployeeSeveranceMember 2019-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2019-12-31 0000721371 us-gaap:FacilityClosingMember 2019-06-30 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2018-10-01 2018-12-31 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2018-07-01 2018-12-31 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2019-07-01 2019-12-31 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2019-10-01 2019-12-31 0000721371 us-gaap:CustomerRelationshipsMember 2019-06-30 0000721371 cah:IPRDTrademarksandOtherMember 2019-06-30 0000721371 cah:TrademarksAndPatentsMember 2019-06-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0000721371 cah:PharmaceuticalMember 2019-07-01 2019-12-31 0000721371 cah:MedicalMember 2019-12-31 0000721371 cah:MedicalMember 2019-07-01 2019-12-31 0000721371 cah:PharmaceuticalMember 2019-06-30 0000721371 cah:PharmaceuticalMember 2019-12-31 0000721371 cah:MedicalMember 2019-06-30 0000721371 us-gaap:CustomerRelationshipsMember 2019-07-01 2019-12-31 0000721371 cah:TrademarksAndPatentsMember 2019-07-01 2019-12-31 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-07-01 2019-12-31 0000721371 cah:IPRDTrademarksandOtherMember 2019-12-31 0000721371 us-gaap:CustomerRelationshipsMember 2019-12-31 0000721371 cah:TrademarksAndPatentsMember 2019-12-31 0000721371 cah:NaviHealthMember 2018-08-01 0000721371 cah:NaviHealthMember 2018-08-01 2018-08-31 0000721371 cah:NaviHealthMember 2018-07-01 2018-12-31 0000721371 cah:NaviHealthMember 2019-06-30 0000721371 cah:NaviHealthMember 2019-12-31 0000721371 cah:OperatingLeaseMember 2019-12-31 0000721371 cah:FinanceLeaseMember 2019-12-31 0000721371 srt:MinimumMember 2019-12-31 0000721371 srt:MaximumMember 2019-12-31 0000721371 2019-07-01 2019-07-01 0000721371 cah:ASC842Member 2019-07-01 2019-07-01 0000721371 cah:A2.616Notesdue2022Member 2019-07-01 2019-12-31 0000721371 us-gaap:CommercialPaperMember 2019-12-31 0000721371 cah:A2.4Notesdue2020Member 2019-11-01 2019-11-30 0000721371 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0000721371 cah:ShortTermCreditFacilitiesMember cah:CommittedReceivablesSalesFacilityProgramMember 2019-12-31 0000721371 cah:A3.2Notesdue2023Member 2019-07-01 2019-12-31 0000721371 cah:A4.6Notesdue2043Member 2019-07-01 2019-12-31 0000721371 cah:A4.9Notesdue2045Member 2019-07-01 2019-12-31 0000721371 cah:A4.368Notesdue2047Member 2019-07-01 2019-12-31 0000721371 cah:FloatingRateNotesdue2022Member 2019-07-01 2019-12-31 0000721371 cah:A3.41Notesdue2027Member 2019-07-01 2019-12-31 0000721371 cah:A4.368Notesdue2047Member 2019-12-31 0000721371 cah:A3.079Notesdue2024Member 2019-12-31 0000721371 cah:A3.2Notesdue2022Member 2019-06-30 0000721371 cah:A4.368Notesdue2047Member 2019-06-30 0000721371 cah:A3.75Notesdue2026Member 2019-12-31 0000721371 cah:A2.616Notesdue2022Member 2019-12-31 0000721371 cah:A3.2Notesdue2023Member 2019-12-31 0000721371 cah:A2.616Notesdue2022Member 2019-06-30 0000721371 cah:A3.2Notesdue2023Member 2019-06-30 0000721371 cah:A3.41Notesdue2027Member 2019-12-31 0000721371 cah:A3.75Notesdue2026Member 2019-06-30 0000721371 cah:A4.5Notesdue2044Member 2019-06-30 0000721371 cah:A4.6Notesdue2043Member 2019-06-30 0000721371 cah:A2.4Notesdue2020Member 2019-12-31 0000721371 cah:A4.625Notesdue2021Member 2019-06-30 0000721371 cah:A4.5Notesdue2044Member 2019-12-31 0000721371 cah:FloatingRateNotesdue2022Member 2019-06-30 0000721371 cah:A4.6Notesdue2043Member 2019-12-31 0000721371 cah:FloatingRateNotesdue2022Member 2019-12-31 0000721371 cah:A2.4Notesdue2020Member 2019-06-30 0000721371 cah:A7.0Debenturesduefiscal2027Member 2019-06-30 0000721371 cah:A3.5Notesdue2025Member 2019-12-31 0000721371 cah:A4.625Notesdue2021Member 2019-12-31 0000721371 cah:A4.9Notesdue2045Member 2019-06-30 0000721371 cah:A7.0Debenturesduefiscal2027Member 2019-12-31 0000721371 cah:A3.079Notesdue2024Member 2019-06-30 0000721371 cah:A4.9Notesdue2045Member 2019-12-31 0000721371 cah:A3.41Notesdue2027Member 2019-06-30 0000721371 cah:A3.5Notesdue2025Member 2019-06-30 0000721371 cah:A3.2Notesdue2022Member 2019-12-31 0000721371 cah:ProductLiabilityLawsuitsMember cah:AlamedaCountyMember us-gaap:SubsequentEventMember 2020-02-04 2020-02-04 0000721371 cah:OpioidLitigationlessCuyahogaandSummitCountiesMember 2019-09-30 0000721371 cah:SterileSurgicalGownRecallMemberDomain 2019-12-31 0000721371 cah:TotalOpioidLitigationMember 2019-09-30 0000721371 cah:SterileSurgicalGownRecallMemberDomain 2019-10-01 2019-12-31 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:PrivatePartiesMember 2020-02-04 0000721371 cah:ProductLiabilityLawsuitsMember cah:OtherJurisdictionsMember us-gaap:SubsequentEventMember 2020-02-04 2020-02-04 0000721371 cah:CVSHealthMember 2019-07-01 2019-12-31 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2020-02-04 0000721371 cah:OpioidLawsuitsStateDomain us-gaap:SubsequentEventMember 2020-02-04 0000721371 cah:OpioidLitigationlessCuyahogaandSummitCountiesMember 2019-07-01 2019-12-31 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:ClassActionLawsuitsMember cah:PrivatePartiesMember 2020-02-04 0000721371 cah:OpioidLitigationCuyahogaandSummitCountiesMember 2019-09-30 0000721371 cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2020-02-04 2020-02-04 0000721371 cah:TotalOpioidLitigationnetoftaxMember 2019-09-30 0000721371 cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2020-02-04 2020-02-04 0000721371 cah:TotalOpioidLitigationMember 2019-07-01 2019-12-31 0000721371 cah:PatientRecoveryBusinessMember 2019-06-30 0000721371 cah:CareFusionMember 2019-06-30 0000721371 cah:TotalOpioidLitigationMember 2019-12-31 0000721371 cah:CareFusionMember 2019-12-31 0000721371 cah:PatientRecoveryBusinessMember 2019-12-31 0000721371 srt:MinimumMember us-gaap:InternalRevenueServiceIRSMember 2019-10-01 2019-12-31 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000721371 us-gaap:CurrencySwapMember 2018-09-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-07-01 2018-12-31 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-12-31 0000721371 us-gaap:CurrencySwapMember 2019-12-31 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000721371 us-gaap:CashFlowHedgingMember 2019-12-31 0000721371 us-gaap:FairValueInputsLevel2Member 2019-06-30 0000721371 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-12-31 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-12-31 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-12-31 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember 2019-07-01 2019-12-31 0000721371 us-gaap:NonUsMember 2019-07-01 2019-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-12-31 0000721371 country:US 2018-07-01 2018-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember 2018-07-01 2018-12-31 0000721371 us-gaap:NonUsMember 2018-07-01 2018-12-31 0000721371 country:US 2019-07-01 2019-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember 2019-10-01 2019-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2018-10-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-10-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-12-31 0000721371 us-gaap:CorporateNonSegmentMember 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-06-30 0000721371 us-gaap:CorporateNonSegmentMember 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2019-07-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-07-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-07-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2019-07-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2019-07-01 2019-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2018-07-01 2018-12-31 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2019-07-01 2019-12-31 0000721371 cah:SterileSurgicalGownRecallMemberDomain 2019-07-01 2019-12-31 0000721371 us-gaap:NonUsMember 2019-10-01 2019-12-31 0000721371 country:US 2019-10-01 2019-12-31 0000721371 country:US 2018-10-01 2018-12-31 0000721371 us-gaap:NonUsMember 2018-10-01 2018-12-31 0000721371 us-gaap:PerformanceSharesMember 2019-12-31 0000721371 us-gaap:PerformanceSharesMember 2019-07-01 2019-12-31 0000721371 us-gaap:PerformanceSharesMember 2019-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-12-31 0000721371 us-gaap:EmployeeStockOptionMember 2018-07-01 2019-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-12-31 0000721371 us-gaap:EmployeeStockOptionMember 2019-10-01 2019-12-31 0000721371 us-gaap:EmployeeStockOptionMember 2018-10-01 2018-12-31 0000721371 us-gaap:PerformanceSharesMember 2019-10-01 2019-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2018-10-01 2018-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-10-01 2019-12-31 0000721371 us-gaap:PerformanceSharesMember 2018-10-01 2018-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-12-31 0000721371 us-gaap:PerformanceSharesMember 2018-07-01 2018-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-12-31 0000721371 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000721371 srt:MinimumMember us-gaap:PerformanceSharesMember 2019-07-01 2019-12-31 0000721371 srt:MaximumMember us-gaap:PerformanceSharesMember 2019-07-01 2019-12-31 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 pure cah:StateAG iso4217:USD shares iso4217:JPY iso4217:USD cah:plaintiff iso4217:EUR shares cah:lawsuit cah:segment false --06-30 Q2 2020 0000721371 5000000 0 0 755000000 755000000 327000000 327000000 2 500000 500000 0 0 28000000 35000000 10-Q true 2019-12-31 false 1-11373 Cardinal Health, Inc. OH 31-0958666 7000 Cardinal Place Dublin OH 43017 (614) 757-5000 Common shares (without par value) CAH NYSE Yes Yes Large Accelerated Filer false false false 291783533 39735000000 37740000000 77076000000 72953000000 38021000000 36010000000 73683000000 69556000000 1714000000 1730000000 3393000000 3397000000 1163000000 1064000000 2270000000 2219000000 56000000 12000000 86000000 44000000 133000000 157000000 265000000 314000000 -7000000 -8000000 -8000000 503000000 -21000000 15000000 -5694000000 -3000000 334000000 504000000 -4930000000 1320000000 12000000 -21000000 -2000000 -25000000 63000000 76000000 129000000 152000000 -4000000 0 -4000000 0 279000000 407000000 -5065000000 1143000000 59000000 126000000 -364000000 269000000 220000000 281000000 -4701000000 874000000 0 1000000 1000000 1000000 220000000 280000000 -4702000000 873000000 0.75 0.94 -15.99 2.90 0.75 0.93 -15.99 2.88 292000000 299000000 294000000 302000000 294000000 300000000 294000000 303000000 0.4811 0.4763 0.9622 0.9526 220000000 281000000 -4701000000 874000000 -1000000 -26000000 -18000000 -29000000 -1000000 -1000000 -6000000 -2000000 -2000000 -27000000 -24000000 -31000000 218000000 254000000 -4725000000 843000000 0 1000000 1000000 1000000 218000000 253000000 -4726000000 842000000 1659000000 2531000000 8280000000 8448000000 13799000000 12822000000 1998000000 1946000000 25736000000 25747000000 2301000000 2356000000 11523000000 11808000000 1482000000 1052000000 41042000000 40963000000 21459000000 21535000000 1192000000 452000000 2239000000 2122000000 24890000000 24109000000 6742000000 7579000000 8408000000 2945000000 0 0 2752000000 2763000000 449000000 5434000000 2099000000 1790000000 -103000000 -79000000 999000000 6328000000 3000000 2000000 1002000000 6330000000 41042000000 40963000000 327000000 2669000000 371000000 -34000000 -2039000000 -101000000 3000000 903000000 220000000 0 220000000 -2000000 -2000000 13000000 10000000 23000000 -70000000 1000000 70000000 0 143000000 143000000 -1000000 0 1000000 327000000 2752000000 449000000 35000000 2099000000 -103000000 3000000 1002000000 327000000 2590000000 5097000000 27000000 1678000000 -96000000 0 5913000000 280000000 1000000 281000000 -27000000 -27000000 18000000 3000000 21000000 -120000000 2000000 120000000 0 143000000 143000000 1000000 -1000000 -2000000 327000000 2728000000 5233000000 29000000 1795000000 -123000000 0 6043000000 327000000 2763000000 5434000000 -28000000 -1790000000 -79000000 2000000 6330000000 -4702000000 1000000 -4701000000 -24000000 -24000000 11000000 41000000 30000000 0 7000000 350000000 350000000 284000000 284000000 1000000 0 1000000 327000000 2752000000 449000000 35000000 2099000000 -103000000 3000000 1002000000 327000000 2730000000 4645000000 18000000 1224000000 -92000000 0 6059000000 873000000 1000000 874000000 -31000000 -31000000 2000000 29000000 27000000 11000000 600000000 600000000 286000000 286000000 -1000000 -1000000 0 327000000 2728000000 5233000000 29000000 1795000000 -123000000 0 6043000000 -4701000000 874000000 464000000 498000000 0 2000000 -8000000 503000000 -4000000 0 41000000 41000000 47000000 40000000 -121000000 191000000 991000000 753000000 -77000000 941000000 -5128000000 213000000 44000000 736000000 0 21000000 149000000 116000000 6000000 10000000 2000000 2000000 2000000 740000000 -151000000 595000000 681000000 0 793000000 2000000 -11000000 -13000000 287000000 293000000 350000000 600000000 -760000000 -908000000 -5000000 -4000000 -872000000 419000000 2531000000 1763000000 1659000000 2182000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">1. Basis of Presentation and Summary of Significant Accounting Policies</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to </span><a href="#s81E79CE77D115EE683A7A2DFC1811749" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 4</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for further information on our equity method investments.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">References to "we," "our," and similar pronouns in in this Quarterly Report on Form 10-Q for the quarter ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our fiscal year ends on June 30. References to fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> in these condensed consolidated financial statements are to the fiscal years ending or ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our condensed consolidated financial statements have been prepared in accordance with the United States Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. To conform to the current year presentation, certain prior year amounts have been reclassified. In addition, financial results presented for this fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (the "</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> Form 10-K"). </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Financial Accounting Standards</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;font-weight:normal;">Derivatives and Hedging </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In October 2018, the </span><span style="font-family:Arial Narrow;font-size:10pt;">Financial Accounting Standards Board ("FASB")</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> issued amended accounting guidance related to derivatives and hedging which permits the use of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") as a benchmark interest rate for hedge accounting purposes. This guidance is </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">effective beginning the first quarter of fiscal 2020 and must be applied on a prospective basis. The adoption did not have a material impact on our consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;font-weight:normal;">Leases</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In February 2016, the FASB issued amended accounting guidance that requires lessees to recognize most leases on the balance sheet as a lease liability and corresponding right-of-use asset. The guidance also requires disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted this guidance during the first quarter of fiscal 2020 and elected the transition option which allows us to apply the guidance prospectively. The adoption resulted in the recognition of lease liabilities in the amount of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$422 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and did not have a material impact on our results of operations, liquidity or debt covenant compliance under our current debt agreements. The majority of our lease spend relates to certain real estate with the remaining lease spend primarily related to vehicles and equipment. The adoption required certain changes to our systems and processes. See </span><a href="#sB3C2086DA4805F06B4D2F13FA24C3AD5" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 5</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for additional information regarding leases.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Issued Financial Accounting Standards Not Yet Adopted</span><span style="font-family:Arial Narrow;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. This guidance will be effective for us in the first quarter of fiscal 2021. We are currently evaluating the impact of adoption on our consolidated financial statements.</span></div> <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to </span><a href="#s81E79CE77D115EE683A7A2DFC1811749" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 4</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for further information on our equity method investments.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">References to "we," "our," and similar pronouns in in this Quarterly Report on Form 10-Q for the quarter ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our fiscal year ends on June 30. References to fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> in these condensed consolidated financial statements are to the fiscal years ending or ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our condensed consolidated financial statements have been prepared in accordance with the United States Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. To conform to the current year presentation, certain prior year amounts have been reclassified. In addition, financial results presented for this fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (the "</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> Form 10-K"). </span></div> <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Financial Accounting Standards</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;font-weight:normal;">Derivatives and Hedging </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In October 2018, the </span><span style="font-family:Arial Narrow;font-size:10pt;">Financial Accounting Standards Board ("FASB")</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> issued amended accounting guidance related to derivatives and hedging which permits the use of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") as a benchmark interest rate for hedge accounting purposes. This guidance is </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">effective beginning the first quarter of fiscal 2020 and must be applied on a prospective basis. The adoption did not have a material impact on our consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;font-weight:normal;">Leases</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In February 2016, the FASB issued amended accounting guidance that requires lessees to recognize most leases on the balance sheet as a lease liability and corresponding right-of-use asset. The guidance also requires disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted this guidance during the first quarter of fiscal 2020 and elected the transition option which allows us to apply the guidance prospectively. The adoption resulted in the recognition of lease liabilities in the amount of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$422 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and did not have a material impact on our results of operations, liquidity or debt covenant compliance under our current debt agreements. The majority of our lease spend relates to certain real estate with the remaining lease spend primarily related to vehicles and equipment. The adoption required certain changes to our systems and processes. See </span><a href="#sB3C2086DA4805F06B4D2F13FA24C3AD5" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 5</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for additional information regarding leases.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Issued Financial Accounting Standards Not Yet Adopted</span><span style="font-family:Arial Narrow;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. This guidance will be effective for us in the first quarter of fiscal 2021. We are currently evaluating the impact of adoption on our consolidated financial statements.</span></div> 422000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:16pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">2. Restructuring and Employee Severance</span><span style="font-family:Arial Narrow;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes restructuring and employee severance costs:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-related costs (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility exit and other costs (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total restructuring and employee severance</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-related costs (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility exit and other costs (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total restructuring and employee severance</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>86</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During fiscal 2020 and 2019, we implemented certain enterprise-wide cost-saving initiatives affecting various functional and commercial areas intended to optimize and simplify our operating model and cost structure. We incurred </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$42 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$8 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> during the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$62 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$34 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, in expenses related to these cost savings initiatives, which are reflected in restructuring and employee severance in the condensed consolidated statements of earnings/(loss).</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Related Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility Exit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">and Other Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Payments and other adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(24</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>99</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes restructuring and employee severance costs:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-related costs (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility exit and other costs (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total restructuring and employee severance</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-related costs (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility exit and other costs (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total restructuring and employee severance</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>86</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.</span></div> 42000000 12000000 14000000 0 56000000 12000000 62000000 41000000 24000000 3000000 86000000 44000000 42000000 8000000 62000000 34000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Related Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility Exit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">and Other Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Payments and other adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(24</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>99</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 64000000 8000000 72000000 56000000 8000000 64000000 21000000 3000000 24000000 99000000 13000000 112000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:16pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">3. Goodwill and Other Intangible Assets</span><span style="font-family:Arial Narrow;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,715</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Goodwill acquired, net of purchase price adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Foreign currency translation adjustments and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,658</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,698</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Intangible Assets</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables summarize other intangible assets by class at:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted- Average Remaining Amortization Period (Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Indefinite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">IPR&amp;D, trademarks and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total indefinite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Definite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,670</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>13</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Trademarks, trade names and patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>673</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>355</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>13</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Developed technology and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>693</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>910</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total definite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,681</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,145</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>12</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Indefinite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">IPR&amp;D, trademarks and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total indefinite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Definite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,562</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,517</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Trademarks, trade names and patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>377</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Developed technology and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,602</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>616</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>986</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total definite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,428</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,428</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Total amortization of intangible assets was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$127 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$133 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$256 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$266 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> through </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2024</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> is as follows: </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$258 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$442 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$408 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$358 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$328 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">.</span></div> <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,715</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Goodwill acquired, net of purchase price adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Foreign currency translation adjustments and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,658</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,698</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div> 2663000000 5715000000 8378000000 -5000000 0 -5000000 0 -17000000 -17000000 2658000000 5698000000 8356000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables summarize other intangible assets by class at:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted- Average Remaining Amortization Period (Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Indefinite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">IPR&amp;D, trademarks and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total indefinite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Definite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,670</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>13</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Trademarks, trade names and patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>673</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>355</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>13</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Developed technology and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>693</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>910</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total definite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,681</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,145</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>12</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Indefinite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">IPR&amp;D, trademarks and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total indefinite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Definite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,562</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,517</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Trademarks, trade names and patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>377</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Developed technology and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,602</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>616</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>986</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total definite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,428</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,428</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div> 22000000 22000000 22000000 22000000 3550000000 1670000000 1880000000 P13Y 673000000 318000000 355000000 P13Y 1603000000 693000000 910000000 P11Y 5826000000 2681000000 3145000000 P12Y 5848000000 2681000000 3167000000 22000000 22000000 22000000 22000000 3562000000 1517000000 2045000000 672000000 295000000 377000000 1602000000 616000000 986000000 5836000000 2428000000 3408000000 5858000000 2428000000 3430000000 127000000 133000000 256000000 266000000 258000000 442000000 408000000 358000000 328000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:16pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">4. Investments</span><span style="font-family:Arial Narrow;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In August 2018, we sold our </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>98 percent</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> ownership interest in naviHealth Holdings, LLC ("naviHealth") to investor entities controlled by Clayton, Dubilier &amp; Rice in exchange for cash proceeds of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$737 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (after adjusting for certain fees and expenses) and a </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>44 percent</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> equity interest in a partnership that owns </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>100 percent</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of the equity interest of naviHealth. We also have certain call rights to reacquire naviHealth. We are accounting for this investment using the equity method of accounting and on a one-month reporting lag.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we recognized a pre-tax gain of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$508 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> related to this divestiture in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The carrying value of this investment was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$330 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$334 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively. During the three and </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, our proportionate share of naviHealth’s net loss, which was recorded in other (income)/ expense, net in the condensed consolidated statements of earnings/(loss), was immaterial.</span></div> 0.98 737000000 0.44 1 508000000 330000000 334000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">5. Leases</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We primarily have operating leases for corporate offices, distribution facilities, vehicles, and equipment. We determine if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of the asset. Our lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Beginning July 1, 2019, operating lease right-of-use assets and corresponding operating lease liabilities are recognized in our condensed consolidated balance sheet at commencement date based on the present value of lease payments over the lease term. Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term. As most of our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our lease agreements include leases that contain lease components and non-lease components. For all asset classes, we have elected to account for both of these provisions as a single lease component. We also, from time to time, sublease portions of our real estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the condensed consolidated financial statements at or for the three and six months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. Short-term lease expense recognized in the three and </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> was not material. In addition, we elected the package of three practical expedients permitted under the transition guidance, which include the carry forward of our leases without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our leases have remaining lease terms from less than </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>1 year</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> up to approximately </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>23 years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table summarizes the components of lease cost:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Finance lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amortization of right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total finance lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Variable lease cost</span><span style="font-family:Arial Narrow;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Primarily includes payments for property taxes, maintenance and insurance. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table summarizes supplemental balance sheet information related to leases:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">   Current portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">   Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>324</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>426</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Finance lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Current portion of finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Long-term finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Operating leases are included in other assets, other accrued liabilities, and deferred income taxes and other liabilities in our condensed consolidated balance sheet. Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, and long-term obligations, less current portion in our condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following tables summarizes supplemental cash flow information related to leases:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating cash flows paid for operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Financing cash flows paid for finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Non-cash right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">New operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">New finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amended lease standard adoption impact as of July 1, 2019 </span><span style="font-family:Arial Narrow;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:Arial Narrow;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>400</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Includes the effect of </span><span style="font-family:Arial Narrow;font-size:8pt;"><span>$22 million</span></span><span style="font-family:Arial Narrow;font-size:8pt;"> from reclassifying deferred rent as an offset to the lease right-of-use asset in accordance with the transition guidance. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our operating leases had a weighted-average remaining lease term of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>6.3</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> years and a weighted-average discount rate of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>2.9 percent</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Future lease payments under non-cancellable leases as of </span><span style="font-family:Arial Narrow;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;"> were as follows:</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Years Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>71</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total future lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>536</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>553</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Less: leases not yet commenced </span><span style="font-family:Arial Narrow;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:Arial Narrow;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>426</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>441</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">As of December 31, 2019, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the condensed consolidated balance sheets. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at </span><span style="font-family:Arial Narrow;font-size:10pt;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;"> for fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;"> through </span><span style="font-family:Arial Narrow;font-size:10pt;">2024</span><span style="font-family:Arial Narrow;font-size:10pt;"> and thereafter were as follows: </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$126 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$100 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$76 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$54 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$33 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$94 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">.</span></div> P1Y P23Y <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table summarizes the components of lease cost:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Finance lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amortization of right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total finance lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Variable lease cost</span><span style="font-family:Arial Narrow;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Primarily includes payments for property taxes, maintenance and insurance. </span></div> 30000000 61000000 4000000 8000000 4000000 8000000 11000000 12000000 45000000 81000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table summarizes supplemental balance sheet information related to leases:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">   Current portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">   Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>324</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>426</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Finance lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Current portion of finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Long-term finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div> 404000000 102000000 324000000 426000000 14000000 4000000 11000000 15000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following tables summarizes supplemental cash flow information related to leases:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating cash flows paid for operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Financing cash flows paid for finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Non-cash right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">New operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">New finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amended lease standard adoption impact as of July 1, 2019 </span><span style="font-family:Arial Narrow;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:Arial Narrow;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>400</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Includes the effect of </span><span style="font-family:Arial Narrow;font-size:8pt;"><span>$22 million</span></span><span style="font-family:Arial Narrow;font-size:8pt;"> from reclassifying deferred rent as an offset to the lease right-of-use asset in accordance with the transition guidance. </span></div> 61000000 3000000 54000000 17000000 -400000000 22000000 P6Y3M18D 0.029 <div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Future lease payments under non-cancellable leases as of </span><span style="font-family:Arial Narrow;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;"> were as follows:</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Years Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>71</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total future lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>536</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>553</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Less: leases not yet commenced </span><span style="font-family:Arial Narrow;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:Arial Narrow;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>426</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>441</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">As of December 31, 2019, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the condensed consolidated balance sheets. </span></div> 59000000 2000000 61000000 108000000 6000000 114000000 89000000 4000000 93000000 67000000 4000000 71000000 47000000 1000000 48000000 166000000 0 166000000 536000000 17000000 553000000 61000000 0 61000000 49000000 2000000 51000000 426000000 15000000 441000000 126000000 100000000 76000000 54000000 33000000 94000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-weight:bold;">6. Long-Term Obligations and Other Short-Term Borrowings</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">At </span><span style="font-family:Arial Narrow;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we had total long-term obligations, including the current portion and other short-term borrowings, of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;text-align:right;vertical-align:bottom;"><span>$7.9 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;text-align:right;vertical-align:bottom;"><span>8.0 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively. </span><span style="font-family:Arial Narrow;font-size:10pt;">All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These obligations are effectively subordinated to the liabilities of our subsidiaries, including trade payables of </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>21.5 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> at both </span><span style="font-family:Arial Narrow;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In November 2019, we repaid the full principal of the 2.4% Notes due 2019 at maturity for </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$450 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. </span><span style="font-family:Arial Narrow;font-size:10pt;">During the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;"> </span><span style="font-family:Arial Narrow;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;">we early repurchased</span><span style="font-family:Arial Narrow;font-size:10pt;"> </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$207 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> of the </span><span style="font-family:Arial Narrow;font-size:10pt;">2.616% Notes due 2022</span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$10 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> of the </span><span style="font-family:Arial Narrow;font-size:10pt;">3.2% Notes due 2022</span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$14 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> of the </span><span style="font-family:Arial Narrow;font-size:10pt;">Floating Rate Notes due 2022</span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$81 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> of the </span><span style="font-family:Arial Narrow;font-size:10pt;">3.41% Notes due 2027</span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$6 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> of the </span><span style="font-family:Arial Narrow;font-size:10pt;">4.6% Notes due 2043</span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$2 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> of the </span><span style="font-family:Arial Narrow;font-size:10pt;">4.9% Notes due 2045</span><span style="font-family:Arial Narrow;font-size:10pt;">, and </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$21 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> of the </span><span style="font-family:Arial Narrow;font-size:10pt;">4.368% Notes due 2047</span><span style="font-family:Arial Narrow;font-size:10pt;">. </span><span style="font-family:Arial Narrow;">The repurchases were paid for with available cash and other short-term borrowings. In connection with the early debt repurchases, we recorded a</span><span style="font-family:Arial Narrow;font-size:10pt;"> </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$4 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> </span><span style="font-family:Arial Narrow;">loss on extinguishment of debt.</span><span style="font-family:Arial Narrow;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table summarizes long-term obligations and other short-term borrowings at:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.76543209876543%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions) (1)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2.4% Notes due 2019</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">4.625% Notes due 2020</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2.616% Notes due 2022</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>873</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.2% Notes due 2022</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Floating Rate Notes due 2022</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>326</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.2% Notes due 2023</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>553</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.079% Notes due 2024</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>780</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>781</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.5% Notes due 2024</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>402</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>402</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.75% Notes due 2025</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>497</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.41% Notes due 2027</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">4.6% Notes due 2043</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>340</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">4.5% Notes due 2044</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">4.9% Notes due 2045</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>443</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>445</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">4.368% Notes due 2047</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">7.0% Debentures due 2026</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>124</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other Obligations (2)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>698</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>7,934</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Less: current portion of long-term obligations and other short-term borrowings</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>452</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">   Long-term obligations, less current portion</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>7,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Maturities are presented on a calendar year basis. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Includes </span><span style="font-family:Arial Narrow;font-size:8pt;"><span>$458 million</span></span><span style="font-family:Arial Narrow;font-size:8pt;"> outstanding under our commercial paper program and </span><span style="font-family:Arial Narrow;font-size:8pt;"><span>$225 million</span></span><span style="font-family:Arial Narrow;font-size:8pt;"> outstanding under our committed receivables sales facility.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Financing Arrangements</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> commercial paper program backed by a </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> revolving credit facility. We also have a </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> committed receivables sales facility. At </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;">, we had </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$458 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> outstanding under our commercial paper program, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$225 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> outstanding under committed receivables sales facility and no amount outstanding under our revolving credit facility.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. CHF was organized for</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial Narrow;font-size:10pt;">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;">Our revolving credit and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021 </span></div><span style="font-family:Arial Narrow;">and as of the end of every quarter thereafter.</span><span style="font-family:Arial Narrow;font-size:10pt;"> </span><span style="font-family:Arial Narrow;">As of </span><span style="font-family:Arial Narrow;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial Narrow;">, we were in compliance with this financial covenant.</span> 7900000000 8000000000.0 21500000000 450000000 207000000 10000000 14000000 81000000 6000000 2000000 21000000 -4000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table summarizes long-term obligations and other short-term borrowings at:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.76543209876543%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions) (1)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2.4% Notes due 2019</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">4.625% Notes due 2020</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2.616% Notes due 2022</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>873</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.2% Notes due 2022</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Floating Rate Notes due 2022</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>326</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.2% Notes due 2023</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>553</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.079% Notes due 2024</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>780</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>781</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.5% Notes due 2024</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>402</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>402</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.75% Notes due 2025</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>497</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">3.41% Notes due 2027</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">4.6% Notes due 2043</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>340</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">4.5% Notes due 2044</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">4.9% Notes due 2045</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>443</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>445</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">4.368% Notes due 2047</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">7.0% Debentures due 2026</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>124</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other Obligations (2)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>698</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>7,934</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Less: current portion of long-term obligations and other short-term borrowings</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>452</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">   Long-term obligations, less current portion</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>7,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Maturities are presented on a calendar year basis. </span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Includes </span><span style="font-family:Arial Narrow;font-size:8pt;"><span>$458 million</span></span><span style="font-family:Arial Narrow;font-size:8pt;"> outstanding under our commercial paper program and </span><span style="font-family:Arial Narrow;font-size:8pt;"><span>$225 million</span></span><span style="font-family:Arial Narrow;font-size:8pt;"> outstanding under our committed receivables sales facility.</span></div> 0 450000000 506000000 508000000 873000000 1079000000 238000000 247000000 326000000 340000000 553000000 551000000 780000000 781000000 402000000 402000000 497000000 494000000 1238000000 1318000000 340000000 346000000 342000000 342000000 443000000 445000000 574000000 594000000 124000000 124000000 698000000 10000000 7934000000 8031000000 1192000000 452000000 6742000000 7579000000 458000000 225000000 2000000000.0 2000000000.0 1000000000.0 458000000 225000000 <div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:16pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">7. Commitments, Contingent Liabilities and Litigation</span><span style="font-family:Arial Narrow;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Commitments</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>10 years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$45.6 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> to CVS Health for the remainder of the initial term.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">We are named from time to time in </span><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:Arial Narrow;font-size:10pt;"> actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a </span><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:Arial Narrow;font-size:10pt;"> action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information have led, and may in the future lead, to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">From time to time, we determine that products we manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions can lead to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, action by regulators and product </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">liability claims and lawsuits, including class actions. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates. Except as otherwise disclosed in this footnote, it is not possible for us to reasonably estimate the amount of any possible loss or range of possible losses in the matters described below. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;font-weight:bold;">Opioid Lawsuits and Investigations</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>3,000</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">States &amp; Political Subdivisions</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Approximately </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>2,500</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the “MDL”).</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In addition, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>23</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> state attorneys general have filed lawsuits against distributors, including us, in various state courts. A trial in New York for cases brought by the New York Attorney General and Nassau and Suffolk counties is scheduled to begin in March 2020. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Additionally, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>43</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> state attorneys general have formed a multi-state task force to investigate the manufacturing, distribution, dispensing and prescribing practices of opioid medications. We have received requests related to the multi-state investigation, as well as separate civil investigative demands, subpoenas or requests for information from these and other state attorneys general offices and governmental authorities. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general that is </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions (the "Settlement Framework"). This Settlement Framework is subject to contingencies and uncertainties as to final terms, but is the basis for our negotiation of definitive terms and documentation. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The Settlement Framework includes (1) a cash component, pursuant to which we would pay up to </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$5.56 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> over </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>eighteen years</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, (2) development and participation in a program for free or rebated distribution of opioid abuse treatment medications for a period of ten years, and (3) industry-wide changes to be specified to controlled substance anti-diversion programs. Final terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. In connection with these matters, in the six months ended December 31, 2019, we accrued</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$5.56 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to reasonably estimate the liability associated with the other components of the Settlement Framework, the potential distribution of treatment medications and any incremental costs for changes to our controlled substance anti-diversion program that we may agree to.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In the six months ended December 31, 2019, we along with two other national distributors entered into a </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$215 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> settlement with two Ohio counties, Cuyahoga and Summit, to resolve all claims in the first bellwether trial in the MDL, which had been set for trial for October 2019. In connection with this settlement, we accrued </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$66 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> in the six months ended December 31, 2019. This accrual is included in other accrued liabilities in the condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In connection with these matters, we recorded a total pre-tax charge of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$5.63 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> (</span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$5.14 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> after tax) during the six months ended December 31, 2019 in litigation (recoveries)/charges, net, in the condensed consolidated statement of earnings for the cash component. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We will regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">Private Plaintiffs</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The Settlement Framework does not address claims by private plaintiffs, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private plaintiffs had brought approximately </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>365</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> lawsuits as of February 4, 2020. Of these, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>105</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We will continue to vigorously defend ourselves in these matters.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">Department of Justice Investigations</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">We have received grand jury subpoenas issued on behalf of the District Courts for the Eastern District of New York and the District of Columbia seeking documents and, in the District of Columbia, testimony, related to our anti-diversion policies and procedures, and our distribution of certain controlled substances. We are cooperating with these requests.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Cordis Product Liability Lawsuits</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">As of February 4, 2020, we are named as a defendant in </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>299</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>3,773</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Another </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>29</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> lawsuits involving similar claims by approximately </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>35</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We are vigorously defending ourselves in these lawsuits.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">At </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;">, we had a total of </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$441 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$885 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Shareholder Securities Litigation</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Surgical Gown Recalls</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In January, 2020, we issued a voluntary recall for </span><span style="font-family:Arial Narrow;font-size:10pt;">9.1 million</span><span style="font-family:Arial Narrow;font-size:10pt;"> AAMI Level 3 surgical gowns and two voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for 2.9 million Presource Procedure Packs containing affected gowns (together, the "Recalls"). These Recalls were necessary because we discovered in December 2019 that one of our FDA-registered suppliers in China had shifted production of some gowns to unapproved sites with uncontrolled environments. Because of this, we could not assure sterility of the gowns. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In connection with these Recalls, in the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;">, we recorded a total charge of </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$96 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, of which </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$56 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> is within cost of products sold and </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$40 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> is </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">within SG&amp;A in the condensed consolidated statements of earnings. In our condensed consolidated balance sheet at December 31, 2019, we had </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$38 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> reserved within inventories, net, and </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$58 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> included in other accrued liabilities related to this charge. This charge represents our best estimate of costs for the Recalls and include inventory write-off costs and certain remediation and supply disruption costs, such as costs to replace recalled products. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. The amount of ultimate loss may differ materially from this accrual. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In addition to the charge for the three months ended December 31, 2019, we expect that the Recalls will have other negative impacts, which could include: government investigations and enforcement actions by the U.S. Food and Drug Administration or other regulators or U.S. or international governmental bodies (possibly resulting in product seizures, additional recalls, the issuance of safety alerts, the suspension or revocation of the authority to produce, distribute and sell products and other civil or criminal sanctions); losses due to patient claims, including product liability claims and lawsuits; and customer claims unrelated to their direct costs from the supply disruption. We are not currently able to reasonably estimate the amount of any possible loss or range of possible losses for any of these potential claims or actions. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Other Civil Litigation </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">Generic Pharmaceutical Antitrust Litigation </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In December 2019, pharmaceutical distributors including us were added as defendants in a civil multidistrict litigation consisting of multiple individual and class action lawsuits filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and informed manufacturers that they wished to maintain current customer allocations for the purpose of avoiding price erosion. We intend to vigorously defend ourselves in these matters. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">Blood Pressure Medication Recall Litigation </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Many participants in the pharmaceutical supply chain, including manufacturers, repackagers (including us), distributors (including us), and retailers have been named as defendants in Multidistrict Litigation in the U.S. District Court for the District of New Jersey (the “Blood Pressure Medication Recall MDL”), which was created in February 2019. The claims arise out of a series of recalls of generic blood pressure medications due to alleged impurities in active pharmaceutical ingredients. In December 2019, two additional medications were added to the Blood Pressure Medication Recall MDL. In January 2020, manufacturers recalled another medication and the FDA continues to investigate other drugs for possible recall. We intend to vigorously defend ourselves in these matters.</span></div> P10Y 45600000 3000 2500 23 43 5560000000 P18Y 5560000000 215000000 66000000 5630000000 5140000000 365 105 299 3773 29 35 441000000 885000000 96000000 56000000 40000000 38000000 58000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:16pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">8. Income Taxes</span><span style="font-family:Arial Narrow;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Fluctuations in our provision for/(benefit from) income taxes as a percentage of pretax earnings (“effective tax rate”) are generally due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Opioid Settlement Framework</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In connection with the </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$5.63 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> pre-tax charge for the opioid litigation, during the six months ended December 31, 2019 we recorded a tax benefit of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$487 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which is net of unrecognized tax benefits of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$468 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the U.S. Tax Cuts and Jobs Act ("Tax Act"). Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See </span><a href="#sDB0FEA7067A25C26AAF654550C2AC47D" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 7</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for more information regarding these matters.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Effective Tax Rate</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, the effective tax rate was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>21.0</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> percent and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>31.0</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> percent, respectively. The change in the effective tax rate from prior period is </span><span style="color:#000000;font-family:Arial Narrow;font-size:10pt;">primarily due to the favorable impact from changes in jurisdictional mix and </span><span style="font-family:Arial Narrow;">discrete items recognized in the second quarter of fiscal 2020, largely driven by changes as a result of tax reform</span><span style="color:#000000;font-family:Arial Narrow;font-size:10pt;">.</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, the effective tax rate was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>7.2</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> percent and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>23.5</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> percent, respectively. The change in the effective tax rate from fiscal 2019 to fiscal 2020 is primarily due to the net effects of </span><span style="font-family:Arial Narrow;font-size:10pt;">the Settlement Framework.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Unrecognized Tax Benefits</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">At </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$940 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$456 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of unrecognized tax benefits, respectively. The </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> balances include </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$791 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$303 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">At </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$132 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$122 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>zero</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and a net decrease of up to </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$350 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, exclusive of penalties and interest.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Other Tax Matters</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>2008</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$171 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$165 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> at </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$21 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$22 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> at </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, and is included in other assets in the condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.</span></div> 5630000000 -487000000 468000000 0.210 0.310 0.072 0.235 940000000 456000000 791000000 303000000 132000000 122000000 0 350000000 2008 171000000 165000000 21000000 22000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:16pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">9. Fair Value Measurements</span><span style="font-family:Arial Narrow;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other investments (1)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Forward Contracts (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other investments (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Forward Contracts (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div>The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets. <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other investments (1)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Forward Contracts (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other investments (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Forward Contracts (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div>The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets. 199000000 0 0 199000000 116000000 0 0 116000000 0 73000000 0 73000000 118000000 0 0 118000000 0 53000000 0 53000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">10. Financial Instruments</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Interest Rate Risk Management</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Currency Exchange Risk Management</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce volatility in earnings, cash flow and net investments in certain subsidiaries to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Commodity Price Risk Management</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Hedges</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense in the condensed consolidated statements of earnings. For the three and </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>no</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, no new pay-floating interest rate swaps were executed. In connection with the debt redemption as described in </span><a href="#s0DDAD322D3D85A4A988436C76DF5D244" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 6</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, two pay-floating interest rate swaps with notional amounts of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$200 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> matured in the second quarter of fiscal 2020. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash Flow Hedges</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of other comprehensive income/(loss) and reclassified into earnings in the </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we entered into forward interest rate swaps with a total notional amount of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$100 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> to hedge probable, but not firmly committed, future transactions associated with our debt.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. All gains and losses currently included within accumulated other comprehensive loss associated with our foreign exchange forward contracts that are expected to be reclassified into net earnings within the next 12 months are immaterial.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Net Investment Hedges</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In August 2019, we entered into a </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>¥64.0 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$600 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">) cross-currency swap maturing in 2022.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In September 2018, we entered into a </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>€200 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$233 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">) cross-currency swap maturing in 2023.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Cross-currency swaps designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive income/(loss) until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. There was no ineffectiveness in our net investment hedges during the </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Economic (Non-Designated) Hedges</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$7 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$8 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> expense during the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively. The principal currencies managed through foreign currency contracts are the euro, Canadian dollar, British pound, Japanese yen, and Chinese renminbi.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> approximate fair value due to their short-term maturities.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Estimated fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,078</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8,065</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Carrying amount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>7,934</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div> 0 200000000 100000000 64000000000.0 600000000 200000000 233000000 -7000000 -8000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Estimated fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,078</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8,065</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Carrying amount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>7,934</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8078000000 8065000000 7934000000 8031000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:16pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">11. Shareholders' Equity</span><span style="font-family:Arial Narrow;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we repurchased </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>7.3 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> common shares having an aggregate cost of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$350 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. The average price paid per common share was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$48.00</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">August 20, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and was completed on </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 4, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we repurchased </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>11.5 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> common shares having an aggregate cost of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$600 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. The average price paid per common share was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$52.32</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We funded the repurchases with available cash and short-term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated Other Comprehensive Loss</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Translation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Gain/(Loss) on</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Derivatives,</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Accumulated Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Loss</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(95</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(79</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other comprehensive loss, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amounts reclassified to earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other comprehensive loss, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(113</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(103</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div> 7300000 350000000 48.00 11500000 600000000 52.32 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Translation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Gain/(Loss) on</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Derivatives,</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Accumulated Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Loss</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(95</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(79</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other comprehensive loss, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amounts reclassified to earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other comprehensive loss, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(113</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(103</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div> -95000000 16000000 -79000000 -18000000 0 -18000000 0 6000000 6000000 -18000000 -6000000 -24000000 -113000000 10000000 -103000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">12. Earnings Per Share Attributable to Cardinal Health, Inc.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:70%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average common shares–basic</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>292</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock options, restricted share units and performance share units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-average common shares–diluted</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>294</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:70%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average common shares–basic</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>294</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>302</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock options, restricted share units and performance share units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-average common shares–diluted</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>294</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>4 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the three months ended December 31, 2019 and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>6 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>1 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of which would be anti-dilutive as a result of the year-to-date net loss).</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>5 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> during both three months and </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">.</span></div> <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:70%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average common shares–basic</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>292</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock options, restricted share units and performance share units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-average common shares–diluted</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>294</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:70%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average common shares–basic</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>294</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>302</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock options, restricted share units and performance share units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-average common shares–diluted</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>294</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 292000000 299000000 2000000 1000000 294000000 300000000 294000000 302000000 0 1000000 294000000 303000000 4000000 6000000 1000000 5000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">13. Segment Information</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our operations are principally managed on a products and services basis and are comprised of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>two</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;font-weight:bold;">Revenue</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>35,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>33,534</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nuclear and Precision Health Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>213</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>35,714</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>33,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical distribution and products (3)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,498</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cardinal Health at-Home Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>525</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>479</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>39,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (4)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>39,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>68,713</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>64,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nuclear and Precision Health Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>429</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>413</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>69,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>65,155</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical distribution and products (3)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6,944</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cardinal Health at-Home Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>996</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>900</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>7,940</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>7,807</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (4)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>77,076</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables present revenue by geographic area:</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>38,670</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>36,716</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,030</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>39,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (1)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>39,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>74,980</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>70,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (1)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>77,076</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;font-weight:bold;">Segment Profit</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on extinguishment of debt; and provision for income taxes. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$17 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$12 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$20 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$19 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In connection with the opioid litigation as discussed further in </span><a href="#s4E63F8E98BD858D2B62213E5E2185201" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 7</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we recognized a pre-tax charge of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$5.63 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> during the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which was retained at Corporate. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In connection with the surgical gown recall as discussed further in </span><a href="#s4E63F8E98BD858D2B62213E5E2185201" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 7</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we recognized a pre-tax charge of $</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>96 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> during the three and </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which was retained at Corporate. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In connection with the naviHealth divestiture, we recognized a pre-tax gain of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$508 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> during the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which was retained at Corporate. </span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>462</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>443</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>188</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total segment profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>657</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>631</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(323</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total operating earnings</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>334</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>860</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>851</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>323</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total segment profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,225</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,174</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total operating earnings/(loss)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(4,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>23,143</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22,446</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>15,490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>15,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,409</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,233</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>41,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>40,963</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:16pt;"><br/></span></div> 2 <div style="line-height:120%;padding-left:4px;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>35,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>33,534</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nuclear and Precision Health Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>213</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>35,714</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>33,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical distribution and products (3)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,498</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cardinal Health at-Home Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>525</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>479</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4,006</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>39,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (4)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>39,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>68,713</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>64,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nuclear and Precision Health Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>429</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>413</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>69,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>65,155</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical distribution and products (3)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6,944</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cardinal Health at-Home Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>996</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>900</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>7,940</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>7,807</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (4)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>77,076</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(4)</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div> 35501000000 33534000000 213000000 206000000 35714000000 33740000000 3498000000 3527000000 525000000 479000000 4023000000 4006000000 39737000000 37746000000 -2000000 -6000000 39735000000 37740000000 68713000000 64742000000 429000000 413000000 69142000000 65155000000 6944000000 6907000000 996000000 900000000 7940000000 7807000000 77082000000 72962000000 -6000000 -9000000 77076000000 72953000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables present revenue by geographic area:</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>38,670</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>36,716</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,030</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>39,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (1)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>39,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>74,980</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>70,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (1)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>77,076</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div> 38670000000 36716000000 1067000000 1030000000 39737000000 37746000000 -2000000 -6000000 39735000000 37740000000 74980000000 70960000000 2102000000 2002000000 77082000000 72962000000 -6000000 -9000000 77076000000 72953000000 17000000 12000000 20000000 19000000 5630000000 96000000 508000000 <div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>462</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>443</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>188</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total segment profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>657</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>631</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(323</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(127</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total operating earnings</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>334</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>860</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>851</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>323</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total segment profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,225</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,174</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(6,155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total operating earnings/(loss)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(4,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 462000000 443000000 195000000 188000000 657000000 631000000 -323000000 -127000000 334000000 504000000 860000000 851000000 365000000 323000000 1225000000 1174000000 -6155000000 146000000 -4930000000 1320000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>23,143</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22,446</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>15,490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>15,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,409</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d1d1d1;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,233</span></span></div></td><td style="vertical-align:bottom;background-color:#d1d1d1;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>41,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>40,963</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:16pt;"><br/></span></div> 23143000000 22446000000 15490000000 15284000000 2409000000 3233000000 41042000000 40963000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:16pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">14. Share-Based Compensation</span><span style="font-family:Arial Narrow;font-size:16pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table provides total share-based compensation expense by type of award:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Restricted share unit expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock option expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Performance share unit expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total share-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Restricted share unit expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock option expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Performance share unit expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total share-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The total tax benefit related to share-based compensation was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$3 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$4 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$7 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$8 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Arial Narrow;font-size:10pt;">six months ended</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Restricted Share Units</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Restricted share units granted under the Plans generally vest in equal annual installments over </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>three years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:52%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Restricted Share Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Grant Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Value per Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nonvested at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>51.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>42.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>60.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nonvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>46.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">At </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$110 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>two years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock Options</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Employee stock options granted under the Plans generally vest in equal annual installments over </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>three years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and are exercisable for </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>ten years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all stock option transactions under the Plans:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:57%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Stock</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Exercise Price per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Common Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Outstanding at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>63.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>63.52</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>63.43</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">At </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$2 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>one year</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables provide additional detail related to stock options:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Aggregate intrinsic value of outstanding options at period end</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Aggregate intrinsic value of exercisable options at period end</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:58%;"/><td style="width:21%;"/><td style="width:2%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in years)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average remaining contractual life of outstanding options</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average remaining contractual life of exercisable options</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Performance Share Units</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Performance share units vest over a </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>three</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>zero</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> to </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>240 percent</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:51%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Performance</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Share Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Grant Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Value per Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nonvested at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>51.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>43.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>48.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>50.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nonvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>52.71</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">At </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$28 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>two years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> if targets are achieved.</span></div> <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table provides total share-based compensation expense by type of award:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Restricted share unit expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock option expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Performance share unit expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total share-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Six Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Restricted share unit expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock option expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Performance share unit expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total share-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 16000000 16000000 1000000 2000000 4000000 4000000 21000000 22000000 33000000 30000000 2000000 6000000 6000000 5000000 41000000 41000000 3000000 4000000 7000000 8000000 P3Y <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:52%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Restricted Share Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Grant Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Value per Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nonvested at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>51.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>42.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>60.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nonvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>46.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 2000000 51.65 2000000 42.40 1000000 60.37 0 0 3000000 46.49 110000000 P2Y P3Y P10Y <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all stock option transactions under the Plans:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:57%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Stock</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Exercise Price per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Common Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Outstanding at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>63.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>63.52</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Exercisable at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>63.43</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6000000 63.78 0 0 0 0 0 0 6000000 63.52 6000000 63.43 2000000 P1Y <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables provide additional detail related to stock options:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Aggregate intrinsic value of outstanding options at period end</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Aggregate intrinsic value of exercisable options at period end</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:58%;"/><td style="width:21%;"/><td style="width:2%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in years)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average remaining contractual life of outstanding options</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average remaining contractual life of exercisable options</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 14000000 10000000 14000000 10000000 P5Y P5Y P5Y P5Y 3 0 2.40 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:51%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Performance</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Share Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Grant Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Value per Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nonvested at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>51.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>43.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>48.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>50.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nonvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>52.71</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 900000 51.45 600000 43.68 100000 48.40 100000 50.58 1300000 52.71 28000000 P2Y XML 42 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements (Tables)
 6 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
 
December 31, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents
$
199

 
$
—

 
$
—

 
$
199

Other investments (1)
116

 
—

 
—

 
116

Forward Contracts (2)
—

 
73

 
—

 
73

 
June 30, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Other investments (1)
$
118

 
$
—

 
$
—

 
$
118

Forward Contracts (2)
—

 
53

 
—

 
53


(1)
The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)
The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
XML 43 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Restructuring and Employee Severance (Tables)
 6 Months Ended
Dec. 31, 2019
Restructuring Charges [Abstract]  
Summary of Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Employee-related costs (1)
$
42

 
$
12

Facility exit and other costs (2)
14

 
—

Total restructuring and employee severance
$
56

 
$
12


 
Six Months Ended December 31,
(in millions)
2019
 
2018
Employee-related costs (1)
$
62

 
$
41

Facility exit and other costs (2)
24

 
3

Total restructuring and employee severance
$
86

 
$
44


(1)
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods.
(2)
Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)
Employee-
Related Costs
 
Facility Exit
and Other Costs
 
Total
Balance at June 30, 2019
$
64

 
$
8

 
$
72

Additions
56

 
8

 
64

Payments and other adjustments
(21
)
 
(3
)
 
(24
)
Balance at December 31, 2019
$
99

 
$
13

 
$
112
XML 44 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Statement of Comprehensive Income [Abstract]        
Net earnings/(loss) $ 220 $ 281 $ (4,701) $ 874
Other comprehensive loss:        
Foreign currency translation adjustments and other (1) (26) (18) (29)
Net unrealized loss on derivative instruments, net of tax (1) (1) (6) (2)
Total other comprehensive loss, net of tax (2) (27) (24) (31)
Total comprehensive income/(loss) 218 254 (4,725) 843
Less: Net earnings attributable to noncontrolling interests 0 (1) (1) (1)
Total comprehensive income attributable to Cardinal Health, Inc. $ 218 $ 253 $ (4,726) $ 842
XML 45 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases Schedule of Lease Costs (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2019
Leases [Abstract]    
Operating Lease, Cost $ 30 $ 61
Amortization of right-of-use assets 4 8
Total finance lease cost 4 8
Variable lease cost 11 12
Total lease cost $ 45 $ 81
XML 47 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended
Nov. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Jun. 30, 2019
Debt Instrument [Line Items]            
Total Long-Term and Short-Term Obligations   $ 7,934   $ 7,934   $ 8,031
Gain (Loss) on Extinguishment of Debt   (4) $ 0 (4) $ 0  
Accounts payable   21,459   21,459   $ 21,535
Commercial Paper [Member]            
Debt Instrument [Line Items]            
Line of Credit Facility, Fair Value of Amount Outstanding   458   458    
Line of Credit Facility, Maximum Borrowing Capacity   2,000   2,000    
Revolving Credit Facility [Member]            
Debt Instrument [Line Items]            
Line of Credit Facility, Maximum Borrowing Capacity   2,000   2,000    
2.4% Notes due 2020 [Member]            
Debt Instrument [Line Items]            
Repayments of Notes Payable $ 450          
2.616% Notes due 2022 [Member]            
Debt Instrument [Line Items]            
Notes Payable Repurchased       207    
3.41% Notes due 2027 [Member]            
Debt Instrument [Line Items]            
Notes Payable Repurchased       81    
Committed Receivables Sales Facility Program [Member] | Short Term Credit Facilities Member            
Debt Instrument [Line Items]            
Line of Credit Facility, Fair Value of Amount Outstanding   225   225    
Line of Credit Facility, Maximum Borrowing Capacity   $ 1,000   1,000    
4.6% Notes due 2043 [Member]            
Debt Instrument [Line Items]            
Notes Payable Repurchased       6    
4.9% Notes due 2045 [Member]            
Debt Instrument [Line Items]            
Notes Payable Repurchased       2    
4.368% Notes due 2047 [Member]            
Debt Instrument [Line Items]            
Notes Payable Repurchased       21    
3.2% Notes due 2023 [Member]            
Debt Instrument [Line Items]            
Notes Payable Repurchased       10    
Floating Rate Notes due 2022 [Member]            
Debt Instrument [Line Items]            
Notes Payable Repurchased       $ 14    
XML 48 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities:    
Net earnings/(loss) $ (4,701) $ 874
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:    
Depreciation and amortization 464 498
Loss on Sale of Investments 0 2
Impairments and (gain)/loss on disposal of assets, net 8 (503)
Loss on Extinguishment of Debt 4 0
Share-based compensation 41 41
Provision for bad debts 47 40
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:    
(Increase)/decrease in trade receivables 121 (191)
Increase in inventories (991) (753)
Increase/(decrease) in accounts payable (77) 941
Other accrued liabilities and operating items, net 5,128 (213)
Net cash provided by operating activities 44 736
Cash flows from investing activities:    
Acquisition of subsidiaries, net of cash acquired 0 (21)
Additions to property and equipment (149) (116)
Purchase of investments (6) (10)
Proceeds from sale of investments 2 2
Proceeds from divestitures and disposal of property and equipment and held for sale assets 2 740
Net cash provided by/(used in) investing activities (151) 595
Cash flows from financing activities:    
Net change in short-term borrowings 681 0
Reduction of long-term obligations (793) (2)
Net proceeds/(tax withholdings) from share-based compensation (11) (13)
Dividends on common shares (287) (293)
Payments for Repurchase of Common Stock (350) (600)
Net cash used in financing activities (760) (908)
Effect of exchange rates changes on cash and equivalents (5) (4)
Net increase/(decrease) in cash and equivalents (872) 419
Cash and equivalents at beginning of period 2,531 1,763
Cash and equivalents at end of period $ 1,659 $ 2,182
XML 49 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - Stock Options - USD ($)
$ in Millions
 6 Months Ended 12 Months Ended
Dec. 31, 2019
Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 2  
Aggregate intrinsic value of outstanding options at period end 14 $ 10
Aggregate intrinsic value of exercisable options at period end $ 14 $ 10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 5 years 5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 5 years 5 years
XML 50 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information (Assets by Reportable Segment) (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Jun. 30, 2019
Segment Reporting Information [Line Items]    
Total assets $ 41,042 $ 40,963
Operating Segments | Pharmaceutical    
Segment Reporting Information [Line Items]    
Total assets 23,143 22,446
Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Total assets 15,490 15,284
Corporate    
Segment Reporting Information [Line Items]    
Total assets $ 2,409 $ 3,233
XML 51 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information (Narrative) (Details)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
segment
Dec. 31, 2018
USD ($)
Sep. 30, 2019
USD ($)
Segment Reporting Information [Line Items]          
Number of operating segments | segment     2    
Number of reportable segments | segment     2    
Project costs on investment and other spending $ 17 $ 12 $ 20 $ 19  
naviHealth [Member]          
Segment Reporting Information [Line Items]          
Pre-Tax Gain on Divestiture       $ 508  
Total Opioid Litigation [Member]          
Segment Reporting Information [Line Items]          
Estimated Litigation Liability 5,630   5,630   $ 5,630
Sterile Surgical Gown Recall [Member] [Domain]          
Segment Reporting Information [Line Items]          
Inventory Recall Expense $ 96   $ 96    
XML 52 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Shareholders' Equity (Narrative) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Class of Stock [Line Items]        
Payments for Repurchase of Common Stock $ 0 $ 0 $ 350 $ 600
Treasury Shares        
Class of Stock [Line Items]        
Treasury Stock, Shares, Acquired (1.0) (2.0) (7.3) (11.0)
Payments for Repurchase of Common Stock $ 70 $ 120 $ 350 $ 600
Treasury shares acquired, average price per share (in usd per share)     $ 48.00 $ 52.32
Treasury Stock Acquired Shares       11.5
XML 53 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes
 6 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes
8. Income Taxes
Fluctuations in our provision for/(benefit from) income taxes as a percentage of pretax earnings (“effective tax rate”) are generally due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Opioid Settlement Framework
In connection with the $5.63 billion pre-tax charge for the opioid litigation, during the six months ended December 31, 2019 we recorded a tax benefit of $487 million, which is net of unrecognized tax benefits of $468 million, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the U.S. Tax Cuts and Jobs Act ("Tax Act"). Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 7 for more information regarding these matters.
Effective Tax Rate
During the three months ended December 31, 2019 and 2018, the effective tax rate was 21.0 percent and 31.0 percent, respectively. The change in the effective tax rate from prior period is primarily due to the favorable impact from changes in jurisdictional mix and discrete items recognized in the second quarter of fiscal 2020, largely driven by changes as a result of tax reform.
During the six months ended December 31, 2019 and 2018, the effective tax rate was 7.2 percent and 23.5 percent, respectively. The change in the effective tax rate from fiscal 2019 to fiscal 2020 is primarily due to the net effects of the Settlement Framework.
Unrecognized Tax Benefits
At December 31, 2019 and June 30, 2019, we had $940 million and $456 million of unrecognized tax benefits, respectively. The December 31, 2019 and June 30, 2019 balances include $791 million and $303 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate.
At December 31, 2019 and June 30, 2019, we had $132 million and $122 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to
activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $350 million, exclusive of penalties and interest.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $171 million and $165 million at December 31, 2019 and June 30, 2019, respectively, and is included in other assets in the condensed consolidated balance sheets.
As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $21 million and $22 million at December 31, 2019 and June 30, 2019, respectively, and is included in other assets in the condensed consolidated balance sheet.
Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.
XML 54 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Investments
 6 Months Ended
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
Investments
4. Investments
In August 2018, we sold our 98 percent ownership interest in naviHealth Holdings, LLC ("naviHealth") to investor entities controlled by Clayton, Dubilier & Rice in exchange for cash proceeds of $737 million (after adjusting for certain fees and expenses) and a 44 percent equity interest in a partnership that owns 100 percent of the equity interest of naviHealth. We also have certain call rights to reacquire naviHealth. We are accounting for this investment using the equity method of accounting and on a one-month reporting lag.
During the six months ended December 31, 2018, we recognized a pre-tax gain of $508 million related to this divestiture in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings.
The carrying value of this investment was $330 million and $334 million as of December 31, 2019 and June 30, 2019, respectively. During the three and six months ended December 31, 2019, our proportionate share of naviHealth’s net loss, which was recorded in other (income)/ expense, net in the condensed consolidated statements of earnings/(loss), was immaterial.
XML 55 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share Attributable to Cardinal Health, Inc.
 6 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Earnings Per Share Attributable to Cardinal Health, Inc.
12. Earnings Per Share Attributable to Cardinal Health, Inc.
The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Weighted-average common shares–basic
292

 
299

Effect of dilutive securities:
 
 
 
Employee stock options, restricted share units and performance share units
2

 
1

Weighted-average common shares–diluted
294

 
300

 
Six Months Ended December 31,
(in millions)
2019
 
2018
Weighted-average common shares–basic
294

 
302

Effect of dilutive securities:
 
 
 
Employee stock options, restricted share units and performance share units
—

 
1

Weighted-average common shares–diluted
294

 
303


The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 4 million for the three months ended December 31, 2019 and 6 million for the six months ended December 31, 2019 (1 million of which would be anti-dilutive as a result of the year-to-date net loss).
The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 5 million during both three months and six months ended December 31, 2018.
XML 56 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation (Tables)
 6 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of Total Share-based Compensation Expense by Type of Award
The following table provides total share-based compensation expense by type of award:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Restricted share unit expense
$
16

 
$
16

Employee stock option expense
1

 
2

Performance share unit expense
4

 
4

Total share-based compensation
$
21

 
$
22


 
Six Months Ended December 31,
(in millions)
2019
 
2018
Restricted share unit expense
$
33

 
$
30

Employee stock option expense
2

 
6

Performance share unit expense
6

 
5

Total share-based compensation
$
41

 
$
41
Schedule of Stock Option Transactions Under the Plans
The following table summarizes all stock option transactions under the Plans:
(in millions, except per share amounts)
Stock
Options
 
Weighted-Average
Exercise Price per
Common Share
Outstanding at June 30, 2019
6

 
$
63.78

Granted
—

 
—

Exercised
—

 
—

Canceled and forfeited
—

 
—

Outstanding at December 31, 2019
6

 
$
63.52

Exercisable at December 31, 2019
6

 
$
63.43
Schedule of Additional Data Related to Stock Option Activity
The following tables provide additional detail related to stock options:
(in millions)
December 31, 2019
 
June 30, 2019
Aggregate intrinsic value of outstanding options at period end
$
14

 
$
10

Aggregate intrinsic value of exercisable options at period end
14

 
10

(in years)
December 31, 2019
 
June 30, 2019
Weighted-average remaining contractual life of outstanding options
5
 
5
Weighted-average remaining contractual life of exercisable options
5
 
5
Schedule of Transactions Related to Restricted Share Units Under the Plans
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)
Restricted Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
2

 
$
51.65

Granted
2

 
42.40

Vested
(1
)
 
60.37

Canceled and forfeited
—

 
—

Nonvested at December 31, 2019
3

 
$
46.49
Schedule of Transactions Related to Performance Share Units Under the Plans
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)
Performance
Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
0.9

 
$
51.45

Granted
0.6

 
43.68

Vested
(0.1
)
 
48.40

Canceled and forfeited
(0.1
)
 
50.58

Nonvested at December 31, 2019
1.3

 
$
52.71
XML 57 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Restructuring and Employee Severance Narative (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]        
Restructuring Costs     $ 64  
Employee-related costs $ 42 $ 12 62 $ 41
Facility Exit and Other Costs 14 0 24 3
Enterprise Wide Cost Saving Measures [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Costs $ 42 $ 8 $ 62 $ 34
XML 58 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Shareholders' Equity (Tables)
 6 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)
Foreign
Currency
Translation
Adjustments
 
Unrealized
Gain/(Loss) on
Derivatives,
net of tax
 
Accumulated Other
Comprehensive
Loss
Balance at June 30, 2019
$
(95
)
 
$
16

 
$
(79
)
Other comprehensive loss, before reclassifications
(18
)
 
—

 
(18
)
Amounts reclassified to earnings
—

 
(6
)
 
(6
)
Other comprehensive loss, net of tax
(18
)
 
(6
)
 
(24
)
Balance at December 31, 2019
$
(113
)
 
$
10

 
$
(103
)
XML 59 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Tables)
 6 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Schedule of Lease Costs
The following table summarizes the components of lease cost:
 
Three Months Ended December 31,
Six Months Ended December 31,
(in millions)
2019
2019
Operating lease cost
$
30

$
61

Finance lease cost




Amortization of right-of-use assets
4

8

Total finance lease cost
4

8

Variable lease cost(1)
11

12

Total lease cost
$
45

$
81

(1)
Primarily includes payments for property taxes, maintenance and insurance.
Leases Supplemental Balance Sheet Information
The following table summarizes supplemental balance sheet information related to leases:
(in millions)
December 31, 2019
Operating Leases
 
Operating lease right-of-use assets
$
404

 
 
   Current portion of operating lease liabilities
102

   Long-term operating lease liabilities
324

Total operating lease liabilities
426

 
 
Finance Leases
 
Finance lease right-of-use assets
14

 
 
Current portion of finance lease liabilities
4

Long-term finance lease liabilities
11

Total finance lease liabilities
$
15
Leases Supplemental Cash Flow Information
The following tables summarizes supplemental cash flow information related to leases:
 
Six Months Ended December 31,
(in millions)
2019
Cash paid for amounts included in the measurement of lease liabilities:


Operating cash flows paid for operating leases
$
61

Financing cash flows paid for finance leases
3

Non-cash right-of-use assets obtained in exchange for lease obligations:

New operating leases
54

New finance leases
17

Amended lease standard adoption impact as of July 1, 2019 (1) 
400

(1)
Includes the effect of $22 million from reclassifying deferred rent as an offset to the lease right-of-use asset in accordance with the transition guidance.
Schedule of Future Lease Payments
Future lease payments under non-cancellable leases as of December 31, 2019 were as follows:
(in millions)
Operating Leases
 
Finance Leases
 
Total
Years Ending December 31,

 

 

Remainder of 2020
$
59

 
$
2

 
$
61

2021
108

 
6

 
114

2022
89

 
4

 
93

2023
67

 
4

 
71

2024
47

 
1

 
48

Thereafter
166

 
—

 
166

Total future lease payments
536

 
17

 
553

Less: leases not yet commenced (1) 
61

 
—

 
61

Less: imputed interest
49

 
2

 
51

Total lease liabilities
$
426

 
$
15

 
$
441

(1)
As of December 31, 2019, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the condensed consolidated balance sheets.
XML 60 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation
 6 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation
14. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
The following table provides total share-based compensation expense by type of award:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Restricted share unit expense
$
16

 
$
16

Employee stock option expense
1

 
2

Performance share unit expense
4

 
4

Total share-based compensation
$
21

 
$
22


 
Six Months Ended December 31,
(in millions)
2019
 
2018
Restricted share unit expense
$
33

 
$
30

Employee stock option expense
2

 
6

Performance share unit expense
6

 
5

Total share-based compensation
$
41

 
$
41

The total tax benefit related to share-based compensation was $3 million and $4 million for the three months ended December 31, 2019 and 2018, respectively, and $7 million and $8 million for the six months ended December 31, 2019 and 2018, respectively.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)
Restricted Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
2

 
$
51.65

Granted
2

 
42.40

Vested
(1
)
 
60.37

Canceled and forfeited
—

 
—

Nonvested at December 31, 2019
3

 
$
46.49

At December 31, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $110 million, which is expected to be recognized over a weighted-average period of two years.
Stock Options
Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.
The following table summarizes all stock option transactions under the Plans:
(in millions, except per share amounts)
Stock
Options
 
Weighted-Average
Exercise Price per
Common Share
Outstanding at June 30, 2019
6

 
$
63.78

Granted
—

 
—

Exercised
—

 
—

Canceled and forfeited
—

 
—

Outstanding at December 31, 2019
6

 
$
63.52

Exercisable at December 31, 2019
6

 
$
63.43


At December 31, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $2 million, which is expected to be recognized over a weighted-average period of one year.
The following tables provide additional detail related to stock options:
(in millions)
December 31, 2019
 
June 30, 2019
Aggregate intrinsic value of outstanding options at period end
$
14

 
$
10

Aggregate intrinsic value of exercisable options at period end
14

 
10

(in years)
December 31, 2019
 
June 30, 2019
Weighted-average remaining contractual life of outstanding options
5
 
5
Weighted-average remaining contractual life of exercisable options
5
 
5

Performance Share Units
Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)
Performance
Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
0.9

 
$
51.45

Granted
0.6

 
43.68

Vested
(0.1
)
 
48.40

Canceled and forfeited
(0.1
)
 
50.58

Nonvested at December 31, 2019
1.3

 
$
52.71


At December 31, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $28 million, which is expected to be recognized over a weighted-average period of two years if targets are achieved.
XML 61 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units
$ / shares in Units, shares in Millions, $ in Millions
 6 Months Ended
Dec. 31, 2019
USD ($)
$ / shares
shares
Performance Share Units  
Nonvested at beginning of period (in shares) | shares 0.9
Granted (in shares) | shares 0.6
Vested (in shares) | shares (0.1)
Canceled and forfeited (in shares) | shares (0.1)
Nonvested at end of period (in shares) | shares 1.3
Weighted-Average Grant Date Fair Value per Share  
Nonvested at beginning of period (in usd per share) | $ / shares $ 51.45
Granted (in usd per share) | $ / shares 43.68
Vested (in usd per share) | $ / shares 48.40
Canceled and forfeited (in usd per share) | $ / shares 50.58
Nonvested at end of period (in usd per share) | $ / shares $ 52.71
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ $ 28
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years
XML 62 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation $ 21 $ 22 $ 41 $ 41
Restricted Share Unit        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation 16 16 33 30
Employee Stock Option        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation 1 2 2 6
Performance Share Unit        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation $ 4 $ 4 $ 6 $ 5
XML 63 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page - shares
 6 Months Ended
Dec. 31, 2019
Jan. 31, 2020
Cover page.    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Dec. 31, 2019  
Document Transition Report false  
Entity File Number 1-11373  
Entity Registrant Name Cardinal Health, Inc.  
Entity Central Index Key 0000721371  
Current Fiscal Year End Date --06-30  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Incorporation, State or Country Code OH  
Entity Tax Identification Number 31-0958666  
Entity Address, Address Line One 7000 Cardinal Place  
Entity Address, City or Town Dublin  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 43017  
City Area Code (614)  
Local Phone Number 757-5000  
Title of 12(b) Security Common shares (without par value)  
Trading Symbol CAH  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   291,783,533
XML 64 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Investments Investments (Details) - naviHealth [Member] - USD ($)
$ in Millions
 1 Months Ended 6 Months Ended
Aug. 31, 2018
Dec. 31, 2018
Dec. 31, 2019
Jun. 30, 2019
Aug. 01, 2018
Investment [Line Items]          
Noncontrolling Interest, Ownership Percentage by Parent         98.00%
Partnership Indirect Ownership         100.00%
Pre-Tax Gain on Divestiture   $ 508      
Proceeds from Divestiture of Businesses $ 737        
Equity Method Investment, Ownership Percentage         44.00%
Equity Method Investments     $ 330 $ 334  
XML 65 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases Supplemental Cash Flow Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Jul. 01, 2019
Dec. 31, 2019
Operating Lease, Payments   $ 61
Finance Lease, Principal Payments   3
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability   54
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability   $ 17
ASC 842    
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification $ (400)  
XML 66 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Balance Sheets (Parenthetical) - shares
Dec. 31, 2019
Jun. 30, 2019
Statement of Financial Position [Abstract]    
Preferred shares, authorized 500,000 500,000
Preferred shares, issued 0 0
Common shares, authorized 755,000,000 755,000,000
Common shares, issued 327,000,000 327,000,000
Common shares in treasury 35,000,000 28,000,000
XML 67 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Restructuring and Employee Severance
 6 Months Ended
Dec. 31, 2019
Restructuring Charges [Abstract]  
Restructuring and Employee Severance
2. Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Employee-related costs (1)
$
42

 
$
12

Facility exit and other costs (2)
14

 
—

Total restructuring and employee severance
$
56

 
$
12


 
Six Months Ended December 31,
(in millions)
2019
 
2018
Employee-related costs (1)
$
62

 
$
41

Facility exit and other costs (2)
24

 
3

Total restructuring and employee severance
$
86

 
$
44


(1)
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods.
(2)
Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.
During fiscal 2020 and 2019, we implemented certain enterprise-wide cost-saving initiatives affecting various functional and commercial areas intended to optimize and simplify our operating model and cost structure. We incurred $42 million and $8 million during the three months ended December 31, 2019 and 2018, respectively, and $62 million and $34 million for the six months ended December 31, 2019 and 2018, respectively, in expenses related to these cost savings initiatives, which are reflected in restructuring and employee severance in the condensed consolidated statements of earnings/(loss).
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)
Employee-
Related Costs
 
Facility Exit
and Other Costs
 
Total
Balance at June 30, 2019
$
64

 
$
8

 
$
72

Additions
56

 
8

 
64

Payments and other adjustments
(21
)
 
(3
)
 
(24
)
Balance at December 31, 2019
$
99

 
$
13

 
$
112
XML 68 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments, Contingent Liabilities and Litigation (Details)
$ in Millions
 3 Months Ended 6 Months Ended
Feb. 04, 2020
StateAG
plaintiff
lawsuit
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Loss Contingencies [Line Items]              
Inventory, Net   $ 13,799.0   $ 13,799.0     $ 12,822.0
Opioid Total Settlement, Cuyahoga and Summit Counties   215.0   215.0      
Cost of Goods and Services Sold   38,021.0 $ 36,010.0 73,683.0 $ 69,556.0    
Selling, General and Administrative Expense   1,163.0 $ 1,064.0 2,270.0 $ 2,219.0    
Other Accrued Liabilities, Current   2,239.0   $ 2,239.0     $ 2,122.0
Opioid Lawsuits State [Domain] | Subsequent Event              
Loss Contingencies [Line Items]              
Loss Contingency, Lawsuits, Number 2,500            
Opioid Litigation, less Cuyahoga and Summit Counties [Member]              
Loss Contingencies [Line Items]              
Cash Component For Settlement Framework, Term       18 years      
Estimated Litigation Liability           $ 5,560.0  
Opioid Litigation, Cuyahoga and Summit Counties [Member]              
Loss Contingencies [Line Items]              
Estimated Litigation Liability           66.0  
Opioid Lawsuits [Member] | Subsequent Event              
Loss Contingencies [Line Items]              
Loss Contingency, Lawsuits, Number 3,000            
Number of State Attorneys General filing lawsuits | StateAG 23            
InvestigationbyMultitateTaskForce | StateAG 43            
Product Liability Lawsuits | Subsequent Event              
Loss Contingencies [Line Items]              
Loss Contingency, New Claims Filed, Number | lawsuit 29            
CVS Health              
Loss Contingencies [Line Items]              
Long-term Purchase Commitment, Period       10 years      
Maximum quarterly payment       $ 45.6      
Product Liability Lawsuits | Subsequent Event              
Loss Contingencies [Line Items]              
Loss Contingency, New Claims Filed, Number | lawsuit 299            
Minimum              
Loss Contingencies [Line Items]              
Loss Contingency Accrual   441.0   441.0      
Maximum              
Loss Contingencies [Line Items]              
Loss Contingency Accrual   885.0   885.0      
Alameda County [Member] | Product Liability Lawsuits | Subsequent Event              
Loss Contingencies [Line Items]              
Loss Contingency, Number of Plaintiffs | plaintiff 3,773            
Other Jurisdictions [Member] | Product Liability Lawsuits | Subsequent Event              
Loss Contingencies [Line Items]              
Loss Contingency, Number of Plaintiffs | plaintiff 35            
Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event              
Loss Contingencies [Line Items]              
Loss Contingency, Lawsuits, Number | lawsuit 365            
Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event              
Loss Contingencies [Line Items]              
Loss Contingency, Lawsuits, Number | lawsuit 105            
Total Opioid Litigation, net of tax [Member]              
Loss Contingencies [Line Items]              
Estimated Litigation Liability           5,140.0  
Total Opioid Litigation [Member]              
Loss Contingencies [Line Items]              
Estimated Litigation Liability   5,630.0   5,630.0   $ 5,630.0  
Sterile Surgical Gown Recall [Member] [Domain]              
Loss Contingencies [Line Items]              
Inventory, Net   38.0   38.0      
Inventory Recall Expense   96.0   96.0      
Cost of Goods and Services Sold   56.0          
Selling, General and Administrative Expense   40.0          
Other Accrued Liabilities, Current   $ 58.0   $ 58.0      
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings $ 334 $ 504 $ (4,930) $ 1,320
Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings 657 631 1,225 1,174
Operating Segments | Pharmaceutical        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings 462 443 860 851
Operating Segments | Medical        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings 195 188 365 323
Corporate        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating earnings $ (323) $ (127) $ (6,155) $ 146
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares
shares in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Earnings Per Share [Abstract]        
Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) 4 5 6 5
shares that would be antidilutive as a result of net loss     1  
XML 71 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments (Narrative) (Details)
€ in Millions, ¥ in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
JPY (¥)
Dec. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2018
EUR (€)
Derivative [Line Items]                
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments $ 0 $ 0   $ 0        
Cash Flow Hedging [Member]                
Derivative [Line Items]                
Derivative Liability, Notional Amount           $ 100    
Currency Swap [Member]                
Derivative [Line Items]                
Derivative Liability, Notional Amount         ¥ 64,000 600 $ 233 € 200
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap                
Derivative [Line Items]                
Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount           $ 200    
Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]                
Derivative [Line Items]                
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net     $ (7) $ (8)        
XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)
 6 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share
The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Weighted-average common shares–basic
292

 
299

Effect of dilutive securities:
 
 
 
Employee stock options, restricted share units and performance share units
2

 
1

Weighted-average common shares–diluted
294

 
300

 
Six Months Ended December 31,
(in millions)
2019
 
2018
Weighted-average common shares–basic
294

 
302

Effect of dilutive securities:
 
 
 
Employee stock options, restricted share units and performance share units
—

 
1

Weighted-average common shares–diluted
294

 
303
XML 74 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Restructuring Charges [Abstract]        
Employee-related costs $ 42 $ 12 $ 62 $ 41
Facility Exit and Other Costs 14 0 24 3
Total restructuring and employee severance $ 56 $ 12 $ 86 $ 44
XML 75 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)
$ in Millions
 6 Months Ended
Dec. 31, 2019
Jun. 30, 2019
Indefinite-lived Intangible Assets [Line Items]    
Net Intangible $ 22 $ 22
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible 5,826 5,836
Accumulated Amortization 2,681 2,428
Net Intangible $ 3,145 3,408
Weighted- Average Remaining Amortization Period (Years) 12 years  
Gross Intangible, Total other intangible assets $ 5,848 5,858
Net Intangible, Total other intangible assets 3,167 3,430
IPR&D, trademarks and other    
Indefinite-lived Intangible Assets [Line Items]    
Net Intangible 22 22
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible 3,550 3,562
Accumulated Amortization 1,670 1,517
Net Intangible $ 1,880 2,045
Weighted- Average Remaining Amortization Period (Years) 13 years  
Trademarks, trade names and patents    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible $ 673 672
Accumulated Amortization 318 295
Net Intangible $ 355 377
Weighted- Average Remaining Amortization Period (Years) 13 years  
Developed technology and other    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible $ 1,603 1,602
Accumulated Amortization 693 616
Net Intangible $ 910 $ 986
Weighted- Average Remaining Amortization Period (Years) 11 years  
XML 76 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments
 6 Months Ended
Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments
10. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce volatility in earnings, cash flow and net investments in certain subsidiaries to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense in the condensed consolidated statements of earnings. For the three and six months ended December 31, 2019 and 2018, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During the six months ended December 31, 2019 and 2018, no new pay-floating interest rate swaps were executed. In connection with the debt redemption as described in Note 6, two pay-floating interest rate swaps with notional amounts of $200 million matured in the second quarter of fiscal 2020.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of other comprehensive income/(loss) and reclassified into earnings in the
same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
During the six months ended December 31, 2019, we entered into forward interest rate swaps with a total notional amount of $100 million to hedge probable, but not firmly committed, future transactions associated with our debt.
Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December 31, 2019 and 2018. All gains and losses currently included within accumulated other comprehensive loss associated with our foreign exchange forward contracts that are expected to be reclassified into net earnings within the next 12 months are immaterial.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
In August 2019, we entered into a ¥64.0 billion ($600 million) cross-currency swap maturing in 2022.
In September 2018, we entered into a €200 million ($233 million) cross-currency swap maturing in 2023.
Cross-currency swaps designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive income/(loss) until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. There was no ineffectiveness in our net investment hedges during the six months ended December 31, 2019.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $7 million and $8 million expense during the six months ended December 31, 2019 and 2018, respectively. The principal currencies managed through foreign currency contracts are the euro, Canadian dollar, British pound, Japanese yen, and Chinese renminbi.
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at December 31, 2019 and June 30, 2019 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)
December 31, 2019
 
June 30, 2019
Estimated fair value
$
8,078

 
$
8,065

Carrying amount
7,934

 
8,031


The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
XML 77 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Long-Term Obligations and Other Short-Term Borrowings
 6 Months Ended
Dec. 31, 2019
Long-Term Obligations and Other Short-Term Borrowings [Abstract]  
Long-Term Obligations and Other Short-Term Borrowings
6. Long-Term Obligations and Other Short-Term Borrowings
Long-Term Debt and Other Short-Term Borrowings
At December 31, 2019 and June 30, 2019, we had total long-term obligations, including the current portion and other short-term borrowings, of $7.9 billion and 8.0 billion, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These obligations are effectively subordinated to the liabilities of our subsidiaries, including trade payables of 21.5 billion at both December 31, 2019 and June 30, 2019.
In November 2019, we repaid the full principal of the 2.4% Notes due 2019 at maturity for $450 million. During the six months ended December 31, 2019, we early repurchased $207 million of the 2.616% Notes due 2022, $10 million of the 3.2% Notes due 2022, $14 million of the Floating Rate Notes due 2022, $81 million of the 3.41% Notes due 2027, $6 million of the 4.6% Notes due 2043, $2 million of the 4.9% Notes due 2045, and $21 million of the 4.368% Notes due 2047. The repurchases were paid for with available cash and other short-term borrowings. In connection with the early debt repurchases, we recorded a $4 million loss on extinguishment of debt.

The following table summarizes long-term obligations and other short-term borrowings at:
(in millions) (1)
December 31, 2019
 
June 30, 2019
2.4% Notes due 2019
$
—

 
$
450

4.625% Notes due 2020
506

 
508

2.616% Notes due 2022
873

 
1,079

3.2% Notes due 2022
238

 
247

Floating Rate Notes due 2022
326

 
340

3.2% Notes due 2023
553

 
551

3.079% Notes due 2024
780

 
781

3.5% Notes due 2024
402

 
402

3.75% Notes due 2025
497

 
494

3.41% Notes due 2027
1,238

 
1,318

4.6% Notes due 2043
340

 
346

4.5% Notes due 2044
342

 
342

4.9% Notes due 2045
443

 
445

4.368% Notes due 2047
574

 
594

7.0% Debentures due 2026
124

 
124

Other Obligations (2)
698

 
10

Total
7,934

 
8,031

Less: current portion of long-term obligations and other short-term borrowings
1,192

 
452

   Long-term obligations, less current portion
$
6,742

 
$
7,579

(1)
Maturities are presented on a calendar year basis.
(2)
Includes $458 million outstanding under our commercial paper program and $225 million outstanding under our committed receivables sales facility.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At December 31, 2019, we had $458 million outstanding under our commercial paper program, $225 million outstanding under committed receivables sales facility and no amount outstanding under our revolving credit facility.
In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.
Our revolving credit and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021
and as of the end of every quarter thereafter. As of December 31, 2019, we were in compliance with this financial covenant.
XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 256 377 1 false 83 0 false 10 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.cardinal.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Earnings Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings Condensed Consolidated Statements of Earnings Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 1003000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsOfShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Restructuring and Employee Severance Sheet http://www.cardinal.com/role/RestructuringAndEmployeeSeverance Restructuring and Employee Severance Notes 9 false false R10.htm 2105100 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 10 false false R11.htm 2107100 - Disclosure - Investments Sheet http://www.cardinal.com/role/Investments Investments Notes 11 false false R12.htm 2108100 - Disclosure - Leases Sheet http://www.cardinal.com/role/Leases Leases Notes 12 false false R13.htm 2110100 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Sheet http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowings Long-Term Obligations and Other Short-Term Borrowings Notes 13 false false R14.htm 2111100 - Disclosure - Commitments, Contingent Liabilities and Litigation Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigation Commitments, Contingent Liabilities and Litigation Notes 14 false false R15.htm 2112100 - Disclosure - Income Taxes Sheet http://www.cardinal.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 2113100 - Disclosure - Fair Value Measurements Sheet http://www.cardinal.com/role/FairValueMeasurements Fair Value Measurements Notes 16 false false R17.htm 2115100 - Disclosure - Financial Instruments Sheet http://www.cardinal.com/role/FinancialInstruments Financial Instruments Notes 17 false false R18.htm 2116100 - Disclosure - Shareholders' Equity Sheet http://www.cardinal.com/role/ShareholdersEquity Shareholders' Equity Notes 18 false false R19.htm 2117100 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Sheet http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthInc Earnings Per Share Attributable to Cardinal Health, Inc. Notes 19 false false R20.htm 2118100 - Disclosure - Segment Information Sheet http://www.cardinal.com/role/SegmentInformation Segment Information Notes 20 false false R21.htm 2119100 - Disclosure - Share-Based Compensation Sheet http://www.cardinal.com/role/ShareBasedCompensation Share-Based Compensation Notes 21 false false R22.htm 2201201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 22 false false R23.htm 2303301 - Disclosure - Restructuring and Employee Severance (Tables) Sheet http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables Restructuring and Employee Severance (Tables) Tables http://www.cardinal.com/role/RestructuringAndEmployeeSeverance 23 false false R24.htm 2305301 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssets 24 false false R25.htm 2308301 - Disclosure - Leases (Tables) Sheet http://www.cardinal.com/role/LeasesTables Leases (Tables) Tables http://www.cardinal.com/role/Leases 25 false false R26.htm 2310301 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables) Sheet http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsTables Long-Term Obligations and Other Short-Term Borrowings (Tables) Tables http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowings 26 false false R27.htm 2313301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.cardinal.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.cardinal.com/role/FairValueMeasurements 27 false false R28.htm 2315301 - Disclosure - Financial Instruments (Tables) Sheet http://www.cardinal.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.cardinal.com/role/FinancialInstruments 28 false false R29.htm 2316301 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.cardinal.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.cardinal.com/role/ShareholdersEquity 29 false false R30.htm 2317301 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Sheet http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncTables Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Tables http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthInc 30 false false R31.htm 2318301 - Disclosure - Segment Information (Tables) Sheet http://www.cardinal.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.cardinal.com/role/SegmentInformation 31 false false R32.htm 2319301 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.cardinal.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.cardinal.com/role/ShareBasedCompensation 32 false false R33.htm 2401402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details) Sheet http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details) Details http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies 33 false false R34.htm 2403402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Sheet http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Details http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables 34 false false R35.htm 2403403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Sheet http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Details http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables 35 false false R36.htm 2403404 - Disclosure - Restructuring and Employee Severance Narative (Details) Sheet http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarativeDetails Restructuring and Employee Severance Narative (Details) Details http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables 36 false false R37.htm 2405402 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Details http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables 37 false false R38.htm 2405403 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Sheet http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Details http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables 38 false false R39.htm 2405404 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details) Sheet http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets (Narrative) (Details) Details http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables 39 false false R40.htm 2407401 - Disclosure - Investments Investments (Details) Sheet http://www.cardinal.com/role/InvestmentsInvestmentsDetails Investments Investments (Details) Details 40 false false R41.htm 2408402 - Disclosure - Leases (Details) Sheet http://www.cardinal.com/role/LeasesDetails Leases (Details) Details http://www.cardinal.com/role/LeasesTables 41 false false R42.htm 2408403 - Disclosure - Leases Schedule of Lease Costs (Details) Sheet http://www.cardinal.com/role/LeasesScheduleOfLeaseCostsDetails Leases Schedule of Lease Costs (Details) Details 42 false false R43.htm 2408404 - Disclosure - Leases Supplemental Balance Sheet Information (Details) Sheet http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases Supplemental Balance Sheet Information (Details) Details 43 false false R44.htm 2408405 - Disclosure - Leases Supplemental Cash Flow Information (Details) Sheet http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails Leases Supplemental Cash Flow Information (Details) Details 44 false false R45.htm 2408406 - Disclosure - Leases Schedule of Future Lease Payments (Details) Sheet http://www.cardinal.com/role/LeasesScheduleOfFutureLeasePaymentsDetails Leases Schedule of Future Lease Payments (Details) Details 45 false false R46.htm 2410402 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details) Sheet http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsDetails Long-Term Obligations and Other Short-Term Borrowings (Details) Details http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsTables 46 false false R47.htm 2410403 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) Sheet http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsSummaryOfDebtDetails Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) Details 47 false false R48.htm 2411401 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details) Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationDetails Commitments, Contingent Liabilities and Litigation (Details) Details http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigation 48 false false R49.htm 2412401 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.cardinal.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.cardinal.com/role/IncomeTaxes 49 false false R50.htm 2413402 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) Sheet http://www.cardinal.com/role/FairValueMeasurementsFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) Details http://www.cardinal.com/role/FairValueMeasurementsTables 50 false false R51.htm 2415402 - Disclosure - Financial Instruments (Narrative) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments (Narrative) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 51 false false R52.htm 2415403 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) Details 52 false false R53.htm 2416402 - Disclosure - Shareholders' Equity (Narrative) (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity (Narrative) (Details) Details http://www.cardinal.com/role/ShareholdersEquityTables 53 false false R54.htm 2416403 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Details http://www.cardinal.com/role/ShareholdersEquityTables 54 false false R55.htm 2417402 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncNarrativeDetails Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncTables 55 false false R56.htm 2417403 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncTables 56 false false R57.htm 2418402 - Disclosure - Segment Information (Narrative) (Details) Sheet http://www.cardinal.com/role/SegmentInformationNarrativeDetails Segment Information (Narrative) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 57 false false R58.htm 2418403 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails Segment Information (Revenue by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 58 false false R59.htm 2418404 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails Segment Information (Segment Profit by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 59 false false R60.htm 2418405 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details) Sheet http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails Segment Information Revenue From External Customers By Geographic Areas (Details) Details 60 false false R61.htm 2418406 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails Segment Information (Assets by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 61 false false R62.htm 2419402 - Disclosure - Share-Based Compensation (Narrative) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation (Narrative) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 62 false false R63.htm 2419403 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 63 false false R64.htm 2419404 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 64 false false R65.htm 2419405 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 65 false false R66.htm 2419406 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 66 false false R67.htm 2419407 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 67 false false All Reports Book All Reports a20q210q123119form10-q.htm a20q210q123119exhibit1.htm a20q210q123119exhibit101.htm a20q210q123119exhibit102.htm a20q210q123119exhibit103.htm a20q210q123119exhibit3.htm a20q210q123119exhibit311.htm a20q210q123119exhibit312.htm a20q210q123119exhibit9.htm cah-20191231.xsd cah-20191231_cal.xml cah-20191231_def.xml cah-20191231_lab.xml cah-20191231_pre.xml chart-0c924314911e5b7b8bf.jpg chart-482220cd78845318873.jpg chart-73ee4c10511c5ef6890.jpg chart-9236314201dd5b538cd.jpg chart-f06b5fff8fb8555489d.jpg chart-f61e989517785cc7bf1.jpg chart-f9153a6cb9dd593fb2b.jpg http://xbrl.sec.gov/dei/2019-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 79 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period $ 903 $ 5,913 $ 6,330 $ 6,059
Total other comprehensive loss, net of tax (2) (27) (24) (31)
Balance at end of period 1,002 6,043 1,002 6,043
Foreign Currency Translation Adjustments        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period     (95)  
Other comprehensive loss, before reclassifications     (18)  
Amounts reclassified to earnings     0  
Total other comprehensive loss, net of tax     (18)  
Balance at end of period (113)   (113)  
Unrealized Gain/(Loss) on Derivatives, net of tax        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period     16  
Other comprehensive loss, before reclassifications     0  
Amounts reclassified to earnings     (6)  
Total other comprehensive loss, net of tax     (6)  
Balance at end of period 10   10  
Accumulated Other Comprehensive Loss        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period     (79)  
Total other comprehensive loss, net of tax     (24)  
Balance at end of period (103)   (103)  
AOCI Attributable to Parent        
AOCI, Net of Tax [Roll Forward]        
Balance at beginning of period (101) (96) (79) (92)
Other comprehensive loss, before reclassifications     (18)  
Amounts reclassified to earnings     (6)  
Balance at end of period $ (103) $ (123) $ (103) $ (123)
XML 80 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - Recurring - USD ($)
$ in Millions
Dec. 31, 2019
Jun. 30, 2019
Assets:    
Cash equivalents $ 199  
Other investments 116 $ 118
Forward contracts 73 53
Level 1    
Assets:    
Cash equivalents 199  
Other investments 116 118
Forward contracts 0 0
Level 2    
Assets:    
Cash equivalents 0  
Other investments 0 0
Forward contracts 73 53
Level 3    
Assets:    
Cash equivalents 0  
Other investments 0 0
Forward contracts $ 0 $ 0
XML 81 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information (Revenue by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Segment Reporting Information [Line Items]        
Total revenue $ 39,735 $ 37,740 $ 77,076 $ 72,953
Operating Segments        
Segment Reporting Information [Line Items]        
Total revenue 39,737 37,746 77,082 72,962
Operating Segments | Pharmaceutical        
Segment Reporting Information [Line Items]        
Total revenue 35,714 33,740 69,142 65,155
Operating Segments | Medical        
Segment Reporting Information [Line Items]        
Total revenue 4,023 4,006 7,940 7,807
Corporate        
Segment Reporting Information [Line Items]        
Total revenue (2) (6) (6) (9)
Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical        
Segment Reporting Information [Line Items]        
Total revenue 35,501 33,534 68,713 64,742
Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical        
Segment Reporting Information [Line Items]        
Total revenue 213 206 429 413
Medical distribution and products [Member] | Operating Segments | Medical        
Segment Reporting Information [Line Items]        
Total revenue 3,498 3,527 6,944 6,907
Cardinal Health At Home [Member] | Operating Segments | Medical        
Segment Reporting Information [Line Items]        
Total revenue $ 525 $ 479 $ 996 $ 900
XML 82 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]        
Amortization of intangible assets $ 127 $ 133 $ 256 $ 266
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 258   258  
Estimated annual amortization of intangible assets - Year Two 442   442  
Estimated annual amortization of intangible assets - Year Three 408   408  
Estimated annual amortization of intangible assets - Year Four 358   358  
Estimated annual amortization of intangible assets - Year Five $ 328   $ 328  
XML 83 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information (Tables)
 6 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Disaggregation of Revenue [Table Text Block]
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical Distribution and Specialty Solutions (1) (2)
$
35,501

 
$
33,534

Nuclear and Precision Health Solutions
213

 
206

Pharmaceutical segment revenue
35,714

 
33,740

Medical distribution and products (3)
3,498

 
3,527

Cardinal Health at-Home Solutions
525

 
479

Medical segment revenue
4,023

 
4,006

  Total segment revenue
39,737

 
37,746

Corporate (4)
(2
)
 
(6
)
Total revenue
$
39,735

 
$
37,740

 
Six Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical Distribution and Specialty Solutions (1) (2)
$
68,713

 
$
64,742

Nuclear and Precision Health Solutions
429

 
413

Pharmaceutical segment revenue
69,142

 
65,155

Medical distribution and products (3)
6,944

 
6,907

Cardinal Health at-Home Solutions
996

 
900

Medical segment revenue
7,940

 
7,807

  Total segment revenue
77,082

 
72,962

Corporate (4)
(6
)
 
(9
)
Total revenue
$
77,076

 
$
72,953


(1)
Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."
(2)
Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)
Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(4)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block]
The following tables present revenue by geographic area:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
United States
$
38,670

 
$
36,716

International
1,067

 
1,030

  Total segment revenue
39,737

 
37,746

Corporate (1)
(2
)
 
(6
)
Total revenue
$
39,735

 
$
37,740

 
Six Months Ended December 31,
(in millions)
2019
 
2018
United States
$
74,980

 
$
70,960

International
2,102

 
2,002

  Total segment revenue
77,082

 
72,962

Corporate (1)
(6
)
 
(9
)
Total revenue
$
77,076

 
$
72,953

(1)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment
The following tables present segment profit by reportable segment and Corporate:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical
$
462

 
$
443

Medical
195

 
188

Total segment profit
657

 
631

Corporate
(323
)
 
(127
)
Total operating earnings
$
334

 
$
504

 
Six Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical
$
860

 
$
851

Medical
365

 
323

Total segment profit
1,225

 
1,174

Corporate
(6,155
)
 
146

Total operating earnings/(loss)
$
(4,930
)
 
$
1,320
Assets by Reportable Segment
The following table presents total assets for each reportable segment and Corporate at:
(in millions)
December 31,
2019
 
June 30,
2019
Pharmaceutical
$
23,143

 
$
22,446

Medical
15,490

 
15,284

Corporate
2,409

 
3,233

Total assets
$
41,042

 
$
40,963
XML 84 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)
$ in Millions
 6 Months Ended
Dec. 31, 2019
USD ($)
Restructuring Reserve [Roll Forward]  
Beginning Balance $ 72
Additions 64
Payments and other adjustments (24)
Ending Balance 112
Employee- Related Costs  
Restructuring Reserve [Roll Forward]  
Beginning Balance 64
Additions 56
Payments and other adjustments (21)
Ending Balance 99
Facility Exit and Other Costs  
Restructuring Reserve [Roll Forward]  
Beginning Balance 8
Additions 8
Payments and other adjustments (3)
Ending Balance $ 13
XML 85 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements
 6 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements
9. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
 
December 31, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Cash equivalents
$
199

 
$
—

 
$
—

 
$
199

Other investments (1)
116

 
—

 
—

 
116

Forward Contracts (2)
—

 
73

 
—

 
73

 
June 30, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Other investments (1)
$
118

 
$
—

 
$
—

 
$
118

Forward Contracts (2)
—

 
53

 
—

 
53


(1)
The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)
The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
XML 86 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases
 6 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Leases
5. Leases
We primarily have operating leases for corporate offices, distribution facilities, vehicles, and equipment. We determine if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of the asset. Our lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.
Beginning July 1, 2019, operating lease right-of-use assets and corresponding operating lease liabilities are recognized in our condensed consolidated balance sheet at commencement date based on the present value of lease payments over the lease term. Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term. As most of our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable.
Our lease agreements include leases that contain lease components and non-lease components. For all asset classes, we have elected to account for both of these provisions as a single lease component. We also, from time to time, sublease portions of our real estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the condensed consolidated financial statements at or for the three and six months ended December 31, 2019.
We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. Short-term lease expense recognized in the three and six months ended December 31, 2019 was not material. In addition, we elected the package of three practical expedients permitted under the transition guidance, which include the carry forward of our leases without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.
Our leases have remaining lease terms from less than 1 year up to approximately 23 years. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option.

The following table summarizes the components of lease cost:
 
Three Months Ended December 31,
Six Months Ended December 31,
(in millions)
2019
2019
Operating lease cost
$
30

$
61

Finance lease cost




Amortization of right-of-use assets
4

8

Total finance lease cost
4

8

Variable lease cost(1)
11

12

Total lease cost
$
45

$
81

(1)
Primarily includes payments for property taxes, maintenance and insurance.
The following table summarizes supplemental balance sheet information related to leases:
(in millions)
December 31, 2019
Operating Leases
 
Operating lease right-of-use assets
$
404

 
 
   Current portion of operating lease liabilities
102

   Long-term operating lease liabilities
324

Total operating lease liabilities
426

 
 
Finance Leases
 
Finance lease right-of-use assets
14

 
 
Current portion of finance lease liabilities
4

Long-term finance lease liabilities
11

Total finance lease liabilities
$
15


Operating leases are included in other assets, other accrued liabilities, and deferred income taxes and other liabilities in our condensed consolidated balance sheet. Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, and long-term obligations, less current portion in our condensed consolidated balance sheet.
The following tables summarizes supplemental cash flow information related to leases:
 
Six Months Ended December 31,
(in millions)
2019
Cash paid for amounts included in the measurement of lease liabilities:


Operating cash flows paid for operating leases
$
61

Financing cash flows paid for finance leases
3

Non-cash right-of-use assets obtained in exchange for lease obligations:

New operating leases
54

New finance leases
17

Amended lease standard adoption impact as of July 1, 2019 (1) 
400

(1)
Includes the effect of $22 million from reclassifying deferred rent as an offset to the lease right-of-use asset in accordance with the transition guidance.
Our operating leases had a weighted-average remaining lease term of 6.3 years and a weighted-average discount rate of 2.9 percent.
Future lease payments under non-cancellable leases as of December 31, 2019 were as follows:
(in millions)
Operating Leases
 
Finance Leases
 
Total
Years Ending December 31,

 

 

Remainder of 2020
$
59

 
$
2

 
$
61

2021
108

 
6

 
114

2022
89

 
4

 
93

2023
67

 
4

 
71

2024
47

 
1

 
48

Thereafter
166

 
—

 
166

Total future lease payments
536

 
17

 
553

Less: leases not yet commenced (1) 
61

 
—

 
61

Less: imputed interest
49

 
2

 
51

Total lease liabilities
$
426

 
$
15

 
$
441

(1)
As of December 31, 2019, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the condensed consolidated balance sheets.
The future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at June 30, 2019 for fiscal 2020 through 2024 and thereafter were as follows: $126 million, $100 million, $76 million, $54 million, $33 million and $94 million.
XML 87 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Other Intangible Assets (Tables)
 6 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill by Reportable Segment
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)
Pharmaceutical
 
Medical
 
Total
Balance at June 30, 2019
$
2,663

 
$
5,715

 
$
8,378

Goodwill acquired, net of purchase price adjustments
(5
)
 
—

 
(5
)
Foreign currency translation adjustments and other
—

 
(17
)
 
(17
)
Balance at December 31, 2019
$
2,658

 
$
5,698

 
$
8,356
Schedule of Finite-Lived Intangible Assets
The following tables summarize other intangible assets by class at:
 
December 31, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
 
Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
 
 
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

 
N/A
Total indefinite-life intangibles
22

 
—

 
22

 
N/A
 
 
 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
 
 
Customer relationships
3,550

 
1,670

 
1,880

 
13
Trademarks, trade names and patents
673

 
318

 
355

 
13
Developed technology and other
1,603

 
693

 
910

 
11
Total definite-life intangibles
5,826

 
2,681

 
3,145

 
12
Total other intangible assets
$
5,848

 
$
2,681

 
$
3,167

 
N/A
 
June 30, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
Indefinite-life intangibles:
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

Total indefinite-life intangibles
22

 
—

 
22

 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
Customer relationships
3,562

 
1,517

 
2,045

Trademarks, trade names and patents
672

 
295

 
377

Developed technology and other
1,602

 
616

 
986

Total definite-life intangibles
5,836

 
2,428

 
3,408

Total other intangible assets
$
5,858

 
$
2,428

 
$
3,430
XML 88 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information
 6 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Segment Information
13. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products.
Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.
Revenue
The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical Distribution and Specialty Solutions (1) (2)
$
35,501

 
$
33,534

Nuclear and Precision Health Solutions
213

 
206

Pharmaceutical segment revenue
35,714

 
33,740

Medical distribution and products (3)
3,498

 
3,527

Cardinal Health at-Home Solutions
525

 
479

Medical segment revenue
4,023

 
4,006

  Total segment revenue
39,737

 
37,746

Corporate (4)
(2
)
 
(6
)
Total revenue
$
39,735

 
$
37,740

 
Six Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical Distribution and Specialty Solutions (1) (2)
$
68,713

 
$
64,742

Nuclear and Precision Health Solutions
429

 
413

Pharmaceutical segment revenue
69,142

 
65,155

Medical distribution and products (3)
6,944

 
6,907

Cardinal Health at-Home Solutions
996

 
900

Medical segment revenue
7,940

 
7,807

  Total segment revenue
77,082

 
72,962

Corporate (4)
(6
)
 
(9
)
Total revenue
$
77,076

 
$
72,953


(1)
Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."
(2)
Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)
Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(4)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following tables present revenue by geographic area:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
United States
$
38,670

 
$
36,716

International
1,067

 
1,030

  Total segment revenue
39,737

 
37,746

Corporate (1)
(2
)
 
(6
)
Total revenue
$
39,735

 
$
37,740

 
Six Months Ended December 31,
(in millions)
2019
 
2018
United States
$
74,980

 
$
70,960

International
2,102

 
2,002

  Total segment revenue
77,082

 
72,962

Corporate (1)
(6
)
 
(9
)
Total revenue
$
77,076

 
$
72,953

(1)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on extinguishment of debt; and provision for income taxes.
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $17 million and $12 million for the three months ended December 31, 2019 and 2018, respectively, and $20 million and $19 million for the six months ended December 31, 2019 and 2018, respectively.
In connection with the opioid litigation as discussed further in Note 7, we recognized a pre-tax charge of $5.63 billion during the six months ended December 31, 2019, which was retained at Corporate.
In connection with the surgical gown recall as discussed further in Note 7, we recognized a pre-tax charge of $96 million during the three and six months ended December 31, 2019, which was retained at Corporate.
In connection with the naviHealth divestiture, we recognized a pre-tax gain of $508 million during the six months ended December 31, 2018, which was retained at Corporate.
The following tables present segment profit by reportable segment and Corporate:
 
Three Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical
$
462

 
$
443

Medical
195

 
188

Total segment profit
657

 
631

Corporate
(323
)
 
(127
)
Total operating earnings
$
334

 
$
504

 
Six Months Ended December 31,
(in millions)
2019
 
2018
Pharmaceutical
$
860

 
$
851

Medical
365

 
323

Total segment profit
1,225

 
1,174

Corporate
(6,155
)
 
146

Total operating earnings/(loss)
$
(4,930
)
 
$
1,320


The following table presents total assets for each reportable segment and Corporate at:
(in millions)
December 31,
2019
 
June 30,
2019
Pharmaceutical
$
23,143

 
$
22,446

Medical
15,490

 
15,284

Corporate
2,409

 
3,233

Total assets
$
41,042

 
$
40,963
XML 89 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments (Tables)
 6 Months Ended
Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)
December 31, 2019
 
June 30, 2019
Estimated fair value
$
8,078

 
$
8,065

Carrying amount
7,934

 
8,031
XML 90 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)
$ / shares in Units, shares in Millions, $ in Millions
 6 Months Ended
Dec. 31, 2019
USD ($)
$ / shares
shares
Restricted Share Units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ $ 110
Restricted Share Units  
Nonvested at beginning of period (in shares) | shares 2
Granted (in shares) | shares 2
Vested (in shares) | shares (1)
Canceled and forfeited (in shares) | shares 0
Nonvested at end of period (in shares) | shares 3
Weighted-Average Grant Date Fair Value per Share  
Nonvested at beginning of period (in usd per share) | $ / shares $ 51.65
Granted (in usd per share) | $ / shares 42.40
Vested (in usd per share) | $ / shares 60.37
Canceled and forfeited (in usd per share) | $ / shares 0
Nonvested at end of period (in usd per share) | $ / shares $ 46.49
Employee Stock Option  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 1 year
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ $ 2
XML 91 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Share-Based Compensation (Narrative) (Details)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Tax benefit related to share-based compensation $ 3 $ 4 $ 7 $ 8
Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period (in years)     3 years  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount 2   $ 2  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition     1 year  
Exercisable period of plans (in years)     10 years  
Restricted Share Units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period (in years)     3 years  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount 110   $ 110  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition     2 years  
Performance Share Units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting Period in years for Shares     3  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 28   $ 28  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition     2 years  
Performance Share Units | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     0.00%  
Performance Share Units | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)     240.00%  
ZIP 92 0000721371-20-000023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000721371-20-000023-xbrl.zip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�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

EE65[9J5"?Z][77[/"S_6U?+ MO'2^BJ&HK+37Y=_[+ZQ?ERD_-O;:K"*;,[ M[E"]X^)L*^&65ONR;$Y=9U=7V6KG+)W+?95OLZH2KS=>YMO&RK>;?'73_JV; M):_P+[-LVS&Q=M9-/A6P^>@X+]:_.)_WA[^0UW?P[\KBBB-KKB,JRIJ)_::>9&D^ M>1C[/1R.U# N6AP=T 8;I_9V*>*1;YMRJGDI21@XX:URUMG=LMR)IO-O-:#; MY?W!K\.7> /A1K-#8997U5[\>IU=[II*K7E=J,HX[_6=W;\,NRM)OA>=V3-H MHQ].OX?0BE>%7?527(CB[54\T?AA^WFYR:H/5[C6$3'^$K]X>WO'U4.TUJY" M"A"!*$D@\<30"Z,D)8/B,1_6OW2.F*<9KJE2VK=.9RLZ\QCFV7/O\8J?71Y5-;B]NN9+\8ZK?U.* M?R-9$6R&.E,AL@M @0AI0$*(H 9'[8&44H9%U))2DMPXQIE%&*.E-/ M??V4UZA^_K6=<],HG(:R*BDZ(]"IIS\UCZ?(#D+4@AM;BWJ9ZI,E,Q3/1*$, M.?-8K$QR)'^PJWE MK/BAVGLDHCX@*4!\SS@X;BU@B,(I%[/T/VVY07 #HZC MKT?*;,D)D$VBU!3GP-$DVZ$>\="C)[J,S4- M-$_.=,VA 652:-*E$Y9]6'+ MO@MEVN?5C1B:?;BBV>5N06."D1M@#-S$!TGH4I1V=L,DC30GC(89'6FRJ)V# M?PA13 L+D.K31 .)EI\B&H%<$Y/LBKQ:FQ?JI>N%.2$S5,]#N@SZ\\QL^CW?%F6^N^_T%V_7#[_2 M/&3]>[:[*?B_$1=!UXMW"Q^&@/J\<.-.0!C#$$6@\X!7=4KS2W/";7G>BCV< MK7(N:\><9GSI[(1KJG7?8>BYEA MU$BX'%D[;"'9-A,G83&-/!PEB-* (A0$81AWRSS<.F*+KUEY6Q++[F8D.@N%?JUY\N&URUUOT\.*5IL*J2?NS2J94J.*1NLL+YJ44U M\JSH&6Y>E&!]-N%;:AK(B*T/-^?MZ22ABA#+D>1'U812Y($K\I#,0 MN+'2O1@*G[5<-;_/=L/6>548DE,12^2H"Z>O1%@V.YR$G.L"+P>U+333>BRNUN]+IM(U\*1ZVD*Z! M+.(D!7$*L1N"R'43%+MA=ZL/0="'&G.CYD&,-%>:5=6_.J>RY"P?=;/MPVZ6 MMPXHUD(6HB2G;Q-%QHP,SE/SE"GMD49[X9F'@EKTKQBKH0_0XX4+@0_]B.+$ MCT# 4(2\^&##@TK3JVI?'K^4>R*=R;+D%[CLAQ]S_$#=F2E2YK%&V)VY>D+YP:FR3W<#6RU2/4)EA>!["9'[*8$*!Q[K%BT3LT32NI$K6+6NI6E]OD;_0V\>*BT'=M182 MF\HK%XWIM/>4U*'JJQ6@5Z2_>O[I*/ )F4U^*]9?GW#;6!Q<^1U]GY_>YF5 M'ZYJD]6'_:[:+;=B+>]04M.(N!$%F!'/![RX9O ( \=828*-&[>LP!U>IP7L M-(C%1NH&LW,"^N+0Z25&G2/%1DZ&)PV+F@K;BX@5+59EMD>*K05I'DILS[UB MI,9N1X?;%DSS:K4IJGV9O=UEM\DD=A0A$!& 9I]P!7$@)?::IA M)$@C:?:;9:L0VX-"G,["5DYQ]$AQLG6LV)E5[Q'#9E'3G4^94)1\DS?7W3K.< M0EEXH8\I3!)(0<@(32) NVVO-(Z B6I:V[9EV>Q&RJ:%4Y_K0=(Y"LUC3%W, M0C[/L:DNH(/C,FL)'>Z=G(@:8E'^/6XQ;OZ\*U9_I_G7?)UMUX?]%S1;;?C_ MK!>( 3_DY6Y].1R S(O3[H8E&H!4:9[8B$'+@IDLJQMGW:%SUBVL)]N]5)_M M-D&UG'2.SK*:7C;PG!J?D,,6X<7I+J\.YMCO>K],7(\T&N5]'GIHUJ4GKWX; MYTOYFMMWV;+*/@DQ_G#U1Y75]XXO0$ 2!' 8019&@+DN:T])$1)&4:#T!.

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
OWSN MZ@X7?H*3%( ()5ZS R8_Z*69$Q__-DE3 ME )AODS*PAL>KBB$*FOS$0ME#T[HAAX;,A+R:5B0D;PM%C!&(8W2R'=3+_,S M_O]A;\>/$E_H^33UKX\E'WVBEL%R."YY]9 D35P[[/&EJ!RB5)D4CE'B)AD MW2$J6JZ+W[=/=T6]B)(0$9QX8>!&KI]Y!$%W,.%%KE!AE-*';1<^[4Z+<4#. M#I&X:,B3=%TLK/(C)Q(2U)@0A[>>GQ$%98*F%P-UZ)6!#B([^#\7#R7/>6[: MW_.G8@%HY$<($A?')/9#+T,QZLT$0>JY<@(@^?%Q1. RN&H9(5 EC!1,;#( ME9(@B-)D3A1>,W!1&!3)FHLXJ,)_)Q!:/(B+!&;A2)VO/VQ6Q8__MWA9A,@- M,T!<'P51&I,H)"$<[*0X]>140O;KX\A$C\KI8#D,EZQ02),FJA0V^5*2"G&J MS(G%&Q(NJH4J87.1"V7\[_1"CPFA7?IMS2]SH&6SS-?_4>3U/A42@B E&8DR MXF,(*8KB9#"51)YP3E/9@&79Z'$Y.V .1Z:0VE2G[[IZC,*B3!) $*>1_?2Y2$L'(.H M?G^L=.?QT.B0R:<[I:D3SW;:9$TQV2E.F,EDYQLBKN0Z56F;7D:T/3B1Z=1C M0UY$=GLT.UM)DJ5Q1#T08K9:"@-"?#+8(FDD=(^]GH61A:3?2M22$BD"9<7$ M%G=ZN7Q& M -1HF7[0*^*N=#N$;/+SPV99U<]5W=T@^*5EJQS,;^:L7W"U*A89)3CS@9=! M J&'28"S05+"P 5"%P";LC5.8O05QANG0\EZBM,C=3A4V5RI)L>BF=/QZ%7* MHVHQ:RZU>I&EBXE6,_Q.+TU&O7F7A#7)DKB,?0K- M"=,94BY*DBZ1R9 99L0%"*Y6K'LU_7\^EIO"6P"79"Y(O2"- T0) M"%$2#[;BV)7<2%:Q,([P])!NAE\X')QSNY$.E)1(%!4=V_PI"8X\=>8$YP0A M%\5&A\"Y"(V6#^]$1I\1:8'![)>W]=?J^V8!LP!',/-ADI'8\Z(HH5YO*:9Q MG"K)B\3W1Q87CHRO%S@V16&1(4]25BSQIBW-)0,)024UDC8PL*?L< MQ !045>DN904%YLTZBF,.(/&9>8-*2):H\KCS 1'V8USJJ/'B[3T?*J:-E__ M?^5SEQ(*LP2& -+43<,0 3_Q,G\P%L),>(]:P\3(LK,#YS!T2NED-18E)<<> M@7J"(\J=<;EY18B(V*@Q.#.I473BG-#H<")4G\M-U47>?1XC1$/?)PF&;DHC M&!#^J/GN\S$*A-='4A^U+"5=1,_!2"J''#'7M<(:)W+J($B'D9K:(X_/#'\E M4J8?\&JP*\W.(#ZH/U:\T.6QV@RG!0.:X"A-7$I@[&6!ZWK^D,--,QH+%Z)( M?]CRX.[P.!T@Z9T;>9*N#W*K_,@-= EJ3 SVMYZ?&?#*!$T_Z-6A5P8ZB/C@ M_U(LMS73%\^_^UJVZV)!*848DC "D9^1Q'/]?7XU]:)(^!"_](")*X \4]<5P"I)<@H@RX\)&7CK_AD94&9I>AE0AUX9Z"7B,O"U MSOGKMU]>GNZJ]2).$6LM@!"_,B1"D*)P.(>3)KXGG#*0^ZIM =B!<79HQ,>] M)#77![T]5B1'O!@A)@;Z*Y?/C'(U6J8?XHJX*]T.(3_'#\\!=:?](8I\#V0H M!#A$$?)]&&9[#0D3*CO/2WW<\E ?,!W>R9*[JT.-,/'IWAI7<@(@29/)&?^8 M@2NSOA)9T\N"'OP3L[\&#Q)W=>R.YN[N#..:U.8M/U/GH22FQ'-(7>"@R*;J/, *)2CL)TOP9O-7C)"47 M]Q(T69Q>9LRX\?ZJ#Q.\R)R280.V>W:Y('F;]]87+ A",<(X!#Z(*5.\(!E" M(82S1+("2]'(.+)S!([?7Y$/XTC^+(P:DZ*R,P*)2K(CS9_)$R^G*+DH.YHL MSD5V=-TX<;C% "]R=Y?6.&^+AZI^6034CPBF7L!LX,B'&/O#=.7_16E08VHNTJ"(_ITTZ+ @+@W94U$_L#71 M7^KJ>_N(JZ?G?/.RB#P:@@B%<9:0",/(R[SAS3?^N*CD830U&^-(Q8#-V8%S M>G2RFJ%(HZAVV&=024-DR3,G)B<)N2@J>A3.15PTO7@G,B98D8A#'HOU>C"2 M @ 3E 8I2H&?1*D'_"']@A,0"S_\J/#ID:(0#DE54.2H$HY!;+&D%H(($60P M CGR_G( HD+37"1"#?S[\$.= XD=FNKIB5_\42W_\>4Q9SWF=MLV;;[A.\B+ M, S]-/8#'T?0\R.77U(V& U3++RI:\#42+LU'42GPWCC[% Z1S"E=VVTV!7> MNQF+6+4='%5.#>[D7"#H\GZ."6;G(DMFG'F_MV..HVNR-;SZ#I=+?DD1,_"I M6I?+LFCV;V4G(7"1[V$8>$D4 Y 1+\99%'HH(RBY6E9AP(*] 74 Y0RHG#\& M7/]'9AP-P^@^;^XZ2+W?N[%4K-MF^).W@^HZ02<&E$%6IQU,)AVIC/_K$(_3@,0.#ZH0<" M+T(!X5LG.TBQZT>+;T5]5UV+#4:!(C,>CU$+#\L./2]U/L;O, %TOFR?GO+Z MA?_=D3/.B7$L%EB,TW1B"CF;-I/3T N-=;F%G#\X?*?#/[+6ZE!]08U':<%Y MZ/4XKE83C! YS?_?1?GPV!8KR(0N?^B/ =W>OXO;./3EPL?\1I/$(U[F@BP- M72].4C<(B8>#$!!)D3=KV[JJ#W!_RW=XG>5N'=-T>/_'_Y/XGO<_[SA6YY=R M^.-?QQ4&*4HO*(&=IIG'T+?D6S5&YS8PN$FYWK(_>P<$KOYSV[3\ONI]F.D# MS*+)V'6CQ$N(BUW,S_KO4(%8[-'NL;#83@?=WQ?+EH<)*XZ95X$UN[II)M+_ M*A>L66\6L7AM3BTB%[)]V"SK@F/)U\[@A=.[,>238-O6Y=VVS>_6A=-6#AF: MK6_)J9;)FJS+:K:%]IRQBMOP5D37K;%L6>D7*?#\&,,44ARCS THB0[S#@%D M!(6_BL&VLC\]KZN7@NDY3U@ZU3,/RYL;A_T3IB!++BU=*.=L-V7+_IRO#)^+ M^KZJGW+64X__4BCN&[?]K$X%1IM.;@IX)_L[S$X/^L2N@G/ _5,HOGFE%VZN MGUKAQ;TTH^R2K&HNS,_A6< D2#R/\9P %&9)F.$T'%# +-8O6+ADM;"7-FV ME(+O89I=F*]Z89C;TOP?#]* M =;5AOURV:UT&OBC;!89=*D717Z0!&E*TQ"3*/.B,$X14Q] I,(ULY8M!VE' M8!T6>3D,[JN4_"O ;&W'()]?UXW1$(*;RI.U@>0^LTGZ[>P^RS!Y:4/:2HO, M0UDM^?9VV]HB@Z*J^I7]].T]7.T6=\GE^KWMO73JA=3ZMOZK KS=:6BX_.1V6W->XN@?JP.?Z!M]NG,,F].#?C?/:0[E0;Z)N(!8KSK\'R$TK$S:^E:C5 M2OM<"'NG[0_SB)LGYJ":TPB5F_%NGPO^HO7FX6.1-\6G_*5+02P2/_&!B^(4 MNR!,($U]! 9C<1 +Q?&:)BS/.7M43@?KQAF R4T5JOR):?T(U,F)M3QK5C3V M-"\71%*3R'FHG*X3E='.):N]34PAC'W?3U$&$(@0\.,A MFL>9!X3N\#!CR;+J].#VHV? IZ@^FJR*B=!XA,IID3J75C3I(DT7I,D,O?-0 M*$.^5#8ZH)Q>?>:;X+?W?VL*V#1%>WO7YN6F6'W8#+=!TZI^+: ?R_RN7)?M MR\)-(P_'T TB&&.?/W*+48^(^('8[:ECX+"L=1WTWZK[WQAXIT/O#/#Y:FY_ M]SG?.'T35SA[)^3TT&JKB:GE7!I,3DOMMI45O=4@^H(:C]%\\]#J43RMQA\< MYG7^>/XYPD,(P1Y,":0 N#!"$ <]'K8ZCX7>Z[*/8D8:_RI>LZGPBNUE3M_M M-Y4]=9=MIN?&FFBI61ZC-?CS&=(DTE*L4D:AP6Y<1)D4"+-9LG M^+E:N*G#Z3Q4R8 ?)TLX]9D15:+AS.^7@A_^84[WU58^HH29\A%*0T(C%^,H M':S!C$J=KU&U85F%!EB_L6&TSOF).*[_DOLQROR)B<\8U,E)S_Z0^![2]?)0 M*[ISAIH+JJ-+YCPT1]N+RFP7D]P5SI?=0A"OJX9I6V^+*5N2(3^D?,,Y(RF M[MX6(+[0>U!Z%FSO O>@G.Q'V787)]RVC_SQ(WG%4610<.?7.GF2.[X#;SV@ MB;3F)"V7=GBU:)R'SFCZ\'9'UP C2MF@?C'WN5JO:55_S^O5PO,1C$@&71Y/ M$42"&.XCJ="5*W73M35J-JC'Y_S!$3H]1)W$D JY"HDAR[SJ)(8D*;6?(WK/ ME6B.2(/E>2B6,6\NY8BT6=)1L444^CX!. /4SV 8HBC$\3XH2Q!8/!=U6:V^ MM'G=J@O853,RH^LM(N&!AHJ' M80+GJS;B+@A(C"0?RGMES8) EV89OT ?9RB*X@2[:)]:!J M578WV4V\1?,*U+A*8\5$??C;HEV91K=KUT4(A\=!4!CZ@9NRN"#!P/-!% 84ABQP M"+"'()&ZJ=^T;_&V\'L6E_RB;0681SRE]M*SM_ M?.TNX)_LI21))B^HH:TVF8=06O.N&J=G&Y'77M/1RZX>A4,Y($E?Y?N3&Z8 $ATAJM]:&?=LRVT/N+B!9MN4WOC\YC/6VVE?0\X?18--4R[+[ MF^]E^SB>+NLUH)8VC]9VFR8Q4[J5[U::S^#?^;,WG+W\;; *8 M@@#@D*(P !&-0R_8V\QP(+TEHFQIC J1W>,^W4W_3@=O@FS,.8*NI66TB9W' M@#+DRZE$C2&&1*X&_CNSQV\XZS*"Y>:ER.OFOJIW;T@L/.J[*'$3B$.8IL C M!$3<'F(HW(0@T;N"]:Q8'E ].&>'CI^V[?!UFP0[A.+7Z&K2>3F,'Y=)N6!] M1B2*7TX\'IEJMQ5KD"IRD?%%]T^HN#G*IK_JV) ?E>G.I'H8J/Y6+HO.%LH; MGHIZ>BXV3=?=ON8_4+$I[LN6,@J._R;[P7]9+%APA@*2Q@F)013%,?0A[:>5 MA'A^J'9VR"HDRW," ^C<[1 Z]2%3U+V^]=L==X>_U+5'K7H$R6ZKB26%9MA@ MDGFBHT;IMX,=6-?\5@/^ZQNGAWCC\%;MW9CJZ),.QR*KU'$:<1X1^-A.GSV' M-2+G(C%]]J.HEV7#CV_A,;,C^S$9E1/9"V3> M[ /3$;D4#_+'Y%0MS/_ZR._.YTEI_F__I6&AQ:9[<7N;KQW6\9_^I!7F7R'@ M3*!OBK;I0WUCGE3F.Y7DWB^?8N[>3C%'L0YZ.?Q('PI!?N*E^Y]^@=)=!=4P MU$O>41^*19A%,,I(D- L#G&61+&/!ZPN@E+%Y-,@M+X8J!^*]M7+Z0\5&YJ_ MY(V3\S_F.$=^DM<*T9;/NJ1(47H7QDOWQ02#V8;@BQ%,.$;2 7Y1X![6A^!=4Y8'7^F*S&1([+ M"XINJ5'F(=6VG*M&Z=B242%;;NR>+KK_L%E63T4'Y>FY+A[9K%!^*_H_O6NZ M1<7"AW$ _ 1%&001\B#[?]K=Z$E2!BX6+B8S;-9B@G! NBL4.X+H[# Z?PPH MQRX8D^/P4GQFJ37F,9RM>?#GKDSK*'[K0'M,?GZ0^G[,W- M$S8;5G_NF$F;&I]/AA8?''../.M:^<@WY^#<\40TG]E'O9$49Z01>L7\9ZDQ M2)"8N49K$Q.S&6'3ZS<&YUO1_/LV7Y?W+_S<9/-OQ>JAV,_!"P;*@P%*0S;7 M)E[LA5$,!EQI1*7>_+"/QO(/FQMGL M=*J]H%-3M9K^K#1^@QF?@(Y<< X^.'GC[+R8YTPC1+SBI&*V4><_?QCV5V*J ML,&TR536 I$ L3G(=Z,H@02%. S@8#I.0[!HJS9?FTM6734HI>U[;.+U!/R? M]-=WO4]*V1%S<;+-9:",\FPQQS0?P=745&GBYR^;\BXII'\D^9*H>GAK=;#( M?K?>\MNT/E5U%Z:W;5W>;5M>4/:U^IWQQDL JS7[^L.'#8L?BZ9=N!2$L1N% M7@1)YB/J@60(W"%(XUA&)\?&-HJDOA;3LO/JS[]P414L\YVLY83K*&;;:-*% M%B+*?./L_7)ZQYQCS_B9G->^.8-SHU=EF&R9RV4;D_2!>4P5DWG_OO!CPE8P M, $M: "("R -/(AIAK,DS*+!H@N!5-"M8V>RB<')WP@)SFO6;.RG_ZW(U^UC MISWG*^_-$ZX]!QCEVI*>OU7O3WE=;.8CUFK"*TS\[$54W!-Q091D1U3J MC\J=^05.W0NP<1RFOA\%40@RC!,:1TQ4 Q3 F. THE@FCZQLQ')Z>/?T^ZM3 MKLHO1ZL3*:98HW H)U>*]%E1HW/T7) B;4;GH4/Z;E2&>YJ^ O5OOT9Q0%$8 MQ1ZB490Q[4,H'@PF7B95A*%A9BH54GH86H=.=26RP*0A+9KD<>CS%$GJD22O M\U4D64<$-$F)&Y&3_[?/19WS,PB=U?[2,(R(%TH5XH))RPT_SWUL)$FS-(LC-W8#F*4(4(318"1( M8Z'W*!0_;;ON=8=(6BI52+HNE);YD9/)5]0HB*0*1>(2:9DJ-8%\19F6/+YW M[XPX:O PO33J@*^,] 79U6W3%,5K'1Z.H;\,SVY]+G@DRUB[O:=EL\S7_/J3 M10!I[&?\IEJ0Q3[QLR3.>D#$"XA0Q#D"#,MRNP?%D]^^Z[NRRV%[_(LNEV=! MO>QRFH.^<=[$;S?[*Q1>;H9; IL;YU4;[? [W(&Q%]VJ1%]I[!:8OEZ&F):@E5BVSY)L4>[U](C*;T5D](QFD \S3%M4ZAE M08PWB4C"1)JH,_D4>X1/GVZQZ%LU1I>UD*PAVX)#^/J]6F ?IH#$@>\3Y(DNQ@!Z!@8_3- N03T 4#S$X)F7 M(*DHV+QU^_.$;S%W($:PA>R!<6['R1]PV#/.('!XIG((4BTTCQC:HG\Z>00% M)HUF$CK[**,I\OS(S^(PB),4)W2OYFD$A;8'S5N=G7H:)-1@/L$XES8S"N-K MI#"'NED%J7:8AR9:\$LELZ# G*G<0FADS.CO1-$>GN3R#<28MIAG&ET91!C63#%*-, \I-.^60HI! M@3=#&8;.^[I9!7D>32:5>#F(S>-HA1&7HBS,&%!/@WWYOT$&Z]?$#(Z M.]$T1Z?!K()I)FUF%4:71E$&=;,*,HTP#RDT[Y9*5D&>-U-9!6XY#CPOS)!+ M 8Q3WP]#G+J#91>$PC?IFK(W&\$S2J*9K()I_FQE%2Y)G#V.S6853'-M.ZL@ M,:TH9Q5.3Q(V&/TYL@I2'DEF%>39,IU5@/=,7_=8@.\2"L,D2[W0#Q*<1 @, M6&)$4QNI!3D$EF>.KX]%7>0O'>/(F!J9,7 PK*HF7.C:4X['%O+\\AV@8& MLAW7)AIK#,\^[Z'HEGCR0X:8S#&0PA!MA'E&W M>;<4\Q22O)E*32PPB'V$71HC/XP#%R24DKT0!Z'0W6G&C/TL"JC/JIDDA%%" M#><=)I"Y:W1I9!:$F9Z'K)ES1S)_(,F32,J@&[7G#49I2#,01C1U(?'#+ RR M<# ( K']*P-FYBY=)IB\GAD8D40YN=KQ=VD9.AZ-XHO]$>E46][O:-UN5F6S MK+:;MEA=7NK?5[5S5[6/3K4/E//-RKGO5(7_KNO:Y[NT2 K@,FEG%OV&F)Y^ MF6_*D+];8(3\E)#,@P'V8S]-083W M(+Q4\@DCHZ8MSPP<\;_VX\;95*WS4K3.;HX4UF@>R[SE W7WLU2 MUOA3S*B=-NW"R'530)/N,9<$XI@D@^DH=8575<8,_D1SDCF2E=)N]ODUD8 S M,/68XUDK+V>?;YT,W3@SC"@MXCDX/5:GGU',NW0Y+V>"+Y$9Y/4BZ\/3\[8M M5A\V3'*+IEVD[/.>Z_L>3J+0C;T$1\.AURB&,!.=-O2LC#)7E#M03MFC$M6H,!Q!FE64!]GV081@$>BC C@"+A\%['QLQ56HN^ZQH]%G-R M"OTZ+Z&NSUKDB:OS6"2J:;,BF2+*?,'Q,[IL@JKI5=F(%Y79#J25??G;40%% M]F/)-*N/W/G;B6X< 3>EL8]2#P (]M9)E&@D8)1MSERQC=*KE'H9A5D3V9=C MH,X.J8GTBSK=6AF846@WF811H%\Q"W..&O%$C#:YT\\:5KRZG(XQQ)IHL?^9 MK>^%EP8)C#&";@2AEQ+7];+!FL>6&S(U_JHV1JF/W17&KGM0I7@AH9GZ\S/< MG!AEIMB<1[6YMA>5V3YFX(C,PF4#,T@!#3(?NBGAXW*H#(F)BX7*,O0L_-\P M8DXRNQNKD MZK='&1UO(C:MJ/@Z6TJ+#:-$&5A46.9(:X5@E"N#*P'3X;YX6"_,R"S#=W'T ME\-T219$ XLOR\=BM5T7M_=,I,N6V?O6)998?RCOU@5LFJ)MON;LEPLWBZ,@ M13[V (0TPUF*/2\*XQ2':>PF0DIJP:QED1V0.M6]L\/Z6P?6.:!U=G"=/SK M_T?NF*[)!K@LSA-S+Z?;!FFW$A2*DW@A4K30$O,('VTX5EGOQ=)+LG-FTX1P!2$@>1"S9A=R]IY9>#>O3@= M7J<#+'V[@3GVQ71S*N*E]T7%.7?^X&A'EDX)'B^OLHVWQCS$TXIG[U?DEM@S M()\'^[_G3P6IGO)RLZ @R8*,8.AF+@MW"8BA.Z#(?$_JS7+3MB>5T9M7 YJC M=O[8X9:,1(VWB+:L6F\,D]*JT@YCZ^LI0M4T5JMI9J^S>MZ):ZT!%@WH[<=R M4WQHBZ=FD;D^BH/8=X/$#P"($\0,=J:!1T,HNZ&@;W#: /4/#M3ID)K34@FV MM074#M%& U(ACL?6R3UO:N(H3_OL%5'!)7$95.5+5/O@4U6WY7]U6?#;^[?6 M%Q!E":)ID 6AEP0TB%&:]D;]T)-[N%;3E&6].T;',VOE83CF'4 YE=/E54S? M1J143MG>LOE.W,;5L\L\75 R0P3/0\-,.5-9Z83&8K9C/-F/YV+3%)\+'CXR M>GE*M%GF:WZ1]<)CP20! 0DS+\.)[R(W]09D'@UD'Y:UCF?BM?2K,=T[+84:C^JQ>$AK MB6T[,P<'\O5[M? ]!@80%SD92F-,(W0@"5+(;(W5X@BL#P[9$U;/N6\U#W? M;+9,'_)K ;/SV^Y1$ ;>YF0@W$(VY-]&XXPA^%<;9@8"WW-K3-)EV^IG%'%I M'[5D6XU1BT+-.BN_T#9+ N2'#)2?)FX6A@CV: */0MDG$:Q@F*]8<_C6Y5JL MG:P)MO$F&D^R+S;/7$2;@S0KVU(M]M,*MYR7^M*MP*H]\:9LN"Q@'& WC&"" M MG*+-9(MX3;>/J/I]L6VF8ELWS_P'F]MMVS ?5N7F@3E3EYNF7/X] M7V^+!0F1[\9I$'J^&V(4A $AJ1N$Q ]2A!(H=:)M,I2V:T8>'NKB@2D_5_@= M+N<;!\9%OSJ@=JJ=(T[>.L]%758KI]BL) _#3=?48G/#S]'*-:?SC3\IW'G'?G'P[\;9>^AT+HY\0,]62UV8BJ;O'?.8 MK6; P]O3@M,CDI_S[J[CO3N#-_M1U,NRX<1(TM,>W-OYVGF_>.')S#O&>EJ:Y-?-/VCQG- M?!,3<6KJFT/;C#7W'PJ<(PX<3L*X M*$EXMN&8;)5CI9*,OV2?I7S-9 MR_^WC1(4VG>=BS6M8 MX+(MOW57B9.R6:ZK9EL77XL?+6(M]H\%(2D!*21) ##)2.IE*>B@>+X;):%4 ML8\5 );GZ5>8'1;M.=G3\[IZ*0KG2\';D75XN7G43C.(3823MX#<3/:>_!ZP MV:& MP?E4K64[_?B^Y'ANMJP7RZ[$+HY#8/&+DUQ@M+ 33R<>I 0;X#AI8G4=2W&C5N/ M.Y=\/;Y[+:9DJ^H#>N<+SSJR%8;D#57F^1?3R4FIEU-,!O68Z-=@YZ.=LHQ> M4%%KC3,//;7G7C52)Y>\W8_97Y7K+8MKBR_%DL6[/+K-?BS7VU6QHHP?GL78 MMOW=75E>\P1$\ZFHNR1&_]IA!*B;NA1X+B4@06%* C=+/. B&.$HD+I?>AQ$ MEM7X4]6REF0RO'YQ!F><8D@$-"UKT*'X[<;AS]_6Y9(O4QON@K/=E&W3+5^? MB_J^JI^Z]Z6/_ZY]S%OG>\%^GQ_1Y?Q2;G8_UOPJ>1GA.-U 3/_GUP/D)H5C M_,[! 6?PP.&RXQSYP$/NP0N'N;'+M-](OA5KZ")$$^1?F#_&;=QY3"HC^_SV M]L4)&!=Y<+#[>L.5['NU7:_NBF,IRQO^E]MU6]UOBG9=-\ M)2[K_-2-(*?F/R/_XH\H3MD.:@\LFF\/D4<8)7DZ,0':9'OZQQNM>5;9[ZOB M4U;WJF1S6)/A.,B2,"28 !< $B)$$ PA?WT"9302.@ZD\EW+4\X.CKA^2=-R M?7ZPR8B<_N^0B&T5ZC,CKMPV&5)39AFF1#3WC8=G-%65A^DU4QEYI=\+Y+)$ M'S;?F/!VR2E2W+5PL\K^N2W;E\-R MXU74G* @;L_Y(T=#T4>B$%"<5)AN/4 M]S!(H2MZR:I!B_:DX0CDC<-A[NH].J#'"_\_!JPCIWW%2;RP8+?0$O-8E=MP MK++>B\4&;MD9/K*_>\PU3)+ 99\.TBR ,8I<1/S!2$2)T!W5BI^V'+(?&Y*99_>JB^_7GG'M>AH/\U5Z#@2(%.$W!"9329FE9) M=,%71GJ+HB)\W+\;Y88DS@B.,]>-79S&'HKI8"BC,%-2!?'/CZ@,'V6?I--A M35(B[!"F+A,B7-G1BH\7'I S0-O,-$/!@7.ZH/N4U^^4"9B@.09S&49 D(<6N'WD#@H!&4EO" M)NU:5IO?6>OSZOQJO>8%(0/B&V>/V3F YH=J=K#E=FN-MH/8>FRJ)I#3+]/L M6UF525!Y85EFHT'FL2ZSXEEEOSN+IY'9A]O>WH?-JJR+Y0' @J8H"I%+48B" MP ,@8HO!O73'KM !&FTCMLMC#MB< =QAC(JG5_6(O)Z%'HU#.9F;!WWBJ>K1 M:%3+6RO2*9+"ON3YF7RV$;*F3VZ;<:,RW(GDXMU/=;4LBE7#:V1(R:/LLMW6 MQ>T]VC8LU&Z:HEEDF9L0 &A 4P\C&*(49/N\74"EKL$U8<^V&P0Q(EX(0QB#O=;&V)5:V9NS:EGW^DV]'5+G /7T MTE)._@Q2+R:"T[ N)X6&"+>BB,+\7=!%\VTP#W6TX%=EN_>:4,IF$2(*B.<" M[(9)Z/M^D.%]SA6%H= VBJZ-B510,MY39E!'WLR29T;,1H[DSA CK5+B5,Y9 MDR2\$%(@65;DBZ_^K5KSRP.;+\O'8K5=L[#PR/K12<$401@$.*6$$!H"'X;] M24$7^E[JRPB1<>.C[?9*:I)YEL7$:E*"E7>'!ZPWSH"6KU"/\$YXM8XLHT*U M;X8;9QZZ:,^]LW5P5G@4OO;TR.BJN#__3E=?@(-]@+/()4& TB#S4IB$.Q P MC'PL5"UGR;1E%7T]J >\YQ[)DZNXL]488G([83O(B:WA)K!SC:84F1=TUE*K MS$-E;3GW]MY)FQR*QZH73:.7O^;_6=5XG3<-_%$V"Y\D 4G2-$)LB0XH31*P M1Y%B*G5CCVG;UB/5_:!>GQO4'*>DK!IO =$P=CKR9:-87=XM1:U2!%X,6NTT MQ3S4U)IW[T)6FRP:TM,#AM_SIX)4_'[@!2)9Z&?8CUR09G$4A@AF Y* Q%([ MTC;L3ZZK-TZ'V^F .QRY\\<.NUFM56L=(WIKO6%,:ZY*FTRAPZ>(5==BK6;Z M*?18ST,Y33; IDCUYH=/G\G7.E\53WG]CR;?K&[;QZ+^:_%T5]0+%WD>RFB< M180D?A!C&H-]6(U=(?'5-F);83]]_A_YT_/_)#=.NX?8'7VM.$CQ^D,])B\+ MY:@D2JKAGK_WX)P_=O D[AC08U&\BG,T-M6J.#]LN@NM&J?<.,^\C*;AO^Q* M:![VMZQMBN_./S;5]W6Q>BB<;5/<;]?\'ZR*;\6Z>N:'!OB/L'^_VBY;IIY. M4]3?RF7!?]G_3?=E]MNV6#YNRG]NB^YWY1/[JV^[MU+:RBE83-A="7KTJ?[? MWG1#A8V<3;/> SN *C?LGS\SU_@_8?Z4#QOG_F#]S"CYJ>0!6WX8YORS#TQ6^T^UO%*VX#>) M-?SB'<;G[N?O^FHE9\.$^,9I7I[NJC7_-YU <+9[2IOV95W\2:O$]E*W/%-B M:Z0G3U]B:\:-RO (MY8P^G@XW>8E"+-IW N2. C\&&0!&J"$7DPM98W$ 4R^ MQ%$XZFJW18QGD>PTAOE4DD@[3)U0^GCAP.TH3?-3+&4T753/+ZGR:4B#=S>% MLCCB+U6U^EZNUPN(@M0EB9LB$$,OI2X:=F=A2%EW-*B_\L8M:^_O17LTS(U* MJP+11F35+L?&)?67/5YG 'S^MNLII/4=G^JRJMXT/X6D:K@G)Z>Z/(I**97, M3@'DIQBE 8H!COP@!13L'N[S4!@'-%I\*^J[2E1+35N7&>;'0(5'.[U8U/ ^ M)SSN,)>D\\(HM]4P\QCDUKRKQNG>BKJ[DDX_H##8_G<#&MDG(8@ M"%TWI%'LQ7&$ 3Y8C*2VWG3L6(Z!!FA.?8Q-+A;2HE$L[!F+0;D(9T_>*UC7 M\[Y6).X"11?DS 2Q\Y N(YY4YKN=^&[4(5\'-ZM/.7]V9C 64Q*E:40AH"'T M H0)@8,QE"*AXBI-$Y:%Z("LWXKJ$L[]TSD[H.+[*#I,7M^+&HE$.2TZ@'(8 M*J>'Y>QPC<.<^/[32 RJ[3Y]?2QFLY_2;S Q1(=/K8N'?+U#Z#S4^88_-G7W MTOW00\5B]\VP<<7_I.)G*;EE_IO=.-KM)SVOJY)?V>\[W@S&:/@6XS_5:/"2 M/<#=)G*'4+: PABU8L'TF)S*36(',@_0G!VVB:+J*UQ=B*Q-L3R/Z-J8-Y6= MOF@LM_>7FK\W WV4DLQ-4(1ADKD(^VF\E\X 2CW!KFW,"-&G4DRT M1F513K6NI3X[?+/)=W9HU!*<PE3AR8!TP25;[FS7+ 9J M;LO_VJW$XBC-4C_UDHQ)J < 1'XP "$^3 R)F:IYR_)V!,LYQF5,YI1IUQ:^ M,1@W*X72C3&V.IZA5$TO==MG]@JJ[:"XIIKATH#*_EZTBPREB0MQ1'#HH]@/ M0Q2[>Z-A)G6=@*:I&=?(Z)*HK8^F^3.KA0S=;&2/85&3.!F*9R]G4LZ(2Y<\ M1P9DZG/!-\[+S<.Q6G[JTKG>(DXQP3@-,J:;," T#L-T0),%8L\$V<9@6=C^ M=\'3#,7J-P=^*VK^AL0>[:O(Q-GA=7[YCR*OF_/5:>.VC[8TCM8T9C7S8AO- M1DTOD:LFLT:::_;Z:\9+<6$VR*IX@?:)5,'[DD8OIA%-$@IJS=?]MFAYD(*\XN5F$;)7\>FFG:J7<5UQ8X4U5$%BV_-XTQ#%C0'*/_O[US:Y(;-\_P?7X% M;U)95\TZ $09"Y2!9"$HRIYI=+*3J7VHHO3P]$P;C45LD_]7A /S@ 0+,I1%+/\T'VFE&I-83H)..FPVRL+S?PV(Z%W MJZTYV!F_/ J>\DV#@5:V+Y. =BE=X9\#OY3O,7THFI(7;7F7UI^_E-NV[X.R MII&"^N/__/O3'WE??._^%ON]:(;7Q]]LVUW3[W%K^P/>'Q^*[;LO_5;57^K^ MQH3R[D.]V8BZZ?ZA59[$&>)PF&:\$_=CMNL MV)6BJ)J_%IO'\CA+0"*((T )"R,08I;$"1NSY#S3FEC]T7*;:L)VG*_MU0:= MW*#3&_2"NQW+>T#_PZ%9I[#F9;>7S^K_#-S]N#<]_3U^!>I[U6]W6=6N-W7[ MV)3LMCNZL=ZM1!+&("6<W-1#,\9XL,\%96:Y1/RT-QJDT31SF:S13>(*;8P\4;E" M@>$_1B'YI=Z5[=UC&8(0#N?(( YBG&:A P"TFWJR.@0BD((E29FK )X9DTO MZY^#7E@@E06=-(,;J,T-O(R:R;S3 \W\MJE?FC")?697)IRTT>IN@'/)G@"O M$V_FOQ? /H7:X;>B@5STQ_ H4#@$BKN]+5S90%P MM4R@=O:%:($5T.0H%!Y"D3S/Y*]'*8IB3)"@!(=#J"2%3/DR,., WN$J9;WX MV+$9+0P-5 *L?^]T$3NW;5J8]6^?*6A/V&B+VI/)GH>MG3>+P*UE"K7#;T4+ MN<>=9C($"F,,< X)AR(6*$<8HD.@G()0 [@F/^\=MR^';L2,&D;6*:'6MVNZ MH)W3,"W(^C;.%+&O#+0%[(E$S^/5QI5%P-4J@=K9%Z(%5GH<*1HCD9@AE.4< M@P@"SC(3W3XJMW[TP! M^]I#6\*>2O4\8JV,601C[3*HW7TF6JM?1X'PV$]FW47E<8QH1@'E%$,8CG.^ MC$*B/A5K]O/>5[Y>?.K8:-!K:)W2JI=OUW37O.8T3&N]R[=QIJM=KPRT7>LZ MD>CYE2X;5Q: 5LL$:F=?B 98Z1]!5M[*+^6QZ:/=5^VZV$B8T_&N;1:"/(LX MS! 3-(Y0G(S3OSS"F3ICK2-YQJW4]\_!D\*^!NPU=KT,:D(2>W,5*#RIKWI M7J2E&IR>U%HS9%^QV [?U_(_1W)GOBT ZNYRJ7U\67H[5OLVY7WQO;C=E"L1 MQRQ'&:=Q*ML.2F,016.(),=:+Z1J_;!GD.\[,(,8O=VH>OYC5__Y(&Z^;IOZ]VGYJ5T+P",:40)[S",&, MAPD?H\B>)M)!@.YO>Z9 +R=XTJ,' FVCU%C@TR,]'"C;XX4(+WRX 53QY;! M!6/UM9OO1O\\R\=A,SO;WJ7%EVI7;-Z615N^N]U4G_8O!::/32,[+JLH[*YW M13!%6!(JC7'$1T*EL0BIWG-(;F/KU!NCQY&>G^/HGT7JM09/8F^"0>WTQSJ4 MC;Q0\?P4R#*JI:?<3IP-\>6@VRJ]RG!$HCSD&93TR#"E&,1C\(RCQ$==OAIT M"95XB777NM(J._\CU5;UI(RJJ:9GJO7S0[GN'@2O[JMU'^?=X^[=_=&+$'W# MWUUDT90/Y;9[)?/-=EU_+C_V@P1&\Q213.0)94!:2[F(0(I"3*(L34.E[5O3 M*/'OLNQ[O,\R"-YV=\/^UJ>@>6[5<\&I#2>64V9Z@P_3 MXMJKOUI@7MALY?4%9$]3ALL@^42YUG/4$CWN'X47=5-6G[;[?N#Z.[O[[\=V MURT$2!7[FSK?=W>XUUNVVS75[>.ND_6Q_D5:7F]WTGX9YM.;K:1FV>Z&V>.< M"9#%F(HXC1$'+([P072$U0X%+T2JYY9C2"D8RQ])2@YO31W,6K MUGS\0"6KU[X#OY2[/Q75MNN2"^EY6K0/8E/__A_EW:>RM1 .L@0B &F6 M\40@C!*<9*-P##-AV!;.)==S>_B7;5,6F^KODIQ=>O_Z4Y?@'P*)QJQLJJ^R M7?Q:MC?!MNP[[+OBFW'#.%MY:S>./T)1FS>0W<, 77K!4-0=\((NQZ!+,MAG M^2,WE9Z*3ZVYG/O;65R3.;LAYYO-V:7I-9WUNK(016'"$YKP-,,BCY*N,3^( MBI-3&BR 8=/NSM_K_ZR:VJ=/Z%9DG/*" P)X8!G M$"=PE,HSJG4<:Q:!OJ=I9&]T_XRM!)74M6]C N&DD9FF!,U:F\45WI2S.28E M/DG+XZ)4-)J@23^"9;9%TUIPI5&:H3R4GP[=U>N_/=0;63SM^*B=_M36"HN8 MAC -04JHP%F>\^@PJ27_=KKZTB?UZZYH=FJMTD3"=%#V,@=EJO%"_L]U&12[ MX+;\5&VW';0DIO8_./$3G4Y\O0"CB0MN&?B9.NF7[UC.X;G6.>)3'6\Y]N>E M'/>7+WG9CO!;Q2&+H<@QQTB0[I'Y-#YTR>.4:$Y6^U3B??IZ/\1>/QMB;Z3P M&\F43GK0O-1N<(K95S&I=6:74CYZ?=8+Y)W)UC;F.50L$1#TE&0A:Q.(J90*/$))$0V9:?NE_].,_4 MQE5]2H1)]H1YE8KZ"/ES_;C=M4>T+^^Z(7%9-%O]JRNF+<#IIS3<%)J;&?1^ MKZ3:I/GA.H!@G\Y\[83+PIAH!D.YS)?1DLR3NL<9"TW_)YZI"$D2A;)RIR+=WD\Y37).E/T\Q9F R2U%N[_Y_?L)-@2T#,E,G[6=^ M0L]S5;"(HFK^6FP>2]:VY:YELMY4Q6VUJ795V?ZY+-K'1A)P*Q$I:2?ER#\@ M]37C_^1%6[7[X[]QFB6(YGF>(I 12 ($PB2C&9Y*+*(ZJS*3:?*\U)&].'?CZJ':,K_ M>>R/8WZKVA5'.9>1<4BAB%-!4"3$$!FE&= Z?N$BGF=B'.D*#L*"WSIIFBOW M3LQ5&[5.[:O>8-3(4K^T/>^3"D<=N+PP0KK(Z!S[G+FE3;53<;/Z+$')$&$[C,3*B,#6BFD6\>:BV%V?*-1M[-;DVD;-.N';-5+]D.^^4 M"MD<^+PPLKG(Z!S9G+EE0[;VT'LF!J'Q M3B&>)UQ$F: LACQG6:IT6LXDS25..[)MR9=_,FW(?EKEJRM&"FG)D M!")==Y<+(NU,%$!DYH[R333].MLA;E:UZTW=C6N>3C(A B*6(R!$D@H0"\BR M(6[$HXQIW29F'H#::[L)CC80/.D+?AL53GVK MS#7'+J#*G=O+ );#?%[>'N/8*55X==C1\L_U:#D]:G H:"9AS!DF!EJ$\J!ZNFY@7W'\6B+)]L=9/Q2[E8)QRDE@D(HF(A%BF@T@I*F ML1\3W\DLJFZ:\ZX_>_/I0R$^9/>X> MZJ9[KF5%,F:R8!VUZ M&+2U5(U]$[JI![PG(WME-\%>6\"NV^F%;Y>-N@ U1PXO@V2NDJF]?(7VS'K3 MMH\R8)I$..(T(3"/\E1DA,1L#$B0T-I0:1%F%:8QI:632,3)VSY!" M'HRS)]#-+!VB,][HH$?3S85B1S>+:\@QG>WU;L^K-M[^Y?7P=UV-;%010"D6 2YP+G7" 8(9!! M 'F">8Y5VV(WP?Q5FX.^[IJU8X7_$NPUSK:_4Z_(>.R@:I3VJ,&# M1^;CA9G.@+RR0VV(H&G=,K!BH?_\L,#("?7[OG=%M2WO\N&RZ2$8S_(8130A M .6A_'D6IG@,A@@B>J^1&87P#(Y159 ;7K-MYIL:0B:P3(\CK]R:"2:GC;E M%$LGEX$5VR1>70WMP!.C&87/N/?3#WJ M2R9=8)@3;Y>!+3>IU!Z^/']\])R!.0QFF"B.RU8"A"\M1[(7&H=]&2 M00"=6F1TO]+5:?>9YMH/%JE,K.O[N8R:8Y/ N2ES4R^L-]RDF"">,IQC GD< MX22C8[0H#I'^>\>FD73JC*<'C(.?JG'%?.+^M<-M)8HV+Z,J66>ANJU$RQ6; M;24@RS!)4T0I0!&(KY2XXO=6E/_]P$MPNM M9/;;*U3]7D;ELLI 87N%GAM&E:H_7+C**0)9!!EDLLN8<48%8F,@DL'(39U2 MB[7$*C5C->I-4ZU%>@XOL!)I)G"I#IEXH7[^K+ZO=MTTX0KE.:*9"/.$" (I MSP1/#P%8ENH-A31^V/L0J'M(]L7KY(>W^(+A,;[@^#6^[G%AW4D<3X>J1A@T(4\ M/(2QN4T40Q8*!Z-!,8$]U%/0W@GV1K WYW+Z@N>]?IO M^WGM[+%[66N87^HGY?K_Y$5;WG6ZI>BB4[>*,Q(S!%**$<7RWSS.#IL+^OW^^[=1*/GSOUU-9T\A_LE^3NPF*>QDL$'5S7U:[ M2]=[3E=0:KB?NXST$.^]>#PM>FM[?'%5W%^)+8/B7C-\M:[NVTU+6O?3OV>$ M1"(1 LYT(]S@""-PS09A>0XQ.-RQT=K9MNH,%@(^6A-[N$.TGG ;55F5MSV M7DXNL.V\;*:D]@6']:'MHK@6S6PG":HAVYV7%KLZV/I_'JNFO%L1@1EB,(E! MQD1.\8!HCR"!&?=D0J81("! MY-"/D2+X<,8AWRIVVTWCZ%2LL%$\V MZ+EB<[(! \)2$H,D1R*)$,+TJ=)F. '/=V$KUR:34 9-]GNS"G5R"_9"JI;] M>095GY=1I:PR4#C/H.>&Q7D&G,H()(YIFO(\!RA&V:&K#6)!7-0DM4A+JD@_ MUBD&56<76'4T$[A^BD'/"^6*4WQ+F_*NVJ5%TWR_WS_]][';8+%*XI!$J?PR M 1(\3S&!$=?"L,M)"KQP$;%SZ]0&CQ.YIC=^E**" MO:K@6%;P6R]LXALFSCMT"33VMBX$. X2>0D>5]Y< ]"Z>.B"_;G8R4K+OE7M M2G $0Y&)-!8T%"E.!8^&WT]$S)5N;M/_5<]XZ6K+7DWP6Z?G?/VP=>/W7KX?B5S'F^>:?#@T0NNRF1Z6,)P0.6K[$Z0T=R!>4%HH;NV M+7L#S&7UYZ+:KIC(LUPP2##D,<4P#2,^1&!(!M,&G>+O3HBZO2*3BJWJD0;N M/-AC#CS_SAA SX-#9M@;[0EDSR/PQ,!]B&L4U+1D01S457Z*A$;9J[#PO?P> MY%?QH5S77\OF.W]LJVW9CM<$8];M#>4\C&#(!4P(3;,A'B<@SU3):!?%,R<' M<<&H+ACEJ3/!TL7K[)S.0#V2GO7N^@V'KDU4Q^QT9II!U\)4%?!>3/\,AMU8 M-C^4'>51N_Z8U(&=%DTI9)!Z.]Y^RR%)*8QBUNT+A1QPQ,8029Q 549K_[!G M+#_I,6")ODO7&>S5(#WL3NR-.EJ]>F1&4QVO5/#Y,L4SQ#1V8GY(FDNO'7P) M>NLE(V_[_;MMU9]*[68-Y.]3@'& MY$2P),F3F,,XP10!?HB+>:HT;G87;08.W02C1LT9-H<>F]/)G[WVG-)Q=C)F M/3-,DUYF9B^78X;Y*!#-QBE5MNVW7WPLOK''W4/==&^8=B E2&0HQ"D@49Q% MC,8I%D.PC"6YUMX3PQ"3[3L)#KKTD&5JG1JG)G!-#TZG#)NE$W7:F0L4LK1R M&>BQ3:)V^GG90F9@FL IB3@7D1"8Q"!#)(_'<&&> SO,* ;Y 4&C:I\I:CPX MYP(VL_1_SKFC!1Q-0Y>*'-TTKD+'R!=U[,CJNBTV'\JOY?:Q_+5LOE;K\LV' M7X<9JA@B3C(!*4Y#@-*("$C&J&DHM!Y"MHWE'4)[><&@+Q@$!C])B7_0G%1V MYJ\JGJ:S5I=2=JYZXM5%NRYBRXW12Z&7HVQ>0WM-*",]@&&9A M F&:@BAA.!^""A)FR/JL@'JHR;I33LX+:%BH1JL)W=.#U=ES YVXH%>WA,,# M!ZLN@,J1Q\O@E*MD5 X2F'JD/=#+OW476)6\W);WU6Z5R,X=[U<#>8Y9%M(, MAV.TB,;<:)RG&6.Z8=X@+/AID#;QB=DS!JF,5PPM749%LL[BW&C%RA75JO.7 M;5.NZT_;ZN_EG8PY!&M7$(B8(DB[]\=P%"4\2L?M\()!'NI4'=,8GJO.L:Q@ M)RO0[2!,KWTW=E"M89_"/+T6_9EO'7CX-=^\\.:,,1=X8VOE,GACG47M]@-S MPIN/#\7N/^O'S=V;SU^*]2Z_OR_7N^IKA\$/Q:YQ5!P?9_1_\<*EHIJ3F%7/UH>JJM!;-7&=)JB'9K:>6Q#YT4]^7VV*SJ\J6 M;>_&-Q_9>MUT%RB)/&%7KHLMU=^%0^69[3EO[0?[_];:XW7Q_7[=MU5T(PB+6 M33[0,*,Q%"$321R/6G*41SI0]Z/ ,\[S=E=][J[K"OJ7%[I;MNZ&/"3/@\>S M/?7?J]V#_ .[AS+8EM]V 0R#S_5V]Z![@[6?8E,C_/PEIL?V[*ADSG?4JS9X M4AV,LB>^3-O$V0LT]UM2R^"XYQQ?7N@]@:/*+YC*SJ*,_%]ET:P0C..0D1CP M*,X I$G*^1B!<*AT-M/D=SUSMI/25]-.C.;+H#KNJ('/ES%Z.%/SQ,^+FT\& M7*".B4W+8(F1\I>O6AIGKW(H^\WVKOR\K>ZK=7\V]4.Y+JNO_25M>4X XB+! M*!0H S2!:3C&P@ I;<2PB^!]G?.9L.!)F?J)9 O[+B-B.N?T8#&S:>KGN:KT^%E#3Y#;30',?Y[<00ZURT]2KS]WF,T] MS =T<[JI'!Y6V\=J^TFV+$VOI%VA*$]%FH0HIY'@"4ACCD8!+ 5:&X@=AO4] MZCZLG!S-R75B^PMLMNMJ4Q7[DXOO2_D+NF_)N_1?K4,YD_5Z38@[U[WT2=4] MO-!E]5 0R^C1^DBL]OX1ZW'SE_)WME[7CUW 3^^;>BO_7&U/((,A8=V$28P0Q%,F^.A*(P9Q0F,4Z*/6KQ#-=I?C@ M25OP7+[\4H-] MTLVK,_-N1P]1KP.&$OGK$5FRE2U=<^0 MH0.UVV?AAR.&67= &H19A&,*TEQD*.*# !KS2.O:!(=AIR;HJ/5U)3:Z@LIE M 1CQ^9A[>'TY XI1GG ,8 MA5$*28P$&'4!1+76[?VK6?H,Q%N% \5S%:3?J0@_93CQ=(1*\2UJ3N*MPI'Q MZ4ITD=SWF:^C^0E3IU7V:[SM-HN]K8K;:E-U&WO+=E?<;JKVH;PKVN)#V3YN M=O7][J$LAO:JOF>_IC$.5YS)1@JA"',:$X9PSJ-<:L$0I"&+L=(2GU\%GEN# M7GAPI#PXDAX4;5 $>_7=[MMN0^V80/>_90J!S$%]DX/'@KJ^MQ]-?UY+DCYORW7U_,Y<< M OVUV#SVAPT/Y]E$437[O_ON/BMO=V^V[:[INQMMOXQ[K!%1%"<91(!@$$%$ M0-AK# &+F-JCW?,H\TSC,9FNX_1T3K"3'_3ZN[__MMY^^EG^]N?@G6QA/^VW M1QWA^]>'NMGM_P"OFZ;^75K2!FG]^4O1[/<5=UTTV21_&;;FC;X%[',WO-6C M_<0?AEICL-QO0J^M./X<#J6T%]T7^*E/I.W^<)=0<)31L%TGF*U%<5HB%QJ< M>4I^&>W13+G72ZA[+UNSXZ_[K?RK?_^G\>_(_[B58Y5__Z?_!5!+ P04 M" %@D90..6YHQ23 #YF < % &-A:"TR,#$Y,3(S,5]P&UL[+U; ME]LXEB;Z/K\B3\US5N)^Z=4ULW#-\AQGVFV[NJ;/"Q>M8$2P2R%&Z6([^M3'[RY_@G\&? M?LIFD^(JG]W\Y4]_^_RS^FS>O?O3__Y?_^-?_Y^??_Z_^M/[GVPQ6=UEL^5/ M9IZER^SJI^_Y\O:GOU]EBW_\=#TO[G[Z>S'_1_XM_?GG3:6?UC],\]D__J7\ MS]=TD?WT8Y'_RV)RF]VE[XM)NEQ_]^UR>?\OO_SR_?OW/__X.I_^N9C?_(( MP+_L:ATL4?[MYZK8S^5'/T/T,X9__K&X^M-/0<+98OW=#;ZD*O[C5?GO>%T: M2BE_6?]V5W21[RL8FH6__-_?WG]>R_ES/ELLT]DD^]/_^A\__;2!8UY,LT_9 M]4_EGW_[].Y9(Y-T'G203O\\*>Y^*0O\HM-%OOAP_7&>+0+Z:]#4[.KSZNXN MG3]\N/Z],0?4]S=YPJFRVRJ_##(A#@JIQ =#HM#>/G MVRQ;'I>A:0.#]?AC.@\XWF;+0/1I=/?WMM:G+,$*+;,U*3Y;'$HJE\YG8;A&J^5E.T/U__-M8/5M M,;T*?J;[YRI?/L1*67:>4[-IK:/6SR-K< Z+X!9.\_6DNS8V M=\5L77/QM\#_4"68G]4R*UVM29BA;3X-?[MR]PU=V+/UYSQX?BD_[QB3YVUV M))=/\_F_I]-5]EN6+E;SC5T[TN_:.GWV:_?AAVNU6 0O9>TJ[AS';=&K#[- MG]5\'K!=KPR:,;3';^P3DT9,:U"SJSY6Z\MWL\5ROFI$IYHJ/?;J1/-^2A,] M]GJWJ'6+97Y7NB-/*/J^F-U\R>9W'[Y.M\NGDJ\?@AL?#$PQ7Y:_T\5\7GPO MS4Y[N?OK1(_(-1LH1RMVU,-?B^+J>SZ=5M"\FRW3V4T>OFEC9X[TLVGU@7I[ MXEAJV]Q TI0[I5>K:>!R55(_?,KN W=+)GS.;DI:="-IFZ\:'(67O^E:]"/M M#R1O(_MP6B,=]7RSV/^2_CC:O3TEN^_#B8.]0C%?*K9?",UY]^3!].4-OI#?4D MP?KOIEBT[?C!^MWV=W4?FBEA2:=/MYS?S:Z+^=T)YPAMF^M-FFJWN0-)CC?5 MJ12-YKY]1;OJQ4EKAF/];-78621I2(\1K*A.Z\-N@6BSKPT]Y>Z^X"P2-QM! M$4UV)-6GK%S73L(,%;XB?+D+[14/65AJ?,OFZ[B0>A$:UQ^JOVH2',I\&59- MTW(CXDMQM,8),^1 WSX45D\/V1>+8I*7??Y[OKQM*F?>U'$[1U>&0C&L8DY8 M_K1M;BAI&AFN$UOIJ._;[8\G/M"1;AZNT%N/-LO^UOM#[1OL3:(3E_?-&^BM MQY\""V>KK$,E-&ZQ;YG\O+AS/Y;9/!0WJ\6RN,OF@1R_9L7-/+V_S2=J'KSR M2#%;?4EODF\_^3@OKO-EASH]L=W>Y&MD<(]5ZZIWY;&S3MXOY'Z4/P9WYDOH2I#J>VB\ M&X#BOK179)K-LPVJ=MG+4X)/>X\M??T%YC:=W62+=S,UF:SN5FNVK[>G]@0? MOR\6IXRR+K^G-_G;^!>-&NBMQ\U97E.M5>^>WEN3F^[-LIM2D^_3K]F+&PC[ MZDWG\V?5R@MSLKPP!]FZU_M:Z[BGOV?+;CO[LL&.^QLFZ+RXK-N>OVZRZSZ7TW/'?7[59'=];D&,Y>MN-F3!_9/; M@N_#!]OR9;L#W(#=="O[LO./ M&BQBFDT(X@13#!"!%$.FL=6Z0HL#Q)J@]92P:C[YJ9B'^?PO?X)_^BG\YCJ; MS[=S9XW;'< ]$8$]2GOO%*0(BJQQ1XKZ"A#F)[/[OR> M?7_2[WDQ"S].MA<%YYL5SWK!LRN1!YV%66GMB]> $=5NPJ&"P"I)N5&*8H49 M$Q5>'%HQI.59OO)W!K0[C8E3G _^1\-S+JJZ=#Y]4%?%>L-4_<@7K8CYJI6$ M@]V!?W[36#]T@_.7O5MF=^T, M9L.V$V)X\%P! 9 A9B 5V(,*,X YC" L>DN$/8\9[4=+QYG]:D,W?)"LP[&? MA-%EBS*:(5_<9E?I(OV4+5;397&]O,W2[; KKM5G(PC:0]"H]I+@4EF,,2.: M"ZHP<9JY("Z!P" 5EGM_%"O:.3V*X;4S^J7OQ6VD88$95X0(9<*9 MC2+2*PXX[3SI9>C0KJ.E%FV^F$R+,J]+@YGHI'82 Y!PWE!B,2<>EA;$5;PP M�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
XML 94 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Sep. 30, 2019
Jun. 30, 2019
Income Taxes            
Income Tax Expense (Benefit) $ 59 $ 126 $ (364) $ 269    
Unrecognized tax benefits 940   940     $ 456
Unrecognized tax benefits that would impact effective tax rate 791   791     303
Unrecognized tax benefits, interest and penalties accrued $ 132   $ 132     122
Effective Income Tax Rate Reconciliation, Percent 21.00% 31.00% 7.20% 23.50%    
Minimum            
Income Taxes            
Estimated range of decrease in unrecognized tax benefits within the next 12 months $ 0   $ 0      
Maximum            
Income Taxes            
Estimated range of decrease in unrecognized tax benefits within the next 12 months $ 350   350      
Internal Revenue Service (IRS) [Member] | Minimum            
Income Taxes            
Open Tax Year 2008          
Patient Recovery Business            
Income Taxes            
Indemnification Receivable $ 21   21     22
CareFusion [Member]            
Income Taxes            
Indemnification Receivable 171   171     $ 165
Total Opioid Litigation [Member]            
Income Taxes            
Estimated Litigation Liability 5,630   5,630   $ 5,630  
Income Tax Expense (Benefit)     (487)      
Unrecognized tax benefits that would impact effective tax rate $ 468   $ 468      
XML 95 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Details) - USD ($)
$ in Millions
Jul. 01, 2019
Dec. 31, 2019
Jun. 30, 2019
Reclassification of deferred rent in accordance with ASC 842 $ 22    
Operating Leases, Future Minimum Payments Due, Next Twelve Months     $ 126
Operating Leases, Future Minimum Payments, Due in Two Years     100
Operating Leases, Future Minimum Payments, Due in Three Years     76
Operating Leases, Future Minimum Payments, Due in Four Years     54
Operating Leases, Future Minimum Payments, Due in Five Years     33
Operating Leases, Future Minimum Payments, Due Thereafter     $ 94
Operating Lease, Weighted Average Remaining Lease Term   6 years 3 months 18 days  
Operating Lease, Weighted Average Discount Rate, Percent   2.90%  
Minimum      
Lessee, Operating Lease, Term of Contract   1 year  
Maximum      
Lessee, Operating Lease, Term of Contract   23 years  
XML 96 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases Schedule of Future Lease Payments (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Remainder of 2020 $ 61
2021 114
2022 93
2023 71
2024 48
Thereafter 166
Total future lease payments 553
Less: leases not yet commenced (1) 61
Less: imputed interest 51
Total lease liabilities 426
Total lease liabilities 15
Total Lease Liability 441
Operating Leases  
Remainder of 2020 59
2021 108
2022 89
2023 67
2024 47
Thereafter 166
Total future lease payments 536
Less: leases not yet commenced (1) 61
Less: imputed interest 49
Total lease liabilities 426
Finance Leases  
Remainder of 2020 2
2021 6
2022 4
2023 4
2024 1
Thereafter 0
Total future lease payments 17
Less: leases not yet commenced (1) 0
Less: imputed interest 2
Total lease liabilities $ 15
XML 97 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2019
Jun. 30, 2019
Current assets:    
Cash and equivalents $ 1,659 $ 2,531
Trade receivables, net 8,280 8,448
Inventories, net 13,799 12,822
Prepaid expenses and other 1,998 1,946
Total current assets 25,736 25,747
Property and equipment, net 2,301 2,356
Goodwill and other intangibles, net 11,523 11,808
Other assets 1,482 1,052
Total assets 41,042 40,963
Current liabilities:    
Accounts payable 21,459 21,535
Current portion of long-term obligations and other short-term borrowings 1,192 452
Other accrued liabilities 2,239 2,122
Total current liabilities 24,890 24,109
Long-term obligations, less current portion 6,742 7,579
Deferred income taxes and other liabilities 8,408 2,945
Preferred shares, without par value:    
Authorized—500 thousand shares, Issued—none 0 0
Common shares, without par value:    
Authorized—755 million shares, Issued—327 million shares at December 31, 2019 and June 30, 2019, respectively 2,752 2,763
Retained earnings 449 5,434
Common shares in treasury, at cost: 35 million shares and 28 million shares at December 31, 2019 and June 30, 2019, respectively (2,099) (1,790)
Accumulated other comprehensive loss (103) (79)
Total Cardinal Health, Inc. shareholders' equity 999 6,328
Noncontrolling interests 3 2
Total shareholders’ equity 1,002 6,330
Total liabilities and shareholders’ equity $ 41,042 $ 40,963

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end XML 93 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Basis of Presentation and Summary of Significant Accounting Policies
 6 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to Note 4 for further information on our equity method investments.
References to "we," "our," and similar pronouns in in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2019 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2020 and 2019 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2020 and June 30, 2019, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the United States Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. To conform to the current year presentation, certain prior year amounts have been reclassified. In addition, financial results presented for this fiscal 2020 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2020. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (the "2019 Form 10-K").
Recently Adopted Financial Accounting Standards
Derivatives and Hedging
In October 2018, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to derivatives and hedging which permits the use of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") as a benchmark interest rate for hedge accounting purposes. This guidance is
effective beginning the first quarter of fiscal 2020 and must be applied on a prospective basis. The adoption did not have a material impact on our consolidated financial statements.
Leases
In February 2016, the FASB issued amended accounting guidance that requires lessees to recognize most leases on the balance sheet as a lease liability and corresponding right-of-use asset. The guidance also requires disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted this guidance during the first quarter of fiscal 2020 and elected the transition option which allows us to apply the guidance prospectively. The adoption resulted in the recognition of lease liabilities in the amount of $422 million and did not have a material impact on our results of operations, liquidity or debt covenant compliance under our current debt agreements. The majority of our lease spend relates to certain real estate with the remaining lease spend primarily related to vehicles and equipment. The adoption required certain changes to our systems and processes. See Note 5 for additional information regarding leases.
Recently Issued Financial Accounting Standards Not Yet Adopted
Financial Instruments - Credit Losses
In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. This guidance will be effective for us in the first quarter of fiscal 2021. We are currently evaluating the impact of adoption on our consolidated financial statements.